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Abstract 
 
Fibrinogen is a vital component of coagulation; cleavage of fibrinogen yields fibrin 
monomers that polymerise to form a network of fibres, constituting the blood clot. 
Human fibrinogen is secreted from hepatocytes in its phosphorylated form, with 
20-25 % of circulating fibrinogen phosphorylated exclusively at A chain Ser3 and 
Ser345. Phosphorylation of fibrinogen is elevated in acute phase conditions, venous 
thrombosis and ovarian cancer, but little is known about the regulation and effects of 
this modification. The aims of this PhD project were to characterise the cellular 
mechanism and functional role of fibrinogen phosphorylation in vivo.  
Human hepatoma cells were incubated in the presence and absence of IL-6 and the 
phosphate content of secreted fibrinogen was analysed by western blotting. 
Interleukin-6 caused a 3.1-fold increase in fibrinogen phosphorylation, demonstrating 
for the first time that the up-regulation of this modification in acute phase conditions is 
regulated at the cellular level. Using real-time PCR, IL-6 was found to significantly 
enhance (6.0-fold) the expression of Golgi casein kinase Fam20A, whose recognition 
sequence matches the Ser3 and Ser345 phosphorylation sites. Expression of other 
potential fibrinogen kinases, including CK2, Fam20B and Fam20C, were unchanged. 
This finding suggests that Fam20A plays an important role in the hepatocellular 
response to acute phase conditions and may phosphorylate fibrinogen in vivo.  
Chromatographic enrichment of phosphorylated human plasma fibrinogen was 
conducted for functional analyses. Binding and activity assays found no effect of 
fibrinogen phosphorylation on FXIII cross-linking of fibrin α and γ chains, plasmin(ogen) 
binding to fibrinogen, or α2-antiplasmin incorporation. Analysis by SDS-PAGE revealed 
a small decrease in the rate of fibrinogen degradation by plasmin with increasing 
phosphorylation, indicating a possible role in protection from fibrinolysis. Scanning 
electron microscopy and turbidimetric assays revealed thinner fibres and more 
extensive branching in clots with a higher phosphate content, which typically 
represents a pro-thrombotic structure.  
This work highlights the importance of fibrinogen phosphorylation in maintaining the 
balance between clot formation and lysis. Investigations have shown that increased 
intracellular kinase activity leads to elevated fibrinogen phosphorylation in acute phase 
conditions. The observed alterations to clot phenotype with elevated fibrinogen 
v 
phosphorylation suggest this modification may help to stem bleeding following trauma. 
Furthermore, it may have important implications in the development of thrombosis, 
which would make it a valuable target for therapeutic intervention in associated 
pathologies.  
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Chapter 1 
Introduction 
 
Haemostasis refers to the vital physiological mechanisms that limit blood loss after 
vessel injury. These mechanisms must be tightly regulated as defects can lead to 
undesired bleeding or thrombus formation. Fibrinogen is a key player in the final stage 
of the coagulation cascade – an essential component of haemostasis – whereby 
cleavage of fibrinogen triggers the formation of a fibrin clot to repair the vascular defect. 
During synthesis, fibrinogen is phosphorylated at serine (Ser) 3 and Ser345 within its 
Aα chain, but the functional significance of this is yet to be characterised. 
Phosphorylation at these sites has been shown to affect clot structure and there is 
evidence to suggest this modification may be associated with thrombosis. Therefore, it 
is important to advance understanding of fibrinogen phosphorylation, including the 
process, its physiological purpose and its contribution to disease. 
1.1. Haemostasis and coagulation 
Haemostasis comprises several complex responses to vascular injury. Damage to the 
blood vessel results in the release of various cytokines, chemokines and proteins from 
endothelial cells, triggering localised pro-inflammatory and pro-coagulant activities. 
Vasoconstriction occurs to minimise blood loss, while platelets aggregate at the site of 
injury via adhesive von Willebrand factor (vWF) and fibrinogen, in order to seal the 
vessel wall. Simultaneously, coagulation factors are activated on the surface of tissue 
factor (TF)-bearing cells and activated platelets, ultimately leading to formation of an 
insoluble fibrin network to stabilise the platelet plug. The known coagulation factors (F) 
include TF, FVII, FXII, FXI, FIX, FVIII, FV, FX, prothrombin, fibrinogen and FXIII. 
Activation of coagulation factors occurs in a sequential manner and includes feedback 
mechanisms. Anticoagulation occurs at the appropriate time to prevent excessive 
coagulation, and is mediated by the activities of protein C, protein S, tissue factor 
pathway inhibitor (TFPI) and antithrombin III. There are two proposed models of 
coagulation: the classic coagulation cascade with intrinsic and extrinsic pathways 
leading to a common pathway, and a more recently established cell-based model of 
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coagulation involving initiation, amplification and propagation steps on TF-bearing cells 
and activated platelets (Hoffman and Monroe, 2001). 
1.1.1. The coagulation cascade 
Early reports described coagulation as a ‘waterfall sequence’ or ‘cascade of 
proenzyme-enzyme transformations’ (Davie and Ratnoff, 1964, Macfarlane, 1964). This 
led to refinement of the cascade model, involving sequential activation of serine 
proteases within separate intrinsic and extrinsic pathways, converging on a common 
pathway (Brandt, 1985).  The extrinsic pathway is also known as the TF-pathway as it 
is triggered by exposure of sub-endothelial TF upon vessel injury. Tissue factor binds 
circulating FVII, which is activated to FVIIa, initiating the cascade. The contact 
activation (intrinsic) pathway involves binding of FXII to a negative surface, causing 
autoactivation of FXII and setting in motion a series of coagulation factor activations. 
These pathways both finish via a common route which ultimately leads to fibrin clot 
formation. Figure 1 illustrates this classic cascade model of coagulation. 
1.1.1.1. Tissue factor pathway 
The TF-pathway is the predominant contributor to coagulation. Tissue factor is a 
glycoprotein which is anchored to endothelial cells via a transmembrane domain. 
Vessel injury exposes TF, enabling interaction with circulating FVII. Tissue factor acts 
as a cofactor for FVII by accelerating its activation to FVIIa and increasing its 
enzymatic activity towards its substrates (Nemerson and Repke, 1985, Bjoern et al., 
1991). The TF/FVIIa complex is the extrinsic tenase complex which feeds into the 
common pathway by activating FX. Activated FVII (FVIIa) also activates FIX, which can 
complex with FVIIIa on a cell surface for FX activation. 
1.1.1.2. Contact activation pathway 
Autoactivation of FXII occurs when it comes into contact with a negatively charged 
surface, such as sub-endothelial collagen, polyphosphate anions released from 
activated platelets, or lipopolysaccharides in bacterial cell walls (Kawamoto and 
Kaibara, 1990, Renne et al., 2005, Morrison and Cochrane, 1974, Smith et al., 2006). 
Surface-bound high molecular weight kininogen (HMWK) brings prekallikrein and FXI 
into proximity, leading to formation of a complex involving FXIIa, HMWK, prekallikrein 
(PK), and FXI (Schmaier et al., 1987). Prekallikrein is converted to kallikrein and 
activation of FXI in turn activates FIX, leading to formation of the intrinsic tenase 
complex involving FIXa and FVIIIa. 
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1.1.1.3. Common pathway 
The common pathway of the coagulation cascade is responsible for thrombin 
generation and fibrin clot formation. Tenase complexes from the tissue factor and 
contact activation pathways activate FX, which binds to FVa in the presence of 
phospholipids and calcium ions to form a prothrombinase complex (Suttie and Jackson, 
1977). Incorporation of FXa into the prothrombinase complex accelerates prothrombin 
cleavage by five orders of magnitude, compared to the activity of FXa alone (Nesheim 
et al., 1979). Production of active thrombin by prothrombinase leads to cleavage of 
N-terminal peptides from fibrinogen to initiate fibrin polymerisation (Blomback et al., 
1966). Thrombin also activates transglutaminase FXIII, which forms covalent 
cross-links between adjacent fibrin molecules to stabilise the clot. 
 
 
 
 
 
Figure 1. The coagulation cascade. The contact activation pathway and tissue factor pathway 
both result in the formation of a tenase complex (blue) in the presence of phospholipids (PL) 
and Ca2+ ions, leading to a common pathway. A prothrombinase complex (PTase) (pink) 
activates thrombin (green), whose generation is further enhanced by positive feedback 
mechanisms (green arrows). Thrombin cleaves fibrinogen, yielding fibrin monomers which 
polymerise to form a fibrin clot. The fibrin clot is stabilised by FXIII cross-linking.  
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1.1.2. The cell-based model of haemostasis 
Although the cascade model of haemostasis appears to work well in vitro, it is 
inconsistent with the nature of certain haemostatic pathologies. For example, activation 
of FX by the extrinsic tenase (TF/FVIIa) would be expected to compensate for FVIII or 
FIX deficiencies in haemophiliacs if the two pathways were distinct. In addition, the 
cascade model does not explain the cross-activation of coagulation factors within 
different pathways, such as activation of FIX by extrinsic tenase, and activation of FXI 
by thrombin (Osterud and Rapaport, 1977, Gailani and Broze, 1993).  Hence, the 
notion of separate intrinsic and extrinsic pathways has come under scrutiny (Gailani 
and Broze, 1991, Broze, 1992a, Broze, 1992b, Roberts et al., 1998), and has since 
been replaced by a cell-based model of haemostasis (Hoffman and Monroe, 2001). 
This model acknowledges the interrelation of various coagulation reactions and is more 
compatible with the in vivo condition.  
The cell-based model of haemostasis consists of three overlapping phases – initiation, 
amplification and propagation – occurring on different cell surfaces. The initiation phase 
is localised to TF-bearing cells, while amplification occurs during transition to activated 
platelet surfaces – the site of propagation (figure 2). Haemostatic mechanisms are 
triggered when TF is exposed to flowing blood following vascular endothelium 
perforation or activation by inflammatory mediators. Factor IXa, FXa and small 
quantities of thrombin are produced on TF-bearing cells. If these exceed a threshold 
level, coagulation is initiated. During amplification, platelets adhere to the damaged 
endothelium and become partially activated. The thrombin produced during initiation 
completes platelet activation and also activates FVIII, FV and FXI. Coagulation factors 
localise to the activated platelet membrane, setting the scene for the propagation 
phase. During propagation, activated proteases combine with their co-factors to form 
tenase and prothrombinase complexes. Activated FXI provides additional FIXa for 
tenase complex formation, enhancing thrombin generation. Prothrombinase catalyses 
the proteolysis of two peptide bonds within the inactive zymogen, prothrombin, 
releasing active thrombin plus two fragments (Nesheim et al., 1979). The resulting 
surge of thrombin is sufficient to clot fibrinogen.  
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1.1.3. Anticoagulant pathways 
Coagulation processes are tightly regulated to maintain an appropriate balance 
between pro- and anti-coagulant activities. Tissue factor pathway inhibitor is the 
principal inhibitor of the extrinsic pathway, inhibiting FXa directly, as well as indirectly 
by forming a quaternary complex with the extrinsic tenase (TF/FVIIa) and FXa (Broze 
gfghfgh
INITIATION
AMPLIFICATION
Platelet
TF-bearing cell
Activated 
platelet
TF-bearing cell
PTase
PTase
Activated platelet
Tenase PTase
PROPAGATION
Figure 2. The cell-based model of haemostasis. Initiation of coagulation occurs on TF-
bearing cells. Tenase complexes activate FX, leading to prothrombinase (PTase) formation and 
low levels of thrombin (T) generation from prothrombin (PT). During amplification, thrombin 
activates FVIII, as well as FV and FXI on the platelet surface. Platelets adhere to the 
extravascular matrix and are also activated by thrombin. Localisation of coagulation factors on 
the surface of activated platelets results in a burst of thrombin generation in the propagation 
phase. Solid arrows represent zymogen cleavage; dashed arrows represent activation. 
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et al., 1991, Sanders et al., 1985). Protein C is a coagulation factor zymogen that is 
activated by low levels of thrombin in vivo (Comp et al., 1982). Activated protein C 
inhibits FVIIIa and FVa which contribute to tenase and prothrombinase complexes 
respectively. Protein S functions as a cofactor for both protein C activation and the 
down-regulation of FXa activity by TFPI. Antithrombin III is a serine protease inhibitor 
which acts on several enzymes in the coagulation system, trapping them in an inactive 
complex via its reactive peptide bond at arginine (Arg) 393-Ser394 (Bjork et al., 1982). 
Its primary target is thrombin, but can also inhibit FXa, FXIa, FIXa, FXIIa, FVIIa, 
plasmin and kallikrein, although these inhibitions may not be physiologically relevant 
(Travis and Salvesen, 1983, Damus et al., 1973, Sanchez et al., 1998, Lawson et al., 
1993, Bjork et al., 1982). Together, the various anticoagulant proteins ensure clotting 
only occurs above a threshold level of activation, and prevent excessive fibrin 
formation. 
1.1.4. The fibrinolytic system 
Following vascular repair, fibrin clots must be broken down and solubilised to prevent 
clot embolisation or thrombosis. This process is known as fibrinolysis. Figure 3 displays 
a simplified diagram of the fibrinolytic system. In brief, cleavage of plasminogen yields 
active plasmin – a serine protease which digests fibrin into fibrin degradation products.  
 
 
 
 
 
Fibrin
Fibrin degradation
products
Plasmin
Plasminogen
α2-AP
TAFI
tPA
uPA
PAI
Fibrinogen
Thrombin
Figure 3. The fibrinolytic system. Fibrin clots are degraded by the enzyme plasmin, yielding 
fibrin degradation products. Plasmin is formed by cleavage of plasminogen by tissue 
plasminogen activator (tPA) or urokinase (uPA) and is inhibited by α2-antiplasmin (α2-AP). The 
plasminogen activators are inhibited by plasminogen activator inhibitor (PAI), and degradation of 
fibrin is inhibited by thrombin-activatable fibrinolysis inhibitor (TAFI). Green lines represent 
activation; red lines represent inhibition. 
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1.1.4.1. Plasminogen and its activators 
Plasminogen is a 90 kilodalton (kDa) glycoprotein existing as two N-terminal variants: 
glutamic acid (Glu)-plasminogen and lysine (Lys)-plasminogen. The N-terminal peptide 
domain of Glu-plasminogen is removed by cleavage at Lys77-Lys78, releasing Lys-
plasminogen. Lys-plasminogen is more readily activated, with a Michaelis constant 
(Km) of 19 µM compared to 65 µM for Glu-plasminogen (Hoylaerts et al., 1982). Glu-
plasminogen is converted to Lys-plasminogen on the endothelial cell surface for 
optimal activation of plasminogen (Gong et al., 2001). Lys-plasminogen also has higher 
affinity for fibrin due to altered conformation (Lucas et al., 1983). For activation, 
plasminogen is cleaved at the Arg561-valine (Val)562 peptide bond by tissue 
plasminogen activator (tPA) or urokinase (uPA) (Robbins et al., 1967). Tissue 
plasminogen activator is a 72 kDa glycoprotein released from endothelial cells to 
initiate fibrinolysis. It is the major intravascular activator of plasminogen, leading to the 
dissolution of fibrin clots in plasma. Urokinase is a 54 kDa glycoprotein which 
predominantly functions in pericellular proteolysis, enhancing activation of cell-bound 
plasminogen (Blasi, 1993).  
Fibrin facilitates its own degradation by binding plasminogen and tPA, creating a 
localised pool of plasmin. This binding enhances plasminogen activation, which has a 
lower Km in the presence of fibrin (Hoylaerts et al., 1982). Unlike tPA, uPA does not 
bind fibrin, yet does increase Glu-plasminogen activation in the presence of fibrin, 
possibly due to a conformational change in fibrin-bound plasminogen (Cesarman-Maus 
and Hajjar, 2005).  Both plasminogen and tPA bind to the αC region of fibrinogen with 
high affinity (dissociation constants (Kd) of 32 nM and 33 nM respectively) at sites that 
are cryptic in fibrinogen but exposed in fibrin (Tsurupa and Medved, 2001a, Tsurupa 
and Medved, 2001b).  Plasminogen and tPA bind to additional sites in fibrinogen D and 
E regions that are also only exposed in fibrin (Varadi and Patthy, 1983, Varadi and 
Patthy, 1984, Lucas et al., 1983), including Aα148-160, and γ312-324 in the case of 
tPA (Nieuwenhuizen, 1994). Plasminogen and tPA binding sites become exposed 
during fibrin assembly when D and E regions interact, disrupting interaction of the β- 
and γ-nodules with the coiled-coil region and Aα148-160 respectively (Yakovlev et al., 
2000). Plasmin generation leads to proteolysis of fibrin into soluble fragments. 
1.1.4.2. Plasmin digestion of fibrin(ogen) 
Plasmin digests both native fibrinogen and polymerised fibrin clots. Evidence suggests 
that fibrinogen evolved from a single polypeptide chain, encoded by a single gene prior 
to duplication (Henschen et al., 1983, Crabtree et al., 1985). Thus, plasmin cleaves 
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sites at similar positions within the Aα, Bβ and γ chains of fibrinogen. Plasmin attacks 
fibrinogen from its C-terminal end, with the Aα chain being most susceptible to 
proteolysis. Sequential plasmin digestion of fibrinogen generates multiple fibrinogen 
degradation products, known as fragment X, fragment Y, fragments D1-D3 and 
fragment E (figure 4). The compositions and molecular weights of these degradation 
products are well characterised (Nussenzweig et al., 1961, Ferguson et al., 1975, 
Gaffney, 1980). The three main steps in plasmin-mediated digestion of fibrinogen are 
as follows. Firstly, two 50 kDa peptides are cleaved from the C-terminal ends of the Aα 
chains (αC), yielding fragment X (240 kDa) and free αC degradation products. 
Secondly, unilateral cleavage of Bβ and γ chain C-termini in fragment X, as well as 
further processing of the Aα chain, generates fragment Y (145 kDa) and fragment D1 
(92 kDa), whereby fragment D1 is the cleaved C-termini, still held together by 
disulphide bonds. Thirdly, the same pattern of digestion on the intact half of fragment Y 
creates fragment E (50 kDa) – a dimer containing disulphide bonded Aα, Bβ and γ 
chain N-termini – and fragment D1. Additional shortening of the γ chain from its 
C-terminal end in fragment D1 creates fragments D2 (86 kDa) and D3 (82 kDa) 
(Southan et al., 1985). In vivo, degradation of cross-linked fibrin also yields a D-D 
dimer, which is used clinically in the diagnosis of thrombosis and pulmonary embolism 
(Brill-Edwards and Lee, 1999). Cleavage of fibrin in this way is essential for clot lysis. 
 
 
 
 
Figure 4. Plasmin digestion of fibrinogen. Carboxy-termini of fibrinogen Aα chains are 
digested by plasmin to generate fragment X and free αC degradation products. Asymmetric 
cleavage of the Aα, Bβ and γ chains of fragment X from their C-terminal ends yields fragment Y 
and fragment D1. Identical cleavage of the second monomer in fragment Y also yields fragment 
D1. The γ chain of fragment D1 is further digested to produce fragment D2 and fragment D3. 
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1.1.4.3. Fibrinolysis inhibitors 
Fibrinolytic mechanisms must be constrained to prevent interference with vital clot 
formation. The key inhibitors of fibrinolysis include α2-antiplasmin (α2-AP), 
plasminogen activator inhibitor (PAI)-1, PAI-2, and thrombin-activatable fibrinolysis 
inhibitor (TAFI). The reactive site in the C-terminus of serine protease inhibitor α2-AP 
(Arg364) interacts covalently with the active site of plasmin to inhibit its proteolytic 
degradation of fibrin (Shieh and Travis, 1987, Lee et al., 1999). Alpha-2-antiplasmin 
also forms non-covalent, high affinity (Kd of 45-68 nM) interactions with fibrin D1 and D-
D fragments, as well as the αC region, at sites that are cryptic in fibrinogen but 
exposed in fibrin (Tsurupa et al., 2010). This binding may orientate α2-AP to facilitate 
subsequent cross-linking of this inhibitor to fibrin by active FXIII. Plasminogen activator 
inhibitor-1 is the most important physiological inhibitor of tPA and uPA, while significant 
levels of PAI-2 in plasma are only detected in early pregnancy or pathological 
conditions (Cesarman-Maus and Hajjar, 2005). Free PAI-1 and PAI-2 complex with the 
active sites of tPA and uPA to prevent conversion of plasminogen to active plasmin. 
Fibrin-bound PAI-1 can also interact with tPA and uPA to prevent activation of 
plasminogen (Wagner et al., 1989). Thrombin-activatable fibrinolysis inhibitor is a 
60kDa glycoprotein which, upon activation by thrombin, removes C-terminal lysine and 
arginine residues of fibrin degradation products, which normally provide additional tPA 
and plasminogen binding sites and induce a 2.5-fold increase in the rate of 
plasminogen activation (Wang et al., 1998). Hence, TAFI limits tPA and plasminogen 
binding to fibrin, thereby reducing plasmin generation and preventing further 
fibrinolysis.   
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1.2. Fibrin(ogen) 
Fibrinogen was first isolated from horse plasma by Hammarsten in 1876, and from 
human plasma 70 years later (Cohn et al., 1946). Hammarsten discovered that 
fibrinogen plays a crucial role in coagulation as a precursor for fibrin upon exposure to 
thrombin. Indeed, the surge of thrombin activation during the propagation phase of 
haemostasis triggers fibrin polymerisation, creating a network of fibres to stabilise the 
platelet plug. Fibrinogen’s structure and functions have been studied extensively since. 
Fibrinogen molecules are highly heterogeneous due to alternative mature messenger 
ribonucleic acid (mRNA) splicing and polymorphisms, described below, as well as post-
translational modification (section 1.4), including Aα chain proteolysis. 
1.2.1. Genetic regulation of fibrinogen 
Fibrinogen Aα, Bβ and γ polypeptides are encoded by three genes – FGA, FGB and 
FGG, respectively – on the long arm of chromosome 4, region q23-32 (Henry et al., 
1984). The location of all three genes on the same chromosome, as well as sequence 
homologies and similarities in 5’ exon-intron domains, indicate divergence of FGA, 
FGB and FGG from a common ancestral gene. It is likely that the original gene 
duplicated to form FGA and a pre-FGB/FGG gene approximately 1 billion years ago, 
followed by subsequent duplication to form individual FGB and FGG genes some 500 
million years ago (Crabtree et al., 1985). The genes are arranged in the order of FGG-
FGA-FGB, with FGB in the opposite transcriptional orientation, which is a somewhat 
unexpected arrangement given the proposed evolutionary process (Kant et al., 1985). 
The three genes are of 5.4 (FGA), 8.2 (FGB) and 8.4 (FGG) kilobases (kb) in length 
and span a compact 50 kb cluster (Chung et al., 1990). The Aα chain gene consists of 
5 exons, FGB of 8 exons, and FGG of 10 exons. Splicing of intron-exon junctions 
generates mRNA (Mount, 1982). Cloning of complementary deoxyribonucleic acid 
(cDNA) for fibrinogen chains enabled characterisation of the individual genes. The 
mRNA molecules coding for the fibrinogen Aα, Bβ and γ chains consist of 1,875, 1,900 
and 1,600 coding nucleotides respectively, producing polypeptides of 625, 461 and 411 
amino acids in length (Rixon et al., 1983, Chung et al., 1983, Haidaris et al., 1989). 
1.2.1.1. Splice variants and polymorphisms  
Francis et al. (1980) identified a larger variant of the fibrinogen γ chain, which was later 
isolated and established as γ’ (Wolfenstein-Todel and Mosesson, 1980). This minor 
variant of the γ chain exists in 10% of fibrinogen molecules and typically forms a 
heterodimer with normal fibrinogen γ chain (γA) – γA/γ’. Fibrinogen γ’ is a result of 
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alternative splicing, leading to replacement of the last four residues of γA with a 
20-amino acid sequence (Chung and Davie, 1984). This extension carries a negative 
charge and is also sulphated at tyrosine (Tyr) residues 418 and 422, together 
impacting the functional properties of fibrinogen (Hortin, 1989, Meh et al., 2001). Lovely 
et al. (2003) reported a high affinity thrombin-binding site between residues 414 and 
427 of the γ’ extension. More recently, γ’ has been shown to interfere with protofibril 
formation, producing clots with thinner fibres and mechanically weaker structures (Allan 
et al., 2012). This variant has been highlighted as a marker for thrombotic disease 
(Farrell, 2012).  
An additional splice variant, Fib420, has a C-terminal extension of 236 amino acids on 
the Aα chain (αE) which is homologous to the C-termini of the Bβ and γ chains and is 
encoded by exon 4 of the FGA gene (Fu and Grieninger, 1994). This sequence is 
N-glycosylated, giving αE a higher than predicted molecular weight of 100 kDa. The αE 
extension contains calcium binding sites that protect fibrinogen from proteolysis by 
plasmin (Applegate et al., 1998). However, no additional polymerisation or cross-linking 
sites were detected. 
Several single nucleotide polymorphisms have been reported in fibrinogen. Two 
common polymorphisms include a threonine (Thr) to alanine (Ala) substitution at 
residue 312 in the Aα chain, and an arginine to lysine substitution at residue 448 in the 
Bβ chain (Baumann and Henschen, 1993).  The fibrinogen Aα Thr312Ala 
polymorphism occurs in the αC region, which has an important functional role in FXIII 
cross-linking. This substitution influences the fibrin clot, leading to thicker fibres and 
increased α chain cross-linking – a proposed mechanism for its association with 
venous thrombosis and clot embolisation (Standeven et al., 2003, Carter et al., 2000). 
The fibrinogen Bβ Arg448Lys polymorphism also resides in the C-terminus, and has a 
frequency of 15 % in the Caucasian population (Baumann and Henschen, 1993). Clots 
composed of BβLys448 fibrinogen have thinner fibres, reduced porosity, increased 
stiffness and slower lysis times in plasma (Ajjan et al., 2008). This polymorphism is 
associated with thrombotic and coronary artery disease (Carter et al., 1997, Behague 
et al., 1996). 
1.2.1.2. Dysfibrinogenemias 
Dysfibrinogenemias are inherited mutations in one of the three fibrinogen genes, 
leading to fibrinogen abnormalities and defective fibrin clot formation. Such mutations 
may create a bleeding or thrombotic tendency depending on the location of the 
mutation.  Certain mutations may also affect fibrinogen synthesis, leading to low levels 
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of circulating fibrinogen (hypodysfibrinogenemia). One of the more common 
dysfibrinogenemias is fibrinogen Dusart, characterised by a heterozygous base 
substitution causing an amino acid change at Aα Arg554 to a cysteine (Cys) residue 
(Soria et al., 1983). This causes a thrombophilic phenotype with abnormal clot 
properties. The Cys554 residue forms a disulphide bond with circulating albumin, which 
can hinder Aα chain interactions and lateral aggregation of protofibrils during clot 
formation, leading to thinner fibres (Koopman et al., 1993). Clots also have reduced 
porosity, increased branching, and increased resistance to fibrinolysis due to reduced 
plasminogen binding and activation by tPA (Collet et al., 1996). Another 
dysfibrinogenemia – fibrinogen Caracas – results from a base substitution and amino 
acid change from serine to N-glycosylated asparagine at position 434 of the Aα chain 
(Maekawa et al., 1991). Similar to fibrinogen Dusart, N-glycosylation of Asn434 impairs 
Aα chain interactions and lateral aggregation of protofibrils, producing clots with thinner 
fibres. In contrast, porosity was increased and clots were more susceptible to 
fibrinolysis (Woodhead et al., 1996). Additional abnormal fibrinogens result from 
replacement of Aα chain Arg16 with histidine or cysteine, as in fibrinogen Milano IV and 
fibrinogen Ledyard respectively (Lee et al., 1991, Bogli et al., 1992). These 
dysfibrinogenemias reduce the rate of cleavage of Aα chain N-terminal peptide 
fibrinopeptide A by thrombin to initiate polymerisation. Hence, clot formation is delayed 
and patients exhibit a bleeding phenotype. These hereditary diseases demonstrate 
how a minor genetic alteration can significantly alter the function of fibrinogen, with 
serious consequences.  
1.2.2. Fibrinogen biosynthesis 
Fibrinogen is predominantly synthesised in hepatocytes and secreted into plasma, 
circulating at an average concentration of 2.6 mg/ml (7.6 µM) (Forman and Barnhart, 
1964, Butenas and Mann, 2002). Early studies with bovine, dog and rat fibrinogen 
revealed that the Aα, Bβ and γ chains are translated from separate mRNA transcripts 
and form a precursor molecule as fully assembled fibrinogen (Chung et al., 1980, Yu et 
al., 1980, Nickerson and Fuller, 1981). As is typical for secretory proteins, each chain 
also contains a signal peptide which is cleaved during co-translational translocation into 
the endoplasmic reticulum (ER). Kudryk et al. (1982) reported that synthesis and 
secretion of dog fibrinogen takes 15-20 minutes and that Aα, Bβ and γ chains are 
secreted to an equal extent. Disulphide bond formation between half molecules of dog 
fibrinogen took place in the ER, while phosphorylation and sulphation of fibrinogen 
occurred in a post-ER compartment. A study by Hartwig and Danishefsky (1991) using 
recombinant fibrinogen expression in monkey kidney (COS) cells provided early 
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evidence for fibrinogen intermediate complexes. Expression of Aα, Bβ and γ chains, 
either individually or as pairs, in baby hamster kidney (BHK) cells established a three-
step model for fibrinogen biosynthesis: i) simultaneous formation of Aα-γ and Bβ-γ 
complexes, ii) addition of an Aα or Bβ chain to these intermediates to form a half 
molecule, and iii) assembly of mature, dimeric fibrinogen which is secreted from the cell 
(figure 5) (Huang et al., 1993b).  
 
 
 
 
 
 
 
This model was supported by subsequent cell fusion experiments, fusing BHK cells 
expressing the Bβ and γ chains with those expressing only the Aα chain, and likewise 
fusing cells expressing the Aα and γ chains with those expressing only the Bβ chain  
(Huang et al., 1996). The predominant intermediate complex was dependent on the 
cellular level of individual chains, and incorporation of preformed Aα-γ and Bβ-γ 
complexes confirmed their role as functional intermediates in fibrinogen assembly. The 
presence of Aα-γ, Bβ-γ and AαBβγ intermediates was also demonstrated in human 
hepatoma (HepG2) cells, which synthesise and secrete fibrinogen naturally, but with 
much higher levels of the Aα-γ complex. 
Surplus fibrinogen Aα and γ chains in HepG2 cells are due to different rates of 
synthesis and degradation. Yu et al. (1984) have demonstrated using pulse-chase 
experiments that Bβ chains are synthesised more slowly than Aα and γ chains, and 
combine with retained Aα and γ chains in the lumen of the ER whilst still being 
translated on the ribosome (figure 5). Retention of Aα and γ chains is mediated by 
lectin chaperones – calnexin and calreticulin – via monoglucosylated N-linked glycans 
Figure 5. Fibrinogen assembly in the ER. Fibrinogen chains are translated on ribosomes 
(green) and translocated into the ER. Pools of intermediate Aα-γ and Bβ-γ complexes combine 
with newly synthesised Bβ or Aα chains respectively to form fibrinogen half molecules (AαBβγ). 
Two half molecules combine via N-terminal disulphide bonds to complete assembly of dimeric 
fibrinogen (AαBβγ)2. Assembled fibrinogen undergoes further processing in the Golgi apparatus 
before secretion from the cell. 
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(Tamura et al., 2013). Lectin chaperones also provide the kinetic pause necessary for 
sequential hexamer formation from two trimers, rather than simultaneous combining of 
all six chains. The slower synthesis of the Bβ chain makes it the rate limiting step in 
fibrinogen assembly and secretion. The C-terminal of the Bβ chain also acts as a 
quality control for fibrinogen secretion. Truncation at Bβ Arg455, removing seven 
residues, inhibits fibrinogen secretion at a pre-Golgi compartment and permits 
secretion of individual chains and intermediate complexes (Vu et al., 2005). This 
suggests that the presence of the most C-terminal residues of the Bβ chain normally 
ensure that only fully assembled fibrinogen is secreted. 
Degradation of fibrinogen chains in the ER is mediated by the ubiquitin-proteasome 
system (Xia and Redman, 1999). Differential degradation of chains also contributes to 
the existence of Aα and γ chain pools. Roy et al. (1992) discovered that lysosome 
inhibitors markedly block the degradation of free Aα chains and Aα-γ complexes, but 
have minimal effect on free γ chains and no effect on Bβ chains. Furthermore, only the 
Bβ chain bound to immunoglobulin binding protein (BiP) – a molecular chaperone 
involved in ER-associated degradation. These findings indicate that Bβ and γ chains 
are degraded in the ER, while Aα chains and Aα-γ complexes are degraded by 
lysosomes. Similarly, upon incubation with proteasome inhibitor MG132, Xia and 
Redman (2001) observed advanced accumulation of Bβ chains, ahead of Aα and γ, on 
translocon component Sec61, indicating unequal rates of retrotranslocation from the 
lumen of the ER for degradation. These mechanisms may be important in regulating 
the level of fibrinogen secretion. 
Several pro-inflammatory stimuli and hormones are known to influence the level of 
fibrinogen secretion. Fibrinogen expression in hepatocytes is increased by conditioned 
media from (pre)adipocytes, and by hormones triiodothyronine, dexamethasone and 
prolonged exposure to insulin (Grieninger et al., 1983, Faber et al., 2012). Conversely, 
Ramackers et al. (2014) demonstrated that tumour necrosis factor (TNF)-α and 
interleukin-1β cause a down-regulation of fibrinogen production. It is well established 
that synthesis of fibrinogen increases in acute phase conditions in response to 
interleukin-6 (IL-6) (also known as hepatocyte stimulating factor). This has been 
demonstrated using cultured hepatocytes or hepatoma cells, as well as in vivo by 
injection of IL-6 into rats, eliciting a 3.4-fold increase in plasma fibrinogen concentration 
(Marinkovic et al., 1989, Faber et al., 2012, Nakata et al., 2012, Ramackers et al., 
2014). Increased fibrinogen expression with IL-6 is mediated by IL-6 responsive 
elements and CCAAT box/enhancer-binding protein (C/EBP)-binding sites in the 
fibrinogen genes (Dalmon et al., 1993, Gervois et al., 2001). The ratio of chains inside 
the cell remains the same with IL-6 as all three genes are up-regulated. Interestingly, 
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pools of Aα and γ chains are also maintained during over-expression of the Bβ chain in 
HepG2 cells, induced by transfection of Bβ cDNA, as their expression is also up-
regulated. Similarly, deficiency of Aα chain synthesis in hormone-deprived cells leads 
to concurrent degradation of surplus Bβ and γ chains (Plant and Grieninger, 1986). 
Although the mechanism is not clear, these co-ordinated responses highlight the 
importance of the correct ratio of individual polypeptides for fibrinogen biosynthesis.  
1.2.3. Fibrinogen structure 
Fibrinogen is a large 340kDa glycoprotein which circulates in blood plasma (Shulman 
1953). It has a dimeric structure composed of two sets of three polypeptide chains – 
Aα, Bβ, and γ – consisting of 610, 461 and 411 amino acids respectively (Henschen et 
al., 1983). A low resolution structure of fibrinogen was first obtained by shadow-cast 
electron microscopy, revealing three nodules connected linearly by thin, thread-like 
strands (Hall and Slayter, 1959). Subsequent electron microscopy studies and low 
resolution X-ray crystallography confirmed that fibrinogen molecules are elongated, 
trinodular structures in which a central E region is linked by α-helical coiled-coils to two 
outer D regions (D-E-D) (figure 6) (Mosesson et al., 1981, Rao et al., 1991, Weisel et 
al., 1981). Recommended terminology for the structural domains of fibrinogen has 
been reviewed by Medved and Weisel (2009). The central E region of fibrinogen 
contains the N-termini of polypeptides from each monomer, which are held together by 
disulphide bonds (section 1.2.3.1). The N-termini of the Bβ chains form the BβN 
domains and, together with the Aα chain N-termini, constitute the funnel-shaped 
domain. Two small N-terminal peptides of the Aα and Bβ chains, termed 
fibrinopeptides (Fp) A and B, are cleaved sequentially by thrombin to release fibrin and 
initiate polymerisation. The N-termini of the γ chains meet in the central E region to 
form a single asymmetric γN domain, which is located on the opposite side of the 
molecule to FpA and FpB.  
Weisel et al. (1985) discovered that the C-terminus of each chain is folded into an 
independent globular domain. The distal D nodules of fibrinogen contain the C-termini 
of the Bβ and γ chains, known as the β and γ nodules. Each of these nodules contains 
an A-, B-, and P- domain. The P-domains of β and γ nodules contain binding sites and 
pockets for fibrin polymerisation. Weisel et al. also characterised an additional fourth 
nodule of fibrinogen, which is non-covalently tethered to the E region and comprises 
the C-termini of the two Aα chains, known as the αC regions. Each αC region has two 
structurally distinct portions: i) the αC domains (residues ~Aα392-610) existing as 
folded, compact units and ii) the αC connectors (residues ~Aα221-391), connecting the 
16 
αC domains to the D regions (figure 6) (Medved et al., 1983, Tsurupa et al., 2002). 
Litvinov et al. (2007) provided the first direct evidence for intramolecular interactions 
involving αC domains, demonstrating that they interact homomerically with each other, 
as well as heteromerically with the central E region via FpB. The αC regions of 
fibrinogen have a wealth of functional importance with regards to fibrin polymerisation, 
cross-linking, fibrinolysis and interactions with other plasma proteins. The structure and 
function of the Aα chain is reviewed in detail in section 1.3.  
 
 
 
 
 
 
 
 
 
1.2.3.1. Disulphide bonds 
The two sets of polypeptide chains in fibrinogen are held together by 29 disulphide 
bonds between cysteine residues (Henschen, 1964), catalysed by protein disulphide 
isomerase ERp57 (Tamura et al., 2013). Cyanogen bromide cleavage of fibrinogen has 
revealed that the central portion of fibrinogen contains 11 disulphide bonds between 
the N-termini of the six polypeptide chains. Five of these hold the two sets of chains 
together: one between two Aα chains (Cys28), two between two γ chains (Cys8 and 
Cys9) and two linking Cys36 of one Aα chain to Cys65 of one Bβ chain, and vice versa 
(Blomback and Blomback, 1972, Blomback et al., 1976, Huang et al., 1993a). The 
Figure 6. Structure of fibrinogen. Schematic diagram of fibrinogen illustrating two sets of three 
polypeptide chains (Aα, Bβ and γ) connecting a central E region to two outer D regions via 
coiled-coil connectors. The central E region comprises the N-termini of the polypeptide chains, 
including FpA and FpB shown in red and green respectively.  The distal D regions include the 
β- and γ-nodules, each with A-, B- and P-domains. A fourth region consists of the αC domains, 
which are connected to the coiled-coils by the αC connectors. The αC domains interact with 
each other and are tethered to the E region via FpB.  
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remaining six occur at the N-terminal side of the coiled-coil region of fibrinogen, three 
per half molecule (Bβ76-Aα49, Bβ80-γ19, γ23-Aα45). An additional six disulphide 
bonds occur at the C-terminal end of the coiled-coil region (Bβ193-Aα165, Bβ197-γ135, 
γ139-Aα161), three per half molecule, giving a total of 17 interchain disulphide bonds 
(Doolittle et al., 1978). Twelve intrachain disulphide bonds form loops between 
proximal cysteine residues: Aα442-472; Bβ201-286, 211-440 and 394-407; γ153-182 
and 326-339 (Blomback et al., 1976, Henschen, 1978, Bouma et al., 1978). The 
N-terminal bonds are required for both assembly and secretion of fibrinogen. The most 
C-terminal disulphide bonds of the coiled-coil region are not necessary for assembly, 
but fibrinogen cannot be secreted in their absence, most likely due to mis-folding 
(Zhang and Redman, 1994, Zhang and Redman, 1996). 
1.2.3.2. Crystal Structures 
Several crystal structures of proteolysed fibrinogen fragments have been reported, 
including fragments D, double D and E, and the γ chain C-terminal (Spraggon et al., 
1997, Madrazo et al., 2001, Yee et al., 1997). Native fibrinogen, however, has proved 
difficult to crystallise due to its high flexibility. This was initially achieved using chicken 
fibrinogen at a resolution of 5.5 angstroms (Å) (Yang et al., 2000b), a success 
attributed to the lack of flexible tandem repeats in the αC regions. This method 
revealed a sigmoidal-shaped structure of 460 Å in length, in agreement with previous 
findings using rotary-shadowed fibrinogen (Williams, 1981). Subsequently, Kollman et 
al. (2009) determined the crystal structure of human fibrinogen at 3.3 Å resolution; they 
observed structural differences in the bending and twisting of the coiled-coil regions, 
suggesting the canonical sigmoid structure becomes distorted in circulation. The αC 
regions could not be detected, providing further evidence of their motility. Until very 
recently, the complete three-dimensional structure of fibrinogen remained elusive. 
Protopopova et al. (2014) have now visualised the αC regions of fibrinogen using an 
alternative approach of high resolution atomic force microscopy. This revealed αC 
protrusions with an average length of 21 nm and average height of 0.4 nm, which is 
less than that of the coiled-coil connectors. This study also elucidated the involvement 
of the αC regions in fibrin polymerisation, as discussed below. 
1.2.4. Functions of fibrinogen in clot formation 
The initial response to vessel damage involves platelet activation and aggregation at 
the site of injury. Although largely mediated by vWF, fibrinogen secreted from activated 
platelets contributes to this process by binding integrin GPIIbIIIa on the platelet surface, 
as well as αvβ3 on endothelial cells (Parise and Phillips, 1985, Cheresh, 1987). The 
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resulting platelet plug is sufficient to temporarily prevent blood loss, but on its own is 
fragile. During the secondary stage of haemostasis, aggregated platelets become 
surrounded by a network of fibrin fibres, forming a stable clot to seal the vessel wall. 
Fibrinogen is the precursor to this vital process. Thrombin generation in response to 
sub-endothelial TF exposure and clotting factor activation leads to cleavage of 
N-terminal peptides from fibrinogen Aα and Bβ chains (Blomback et al., 1967), 
triggering polymerisation and fibre formation. The resulting clot is further stabilised by 
covalent cross-links between fibrin α and γ chains, promoting fibre thickness, elasticity 
and clot stiffness (Duval et al., 2014). Cross-linking by FXIII is also important for 
incorporation of fibrinolytic proteins, to facilitate clot degradation when wound healing is 
complete. The balance between clot formation and degradation is critical. Clot structure 
is an important determinant of resistance to fibrinolysis, and is therefore relevant to 
thrombotic diseases. The following sections outline the processes involved in fibrin clot 
formation, as well as the importance of clot structure, in greater detail. 
1.2.4.1. Fibrin polymerisation 
In 1978, Blomback et al. proposed the widely accepted two-step model of fibrin 
polymerisation (figure 7A). This model of fibrin polymerisation was enhanced by 
obtaining the crystal structure of fibrinogen, enabling characterisation of the various 
interactions at each stage (Yang et al., 2000a). In this model, thrombin cleaves FpA 
and FpB sequentially from fibrinogen Aα and Bβ chains at the AαArg16-glycine (Gly)17 
and BβArg14-Gly15 bonds, yielding fibrin monomers. A third bond – AαArg19-Val20 – 
is cleaved more slowly (Blomback et al., 1967). The initial fibrinopeptide A cleavage 
exposes polymerisation site ‘EA’ in the central E region, which binds a complementary 
pocket ‘Da’ in the D region of a neighbouring molecule. The resulting end-to-middle 
EA:Da associations generate intermediate protofibrils, in which fibrinogen molecules are 
arranged end-to-end as part of a double-stranded, half-staggered oligomer, typically of 
15 units in length (Bale et al., 1982). Initial lateral interactions primarily occur between 
γ-nodules, involving segments γ350-360 and γ370-380 (Yang et al., 2000a). Several 
studies have demonstrated that the initial rate of FpB cleavage is very low, but is 
accelerated subsequent to FpA cleavage and protofibril formation (Higgins et al., 1983, 
Martinelli and Scheraga, 1980, Hanna et al., 1984). Pechik et al. (2006) have provided 
structural evidence for this, with FpA located in the vicinity of fibrinogen-bound 
thrombin, and FpB some distance away due to its length and orientation. Furthermore, 
Pechik et al. suggested that the D:E:D interactions during protofibril formation lead to 
binding of BβN domains to the D regions and consequent repositioning of FpB in 
proximity to the active site of thrombin. The lag period preceding FpB cleavage dictates 
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its effects on lateral aggregation rather than earlier steps of assembly and is crucial for 
normal protofibril and fibre formation (Weisel et al., 1993). Yang et al. have proposed 
that, upon FpB removal, binding of ‘EB’ to its complementary pocket ‘Db’ in an adjacent 
molecule repositions the β-nodules away from the coiled-coils, enabling a second type 
of lateral, intermolecular contact between β-nodules. Consequently, two protofibrils can 
associate with a half-stagger (figure 7B). Removal of FpB also causes several 
conformational changes in the αC region leading to dissociation of the αC domains 
from the central E region, making them available for lateral, intermolecular interaction 
with adjacent αC domains (figure 7A) (Gorkun et al., 1994, Rudchenko et al., 1996). In 
this way, αC domains enhance lateral aggregation of protofibrils to produce thicker 
fibres (Collet et al., 2005a). A scanning electron micrograph of fibrin fibres is displayed 
in figure 7C. 
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Figure 7. Protofibril and fibre formation. A) Two-step model of fibre formation. 
Fibrinopeptide A cleavage causes end-to-middle associations between the central E region and 
the D region of an adjacent molecule, leading to formation of double-stranded protofibrils. 
Protofibrils aggregate laterally after FpB cleavage into a fibrin fibre. Factor XIII cross-links α and 
γ chains to form a stable fibrin clot. B) Fibrin D:E region interactions form a half-stagger 
arrangement in the resulting fibre with 22.5nm periodicity. C) Scanning electron micrograph of 
fibrin fibres at 50,000X magnification. 
22.5nm 
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In disrepute with the popular two-step model, Rocco et al. (2014) have recently 
proposed an alternative ‘Y-ladder-to-double-stranded’ (YLDS) model. Using X-ray 
and light scattering techniques, they identified structures that were thinner than those 
predicted by the classic two-step method generating half-staggered, double stranded 
protofibrils. The YLDS model involves a single EA:Da association between two fibrin 
monomers, creating a Y-shape which is repeated along the elongating single stranded 
protofibril. A second EA:Da interaction completes double stranded protofibril formation, 
ready for lateral aggregation. Since then, investigations by Protopopova et al. (2014), 
involving visualisation of αC regions in polymerising fibrin, have shed light on the 
contribution of this functional domain to fibre formation. In addition to the αC-mediated  
aggregation of protofibrils, Protopopova et al. presented a novel finding that αC regions 
contribute to the initial E:D region interactions, dampening previous speculations that 
they are only available for interaction after FpB cleavage, which normally anchors them 
to the E region (figure 7A) (Litvinov et al., 2007). Furthermore, Protopopova et al. 
observed an additional method of fibre thickening, whereby single fibrin molecules 
could join the growing fibre, facilitated by long-range αC-αC contacts. Again, this does 
not fit with the two-step model of polymerisation, but does partially support the YLDS 
model. These recent findings bring a new level of complexity to the established model 
of fibrin assembly. Protopova et al. describe a new model which encompasses lateral 
aggregation of protofibrils, fibre thickening by addition of single fibrin molecules, and 
lengthening of fibres with single stranded protofibrils. Advances in high resolution 
imaging and crystallography techniques will continue to feed our comprehension of this 
process.  
1.2.4.2. Fibre branching 
Growing fibrin fibres frequently form branch points, producing a three-dimensional 
network. There are two opportunities for branching to occur: i) during protofbril 
extension by end-to-end association of fibrin monomers, and ii) during lateral 
aggregation of protofibrils, which may diverge into two separate fibres upon 
interference from a third fibrin molecule. These situations give rise to trimolecular or 
tetramolecular branch points, respectively (Mosesson et al., 1993). Trimolecular 
branching occurs when an extraneous fibrin molecule bridges unpaired polymerisation 
sites within two separate fibrils. This produces three branches of equal linear density 
and is more common in clots with thinner fibres. Tetramolecular branching, or 
divergence of protofibrils, produces a third branch that has twice the linear density of its 
constituents. This form of branching predominates in clots composed of thicker fibres. 
Typically there is a mixture of the two, with approximately 1 million fibrin molecules 
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between branch points (Collet et al., 2005b). The degree of fibrin branching can be 
influenced by a number of factors. Fogelson and Keener (2010) have shown that 
divergence of protofibrils is dependent on fibrin monomer supply rate, and therefore is 
influenced by thrombin concentration and the rate of fibrinopeptide cleavage. There is 
also a reported relationship between branching and fibre thickness, as well as clot 
stiffness (Ryan et al., 1999). The process of lateral aggregation is constrained by 
higher degrees of branching, but enhanced by greater distances between branch 
points (Baradet et al., 1995). Hence, clot structures with increased branching tend to 
have thinner fibres, and vice versa. Clots with elevated branching also tend to exhibit 
increased rigidity. Thus, it is apparent that the branching pattern of a clot impacts its 
structural and functional properties. 
1.2.4.3. Cross-link formation by FXIII 
Networks of fibrin fibres are stabilised by FXIII-mediated cross-linking. Factor XIII is a 
transglutaminase enzyme which catalyses the incorporation of reciprocal, antiparallel 
ε–amino(γ-glutamyl)lysine covalent crosslinks between lysine and glutamine residues 
in fibrin(ogen) α and γ chains. In plasma, the zymogen form of FXIII (FXIII-A2B2) is a 
320 kDa heterotetramer with two identical A subunits (75 kDa) non-covalently bound to 
two identical B subunits (88 kDa) (Schwartz et al., 1973). The A subunits contain the 
active site for cross-linking activity, while the B subunits may serve to protect the 
zymogen from proteolytic degradation and facilitate its interaction with fibrin(ogen) 
(Souri et al., 2008, Smith et al., 2011). Thrombin activates FXIII-A2B2 by cleaving the 
Arg37-Gly38 bond within one FXIII-A subunit (Takagi and Doolittle, 1974). In this way, 
an N-terminal activation peptide is cleaved from the FXIII-A subunit but remains 
attached to the enzyme, occluding its active site. This proteolytic separation weakens 
the interaction between A and B subunits (Radek et al., 1993). The binding of calcium 
ions (Ca2+) leads to dissociation of the A subunits from the B subunits and unmasking 
of the active site cysteine via conformational change in the separated FXIII-A2, yielding 
FXIII-B2 and catalytically active FXIII-A2 (FXIII-a) (Lorand et al., 1993, Hornyak and 
Shafer, 1991).  
1.2.4.3.1. Fibrin α and γ chain cross-links 
Factor XIII forms covalent cross-links between fibrin α and γ chains during clot 
formation. Fibrin γ chain cross-links are introduced prior to lateral aggregation of 
protofibrils, while they are still easily accessible by FXIII (Dyr et al., 1989). Active FXIII 
cross-links γ chain Lys406 with glutamine (Gln)398 or Gln399 of another γ chain, 
generating γ-γ dimers (Purves et al., 1987). These isopeptide bonds confer the 
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elasticity of cross-linked fibrin, which is able to stretch up to 1.8-fold and subsequently 
recover its original form (Roska and Ferry, 1982). They also play a role in determining 
fibre density (Duval et al., 2014). The process of γ-γ dimer formation is very rapid (0-5 
minutes) and reinforces growing protofibrils prior to their lateral association (McKee et 
al., 1970). Following FpB cleavage, the rearrangement of αC domains enables 
additional cross-linking at multiple sites within the αC regions, generating α-α oligomers 
and high molecular weight α polymers. McKee et al. demonstrated that this reaction is 
much slower than γ-γ dimer formation (60-90 minutes), possibly due to FXIII diffusion 
constraints within the polymerising fibre, as well as the motility of αC domains. Four 
glutamine acceptor sites – Gln221, Gln237, Gln328, Gln366 - and multiple lysine donor 
sites – Lys539, Lsy556, Lys580, Lys601 – have been identified within the fibrinogen Aα 
chain (Cottrell et al., 1979, Matsuka et al., 1996, Sobel and Gawinowicz, 1996). Fibrin α 
chains can also be cross-linked to γ chains (α-γ). Clot stiffness is increased 2.5-fold by 
α-α cross-links, while α-γ cross-links have minimal effect (Standeven et al., 2007). 
Fibre thickening, straightening and resistance to fibrinolysis are also significantly 
promoted by α chain cross-linking (Gaffney, 1980, Duval et al., 2014). Binding of FXIII 
to the fibrinogen αC region enhances its cross-linking activity (Lewis et al., 1985); this 
interaction is reviewed in section 1.3.1. Cross-linked fibrin fibres are insoluble and form 
an extensive three-dimensional network.  
1.2.4.4. Fibrin clot structure 
Fibrin clot structure is influenced by a variety of factors, including genetic and 
environmental factors (section 1.2.1), post translational modifications (section 1.4), and 
cardiovascular disease (discussed below). These factors can influence the activity, 
function or plasma concentrations of the various clotting factors. Changes to clot 
structure can have a critical effect on haemostasis, due to altered mechanical and 
fibrinolytic stability. Clots with thicker fibres and increased branching tend to be more 
rigid, exhibiting higher degrees of inelasticity (Weisel, 2007, Ryan et al., 1999). On an 
individual basis, fibres with larger diameters take longer to lyse due to a greater 
number of fibrin molecules. However, clot lysis times are dependent on fibre number, 
branching and density. Typically, lysis is slower in clots with a more compact structure, 
with thinner fibres and increased branching, in comparison to clots with thicker fibres 
and a looser structure (Gabriel et al., 1992, Carr and Alving, 1995, Collet et al., 2000). 
This is at least in part due to the increased density, hindering penetration of fibrinolytic 
proteins through the fibre network. 
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1.2.4.4.1. Clinical implications 
Structural changes to fibrin clots have been observed in a number of diseases. 
Premature coronary artery disease (CAD) results in clots with increased density and 
reduced permeability (Collet et al., 2006), while peripheral arterial disease (PAD), 
venous thromboembolism (VTE), acute myocardial infarction (AMI) and ischemic stroke 
all cause a reduction in permeability, along with increased fibre thickness and 
resistance to fibrinolysis (Bhasin et al., 2009, Undas et al., 2009b, Undas et al., 2008, 
Undas et al., 2009a). In addition, the increased incidence of myocardial infarction with 
elevated circulating fibrinogen levels can, to some extent, be attributed to an increase 
in clot stiffness. Diabetes and metabolic syndrome generate clots with reduced 
permeability and fibre thickness, increased clot density and branching, and longer lysis 
times (Dunn et al., 2005, Carter et al., 2007). Although complex and variable, the 
common denominator of these structural changes is a reduction in clot permeability, 
which results in slower fibrinolysis, thereby yielding a pro-thrombotic phenotype. Thus, 
an awareness of changes to fibrin clot morphology in relevant pathologies and the risks 
they pose to the patient is highly important. 
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1.3. Structure and function of the fibrinogen Aα chain 
The fibrinogen Aα chain comprises three major zones of approximately 200 residues 
each: an N-terminal coiled-coil sequence, a central flexible domain with tandem 
repeats, and a C-terminal globular domain (αC domain) (Doolittle et al., 1979). The 
N-terminal zone (Aα1-194) is connected to the Bβ and γ chains via two disulphide 
rings, in between which lies the coiled-coil region (Doolittle et al., 1978). Although 
largely unstructured, the coiled-coils, which adopt an α-helical conformation, bring 
some order to the N-terminus. Following a short interzonal stretch, the central zone is 
composed of residues Aα240-424. Within this zone lie eight sets of tandem repeats 
(Aα270-372), each with 13 residues (Rixon et al., 1983). The tandem repeats have a 
high proportion of polar glycine, serine, proline or threonine residues, yet the majority of 
fibrinogen Aα chain non-polar tryptophan residues are also located in this region. It has 
been suggested that proteins with proline-rich tandem repeats adopt a helical 
poly-L-proline type II (PPII) conformation (Williamson, 1994). This conformation 
describes a left-handed helix with three residues per turn, which is stabilised by forming 
hydrogen bonds with water molecules. Such a conformation would explain the high 
hydration status of fibrinogen and also contribute some order to the C-terminal portion 
of the Aα chain (Doolittle, 1973). 
The αC region of fibrinogen (Aα221-610) makes up two thirds of the Aα chain and 
contributes approximately 25 % of the mass of fibrinogen. It is composed of an 
N-terminal αC connector containing the tandem repeat sequences, and a C-terminal 
αC domain (Aα392-610). The low content of non-polar residues in the tandem repeats 
of the αC connectors confers flexibility rather than a compact structure. In contrast, an 
abundance of non-polar amino acid side chains in the αC domains are likely to form a 
compact core (Rixon et al., 1983). Tsurupa et al. (2002) have demonstrated that the αC 
domain is indeed folded into a compact, globular structure, as inferred by heat-induced 
unfolding transitions in αC domain fragments using spectroscopy and thermoanalytical 
techniques. This was not observed in αC connector fragments, but their behaviour was 
typical of the extended helical PPII conformation. These findings were supported by 
more recent nuclear magnetic resonance studies (Burton et al., 2006). Burton et al. 
identified a β-hairpin structure in an αC domain fragment (Aα374-538), with one face 
consisting mostly of uncharged residues and the other of charged residues that are 
highly conserved among species. They proposed that an adjacent hydrophobic region 
may interact with the charged surface of the β-hairpin to form a compact unit. In 
addition, the isolated αC domain was found to be unstable, which may explain its 
propensity for inter- and intramolecular interactions. Subsequent work revealed a 
second β-hairpin, formed by residues Aα459-476, with an unstable β-sheet structure 
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(Burton et al., 2007). Oligomerisation of αC domain fragments increased their stability, 
suggesting that αC-αC interactions are thermodynamically driven. 
1.3.1. Interaction with plasma proteins 
The N-terminal zone of the fibrinogen Aα chain is functionally important for fibrin 
polymerisation via cleavage of FpA (residues Aα1-19) by thrombin; residues 1-5 are 
important in this interaction, particularly in phosphorylated FpA (Maurer et al., 1998). 
However, the majority of interactions involve the αC region of fibrinogen. Figure 8 in 
section 1.5.1 illustrates the key sites of interaction in the Aα chain in relation to 
fibrinogen phosphorylation sites. Proteins that bind the αC region include FXIII, 
plasminogen, tPA, α2-AP, PAI-2 and fibronectin, as discussed below. Binding of FXIII 
to fibrinogen promotes its cross-linking activity (Lewis et al., 1985). Using surface 
plasmon resonance, Smith et al. (2011) localised the binding of inactive FXIII-A2B2 to 
fibrinogen αC residues 371-425 and deemed this a high affinity interaction, with a Kd of 
less than 35 nM. Calcium-dependent binding of active FXIII-A subunit with residues 
389-403 was also reported (Kd of 2.35 µM), and Glu389 highlighted as a key residue. 
Further characterisation of this interaction revealed that fibrinogen Aα389-403 binds 
within a cleft in the β-sandwich domain of activated FXIII-A2 (FXIII-a2), exposed 
following cleavage of the activation peptide (Smith et al., 2013). This binding facilitates 
cross-linking to acceptor residue Gln366 by localising it to the active site of FXIII-a2. 
Inhibition of the FXIII-a2–fibrinogen interaction caused a reduction in fibrin α and γ 
chain cross-linking as well as cross-linking of α2-AP to the fibrinogen αC region. 
Hence, the binding of FXIII to fibrinogen is important for its function in stabilising clots 
and incorporating fibrinolytic proteins.  
Fibrin(ogen) controls its own degradation by binding fibrinolytic proteins plasminogen 
and tPA, as well as their inhibitors, α2-AP and PAI-1, to achieve a localised action. 
Plasminogen binds to fibrin fragments D and E, as well as to the αC domain (residues 
392-610) with high affinity (Kd of 32 nM) (Varadi and Patthy, 1983, Varadi and Patthy, 
1984, Lucas et al., 1983, Tsurupa and Medved, 2001b). Residues Aα148-160 in the D 
region of fibrinogen enhance the rate of plasminogen activation by tPA by binding both 
proteins with equal affinity (Kd ~ 1 µM) (Voskuilen et al., 1987, Yakovlev et al., 2000). 
However, the large molar excess of plasminogen in the blood indicates that in 
physiological conditions this binding region may be saturated with plasminogen. 
Tsurupa and Medved (2001b) also discovered high affinity binding of tPA to the αC 
domain (Kd of 33 nM) at an independent site to that of plasminogen, and demonstrated 
that both plasminogen and tPA bind to sites that are cryptic in fibrinogen but exposed in 
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fibrin (Tsurupa and Medved, 2001a). Similarly, α2-AP binds with high affinity to fibrin 
fragments D1 and the D-D dimer, and to the αC region (Tsurupa et al., 2010). Again, 
these binding sites are only exposed in fibrin, not fibrinogen, with the exception of 
adsorbed fibrinogen. Tsurupa et al. proposed that the binding of α2-AP to fibrin induces 
a suitable orientation for subsequent cross-linking. Plasminogen activator inhibitor-1 
also binds to the fibrin α chain N-terminus at residues 20-88 at sites that are cryptic in 
fibrinogen (Smolarczyk et al., 2005). 
Additional proteins that interact with the fibrinogen Aα chain include thrombospondin 
and fibronectin. Both of these proteins are extracellular matrix glycoproteins that 
mediate intercellular and cell-matrix interactions. The thrombospondin binding region 
on the Aα chain has been localised to N-terminal residues 92-147; this interaction is 
thought to play a role in platelet aggregation (Bacon-Baguley et al., 1990). Conversion 
of fibrinogen to fibrin also enables a high affinity interaction between fibronectin and the 
fibrin αC region, localised to residues 221-391 (Makogonenko et al., 2002). This 
binding is thought to promote matrix formation, thereby encouraging cell adhesion and 
migration during vessel repair.  
1.3.1.1. Cross-linking to fibrinolytic proteins 
Several proteins are covalently cross-linked to the Aα chain by FXIII, in particular those 
of the (anti-)fibrinolytic system. In this way, the developing clot incorporates a timely 
mechanism to regulate its own destruction, enabling vessel repair while preventing 
problematic clot growth. Alpha-2-antiplasmin is cross-linked to the αC connectors at 
Lys303 (Kimura and Aoki, 1986b). Interestingly, Fraser et al. (2011) have 
demonstrated that covalent incorporation of α2-AP is the principal determinant of the 
antifibrinolytic function of FXIII, rather than fibrin α and γ chain cross-linking. The FXIII-
mediated cross-linking of α2-AP has a half-life of approximately 20 minutes, which 
demonstrates the incorporation of antifibrinolytic agents into new thrombi (Robinson et 
al., 2000). Inhibitors PAI-2 and TAFI are also cross-linked to the fibrin α chain. 
Plasminogen activator inhibitor-2 is cross-linked to N-terminal Lys148, Lys176, and 
Lys183, as well as Lys230 in the αC connectors, and Lys413 and Lys457 in the αC 
domain, leading to increased resistance to fibrinolysis (Ritchie et al., 2000, Ritchie et 
al., 2001). Cross-links are formed between unidentified fibrinogen lysine residues and 
the activation peptide of TAFI (Gln2, Gln5), as well as the mature enzyme (Gln292), 
and may facilitate activation of this inhibitor, enhance its antifibrinolytic activity or 
prevent it from further proteolytic degradation (Valnickova and Enghild, 1998). Thus, it 
is apparent that the fibrinogen Aα chain, in particular the αC region, has a major role in 
the regulation of fibrinolysis.  
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1.3.2. Cell surface interactions 
In addition to its role in binding plasma proteins, fibrinogen is also able to bind to 
integrins on cell surfaces, including platelets and endothelial cells. The fibrinogen Aα 
chain contains two Arg-Gly-Asp (RGD) recognition motifs for integrin binding – one in 
the N-terminus (residues 95-97) and one in the C-terminus (residues 572-574) – in 
addition to a γ chain C-terminal Ala-Gly-Asp-Val (AGDV) attachment site (Hawiger et 
al., 1989, Kloczewiak et al., 1984). Contrary to previous speculation, it has been shown 
that only the fibrinogen γ chain AGDV domain is needed for interaction with activated 
GPIIbIIIa on the platelet surface (Cheresh et al., 1989, Liu et al., 1997). The Aα chain 
RGD sequences, on the other hand, are important for endothelial cell binding. Initial 
interactions with endothelial cells are dependent of the C-terminal RGD motif as the 
N-terminal site is buried within the coiled-coil domain, and is therefore not readily 
available for interaction (Doolittle et al., 1978, Ugarova et al., 1993). Binding of the 
fibrinogen αC region to integrin αVβ3 on the surface of endothelial cells induces a 
conformational change in fibrinogen, leading to exposure of the second Aα95-97 RGD 
motif (Cheresh et al., 1989, Ugarova et al., 1993). This serves to anchor aggregating 
platelets and localise clot formation to the damaged sub-endothelium. 
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1.4. Post-translational modification of fibrinogen 
The complexity of the human proteome far outweighs that of the human genome. The 
International Human Genome Sequencing Consortium (2004) reported that there are 
only 20,000 to 25,000 human genes, yet there are over 1 million proteins (Jensen, 
2004). Initiation of transcription by alternative promoters, differential termination of 
transcription, alternative mRNA splicing, and genetic recombination are the four basic 
mechanisms that contribute to the diversity of the human transcriptome, producing 
multiple mRNA transcripts (approximately 100,000 in total) from single genes (Ayoubi 
and Van De Ven, 1996). This complexity is exponentially amplified by post-translational 
modification (PTM) of proteins. Post-translational modifications are chemical 
modifications that regulate functional aspects of the protein in question, such as 
activity, localisation, or interaction with other proteins, molecules or cells. This is a 
highly abundant and important phenomenon, and approximately 5 % of the human 
genome encodes enzymes that effectuate post translational modification (Rogers and 
Overall, 2013). Protein properties can be changed in a timely manner in response to 
specific circumstances or stimuli, and PTMs provide a significant expansion in 
combinatorial molecular states. In order of the number of reported cases in PubMed 
(Seo and Lee, 2004), common PTMs include phosphorylation, methylation, cysteine 
oxidation, glycosylation, acetylation, acylation, ubiquitination, deamidation, 
nitrosylation, SUMOylation and nitration. Proteolysis is also a form of post-translational 
modification involving cleavage of peptide bonds by proteases. Proteolysis has a 
variety of biological functions, including regulation of protein activity, cleavage of signal 
peptides and pro-proteins during biosynthesis, and protein degradation to remove 
abnormal or misfolded proteins, or to maintain physiological protein concentrations. 
There are numerous reports of fibrinogen PTMs in vivo that occur naturally, or in 
response to certain drugs or pathophysiological conditions. Naturally-occurring 
modifications may also be elevated by disease. Phosphorylation of fibrinogen is the 
focus of this thesis and is discussed in more detail in section 1.5. Importantly, post-
translational modification of fibrinogen leads to altered function and fibrin clot 
properties. Individual fibrinogen PTMs and their specific effects are described below 
and summarised in table 1. 
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Modification Site Functional effects References 
Naturally-occurring fibrinogen PTMs 
Phosphorylation Aα: S3, S345 
 Resistance to fibrinolysis, enhanced thrombin-
binding 
Blomback et al., 1966, Seydewitz et al., 1984, 
Martin et al., 1992, Maurer et al., 1998 
N-glycosylation Bβ: N364; γ: N52  Clot formation,  fibre thickness,  branching,  
porosity 
Blomback et al., 1972, Topfer-Peterson et al., 
1976, Langer et al., 1988, Zauner et al., 2012 O-glycosylation αC region (unknown sites) 
Sulphation γ’: Y418, Y422 Enhanced thrombin-binding Hortin, 1989, Meh et al., 2001, Lovely et al., 2003 
Deamidation Aα, Bβ, γ (unknown sites) Unknown Henschen-Edman, 2001 
Hydroxylation Bβ: P31 Unknown Henschen et al., 1991 
Glutamine cyclisation Bβ: Q1 Protection from aminopeptidases Blomback et al., 1966 
Proteolysis 
Aα: A1-D2 Unknown Blomback et al., 1966 
Aα: K583-M584 Unknown Rudchenko et al., 1996 
Aα: V610-R611 Unknown Rixon et al., 1983 
Aα: N269-P270, G297-G298, 
P309-G310 
 clot formation,  fibre density,  fibre thickness, 
 porosity,  clot stiffness 
Nakashima et al., 1992, Holm et al., 1985, 
Kaijzel., 2006 
Abnormal fibrinogen PTMs 
Glycation Lysine residues 
 fibre density,  clot stiffness,  resistance to 
fibrinolysis 
Alzahrani and Ajjan, 2010, Undas and Ariens, 
2011 
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Nitration Bβ:Y292, Y424 
 Clot formation,  fibrinolysis, altered clot 
structure,  clot stiffness. 
Vadseth et al., 2004, Parastatidis et al., 2008 
Methionine-oxidation Aα: M476; Bβ M367; γ: M78 
 Clot formation,  fibre density,  fibre thickness, 
 porosity,  clot stiffness 
Weigandt et al., 2012 
Metal-ion catalysed 
oxidation 
Aα, Bβ (unknown sites)  Clot formation,  fibre thickness Belisario et al., 1997, Shacter et al., 1995 
Acetylation 
Aα: K191, K208, K224, K429, 
K457, K539, K562; Bβ: K233; 
γ: K170, K273. 
 Clot formation and fibrinolysis,  fibre thickness, 
 porosity,  fibre thickness 
Svensson et al., 2012, Ajjan et al., 2009, Williams 
et al., 1998, He et al., 2001 
Homocysteinylation Cysteine and lysine residues 
 Fibre diameter,  branching,  permeability,  
clot stiffness,  resistance to fibrinolysis 
Lauricella et al., 2006, Undas et al., 2006, Rojas 
et al., 2009, Sauls et al., 2011 
 
 
Table 1. Post-translational modification of fibrinogen. Modifications are divided into naturally-occuring PTMs and abnormal PTMs that occur with drugs or 
disease. Modified sites on the Aα, Bβ and γ chains of fibrinogen are displayed (S: serine, N: asparagine, Y: tyrosine, P: proline, Q: glutamine, A: alanine, D: aspartic 
acid, V: valine, R: arginine, G: glycine, M: methionine, K: lysine) with their functional effects on fibrin clot formation. The table is adapted and updated from 
Henschen-Edman (2001). 
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1.4.1. Glycosylation 
Glycosylation involves covalent attachment of carbohydrate to a protein during 
biosynthesis via an N-glycosidic or O-glycosidic bond. The terminal monosaccharide of 
an N-glycosylating carbohydrate is usually sialic acid, which carries a negative charge 
and influences the glycoprotein’s structural and functional properties. Fibrinogen is 
N-glycosylated at asparagine (Asn)52 in the Bβ chain and Asn364 in the γ chain, both 
comprising biantennary digalactosylated mono- or di-sialylated structures (Blomback et 
al., 1972, Adamczyk et al., 2013, Topfer-Peterson et al., 1976). Increased glycosylation 
of fibrinogen has been reported in foetal fibrinogen and liver disease (Galanakis et al., 
1983, Martinez and Barsigian, 1987). The use of deglycosylated fibrinogen has 
indicated that glycosylation hinders lateral aggregation and clot formation, and 
produces clots with reduced fibre thickness, increased branching and reduced porosity 
(Langer et al., 1988). Although the Aα chain is not N-glycosylated, mass spectrometric-
based approaches have recently revealed O-glycosylation of the αC region (Zauner et 
al., 2012, Nagel and Meyer, 2014). Nagel and Meyer identified O-glycosylation of six 
distinct Aα chain peptides, corresponding to residues 262-271, 301-305, 328-337, 
505-512, 529-554 and 557-580. The exact residues and their functional implications 
remain to be characterised. 
1.4.2. Sulphation 
Tyrosine-O-sulphation is catalysed by type 1 and type 2 tyrosylprotein 
sulphotransferases in the trans-Golgi compartment during protein biosynthesis 
(Baeuerle and Huttner, 1987, Blomback et al., 1972). This modification was originally 
discovered in FpB of bovine fibrinogen (Bettelheim, 1954), and has since also been 
detected in fibrinogen γ’ at Tyr418 and Tyr 422 (Hortin, 1989, Meh et al., 2001). The 
fibrinogen γ chain contains a low affinity thrombin-binding site in the E domain, while γ’ 
also has a high affinity thrombin-binding site within its C-terminal extension (γ’408-427) 
(Meh et al., 1996). Tyrosine-sulphated residues in fibrinogen γ’ reside within this 
binding site and are important for optimal thrombin binding, with doubly sulphated γ’ 
chains exhibiting 4 to 8-fold greater affinity (Lovely et al., 2003, Meh et al., 2001).  
1.4.3. Deamidation, hydroxylation and cyclisation 
Deamidation, proline hydroxylation and glutamine cyclisation have been reported in 
fibrinogen but are not well understood. Partial deamidation is present on all three 
fibrinogen chains at asparagine and glutamine residues, but the exact position and 
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function of this hydrolysis reaction are yet to be characterised (Henschen-Edman, 
2001). Similarly, an N-terminal residue of the fibrinogen Bβ chain – Pro31 – is 
hydroxylated with unknown function (Henschen et al., 1991). Blomback et al. (1966) 
have also identified cyclisation of Bβ Gln1 to pyroglutamic acid, which may protect 
fibrinogen from degradation by aminopeptidases. 
1.4.4. Proteolysis 
The fibrinogen Aα chain cDNA sequence predicts an additional 15 amino acids at the 
C-terminal end of the polypeptide chain (Aα611-625), which does not appear in plasma 
fibrinogen, suggesting that fibrinogen may be first exposed to proteolysis during 
biosynthesis (Rixon et al., 1983). This peptide is likely to be removed by cellular 
proprotein convertases, given that a prediction score for proprotein cleavage at position 
Arg611 (0.451) falls just short of the threshold (>0.5) using ProP 1.0 Server (Duckert et 
al., 2004), which only has a 62 % sensitivity for general (non-furin) proprotein 
convertase-specific networks. By introducing an Arg611Gly mutation into the fibrinogen 
Aα chain, Farrell et al. (1993) found that fibrinogen could be assembled and secreted in 
the presence or absence of this peptide, and could be clotted upon activation by 
thrombin in either case. Thus, cleavage of this peptide is not required for biological 
activity, and its function remains unclear. 
Post-synthesis, the fibrinogen Aα chain is highly susceptible to proteolytic degradation 
in plasma. This predominantly affects the αC region, however the first residue of the 
N-terminus is also cleaved by an amino-peptidase in 10 % of Aα chains (Blomback et 
al., 1966). Blomback et al. demonstrated that this cleavage is protected by 
phosphorylation of FpA at Ser3. Cleavage of C-terminal Lys583 by plasmin reportedly 
occurs in 25 % of fibrinogen molecules, but with unknown function (Rudchenko et al., 
1996, Henschen-Edman, 2001). Proteolysis of the αC region in plasma also generates 
a 305 kDa low molecular weight (LMW) fibrinogen, with one intact and one degraded 
Aα chain, and a 270 kDa LMW’ fibrinogen with two degraded Aα chains (Holm et al., 
1985). Approximately 70 % of circulating fibrinogen molecules are the normal high 
molecular weight (HMW) fibrinogen (340kDa), while LMW and LMW’ fibrinogens 
represent just 25 % and 5 % of the plasma pool respectively. Generation of LMW and 
LMW’ fibrinogen occurs via cleavage of the Aα chain at Asn269, Gly297 and proline 
(Pro)309 (Nakashima et al., 1992). Sites of fibrinogen cleavage have been determined 
by N-terminal sequence analyses using a variety of proteases (Blomback et al., 1966, 
Nakashima et al., 1992, Henschen-Edman, 2001). However, most enzymes (thrombin, 
snake venom enzymes, leukocytes elastase, trypsin) attack from the N-terminal end of 
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fibrinogen, while those that target the C-terminal end (plasmin, leukocyte elastase, 
matrix metalloproteinases) cleave the Aα chain before Asn269 – the earliest cleavage 
site present in plasma. The molecular weights of the Aα chain fragments also differ 
from those of LMW and LMW’ fibrinogen. The relevant protease therefore remains a 
mystery. 
Clottability is impaired in proteolysed fibrinogen; Holm et al. (1985) reported clottability 
values of 98 % for HMW fibrinogen, 92 % for LMW fibrinogen and 80 % for LMW’ 
fibrinogen. The clotting time of LMW (20 minutes) and LMW’ fibrinogens (25 minutes) 
were also delayed when compared to HMW fibrinogen (14 minutes). Scanning electron 
microscopy of fibrin clots formed from HMW and LMW fibrinogen revealed significant 
differences in clot structure (Kaijzel et al., 2006). Clots composed of LMW fibrin 
exhibited increased fibre density, reduced fibre thickness, reduced porosity and 
increased clot stiffness. These findings demonstrate the importance of the αC region in 
fibrin polymerisation and clot morphology, and highlight the need for tight regulation of 
Aα chain proteolysis in plasma.  
The relative proportions of the three fibrinogens are altered in acute phase conditions. 
Reganon et al. (1993) reported an increase in the circulating fraction of HMW 
fibrinogen from 70 % to 95 % in the plasma of AMI patients, and proposed that this is 
caused by the increased synthesis of fibrinogen in acute phase conditions, rather than 
reduced proteolytic activity. The rise in HMW fibrinogen coincided with elevated 
phosphorylation of Ser3 in FpA, and resulted in faster coagulation. Reganon et al. have 
therefore postulated that HMW fibrinogen and phosphorylation of FpA are risk factors 
for thrombosis. In contrast, the proportion of circulating LMW fibrinogen is significantly 
increased in individuals with diabetes (Lipinski and Lipinska, 2000). Hence, changes in 
abundance of HMW, LMW and LMW’ fibrinogens may contribute to pathophysiological 
processes.   
1.4.5. Glycation 
Glycation of proteins involves a non-enzymatic reaction between the -amino group of 
a lysine residue and the aldehyde group of a sugar molecule, such as glucose or 
fructose. Complex rearrangements, as well as dehydration, β-elimination and 
condensation reactions lead to formation of covalently cross-linked advanced glycation 
end products (AGEs). Formation of AGEs has been implicated in several pathologies, 
including Alzheimer’s disease, renal disease, and vascular damage in atherosclerosis 
and diabetes (Bierhaus et al., 1998). Protein glycation is particularly prevalent in 
diabetes due to hyperglycaemia; glycation of fibrinogen is significantly elevated in the 
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absence of glycaemic control (Pieters et al., 2007, Hammer et al., 1989). Glycated 
fibrinogen produces clots that are denser, stiffer and more resistant to fibrinolysis, 
possibly due to modification of lysines that would normally be targeted by plasmin 
(Undas and Ariens, 2011, Alzahrani and Ajjan, 2010). Fibrinogen can also be modified 
by glycoaldehyde – a by-product of glycation – leading to delayed polymerisation, 
thinner fibrin fibres and increased resistance to fibrinolysis (Andrades et al., 2009). 
1.4.6. Nitration 
Vadseth et al. (2004) have reported increased nitration of fibrinogen in patients with 
coronary artery disease. They demonstrated that nitrated fibrinogen exhibits faster clot 
formation and FXIII cross-link incorporation, suggesting a pro-thrombotic effect of this 
PTM. Clots formed from fibrinogen exposed to nitrating oxidants were comprised of 
thinner fibres with higher porosity, and could be more easily deformed by mechanical 
stress. Nitration of fibrinogen did not influence the rate of fibrinolysis, or platelet 
aggregation and binding. Parastatidis et al. (2008) have also highlighted fibrinogen Bβ 
chain tyrosine nitration as a pro-thrombotic risk factor. Using high resolution liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) they identified nitration of 
Tyr292 and Tyr424 in the C-terminus of the Bβ chain in vivo. This modification resulted 
in four functional consequences: i) faster clot formation, ii) altered clot structure, with 
apparent ‘fibrin clusters’ but no effect on fibre diameter, iii) increased clot stiffness, and 
iv) slower fibrinolysis. Parastatidis et al. have suggested that tyrosine nitration may 
facilitate EB:DB interactions, accelerating lateral aggregation. Overall these studies 
demonstrate a link between nitrative stress and thrombosis, mediated to some extent 
by fibrinogen. 
1.4.7. Oxidation 
Reactive oxygen species can lead to formation of dityrosine, methionine sulphoxides 
and carbonyl groups (aldehydes and ketones) on amino acid side chains. Fibrinogen is 
highly susceptible to oxidative modification (Shacter et al., 1994), and may be exposed 
to reactive oxygen species in vivo during the oxidative stress associated with ischemia-
reperfusion injury and inflammation (Cohen, 1989, Cao et al., 1988, Fantone and Ward, 
1982, Weitzman and Gordon, 1990). The functional effects of fibrinogen oxidation have 
been studied in vitro using metal-ion catalysed oxidation and hypochlorite (Weigandt et 
al., 2012, Belisario et al., 1997, Shacter et al., 1995). Metal-ion catalysed oxidation 
induced dityrosine and carbonyl formation in fibrinogen, leading to delayed fibrin 
polymerisation and thinner fibres. Incubation of fibrinogen with hypochlorite resulted in 
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oxidation of the following methionine (Met) residues: AαMet476, BβMet367 and 
γMet78, which impaired clot formation, increased fibre density, reduced fibre thickness, 
reduced porosity and reduced clot stiffness.  
1.4.8. Acetylation 
Acetylation of fibrinogen is relevant to the treatment of diabetic patients with aspirin 
(acetylsalicylic acid). Fibrinogen incubated with aspirin is acetylated at multiple lysine 
residues on its Aα chain, plus two residues on its Bβ chain, and one on its γ chain 
(Svensson et al., 2012). Interestingly, some of the identified acetylated residues in the 
Aα chain – Lys208, Lys224, Lys429 and Lys539 – are involved in FXIII-mediated 
cross-linking of fibrin chains, providing a potential mechanistic explanation for 
enhanced fibrinolysis in the presence of aspirin. In addition, clot formation and lysis 
rates are increased in the presence of aspirin, while the developed clots have a looser 
structure with increased fibre thickness, increased porosity and reduced rigidity (Ajjan 
et al., 2009, Williams et al., 1998, He et al., 2001). Hence, acetylation of fibrinogen has 
significant effects on clotting dynamics as well as structural properties. 
1.4.9. Homocysteinylation 
Homocysteinylation of proteins involves acylation of the -amino group of lysine 
residues by a metabolite of homocysteine – homocysteine thiolactone, or oxidation of 
thiol groups in cysteine residues by free homocysteine. Homocysteine is present in 
plasma due to a cellular export mechanism (Christensen et al., 1991). Disruption of this 
mechanism leads to hyperhomocysteinemia, which is associated with vascular and 
thrombotic diseases (D'Angelo and Selhub, 1997). Homocysteinylation of fibrinogen 
occurs with elevated plasma homocysteine levels and significantly affects clot 
properties, leading to a more compact structure with increased fibre diameter and 
branching, reduced permeability, increased stiffness and increased resistance to 
fibrinolysis (Lauricella et al., 2006, Undas et al., 2006, Rojas et al., 2009, Sauls et al., 
2011). Hence, homocysteinylated fibrinogen is a risk factor for thrombosis. 
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1.5. Fibrinogen phosphorylation 
Phosphorylation is a fundamental form of post-translational modification which can 
activate or deactivate a protein, label it for destruction, facilitate its subcellular 
trafficking or affect its interactions with other proteins. The mechanism of 
phosphorylation involves transfer of the terminal γ-phosphate of an adenosine 
triphosphate (ATP) molecule to a serine, threonine or tyrosine residue in a protein. This 
reaction is catalysed by serine/threonine or tyrosine protein kinases. Kinases represent 
the largest enzyme family in the human genome, comprising approximately 2% with 
over 2,000 genes (Manning et al., 2002). Roughly 30% of all human proteins are 
phosphorylated by one or more of over 500 known protein kinases, which may 
represent only a quarter of the actual number (Hunter, 1994). Different kinases exhibit 
substrate specificity via the sequences around their active site that target the enzyme 
to a particular consensus motif in the protein, usually several amino acids around the 
site of phosphorylation (Ubersax and Ferrell, 2007). However, meeting the sequence 
requirements does not guarantee phosphorylation of a protein, nor do the 
phosphorylation sites always conform to the consensus motif. An additional specificity 
determinant is the location of the kinase. For example, they may reside along the 
secretory pathway for phosphorylation of secretory proteins during biosynthesis. The 
localisation of kinases is dictated by targeting subunits within the kinase, which direct 
the catalytic subunit to the target locus – an organelle, membrane, or cytoplasm – in 
proximity to its substrate or away from inhibitors (Hubbard and Cohen, 1993).  
Phosphorylation is a reversible process and phosphorylated proteins are also 
subjected to dephosphorylation by phosphatases, which catalyse the removal of 
phosphate by hydrolysis. This is important to regulate the degree of phosphorylation, in 
order to limit its function to the appropriate time and conditions. Phosphatases also 
have an important role in proofreading the activity of kinases, whereby a requirement 
for more than one phosphorylation site allows time for error correction by 
phosphatases, before the second (or nth) phosphorylation site induces function (Swain 
and Siggia, 2002). The process of phosphorylation is very complex and, in the past, 
has largely been studied using in vitro assays. This has been less than ideal as kinases 
exhibit reduced substrate specificity in vitro. More recent developments have enabled 
analysis of in vivo phosphorylation sites by mass spectrometry (Mann et al., 2002). 
This will lead to further characterisation of this highly abundant modification and its 
functional significance in individual proteins. 
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1.5.1. Ser3 and Ser345 phosphorylation 
In 1962, Blomback et al. reported the presence of phosphate in a peptide cleaved from 
fibrinogen by thrombin and tentatively identified this as a phosphoserine at residue 3. 
Further investigations revealed that human and bovine fibrinogen have similar 
phosphate contents of 9.4 µg/100 mg and 14.5 µg/100 mg respectively (Blomback et 
al., 1963). However, fibrinogen from haemophiliacs with FVIII- or FIX-deficiency had 
slightly lower phosphate contents (7.8 µg/100 mg and 8.0 µg/100 mg respectively). 
During clotting assays, only 25-40 % of fibrinogen-bound phosphate was lost after 
thrombin digestion, and it was suggested that only 30-40 % of FpA was released. 
Incubation of fibrinogen with calf intestinal alkaline phosphatase achieved a 70-80 % 
removal of phosphate, without any major change in size or shape. Dephosphorylation 
prolonged the clotting time of human fibrinogen, but had no effect on bovine fibrinogen. 
Blomback et al. (1966) later reported that approximately 25 % of cleaved FpA from 
human plasma fibrinogen contained phosphate. Furthermore, only trace amounts of 
N-terminal alanine were detected in the clot, excluding the possibility of incomplete 
cleavage of FpA, as previously speculated. These findings pointed towards the 
presence of additional phosphorylated residues in fibrinogen.  
The phosphorylation of FpA was further characterised using recombinant fibrinogen 
expressed in CHO cells (Binnie et al., 1993). Gorkun et al. (1997) have demonstrated 
that recombinant fibrinogen expressed in this way typifies plasma fibrinogen in terms of 
fibrinopeptide release, polymerisation and FXIII cross-linking. Upon separation of 
thrombin digestion products by high performance liquid chromatography (HPLC), 
Binnie et al. identified two separate peaks corresponding to phosphorylated and non-
phosphorylated FpA, and deduced from this a 22 % degree of phosphorylation. As 
recombinant fibrinogen was used, this finding indicated that partial phosphorylation of 
FpA is regulated at the synthesis stage rather than in circulation. With regards to its 
function, Hanna et al. (1984) reported accelerated cleavage of phosphorylated FpA due 
to enhanced binding of thrombin. Subsequent work by Maurer et al. (1998) supported 
this result, with phosphorylation of Ser3 causing a 65 % enhancement of substrate 
specificity for thrombin, thereby aiding enzyme-substrate complex formation and 
facilitating FpA cleavage. They proposed that the phosphate serves as an anionic 
linker, binding basic residues in thrombin to promote binding of FpA residues 1-5. 
In 1984, Seydewitz et al. determined the phosphate content of adult and foetal human 
fibrinogen by alkaline hydrolysis, analysing each polypeptide individually. They found a 
ratio of 0.9 mol phosphate/mol fibrinogen for adult fibrinogen, and an elevated 
proportion of 1.4 mol phosphate/mol fibrinogen for foetal fibrinogen. In addition, the 
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phosphate content of fibrinogen was exclusively on the Aα chain, which supports 
previous findings of a high degree of Aα chain phosphorylation in dog, pig and sheep 
fibrinogen (Kudryk et al., 1982, Cierniewski and Krajewski, 1974). For both adult and 
foetal fibrinogen, approximately 50 % of the phosphate was lost after thrombin 
digestion, suggesting that a second phosphorylation site in the Aα chain is modified to 
the same extent. This site was identified by Seydewitz et al. as Ser345, located in the 
αC connectors. More recently, a novel approach using liquid chromatography-
electrospray ionisation-tandem mass spectrometry has clearly confirmed exclusive 
phosphorylation of human fibrinogen Aα chain at Ser3 and Ser345 in vivo (Wind et al., 
2003). This was again demonstrated, using the same approach, by Nagel and Meyer 
(2014).  
Given that there are two phosphorylation sites per Aα chain, and thus four per 
fibrinogen molecule, the degree of phosphorylation reported by Seydewitz et al. (1984) 
(0.9 mol phosphate/mol fibrinogen) is equivalent to 22.5 %, the same as that of 
recombinant fibrinogen (Binnie et al., 1993). Whether all 22.5 % of molecules were fully 
phosphorylated, or represented a mixture of one, two or three phosphorylation sites, 
was not determined. Recently, Nagel and Meyer (2014) have reported a 1:1:1 ratio of 
non-, mono- and di-phosphorylated fibrinogen Aα chains, indicating that approximately 
two thirds of fibrinogen molecules (55-75 %) contain either one or two phosphate 
groups.  
The function of the Ser345 phosphorylation site has not yet been investigated. Figure 8 
shows Aα chain residues 1-220 (N-terminus) and 221-610 (C-terminus), with the Ser3 
and Ser345 phosphorylation sites in relation to various functional regions, as reviewed 
in section 1.3. The illustration highlights potential functions of the two phosphorylation 
sites, particularly Ser345, in the FXIII-mediated cross-linking of fibrin chains and 
fibrinolytic proteins to the αC region, interaction with FXIII-A2B2 and other proteins or 
cells, and exposure or protection of plasmin cleavage sites. Several in vitro studies 
have investigated the effect of fibrinogen phosphorylation on fibrin clot formation and 
resistance to fibrinolysis, as discussed below. 
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1.5.2. In vitro phosphorylation of fibrinogen 
A variety of protein kinases have been demonstrated to phosphorylate the fibrinogen 
Aα chain in vitro, including protein kinases (PK) A and C, and casein kinases (CK) 1 
and 2 (Engstrom et al., 1980, Papanikolaou et al., 1982, Guasch et al., 1986, Itarte et 
al., 1983), causing alteration of clot properties. Phosphorylation with CK2 augments 
clot turbidity and significantly enhances the rate of whole blood coagulation in vitro, an 
effect which is synergistic with polycationic compounds thought to increase CK2 activity 
(Heldin, 1987, Suk et al., 1997). Conversely, phosphorylation with PKC causes 
reversible reductions in fibre thickness and clot turbidity; this is coupled with an 
irreversible inhibition of plasmin-mediated fibrinolysis, as demonstrated with alkaline 
phosphatase, which removed approximately 80% of fibrinogen phosphate content 
(Forsberg, 1989, Forsberg and Martin, 1990, Heldin et al., 1987b). In 1991, Martin et al. 
compared the effects of fibrinogen phosphorylation by three kinases: PKA, CK1 and 
CK2. Phosphorylation with PKA resulted in thinner fibres, while phosphorylation with 
Figure 8. The location of fibrinogen Aα chain phosphorylation sites. Fibrinogen Aα chain 
residues are shown in blue with the Ser3 and Ser345 phosphorylation sites (P). A) N-terminal 
residues 1-220; B) C-terminal residues 221-610 (αC region). Protein binding regions (coloured 
bars), cross-linking (XL) donor and acceptor sites (black bars), and RGD sequences (green) are 
indicated at the appropriate locations. Thrombin cleavage of FpA (light blue) at the Arg16-Gly17 
bond is also indicated with an arrow. Upward arrows represent plasmin cleavage sites (▲), or 
sites of proteolytic degradation in circulation (▲) generating LMW and LMW’ fibrinogen. 
Additional proteins that bind the αC region at undefined sites are not displayed. The figure 
highlights the functional significance of the fibrinogen Aα chain, including potential functions of 
the phosphorylation sites.   
A 
B 
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the casein kinases increased fibre thickness, in support of previous findings. In each 
case, a rise in fibre thickness was observed after dephosphorylation with alkaline 
phosphatase and the rate of plasmin degradation was slower than for control 
fibrinogens, which persisted after phosphate removal. It was proposed that 
phosphorylation may serve to protect fibrinogen from plasmin digestion in circulation, 
with the non-reversible nature of this regulatory mechanism perhaps explicable by a 
phosphorylation-induced conformational change, impeding interaction between 
fibrinogen and plasmin(ogen). Indeed, it was later confirmed that both PKC- and CK2-
phosphorylated fibrinogens undergo a conformational change to their secondary 
structure, while phosphorylation with PKA or PKC caused changes in the tertiary 
structure of fibrinogen around tryptophan residues. These conformational changes  
resulted in a decreased rate of proteolysis by plasmin, which was again shown to be 
irreversible (Martin and Bjork, 1990).  
Subsequent characterisation of in vitro phospho-acceptor residues in the fibrinogen Aα 
chain following incubation with PKC or CK2 has identified multiple sites, predominantly 
in the αC domain, strengthening the notion that the C-terminal peptide cleavage by 
plasmin is hindered after phosphorylation by these kinases. Protein kinase C was 
found to phosphorylate Ser557, Ser558, Ser559 and Ser599, as well as additional sites 
in the central portion of the polypeptide chain near to, and not excluding, Ser345 
(Heldin and Humble, 1987). On the other hand, CK2 phosphorylated Ser523 and 
Ser590, plus other undefined serine and threonine residues between amino acids 259 
and 268 (Heldin, 1987). Heldin and colleagues did not demonstrate phosphorylation of 
Ser3 or Ser345 with these particular enzymes; however, this does not rule out a 
potential role for PKC or CK2 in the cellular phosphorylation of fibrinogen, since 
kinases are known to exhibit altered substrate specificity in vitro (Olsen et al., 2006). It 
is not yet clear which particular kinase phosphorylates fibrinogen in vivo. A summary of 
identified fibrinogen phosphorylation sites and their effects on clot formation are 
summarised in table 2.  
1.5.3. In vivo phosphorylation of fibrinogen 
Despite the lower specificity, it is plausible that the additional sites phosphorylated in 
vitro by CK2 or PKC do exist under physiological circumstances, being modified 
extracellularly in circulation when several protein kinases and pools of ATP are 
released from platelet granules during platelet activation. The earliest evidence for 
phosphorylation of fibrinogen by platelet kinases came from Krust et al. (1983), who 
found that treatment of patients with interferon, which increases platelet kinase activity, 
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leads to phosphorylation of a 70-72 kDa protein, identified as the fibrinogen Aα chain. 
Similarly, a low platelet count in patients with Argentine haemorrhagic fever coincided 
with a reduction in the level of fibrinogen phosphorylation (Lerer et al., 1991). In 
contrast, an elevated degree of fibrinogen phosphorylation has been reported in 
systemic lupus erythematous (SLE), and was associated with platelet activation 
(Ekdahl et al., 1997). Most recently, Zahedi et al. (2008) have determined the 
phosphoproteome of resting human platelets by enriching phosphopeptides and 
analysing phosphorylation sites by nano-liquid chromatography-tandem mass 
spectrometry or precursor ion scanning. They identified multiple phosphorylated 
residues on platelet fibrinogen: Ser345, Thr393, Ser505, Ser527, Ser530 and Ser590. 
Despite these findings, phosphorylation of recombinant fibrinogen, and the presence of 
phosphorylated fibrinogen in circulation under basal, non-stimulated conditions, implies 
that phosphorylation of Ser3 and Ser345 occurs via a different mechanism, most likely 
during biosynthesis (Binnie et al., 1993, Blomback et al., 1962). The reason for 
additional phosphorylation of fibrinogen by activated platelets is unknown; however, it 
is plausible that different protein kinases with distinct spatial and temporal dispositions 
may regulate multiple functions of fibrinogen as appropriate for the given milieu. Martin 
et al. (1992) have demonstrated that in vivo fibrinogen phosphorylation, elevated in 
acute phase conditions, produces clots with increased fibre thickness and an 
irreversible 50 % reduction in susceptibility to plasmin digestion. This was not 
associated with platelet activation and likely represents an increase in Ser3 and Ser345 
phosphorylation, as other studies have reported elevated phosphorylation of FpA in 
acute phase conditions (refer to section 1.5.5).  
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Kinase Phosphorylation sites Functional effects References 
In vitro phosphorylation 
PKA Unknown  Fibre thickness,  resistance to fibrinolysis Martin et al. 1991 
PKC S557, S558, S559, S599, 
additional sites in the central zone 
 Fibre thickness,  resistance to fibrinolysis, 
conformational change 
Forsberg, 1989, Forsberg and Martin, 1990, 
Heldin et al. 1987, Martin et al., 1991, Martin and 
Bjork, 1990, Heldin and Humble, 1987 
CK1 Unknown  Fibre thickness,  resistance to fibrinolysis Martin et al., 1991, Itarte et al., 1983 
CK2 S523, S590, additional residues 
between 259 and 268 
 Fibre thickness,  resistance to fibrinolysis, 
conformational change 
Guasch et al., 1986, Heldin, 1987, Suk et al., 
1997, Martin et al., 1991, Martin and Bjork, 1990 
In vivo phosphorylation 
Unknown (normal 
conditions) 
S3, S345 S3: enhanced thrombin-binding; S345: unknown Blomback et al., 1966, Seydewitz et al., 1984, 
Maurer et al., 1998 
Unknown (acute 
phase conditions) 
S3 (other sites not investigated)  Fibre thickness,  resistance to fibrinolysis Seydewitz and Witt 1985, Reganon et al. 1993, 
Martin et al.1992 
 
 
Table 2. In vitro and in vivo fibrinogen phosphorylation. Kinases that have been demonstrated to phosphorylate fibrinogen in vitro are shown with identified 
phosphorylation sites (S: serine) and their functional effects on fibrinogen structure and fibrin clot formation. The sites and effects of in vivo fibrinogen 
phosphorylation in normal and acute phase conditions are also shown for comparison, but the kinases are unknown. 
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1.5.4. Potential fibrinogen kinases 
As mentioned, the specificity of kinases for their substrates is largely dependent on a 
consensus sequence recognition motif. Consensus motifs for the kinases that have 
been demonstrated to phosphorylate fibrinogen in vitro are as follows: PKA, 
R-R-X-S/T-Y, where Y tends to be a hydrophobic amino acid; PKC, R-X-X-S/T-X-R-X; 
CK1, pS-X-X-S/T; CK2, S/T-D/E-X-E/D/pS (Ubersax and Ferrell, 2007, Pearson and 
Kemp, 1991). The Ser3 and Ser345 fibrinogen phosphorylation sites contain sequence 
homology conforming to S-X-E. Based on this homology, Seydewitz et al. (1984) 
postulated that CK2 may phosphorylate fibrinogen in vivo, as the sequence is similar to 
the requirements of CK2. Martin et al. (1992) also hypothesised that CK2 may be the in 
vivo fibrinogen kinase, as fibrinogen with elevated phosphorylation, from patients 
undergoing hip replacement surgery, had similar effects on clot formation to those 
observed by in vitro phosphorylation of fibrinogen by CK2 (Heldin, 1987, Martin et al., 
1991). Another possibility that has not yet been explored is the Golgi casein kinase 
(G-CK).  Despite their names, it is now known that CK1 and CK2 do not phosphorylate 
casein in vivo, and that G-CK is the true casein kinase. The G-CK phosphorylates 
secretory proteins at S-X-E consensus motifs, distinct from that of CK2 and exactly 
matching the fibrinogen phosphorylation sites (Lasa-Benito et al., 1996). Recently, 
Tagliabracci et al. (2012) identified the G-CK as a family of secreted protein kinases: 
Fam20A, Fam20B, Fam20C, Fam198A and Fam198B. They discovered that Fam20C 
phosphorylates a variety of secretory proteins involved in biomineralisation processes. 
Interestingly, it has also been suggested that the G-CK has a prominent role in 
generating the human plasma phosphoproteome (Salvi et al., 2010). Plasma 
phosphoproteins represent a distinct set of substrates from that of CK2, and the 
majority of phosphorylation sites satisfy the S-X-E consensus motif. In further support 
of this possibility, FpA has been phosphorylated in vitro by a casein kinase isolated 
from the Golgi apparatus of bovine mammary glands (Szymanski and Farrell, 1982). It 
is therefore likely that the G-CK may phosphorylate fibrinogen in vivo. 
1.5.5. Elevated fibrinogen phosphorylation 
Elevated levels of fibrinogen phosphorylation have been observed in various 
pathological states, suggesting a possible link to the development of thrombosis. 
Firstly, Ogata et al. (2006) reported up-regulated phosphorylation of the fibrinogen Aα 
chain in ovarian cancer patients. This is interesting as there is a well-known association 
between cancer and VTE, and a high VTE incidence has been reported in ovarian 
cancer patients (Tateo et al., 2005). Secondly, SLE leads to a substantial increase in 
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fibrinogen (Ekdahl et al., 1997). This disease is also associated with arterial or venous 
thrombosis, occurring in more than 10 % of SLE patients, possibly exceeding 50 % in 
high risk patients, and causing approximately one quarter of deaths (Love and Santoro, 
1990, Cervera et al., 2003). Thirdly, patients with VTE itself have exhibited an increase 
in fibrinogen phosphorylation (Leeksma et al., 1986, Seydewitz et al., 1987). Seydewitz 
et al. reported a rise from control levels (20-25 %) to 35 %, followed by a further 
increase to 50-70 % after two days of receiving thrombolytic therapy. Finally, several 
studies have reported an association between acute phase conditions and an elevated 
degree of fibrinogen phosphorylation. Seydewitz and Witt (1985) observed increased 
phosphorylation of FpA in patients following hip replacement surgery. The degree of 
phosphorylation increased significantly 24 hours post-operation, and declined to normal 
levels after 1 week. This was supported by a subsequent investigation, whereby the 
phosphate content of fibrinogen doubled 24 hours after hip replacement surgery 
(Martin et al., 1992). As mentioned previously (section 1.5.3), Martin et al. 
characterised the effects of this increase in phosphorylation on clot formation, and 
found a direct relationship between phosphate content and fibre thickness. 
Susceptibility to plasmin digestion was also compromised, however this remained the 
case after 8 days, by which time the phosphate content had returned to normal. This 
suggests that increased phosphorylation of fibrinogen in acute phase conditions has an 
irreversible effect on fibrinolysis, supporting findings from in vitro phosphorylation of 
fibrinogen (section 1.5.2).  
Increased fibrinogen phosphorylation in AMI patients undergoing thrombolytic therapy 
has also been reported. Patients exhibited a three-fold increase in the degree of 
fibrinogen phosphorylation, approaching the theoretical maximum of 4 mol 
phosphate/mol fibrinogen (Haglund et al. 2000). In addition, Reganon et al. (1993) 
found an initial 30% increase in FpA phosphorylation prior to treatment, rising to 65% 
after 5 hours of streptokinase therapy; this was accompanied by faster FpA release 
and clotting of the newly synthesised fibrinogen. Elevated phosphorylation of fibrinogen 
may therefore be a risk factor for thrombosis. They also found that the fraction of HMW 
fibrinogen in AMI patients receiving thrombolytic treatment was elevated beyond 
physiological levels, representing approximately 95% of total fibrinogen. Thrombolytic 
therapy depletes circulating fibrinogen and triggers synthesis of new HMW molecules, 
which have higher coagulability than other fibrinogen species (Vila et al. 1990). As 
fibrinogen is secreted in its phosphorylated form, it has been hypothesised that the 
increase in fibrinogen turnover rate and HMW fibrinogen may account for the 
concomitant rise in phosphorylation with thrombolytic therapy (Leeksma et al., 1986). 
However, given that fibrinogen is only partially phosphorylated when secreted (22 %) 
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(Binnie et al., 1993), and only one phosphorylation site (Ser345) is lost in LMW and 
LMW’ fibrinogen, it is unlikely that this would cause a such a significant elevation. It 
remains to be determined whether the balance of kinase and phosphatase activity is 
altered in acute phase conditions. Importantly, these studies collectively highlight a role 
of fibrinogen phosphorylation in haemostasis, with pro-thrombotic effects. Elevated 
fibrinogen phosphorylation may promote coagulation and present a risk factor for 
reocclusion in AMI patients. 
1.5.5.1. Ser3 phosphorylation and VTE 
In a recent study testing for gene associations with blood metabolites, loci from three 
functionally-linked genes were found to be associated with phosphorylation of 
fibrinogen Aα chain Ser3: i) the ABO gene encoding ABO blood group, ii) the FUT2 
gene encoding fucosyltransferase 2, also involved in determining blood group and iii) 
the ALPL gene encoding a tissue non-specific alkaline phosphatase (Suhre et al., 
2011). Both the ALPL and ABO loci are associated with circulating levels of alkaline 
phosphatase (Yuan et al., 2008), suggesting their influence on the degree of fibrinogen 
phosphorylation may be mediated by this enzyme. Notably, the ABO locus is also 
associated with VTE risk, whereby non-O blood group individuals have a higher risk 
than O blood group carriers (Tregouet et al., 2009). This highlights a potential role of 
fibrinogen phosphorylation in the underlying pathology of VTE. Hence, Suhre et al. 
have provided the first evidence of a genetic link between fibrinogen phosphorylation 
and thrombosis. 
To summarise, phosphorylation of fibrinogen occurs at Aα chain Ser3 and Ser345 and 
is elevated in acute phase conditions and thrombosis, suggesting an important 
contribution to haemostatic processes. However, the mechanism and functional effects 
of this modification are yet to be determined. Fibrinogen can be phosphorylated by 
several kinases in vitro with conflicting effects on clot structure, but the in vivo 
fibrinogen kinase has not been identified. With regards to function, existing research 
has focused on Ser3 phosphorylation in relation to enhanced thrombin binding and FpA 
cleavage but little is known about the role of Ser345 phosphorylation. As Ser345 is 
positioned between FXIII cross-linking acceptor sites and close to the FXIII-A2B2 
binding region, this site might be implicated in the regulation of α chain crosslinking. It 
may also coordinate fibrinolysis as several fibrinolytic proteins interact with the αC 
region of fibrinogen. Advancing understanding of the regulation of fibrinogen 
phosphorylation and its effects on clot formation and fibrinolysis may prove valuable for 
the management of thrombosis. 
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1.6. Aims and hypothesis 
1.6.1. Hypothesis 
Elevated phosphorylation of fibrinogen, as occurs in acute phase conditions, is directly 
responsible for inducing pro-thrombotic changes in the fibrin network, and is mediated 
by increased activity of a hepatocellular kinase. 
1.6.2. Aims 
This project aims to provide an in-depth investigation into the cellular mechanism and 
functional role of in vivo fibrinogen phosphorylation at Aα chain Ser3 and Ser345. The 
function of the individual phosphorylation sites will be investigated by expression of 
recombinant wild-type (WT) fibrinogen and variant fibrinogens with mutations at Ser3 
and/or Ser345 to prevent phosphorylation. This will be achieved using an established 
expression system in Chinese hamster ovary (CHO) cells (Binnie et al., 1993). 
Preliminary analysis by matrix assisted laser desorption ionisation (MALDI)-time of 
flight (TOF)/TOF mass spectrometry has confirmed that CHO cells are capable of 
phosphorylating WT fibrinogen at Ser3 and Ser345 (Appendix 3). Purified recombinant 
fibrinogens will be compared in a variety of functional studies designed to investigate 
the impact of each phosphorylation site on fibrin clot properties, including structure, 
polymerisation and lysis rates, and interactions with other haemostatic plasma 
components, such as FXIII, plasmin(ogen) and α2-AP. To characterise the mechanism 
of fibrinogen phosphorylation, methods will be developed to visualise and quantify 
phosphorylated fibrinogen inside, or secreted from, human hepatoma (HepG2) cells. 
These methods will be used to determine the subcellular location of fibrinogen 
phosphorylation, as well as the relevant fibrinogen kinase. The effect of acute phase 
cytokine interleukin-6 (IL-6) on fibrinogen expression, phosphorylation and kinase 
activity will also be examined. 
The key aims of this thesis are summarised below: 
1. To express and purify recombinant WT fibrinogen and fibrinogen variants 
lacking the Ser3 and/or Ser345 phosphorylation sites using a CHO cell 
expression system. 
 
2. To investigate the functional effect of fibrinogen phosphorylation on fibrin clot 
structure and function, including clot formation, FXIII-mediated clot stabilisation, 
interaction with fibrinolytic proteins, and plasmin digestion of fibrin(ogen). 
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3. To characterise the mechanism of fibrinogen phosphorylation by identifying the 
subcellular location and in vivo fibrinogen kinase, as well as changes to this 
regulatory process in acute phase conditions.  
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Chapter 2 
Materials and Methods 
2.1. Recombinant Fibrinogen Expression 
Full-length recombinant WT fibrinogen was expressed in CHO cells and purified by 
affinity chromatography. The integrity and functionality of this fibrinogen was then 
analysed using a variety of methods. To investigate the function of the Ser3 and 
Ser345 phosphorylation sites, a plasmid coding for the Aα chain of fibrinogen was 
mutated to change the serine residues of interest to alternative amino acids. The 
resulting vectors were transfected into CHO and Expi293F cells for expression of 
variant fibrinogen lacking the phosphorylation sites of interest.  
2.1.1. Expression of recombinant WT fibrinogen in CHO cells 
Chinese hamster ovary cells previously transfected with plasmids containing human 
fibrinogen Aα, Bβ and γ chain cDNA for expression of recombinant WT fibrinogen 
(CHO-WT) (kindly donated by Prof Susan Lord, University of North Carolina at Chapel 
Hill) were cultured in 10 x 100 mm dishes with 10 ml growth medium per dish 
(Appendix 1) and incubated at 37°C, 5 % carbon dioxide (CO2). When confluent, cells 
were split using trypsin-ethylenediamine tetraacetic acid (EDTA) solution (Sigma-
Aldrich, USA) and transferred to 10 x 2 L roller bottles, each with 200 ml growth 
medium containing 4 g Cytodex 1 dextran microcarrier beads (60-87 µm) (Sigma-
Aldrich) previously swollen in phosphate buffered saline (PBS) pH 7.4 (Appendix 1), 
autoclaved at 120°C and resuspended in growth medium after sedimentation. The 
microcarrier beads were added to roller bottles to increase surface area for cell 
adhesion and growth. Roller bottle cultures were incubated in a rolling incubator at 
37°C, 5 % CO2. After 3 days, or when confluent, cells were incubated overnight in 
100ml serum-free growth medium per bottle for adjustment to serum-free conditions. 
The cells were then cultured in insulin transferrin selenium (ITS)-supplemented 
medium (Appendix 1), using ITS as a growth factor supplement in place of serum for 
easier downstream protein purification. Fibrinogen-containing medium (100 ml) was 
harvested from each roller bottle and replaced with 100ml fresh ITS medium every 2-3 
50 
days for approximately 3 months. Harvested medium was filtered and stored at -20°C 
with serine protease inhibitor phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich) 
[150 nM] until purification. An aliquot of medium was taken from each harvest for an 
enzyme-linked immunosorbent assay (ELISA) to quantify fibrinogen (method 2.1.2); 
this was performed every 2 weeks to monitor the degree of fibrinogen secretion and the 
culture was terminated once productivity was seen to significantly decline.  
2.1.2. ELISA for quantification of fibrinogen in harvested medium 
A 96-well microtiter plate was coated with 100 µl per well of polyclonal anti-human 
fibrinogen antibody (DAKO, Denmark) diluted 1/4000 [1.5 µg/ml] in Buffer A (Appendix 
1) and incubated at 4°C overnight. Following incubation, the plate was washed with 3 x 
300 µl Buffer B (Appendix 1). To generate a standard curve, Calbiochem® human 
fibrinogen from plasminogen-depleted plasma (Millipore, USA) was diluted to eight 
known concentrations ranging from 0.016 to 1 µg/ml in Buffer B. The fibrinogen 
standards were added to the plate in duplicate, along with samples of medium 
containing recombinant WT fibrinogen – undiluted, or diluted 1/10, 1/20 and 1/40 in 
Buffer B – and incubated for 2 hours at room temperature on a shaker. The plate was 
washed with 3 x 300 µl Buffer B and 100 µl per well of a horseradish peroxidase 
(HRP)-conjugated anti-fibrinogen antibody (abcam, UK) diluted 1/16,000 [0.625 µg/ml] 
in Buffer B was applied for 1 hour at room temperature. After a final wash step with 
Buffer B, bound fibrinogen was detected using 100 µl per well of o-phenylenediamine 
dihydrochloride (OPD) substrate (DAKO) dissolved in distilled water (dH2O) to 
0.5 mg/ml. Hydrogen peroxide was added at 0.01 % (v/v) to catalyse the oxidation of 
OPD by horseradish peroxidase; this produces a yellow colour with intensity 
proportionate to the amount of fibrinogen in the well. The reaction was stopped with 
100 µl per well of 1 M sulphuric acid and absorbance was measured at 490 nm using 
an MRX-TC plate reader (Dynex, USA). 
2.1.3. Purification of recombinant WT fibrinogen 
2.1.3.1. Ammonium sulphate precipitation of fibrinogen 
Harvested cell culture medium was mixed with a protease inhibitor cocktail (Appendix 
1) to prevent proteolytic degradation. The cocktail was buffered with 2-(N-
morpholino)ethanesulfonic acid (MES) at pH 5.6, the isoelectric point (pI) of fibrinogen, 
to encourage precipitation. Saturated ammonium sulphate solution was prepared by 
dissolving 1520 g ammonium sulphate (Fisher Scientific, USA) in 2 L dH2O heated to 
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90°C. The solution was cooled at 4°C overnight, or until crystals had formed, and 
added dropwise to the culture medium by passing through filter paper. The volume of 
100 % (v/v) saturated ammonium sulphate required for a final concentration of 40 % 
(v/v) when mixed with the media was calculated using the following formula: VAS = 
0.667VM, where VAS is the volume of ammonium sulphate to add, and VM is the starting 
volume of media. The solution was incubated overnight at 4°C with gentle stirring to 
precipitate the fibrinogen. The following day, the precipitate mix was centrifuged at 
9000 rpm, 4°C for 45 minutes without braking (Sorvall instrument RC5C) and the 
pellets resuspended in 1.2 ml pellet cocktail (Appendix 1) containing protease inhibitors 
and Tris buffer at physiological pH (7.4). Resuspended pellets were pooled and 
centrifuged at 19,000 rpm, 4°C for 30 minutes with braking (Sorvall, SS-34) and the 
supernatants containing the fibrinogen were decanted and stored at -20°C until 
purification. 
2.1.3.2. Affinity chromatography with IF-1 anti-fibrinogen antibody 
A BioCad Sprint Perfusion Chromatography System was used for purification of 
recombinant WT fibrinogen by affinity chromatography.  The column consisted of an 
anti-fibrinogen IF-1 monoclonal antibody (Kamiya Biomedical, USA) coupled to a 
cyanogen bromide-activated sepharose 4B resin (GE Healthcare, UK) in IF-1 
equilibration buffer (Appendix 1). Fibrinogen-containing supernatants were mixed with 
calcium chloride (CaCl2) [10 mM] prior to loading on the column, as the IF-1 antibody 
recognises an epitope within the D-domain of fibrinogen in a calcium dependent 
manner. The column was equilibrated with 1 column volume (CV) (7.599ml) of IF-1 
equilibration buffer before injecting 5ml supernatant; this volume of supernatant was 
reduced from 15 ml to 5 ml to prevent overloading and loss of fibrinogen in the flow 
through. IF-1 wash buffers I and II (Appendix 1) were applied sequentially to the 
column to remove any unbound sample before eluting fibrinogen with 6 CV of IF-1 
elution buffer (Appendix 1). Elution was achieved with EDTA (Sigma-Aldrich) to chelate 
calcium ions from binding pockets in the fibrinogen D domain, impeding its interaction 
with the IF-1 column. The concentration of eluted fibrinogen in selected fractions was 
verified by reading absorbance at 280 nm (A280 nm) using a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific) and extinction coefficient 1.51. All fractions 
containing a reasonable amount of fibrinogen were pooled and stored at -80°C.  
2.1.3.3. Concentration and dialysis of purified fibrinogen 
Dialysis tubing (25 mm) with a 12 kDa molecular weight cut off (MWCO) (Sigma-
Aldrich) was prepared by heating in dH2O with 10 mM EDTA (Sigma-Aldrich) to remove 
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divalent cations and prevent binding of protein to the membrane. Purified samples were 
transferred to dialysis tubing and placed in Tris-buffered saline (TBS)-1 pH 7.4 
(Appendix 1), three samples per litre, with gentle stirring at 4˚C overnight. The buffer 
was changed the following morning and stirred for a further hour. Samples were 
concentrated to approximately 1 mg/ml by centrifugation at 3,000 g (Hettich Rotanta 
460R) using Vivaspin 20 concentrator tubes with a 100 kDa MWCO (Life Technologies, 
USA). Finally, samples were pooled, divided into aliquots and stored at -80˚C. 
Fibrinogen from later harvests was pooled separately in case of degradation, as 
determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) (method 2.1.4). 
2.1.4. SDS-PAGE 
All materials and reagents were purchased from Life Technologies unless otherwise 
stated. Samples containing 15 µg protein were mixed with 10X reducing agent, 4X 
lithium dodecyl sulphate (LDS) sample buffer and dH2O to a final volume of 40 µl. The 
samples were then heated to 95°C for 15 minutes to denature proteins and reduce 
disulphide bonds, cooled on ice for 2 minutes and centrifuged briefly (Eppendorf 
MiniSpin Plus). Reduced samples (40 µl) were loaded onto pre-cast 4-12 % Bis-Tris 
polyacrylamide gels (1.0 mm, 10 well) with a Precision Plus Protein WesternC standard 
(molecular weight marker) (7.5 µl) (BIO-RAD, USA), consisting of 10 pre-stained 
recombinant proteins of known size ranging from 10-250 kDa. Electrophoresis was 
carried out at 200 V for 40 minutes in 500 ml MES running buffer, prepared by diluting 
a 20X concentrated stock solution with filtered dH2O. Gels were rinsed for 30 minutes 
in dH2O to remove residual buffer, stained with GelCode Blue Stain Reagent (Thermo 
Scientific, USA) for 1 hour at room temperature with shaking, destained in dH2O 
overnight and imaged the next day by transillumination with Chemi-imager software 
(Alpha Innotech, USA).  
2.1.5. Expression and purification of recombinant FXIII-A 
For use in functional studies with recombinant WT fibrinogen, recombinant FXIII-A 
(rFXIII-A) was expressed in Escherichia Coli (E. Coli) and purified by glutathione S-
transferase (GST)-affinity chromatography, according to methods described by Smith 
et al. (2011).  
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2.1.5.1. Expression of recombinant GST-FXIII-A in E. Coli 
The expression construct for recombinant GST-FXIII-A, kindly provided by Dr Penelope 
Adamson, had previously been transformed into BL21-Gold (DE3) competent E. Coli 
cells (Stratagene, USA), as described in method 2.1.8.3. Two starter cultures, each 
with 180 ml terrific broth, 20 ml phosphate buffer (Appendix 1) and 200 µl 100 mg/ml 
ampicillin, were inoculated with 10 µl of a glycerol stock of the transformed E. Coli and 
incubated for 16 hours at 37°C, 225 rpm. All buffers are detailed in Appendix 1 and 
were autoclaved before use. The next day, each starter culture was used to inoculate a 
new expression culture containing 1.8 L terrific broth, 200ml phosphate buffer and 2ml 
100mg/ml ampicillin and incubated at 37°C, 180rpm for 2 hours. Expression of 
GST-FXIII-A was induced using isopropyl β-D-1-thiogalactopyranoside [1 mM] and the 
cultures were incubated for 16 hours at 30°C, 180 rpm. Cells were harvested by 
centrifugation at 5450 rpm, 4°C for 10 minutes (Sorvall instrument RC5C) and the 
bacterial pellets were resuspended in ice cold E. Coli wash buffer (180 ml per 2 L 
culture) (Appendix 1). An additional centrifugation step at 4600 rpm, 4°C for 1 hour was 
performed to remove the wash buffer; this was discarded and the pelleted cells were 
stored at -20°C until lysis and rFXIII-A purification. 
2.1.5.2. Cell lysis of BL21-Gold E. Coli 
All reagents were purchased from Sigma-Aldrich. Frozen cell pellets from method 
2.1.5.1 were thawed and resuspended in 176 ml ice cold PBS pH 7.4 (Appendix 1) by 
stirring for 1 hour at room temperature. Bacterial cells were lysed with lysozyme 
[1 mg/ml] in the presence of dithiothreitol (DTT) [1 mM] to increase binding of the GST 
fusion protein to glutathione during subsequent affinity chromatography purification; the 
mixture was stirred gently for an additional 30 minutes at room temperature. A protease 
inhibitor cocktail containing aprotinin [2 µg/ml], pepstatin A [1 µM], leupeptin [10 µM] 
and benzamidine dihydrochloride [4 mM] was added to the culture and stirred at 4°C 
for 30 minutes, before addition of PMSF [0.5 mM] and 0.05 % (v/v) sodium 
deoxycholate – an ionic detergent used to solubilise cell membranes. After 30 minutes 
of stirring at room temperature, the culture was transferred back to 4°C and mixed 
vigorously for a further 10 minutes with 1 % (v/v) triton X-100 to aid solubilisation of 
proteins, plus DNase I [5 µg/ml] with magnesium chloride [5 mM] for DNA degradation. 
The DNase activity was halted by chelation of magnesium ions with EDTA [6 mM]. To 
separate soluble recombinant GST-FXIII-A from insoluble cellular components, lysates 
were centrifuged at 13,570 rpm for 20 minutes, 4°C (Sorvall instrument RC5C). The 
supernatant was carefully decanted, mixed briefly with 2 g streptomycin sulphate to 
precipitate nucleic acids, and centrifuged again at 13,570 rpm for 20 minutes, 4°C. 
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Finally, the supernatant was filtered through a 0.22 µm vacuum filter (Thermo 
Scientific) and made up to a 300 ml volume with PBS pH 7.4, ready for purification by 
GST-affinity chromatography.  
2.1.5.3. Purification of rFXIII-A by GST affinity chromatography 
An ÄKTA prime chromatography system (GE Healthcare, UK) was used for purification 
of GST-FXIII-A from cell lysate by exploiting the high affinity interaction between GST 
and glutathione. The system was fitted with 3 x 5 ml GSTrap Fast Flow affinity columns 
(GE Healthcare) pre-packed with Glutathione Sepharose media to bind the GST fusion 
protein. All buffers used during purification contained 15 % (v/v) glycerol for protein 
stability and are detailed in Appendix 1. The columns were equilibrated with 50 ml GST 
equilibration buffer pH 7.4 at 5 ml/min before loading 300 ml lysate at a reduced flow 
rate of 0.5 ml/min. To remove any unbound sample and wash the bound GST-FXIII-A, 
250 ml GST wash buffer was applied at a flow rate of 0.5 ml/min. The flow rate was 
gradually increased and a further 60 ml GST wash buffer was applied at 1.5 ml/min, 
followed by a final equilibration step with 420 ml equilibration buffer at 2.5 ml/min.  
Upon completion of the loading and washing steps, the GSTrap Fast Flow columns 
containing the bound GST-FXIII-A were removed from the ÄKTA prime and manually 
loaded with PreScission Protease (GE Healthcare) for cleavage of the GST tag from 
FXIII-A. PreScission Protease is a fusion protein consisting of the human rhinovirus 3C 
protease and GST. Its action involves simultaneous interaction of GST with glutathione 
and site-specific cleavage of GST between the glutamine (Q) and glycine (G) residues 
of the following amino acid sequence: LQVLFQ/GP. The PreScission Protease (2 U per 
100 µg protein) was added to 15 ml equilibration buffer and injected manually into the 
GSTrap Fast Flow columns, which were then incubated horizontally at 4°C for a 
minimum of 8 hours. Following cleavage, the columns were re-fitted to the ÄKTA prime, 
with an additional fourth 5 ml GSTrap Fast Flow column at the bottom to prevent loss of 
FXIII-A. The cleaved FXIII-A was eluted with 35 ml PBS equilibration buffer pH 7.4 at a 
flow rate of 1 ml/min, whilst collecting 1 ml fractions. The bound GST was subsequently 
eluted in 2 ml fractions using 35 ml GST elution buffer pH 8.0 containing 20 mM 
glutathione at a flow rate of 1 ml/min. The columns were regenerated at 5 ml/min with 
45 ml 5 M urea, 45 ml equilibration buffer, 45 ml 70 % (v/v) ethanol and a further 
100 ml equilibration buffer. Fractions from the FXIII-A (peak 2) and GST elution peaks 
were pooled separately and the FXIII-A was concentrated using Vivaspin concentrator 
tubes with a 30 kDa MWCO (Life Technologies). A NanoDrop ND-1000 
spectrophotometer was used to determine the concentration of FXIII-A at A280nm with 
extinction coefficient 1.58. Purified FXIII-A (7 µg) and GST (4 µl at unknown 
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concentration) samples were analysed by SDS-PAGE (method 2.1.4) and western 
blotting using an HRP-conjugated FXIII-A antibody (method 2.1.6; table 3). The blot 
was developed by addition of 1-2 ml 3,3',5,5'-Tetramethylbenzidine (Sigma-Aldrich); 
the reaction was quenched with dH2O before imaging by transillumination using a 
Kodak Image Station 2000R and Kodak 1D Image Analysis Software (Labtech 
International, UK). Finally, the activity of the purified FXIII-A was analysed by means of 
a biotin-pentylamine incorporation FXIII-A activity assay (method 2.1.7.2). 
2.1.6. Western blotting 
Samples were subjected to SDS-PAGE as described in method 2.1.4, loading 
nanogram quantities of protein with 5µl Precision Plus Protein WesternC standard to 
compensate for the more sensitive detection. Each protein within the molecular weight 
standard has a synthetic Strep-tag of 8 amino acids in length, which binds StrepTactin 
– an engineered form of streptavidin – with high affinity, enabling detection. After 
electrophoresis, gels were rinsed for 10 minutes in transfer buffer pH 8.1-8.4 (Appendix 
1) on an orbital shaker. Immobilon-P polyvinylidene-difluoride (PVDF) transfer 
membrane (Millipore) (0.45 µm pore size) was cut to 3 x 2.5 inches and pre-wetted in 
methanol for 15 seconds, rinsed in dH2O for 2 minutes and equilibrated in chilled 
transfer buffer for 2 minutes.  Filter paper and sponges of the same size were also pre-
soaked in transfer buffer before assembling into blotting cassettes in the following 
order: sponge – filter paper – SDS-PAGE gel – PVDF membrane – filter paper – 
sponge. Cassettes were inserted into a tank containing an ice pack and filled with 
chilled transfer buffer. The transfer was run at 100 V for 1 hour and the buffer was 
stirred gently throughout to maintain even temperature and ion distribution. After 1 
hour, membranes were carefully removed from the tank and washed 3 x 10 minutes in 
TBS-2-Tween 20 pH 7.4 (Appendix 1). A blocking solution of TBS-2-Tween 20 with 5 % 
(w/v) skimmed milk powder was added for 1 hour at room temperature, or 4°C 
overnight, to prevent non-specific binding of antibodies during subsequent incubation 
steps. The membrane was washed 3 x 10 minutes with TBS-2-Tween 20. The primary 
antibody was diluted in 10 ml blocking solution and incubated with the membrane for 1 
hour at room temperature on a roller. Another three wash steps were performed with 
TBS-2-Tween 20. A secondary HRP-conjugated antibody directed against the primary 
antibody species, plus a Precision Protein StrepTactin-HRP Conjugate (BIO-RAD) 
(1/5000) for detection of the molecular weight marker, were diluted in 10 ml blocking 
solution and incubated with the membrane for 1 hour at room temperature. Primary and 
secondary antibodies used for western blotting are listed in table 3. The membrane 
was washed 3 x 10 minutes with TBS-2-Tween 20 prior to development with 
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SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) or Clarity ECL 
Substrate (BIO-RAD). Enhancer and peroxide solutions were mixed in a 1:1 ratio, 
added to the blot and left for 5 minutes. Blots were imaged by chemiluminescence 
using a Kodak Image Station 2000R with Kodak 1D Image Analysis Software, or a 
G:BOX F3 with GeneSys software (Syngene, UK), for varying lengths of exposure 
depending on the amount of protein. 
 
Antibody Host species Clonality Dilution 
Anti-FXIII-A HRP  
(Enzyme Research Laboratories) 
Sheep Polyclonal 1/2000 
Anti-fibrinogen (DAKO) Rabbit Polyclonal 1/1000 
Anti-fibrinogen Aα 290-348/349-406 
(Accurate Chemical, USA) 
Mouse Monoclonal 1/1000 
Anti-fibrinogen γ 15-35 
(Accurate Chemical) 
Mouse Monoclonal 1/5000 
Anti-phosphoserine (abcam) Rabbit Polyclonal 1/100 
Anti-phosphoserine (Millipore) Mouse Monoclonal 1/1000 
Anti-rabbit HRP (DAKO) Goat Polyclonal 1/1000 
Anti-mouse HRP (DAKO) Rabbit Polyclonal 1/1000 
 
 
 
2.1.7. Functional studies with recombinant WT fibrinogen 
2.1.7.1. Turbidity and lysis assay 
Formation and lysis of a clot can be monitored in vitro by recording changes in optical 
density, or turbidity, during these dynamic processes. Turbidity increases with lateral 
aggregation of protofibrils and fibre formation in the presence of thrombin and calcium, 
and declines with proteolytic clot degradation by plasmin. Additional haemostatic 
proteins may be added to examine their influence on clot turbidity and lysis. All 
reagents were diluted to the desired concentrations in sufficient TBS-1 pH 7.4 for a 
Table 3. Western blotting antibodies. Primary and secondary antibodies used for detection of 
fibrinogen, fibrinogen Aα chain or phosphoserine by western blotting are listed with details of 
host species, clonality and working dilution. 
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final volume of 150 µl per well. Recombinant WT fibrinogen (0.5 mg/ml) was added to a 
96 well microtiter plate in duplicate ± rFXIII-A [1.1 µg/ml] in an 80 µl volume per well. 
This was overlaid with 35 µl plasminogen (Enzyme Research Laboratories) (35 µg/ml) 
and the plate was inserted into the preheated chamber of an ELx808 Absorbance 
Microplate Reader (BIO-TEK, USA) at 37°C. For activation, 35 µl of a mix containing 
recombinant tPA [0.3 µg/ml] (Technoclone, Austria), thrombin (Calbiochem) [0.5 U/ml] 
and CaCl2 [2.5 mM] were added to each well in one step and the plate was immediately 
shaken. Absorbance at 340 nm was recorded for 59 minutes in 12 second intervals and 
a customised software application was used for calculation of turbidimetric variables 
(Carter et al., 2007): lag time (Lag), representing the onset of lateral aggregation of 
protofibrils preceding exponential increase in turbidity; maximum absorbance 
(MaxAbs), representing fibre thickness and clot compactness; clotting rate; time to 
50 % lysis (Lys50MA); lysis rate; and lysis area, which encompasses clot formation, 
MaxAbs and fibrinolysis (figure 9).  
 
 
 
 
 
 
 
2.1.7.2. Biotin-pentylamine incorporation FXIII-A activity assay 
The FXIII-A activity assay relies on cross-linking of biotin-pentylamine to fibrinogen via 
its primary amine group, catalysed by the transglutaminase activity of FXIII-A. The 
degree of cross-linked biotin-pentylamine is hence used as a measure of FXIII activity. 
All reagents were from Sigma-Aldrich unless otherwise stated. Recombinant WT 
Figure 9. Turbidity and lysis curve analysis. The graph displays a typical curve with change 
in OD over time during a turbidity and lysis assay. The Lag phase is shown as the period prior to 
the onset of increase in turbidity; maximum absorbance (MaxAbs) can be read from the peak of 
the curve, while half this value (½ MaxAbs) is used to determine time to 50 % lysis (Lys50MA); 
lysis area is depicted by the grey shading. 
Time 
O
D
 
½ MaxAbs 
MaxAbs 
Lys50MA 
Lag 
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fibrinogen and a Calbiochem® fibrinogen control were added to a 96-well microtiter 
plate in duplicate for six different time points ± rFXIII-A. The plate was coated with 
100 µl per well of fibrinogen [40 µg/ml] in TBS-3 pH 8.3 (Appendix 1) for 40 minutes at 
room temperature and the surface blocked with 300 µl per well 1 % (w/v) bovine serum 
albumin (BSA)-TBS-1 at 37°C pH 8.3 for 90 minutes. The plate was washed with 4 x 
300 µl TBS-1, and 10 µl of rFXIII-A diluted to 11 µg/ml in TBS-1 were added to each 
well, giving a final concentration of 1.1 µg/ml after addition of the master mix.  Using a 
multi-channel pipette, 90 µl of master mix containing DTT [0.1 mM], 5-(biotinamido) 
pentylamine (Thermo Scientific) [2.7 µM], CaCl2 [1 mM] and thrombin [1 U/ml] in TBS-1 
were added to each well for 0-25 minutes in 5 minute intervals and reactions were 
stopped using 200 µl per well of 200 mM EDTA to chelate calcium ions. For the zero 
time point, EDTA was added prior to addition of the master mix. The plate was washed 
with 4 x 300 µl TBS-3-Tween 20 pH 8.3 (Appendix 1) and 100 µl per well of streptavidin 
alkaline phosphatase [2 µg/ml], diluted in 1 % (w/v) BSA-TBS-3-Tween 20, was added 
for 1 hour at 37˚C to bind incorporated biotin-pentylamine via a high affinity interaction 
between streptavidin and biotin. After a final four washes with TBS-3-Tween 20, biotin-
pentylamine was detected by addition of 100 µl per well of p-nitrophenol phosphate 
(PNPP) – a substrate for streptavidin alkaline phosphatase – dissolved in dH2O to a 
final concentration of 1 mg/ml. Once the colour had developed, reactions were stopped 
using 100 µl per well of 4 M sodium hydroxide and absorbance was measured at 
405 nm using a Dynex MRX-TC plate reader.  
2.1.7.3. Fibrin polymerisation time course experiment by SDS-PAGE 
Recombinant WT fibrinogen [0.5 mg/ml] and rFXIII-A [1.1 µg/ml] were diluted in TBS-1 
pH 7.4 to 15 µl and mixed with 5 µl activation mix containing thrombin [0.05 U/ml] and 
CaCl2 [1.5 mM], also diluted in TBS-1. Eight separate reactions were prepared and 
activation mix was added at controlled time points. After addition of the activation mix, 
each reaction was immediately transferred to a hot block at 37˚C for 0, 5, 10, 20, 30, 
60, 120 or 180 minutes. Reactions were stopped at the aforementioned time points by 
addition of 4X LDS sample buffer and 10X reducing agent. Each sample, plus a 
fibrinogen-only control, was reduced by heating at 95°C for 15 minutes and loaded onto 
a 4-12 % Bis-Tris polyaccrylamide gel with 7.5 µl Precision Protein WesternC standard. 
Samples were electrophoresed at 150 V for 85 minutes in 700 ml 3-(N-
morpholino)propanesulfonic acid (MOPS) SDS running buffer (Life Technologies), 
prepared from a 20X concentrated stock by diluting in filtered dH2O. Electrophoresis 
conditions differed to method 2.1.4, with a lower voltage, extended running time and 
use of MOPS buffer to aid separation of high molecular weight fibrin α-α, α-γ and γ-γ 
59 
polymers. The gel was washed twice in dH2O, stained for 1 hour with GelCode Blue 
Stain Reagent and rinsed in dH2O overnight before imaging by transillumination the 
next day. 
2.1.8. Generation of variant fibrinogen Aα chain constructs 
In order to substitute fibrinogen Aα chain Ser3 and Ser345 for residues which cannot 
be phosphorylated, relevant nucleotides within the Aα chain DNA sequence were 
mutated by site directed mutagenesis. Site directed mutagenesis can be used to create 
single or multiple base substitutions within a known DNA sequence. Base changes are 
designed in such a way to encode a different amino acid of choice at a particular 
location within the transcribed protein. 
Three expression vectors, created from the pMLP vector (figure 10) by insertion of 
fibrinogen Aα (pMLP-Aα), Bβ (pMLP-Bβ) or γ (pMLP-γ) chain cDNA into the multiple 
cloning site (figure 11), were kindly provided by Prof Susan Lord, University of North 
Carolina at Chapel Hill. For expression of fibrinogen variants, Aα chain Ser3 and 
Ser345 residues within the pMLP-Aα vector were mutated to asparagine, glutamic acid 
or alanine residues; the effects of each amino acid on the expression and secretion of 
fibrinogen variants were compared in a series of transfection experiments. Serine 
codons were initially changed to asparagine as these two residues have similar charge 
and polarity. Alanine has similar charge but different polarity to serine and is commonly 
used for transfection due to its structural simplicity, which is unlikely to disrupt 
secondary protein structure. Glutamic acid was employed as a phosphomimetic by 
exploiting its negative charge, resembling that of a phosphate group. The properties of 
these four amino acids are compared in table 4. 
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 Serine Asparagine Glutamic Acid Alanine 
Abbreviations Ser (S) Asn (N) Glu (E) Ala (A) 
Structure 
 
 
 
 
Charge Uncharged Uncharged *Negative  Uncharged 
Polarity Polar Polar Polar **Nonpolar 
Functional 
group 
Hydroxyl Amide Carboxyl Methyl 
 
 
 
 
 
Mutagenesis of pMLP-Aα was carried out using polymerase chain reaction (PCR) with 
primers designed to introduce the desired mutations. The variant constructs were then 
transformed into E. Coli for amplification, harvested by cell lysis and purified. Analyses 
of DNA quality and sequence integrity were performed prior to transfection into CHO 
cells. Seven new pMLP-Aα vectors were created in this way for expression of 
fibrinogen variants with the following Aα chain mutations: 
1. Ser3Asn (S3N) 
2. Ser345Asn (S345N) 
3. Ser3/345Asn (S3/345N) (double variant) 
4. Ser3Glu (S3E) 
5. Ser345Glu (S345E) 
6. Ser3/345Glu (S3/345E) (double variant) 
7. Ser345Ala (S345A) 
 
 
Table 4. Comparison of amino acid properties. The table details the structure, charge, 
polarity and side chain functional groups of the four amino acids involved in site directed 
mutagenesis of Ser3 and Ser345 phosphorylation sites: serine, asparagine, glutamic acid and 
alanine. Serine and asparagine share similar chemical properties, while glutamic acid differs by 
its negative charge (*) and alanine by its polarity (**). 
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Figure 10. pMLP vector map. Downstream of the SV40 enhancer, the pMLP vector contains 
the major late promoter (MLP) and tripartite leader sequence (L1-3) from adenovirus 2, 5’ and 
3’ splice sites, a multiple cloning site (MCS) and the SV40 mRNA polyadenylation (poly(A)) 
signal. The MCS is detailed above the map; restriction sites used for insertion of Aα (SmaI), Bβ 
(SalI and SmaI) or γ (SmaI) chain cDNA are highlighted in red, with cleavage sites indicated by 
arrows (▲). The vector also contains an origin of replication (ori), ampicillin resistance gene 
(AmpR) and AmpR promoter in the opposite orientation. 
AATTGTCGACCGCGGCCCCGGGCGGCCGC 
SalI SmaI 
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Figure 11. pMLP-Aα, -Bβ and -γ vector maps. The vector maps show pMLP with fibrinogen Aα, Bβ or γ chain cDNA inserts in the multiple cloning site. Expression 
of these polypeptide chains is driven by the adenovirus 2 major late promoter (MLP). The locations of restriction sties used to linearise the vectors (PvuI and EcoRI), 
as well as those used to remove the Aα chain insert from pMLP-Aα (NotI and SalI), are also indicated.  
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2.1.8.1. Primer design for site directed mutagenesis 
A Quikchange Primer Design tool by Agilent Technologies (USA) was used to design 
primers in accordance with the Quikchange II site directed mutagenesis kit manual. 
Serine 3 and Ser345 codons (AGT and AGC respectively) were located within the Aα 
chain sequence. Forward and reverse primers of 25-45bp in length were designed to 
target these regions with complementary sequence either side of the codon of interest, 
while primer bases within the Ser3 and Ser345 codons were changed to introduce 
codons transcribing the desired amino acids (table 5). Primers were designed to have 
40-60% guanine/cytosine (GC) content, including a G or C at the beginning and end of 
each primer, and a melting temperature (Tm) of approximately 80°C to ensure good 
annealing to the template. All custom oligonucleotides were purchased from Life 
Technologies. 
 
Primer Sequence (5’ to 3’) 
Length 
(nt) 
Tm 
(°C) 
S3N F GCACAGCATGGACTGCAGATAATGGTGAAGGTG 33 79.14 
S3N R CACCTTCACCATTATCTGCAGTCCATGCTGTGC 33 79.14 
S345N F CCTGGAATCCTGGCAACTCTGAACGCGGAAG 31 80.31 
S345N R CTTCCGCGTTCAGAGTTGCCAGGATTCCAGG 31 80.31 
S3E F GGCACAGCATGGACTGCAGATGAGGGTGAAGGTGACTTTCTAG 43 78.85 
S3E R CTAGAAAGTCACCTTCACCCTCATCTGCAGTCCATGCTGTGCC 43 78.85 
S345E F GAACCTGGAATCCTGGCGAGTCTGAACGCGGAAGTGC 37 78.42 
S345E R GCACTTCCGCGTTCAGACTCGCCAGGATTCCAGGTTC 37 78.42 
S345A F CCTGGAATCCTGGCGCCTCTGAACGCGGAAG 31 81.69 
S345A R CTTCCGCGTTCAGAGGCGCCAGGATTCCAGG 31 81.69 
 
 
 
2.1.8.2. Site directed mutagenesis 
Polymerase chain reaction was performed using a Quikchange II site directed 
mutagenesis kit (Stratagene) in accordance with the manufacturer’s instructions. All 
Table 5. Ser3 and Ser345 primers used for site directed mutagenesis. 5’ to 3’ sequences of 
forward (F) and reverse (R) primers are displayed, with the altered codons of interest 
highlighted in red, as well as nucleotide (nt) length and Tm of each primer. 
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templates and primers were diluted in molecular grade BDH® H2O (VWR International, 
USA). Each cDNA template (1 ng) was mixed with the relevant forward and reverse 
primers listed in table 5 (125 ng each), 10X reaction buffer, 1 µl of deoxynucleotide 
triphosphate (dNTP) mix, 2.5 U PfuUltra high fidelity DNA polymerase and molecular 
grade H2O up to a final volume of 50 µl in a PCR reaction tube. The cDNA was 
amplified during a process of thermal cycling in a PTC-200 thermal cycler (MJ 
Reseasrch, Canada) using the following conditions: 
1. Initiation 95°C 30 seconds 
2. Denaturation 95°C 30 seconds 
3. Annealing 55°C 1 minute 
4. Elongation 68°C 7 minutes 
The extension time represented 1 minute per kilobase of pMLP-Aα plasmid length 
(6.2 kb). A two-step site directed mutagenesis was performed to generate the 
Ser3/345Asn double variant, whereby pMLP-Aα Ser3Asn cDNA was used as the 
template in a reaction with Ser345Asn primers. Upon completion of PCR, all reactions 
were stored overnight at 4°C and the parental (non-mutated) template was digested the 
following day with 10 U DpnI for 1 hour at 37°C in a PTC-200 thermal cycler. This 
restriction enzyme has specificity for methylated-DNA and is therefore unable to cleave 
plasmid cDNA which has been propagated in vitro. Reactions were returned to 4°C 
until transformation.  
2.1.8.3. Transformation into E. Coli 
XL-1 Blue supercompetent E. Coli cells (Stratagene) were transformed with the PCR-
amplified pMLP-Aα expression vectors in accordance with the manufacturer’s 
instructions. Plasmid DNA (1 µl) was added to 50µl cells and incubated on ice for 30 
minutes. Cells were heat-shocked at 42°C for 45 seconds to facilitate uptake of DNA 
and incubated on ice for a further 2 minutes. Pre-warmed lysogeny broth (LB) 
(Appendix 1) (500 µl) was added to the cells and incubated for 1 hour at 37°C, 225 rpm 
before spreading the transformed cells (50-100 µl) onto pre-warmed LB agar (Appendix 
1) containing ampicillin [100 µg/ml]. Plates were incubated inverted overnight at 37°C, 
checked for the appearance of single colonies the following day and stored at 4°C until 
plasmid purification. 
2.1.8.4. Plasmid purification (Mini-prep) 
A QIAprep Mini-prep Kit (QIAGEN, Netherlands) was used for purification of up to 
20 μg high-copy plasmid DNA. Single bacterial colonies were picked from agar plates 
x 18 
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using a 10 µl inoculation loop and used to inoculate starter cultures of 4.5 ml 
LB/ampicillin (100 µg/ml). These cultures were incubated overnight in an orbital shaker 
at 37°C, 300 rpm. Bacterial cells were harvested by centrifugation in a bench-top 
centrifuge at 13,000 rpm (Eppendorf MiniSpin Plus) for 2 minutes, resuspended in 
250 µl Buffer P1 and lysed with SDS under alkaline conditions by mixing with 250 µl 
Buffer P2. Chromosomal DNA and proteins are denatured under the alkaline conditions 
used for bacterial cell lysis, while plasmid DNA remains stable for subsequent 
purification. After a maximum of 5 minutes, 350 µl neutralising Buffer N3 was mixed 
with the lysate, causing precipitation of the denatured protein and genomic DNA, 
cellular debris and SDS. Precipitate was removed by centrifugation for 10 minutes at 
13,000 rpm and the resulting supernatant was applied to a QIAprep spin column. The 
sample was then centrifuged at 13,000 rpm for 1 minute to enable binding of plasmid 
DNA to the membrane. The column was washed with 750 µl Buffer PE and centrifuged 
again to remove residual buffer (13,000 rpm, 1 minute). Plasmid DNA was eluted from 
the column into a clean 1.5 ml microcentrifuge tube with 50 µl molecular grade H2O 
and centrifuged at 13,000 rpm for 1 minute. The concentration of DNA within the eluate 
was analysed at A260nm using a NanoDrop ND-1000 spectrophotometer, while 
qualitative assessment of the Mini-preps was carried out by agarose gel 
electrophoresis (method 2.1.8.7). 
2.1.8.5. Plasmid purification (Maxi-prep) 
A QIAprep Maxi-prep Kit (QIAGEN) was used for purification of up to 100 μg high-copy 
plasmid DNA. Starter cultures were prepared in the same way as for a Mini-prep 
(method 2.1.8.4) and incubated for 8 hours at 37°C, 300 rpm. A second culture with 
100 ml LB/ampicillin [100 µg/ml] was inoculated with 200 μl starter culture and 
incubated at 37°C overnight, 300 rpm. The culture was centrifuged (Hettich Rotanta 
460R) the next day for 30 minutes at 4,600 x g, 4°C to pellet the cells. Pelleted cells 
were resuspended in 10 ml Buffer P1 and lysed with 10 ml Buffer P2. Buffer P3 (10 ml) 
was added to precipitate debris and the lysate was filtered through a QIAfilter Maxi 
Cartridge. For removal of endotoxins, the filtered lysate was mixed with 2.5 ml Buffer 
ER and incubated on ice for 30 minutes. A QIAGEN-tip 500 was equilibrated with 10 ml 
Buffer QBT and the filtered lysate passed through the tip by gravity flow for binding of 
plasmid DNA to the resin. After washing with 2 x 30 ml Buffer QC, DNA was eluted with 
15 ml Buffer QN and precipitated by addition of 10.5 ml room temperature isopropanol. 
The solution was centrifuged for 1 hour at 4,600 x g, 4°C to pellet the DNA. The 
supernatant was discarded and pelleted DNA was washed with 5 ml endotoxin-free, 
room temperature 70 % ethanol before a final centrifugation step for 1 hour at 
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4,600 x g, 4°C. The supernatant was again carefully decanted and the DNA pellet 
air-dried for 5 minutes before re-dissolving in 30 µl molecular grade H2O. The DNA 
concentration at A260nm was determined with a NanoDrop ND-1000 spectrophotometer 
and the Maxi-prep quality was analysed by agarose gel electrophoresis (method 
2.1.8.7). 
2.1.8.6. Restriction digestion of plasmid DNA 
Restriction digestion was used to linearise plasmid DNA for analysis by agarose gel 
electrophoresis. Restriction enzymes recognise and cleave specific sequences of DNA; 
an online restriction mapping tool – Webcutter 2.0 – was used to identify enzymes 
which cleave at only one site within the pMLP vector sequences to enable linearisation 
without producing multiple fragments. Plasmid DNA (pMLP) (350 ng) was digested with 
30 U EcoRI restriction enzyme in a 30 µl reaction mix containing 10X EcoRI buffer, 
BSA [100 µg/ml] and molecular grade H2O for 16 hours at 37°C. Reagents were 
supplied by New England Biolabs. 
2.1.8.7. Agarose gel electrophoresis 
Linearised plasmids were electrophoresed to assess their quality. Agarose gels were 
prepared by mixing 1 % or 2 % (w/v) electrophoresis-grade agarose (Life 
Technologies), for large (>1000 bp) or small (<1000 bp) strands of DNA respectively, 
with 120 ml Tris-acetate EDTA (TAE) buffer (Appendix 1) by heating until molten and 
clear. After cooling to 50°C, 8 µl ethidium bromide (0.5 mg/ml) (Sigma-Aldrich) was 
added for fluorescent staining of nucleic acids and the agarose was immediately 
poured into a cast with a well comb and left for 30 minutes to set. Linearised plasmid 
DNA samples were mixed with 6X DNA loading buffer (Appendix 1) and loaded onto 
the gel. Hyperladder I (200-10,000 bp) or Hyperladder IV (100-1000 bp) (Bioline, UK) 
was used as a molecular weight marker. Samples were electrophoresed at 100 V for 
90 minutes in TAE buffer and the DNA imaged under ultraviolet (UV)-transillumination 
using Chemi-imager software.  
2.1.8.8. Sequencing of variant Aα chain cDNA open reading frames 
The mutations introduced into the pMLP vectors did not introduce unique restriction 
sites; hence the success of mutagenesis could only be verified by DNA sequencing. 
Samples were sent to a DNA sequencing service (DNA Sequencing & Services, 
University of Dundee), which uses automated high-throughput sequencing with dye-
labelled dideoxynucleotide triphosphates as chain terminators. Isolated plasmid DNA 
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from selected clones was reacted individually with four forward primers designed to 
bind regions spanning the entire fibrinogen Aα chain open reading frame. Primers were 
designed using GenScript DNA Sequencing Primers Design Tool and adapted to 
satisfy the criteria detailed by DNA Sequencing & Services. Primer sequences are 
listed in table 6. For analysis, sequencing data was compared to the original DNA 
sequences to highlight any errors. Nucleotide sequences for the original and mutated 
plasmids were then translated into protein sequence using ExPASy Translate Tool and 
aligned using a Basic Local Alignment Search Tool (BLAST) (National Center for 
Biotechnology Information, USA) to highlight and verify the desired mutations 
(Appendix 2). 
 
Primer Position (nt) Sequence (5’ to 3’) Length (nt) 
Aα forward 1 1398 CTCTCGAGTGAATTGTCG 18 
Aα forward 2 1936 AAATGTTAGGGCCCAGTTGGTTGA 24 
Aα forward 3 2572 TGCTGGGCACTGGACCTCTG 20 
Aα forward 4 3175 CCCTTCCCGTGGTAAATCTT 20 
 
 
 
2.1.9. Transfection of pMLP-Aα variants into CHO-Bβγ cells 
Calcium phosphate (CaPO4) precipitation was used for transfection of pMLP-Aα 
vectors into CHO cells; this technique relies upon complex formation between DNA and 
precipitated CaPO4 to enable entry of DNA into the cells. Chinese hamster ovary cells 
previously transfected with pMLP-Bβ and pMLP-γ constructs by the same method were 
cultured in 100 mm dishes with 10 ml growth medium containing 400 µg/ml neomycin 
analogue G418 and incubated at 37°C, 5 % CO2. Cells were split (1:10) 1 day ahead of 
transfection and medium was replaced with a fresh 10 ml G418 medium 2 hours ahead 
of transfection. For transfection, 10 μg pMLP-Aα DNA was combined with 10X less 
(1 µg) pMSVHis selection vector (provided by Prof Susan Lord, University of North 
Carolina at Chapel Hill), filter-sterilised cell culture-grade CaCl2 [250 mM] and filter-
sterilised dH2O up to a final volume of 500 μl. The DNA/CaCl2 mixture was combined 
with 500 μl 2X HEPES-buffered saline (HeBS) (Appendix 1); the HeBS solution was 
bubbled using a mechanical pipettor and the DNA/CaCl2 mixture was simultaneously 
Table 6. Aα chain sequencing primers. Forward primers used for sequencing of the pMLP-Aα 
open reading frame are listed with their starting position in the pMLP vector (6262 bp; open 
reading frame: nucleotides 1466-3400), 5’ to 3’ sequences and nucleotide (nt) length.  
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added dropwise using a Pasteur pipette to encourage CaPO4 precipitation. The 
transfection mix was vortexed for 15 seconds and incubated at room temperature for 
30 minutes before adding 500 µl to each dish of cells. Dishes were incubated for 4 
hours at 37°C, 5 % CO2 and the cells were subjected to an osmotic shock for by 
addition of 2 ml per dish of 10 % (v/v) glycerol solution in G418 medium for 3 minutes 
to facilitate intracellular transport of DNA to the nucleus. The dishes were washed with 
3 x 5 ml growth medium and incubated for 2 days in 10 ml G418 medium at 37°C, 5 % 
CO2. At the end of this incubation period, transfected cells were trypsinised, re-plated 
at varying dilutions in growth medium (1:10, 1:20 and 1:40) and returned to 37°C, 5 % 
CO2. The following day, 10 ml growth medium containing 400 µg/ml G418 and 250 µM 
L-histidinol dihydrochloride (Sigma-Aldrich) were added to each dish to achieve stable 
transfection. The medium was replaced every 2-3 days until the appearance of large, 
healthy and well-separated colonies. Approximately 24 colonies were selected by 
aspirating medium, sealing glass cloning cylinders over the colonies using sterile 
Vaseline, and adding a few drops of trypsin/EDTA solution to each cylinder for 5 
minutes at room temperature. Cells were transferred to a 24-well plate with 0.5 ml 
L-histidinol/G418 selection medium per well and incubated overnight at 37°C, 5 % CO2 
to adhere. Fresh selection medium was added the next day and clones were cultured 
without medium change until 60-70% of the wells had reached confluence. At this 
point, medium from each clone was removed and screened for fibrinogen content by 
ELISA, according to section 2.1.2. Selected clones were then trypsinised and 
transferred to 60 mm dishes with 4 ml selection medium. Cells were cultured at 37°C, 
5 % CO2 until confluent and ready for further screening by ELISA or storage in liquid 
nitrogen (method 2.1.10). Due to problems with expression, clones were further 
analysed for the presence of intracellular fibrinogen using a variety of methods outlined 
in section 2.1.11. 
2.1.10. Freezing cells for storage in liquid nitrogen 
Confluent cells were trypsinised from plates using trypsin/EDTA solution and mixed 
with a 4X excess of growth medium before centrifuging at 1000 rpm for 15 minutes 
(Eppendorf Centrifuge 5702 R). Cell pellets were resuspended in 2 ml per dish of 
sterile freeze solution, containing 90 % (v/v) newborn calf serum (Fisher Scientific) with 
10 % (v/v) cryoprotective dimethyl sulfoxide (DMSO) (Sigma-Aldrich), and divided into 
1 ml aliquots in cryovials (Fisher Scientific). The cryovials were placed in an 
isopropanol chamber and stored at -80°C overnight for slow cooling 
(approximately -1°C/minute), before transferring to liquid nitrogen the next morning. 
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2.1.11. Analysis of intracellular CHO fibrinogen 
Expression of variant fibrinogen Aα chain in transfected CHO cells was investigated by 
cell lysis, western blotting with cell lysate and conditioned medium, 
immunofluorescence, and end-point reverse transcription PCR (RT-PCR), as detailed 
below. 
2.1.11.1. Lysis of CHO cells and harvest of conditioned medium for western 
blotting and ELISA 
In order to investigate fibrinogen expression and secretion from CHO cells transfected 
with the variant Aα chain constructs, selected clones were cultured in 60 mm dishes 
and lysed using a non-denaturing Mammalian-Protein Extraction Reagent (M-PER) 
(Thermo Scientific). A 1 ml aliquot of medium was removed, mixed with protease 
inhibitor cocktail (1:100) (Sigma), and stored at -20°C until further analysis. The 
remaining medium was aspirated and cells were washed once with 1X PBS pH 7.4, 
containing CaCl2 and magnesium chloride (MgCl2) to minimise cell detachment 
(Appendix 1), before adding 250 µl M-PER pre-mixed with protease inhibitor cocktail 
(1:100). The plates were incubated on a shaker at room temperature for 5 minutes and 
cell lysate was collected into a centrifuge tube using a pipette. Lysates were 
centrifuged at 14,000 x g for 10 minutes in a bench top centrifuge (Eppendorf MiniSpin 
Plus) to pellet cell debris, while the supernatant was transferred to a clean tube and 
stored at -20°C. Lysates were concentrated 5X using centrifugal filters with a 30 kDa 
MWCO (Millipore). Both lysate and medium (30 µl) from each clone were loaded onto a 
4-12 % Bis-Tris polyacrylamide gel for SDS-PAGE, followed by western blotting with a 
rabbit polyclonal anti-fibrinogen antibody and goat anti-rabbit HRP secondary antibody 
(methods 2.1.4 and 2.1.6; table 3). The western blot results revealed an additional 
band between the fibrinogen Aα and Bβ chain bands, which was investigated further by 
repeating the western blot without the primary antibody incubation step, probing only 
with goat anti-rabbit HRP and StrepTactin HRP before developing with SuperSignal 
West Pico Chemiluminescent Substrate. This confirmed it to be a non-specific band, 
rather than fibrinogen-related (refer to 3.1.3). In a repeat cell lysis experiment, 
harvested medium was also concentrated 5X so that sufficient fibrinogen was loaded 
onto the gel. The western blot was probed with a mouse monoclonal anti-fibrinogen Aα 
chain antibody followed by a rabbit anti-mouse HRP secondary antibody (table 3). 
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2.1.11.2. Immunofluorescent detection of fibrinogen Aα chain in CHO cells 
For details of immunofluorescence methodology and assay development, refer to 
section 2.3.2. Briefly, CHO cells transfected with variant fibrinogen Aα chain constructs, 
as well as CHO-WT and CHO-Bβγ cells, were fixed onto a microscope slide, 
permeabilised and probed with a mouse monoclonal anti-fibrinogen Aα chain primary 
antibody (table 3), followed by a Cy3-AffiniPure donkey anti-mouse secondary antibody 
(1/500) (Stratech, UK). Slides were imaged by laser-scanning confocal microscopy 
(LSCM) (method 2.3.2.3), using the same settings for control and experiment wells to 
enable comparison of fluorescence intensity. 
2.1.11.3. RNA extraction from CHO cells 
Extraction of RNA from CHO cells cultured in 6-well plates or 60 mm dishes was 
carried out using an RNeasy plus mini kit (QIAGEN), complete with genomic 
DNA-eliminator spin columns, according to the accompanying instructions. Work was 
carried out in a DNA/RNA laboratory to minimise risk of contamination with RNases 
and filter pipette tips (Gilson, USA) were used throughout the procedure to avoid cross-
contamination of samples. Cells were lysed directly by addition of 350 µl Buffer RLT; 
the lysate was collected using a cell lifter (Sigma-Aldrich) and homogenised by passing 
at least five times through a 20-gauge needle. Homogenised lysate was transferred to 
a genomic DNA-eliminator spin column in a 2 ml collection tube and centrifuged for 30 
seconds at 10,000 rpm in a bench top centrifuge (Eppendorf MiniSpin Plus). The 
column was discarded and the flow through mixed with 1 ml 70 % ethanol for 
precipitation of RNA. The sample was transferred to an RNeasy spin column in a 2 ml 
collection tube and centrifuged for 15 seconds at 10,000 rpm to allow RNA to bind the 
column. Flow-through was discarded and the column was washed with 700µl Buffer 
RW1 by inverting the tube several times and centrifuging for 15 seconds, 10,000rpm. 
Two more wash steps were performed with 500 µl Buffer RPE for 15 seconds and 2 
minutes at 10,000 rpm. The column was then placed in a clean collection tube and 
centrifuged for an additional minute to remove residual wash buffer. Finally, the spin 
column was again placed in a clean 1.5 ml microcentrifuge tube and 30 µl RNase-free 
H2O was added directly to the membrane before centrifuging for 1 minute to elute the 
RNA. The RNA yield was determined by measuring A260 nm using a NanoDrop ND-
1000 spectrophotometer and samples were stored at -20°C. 
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2.1.11.4. Reverse transcription-PCR with RNA from transfected CHO cells 
Clones of CHO cells transfected with S3N and S345N Aα chain constructs were 
screened for expression of fibrinogen Aα by RT-PCR; CHO-WT and untransfected 
CHO cells were included as positive and negative controls respectively. The extracted 
RNA was reverse transcribed and amplified in a single reaction using a QIAGEN 
OneStep RT-PCR Kit, with primers specific to the Chinese hamster fibrinogen Aα chain 
nucleotide sequence (table 7). Forward and reverse primers were designed using 
Primer-BLAST (National Center for Biotechnology Information, USA) – an online tool 
for finding specific primers to a given sequence. Primers were designed to be 18-30 
nucleotides in length with 40-60 % GC content and an annealing temperature 5°C 
below the Tm.  
Optimal reaction conditions were achieved with 100 ng RNA template and 40 cycles of 
amplification. Reactions were set up to contain 10 µl 5X OneStep RT-PCR buffer, 2 µl 
dNTP mix (with each dNTP at a final concentration of 400 µM), 3 µl each of forward 
primer and reverse primers [0.6 µM], 2 µl OneStep RT-PCR enzyme mix and 28 µl 
RNase-free H2O up to a final volume of 50 µl. Reactions were placed in a PTC-200 
thermal cycler and subjected to the following cycling conditions: 
1. Reverse transcription 50°C 30 minutes 
2. PCR activation 95°C 15 minutes 
3. Amplification: 
a. Denaturation 94°C 30 seconds 
b. Annealing 55°C 1 minute 
c. Extension 72°C 1 minute 
4. Final extension 72°C 10 minutes 
Reactions were stored at 4°C overnight upon completion. Five microlitres of each 
reaction were mixed with 3 µl 6X loading dye and 10 µl molecular grade H2O before 
loading on a 1 % agarose gel with 5 µl Hyperladder IV. Electrophoresis and imaging 
were carried out according to method 2.1.8.7.  
 
 
x 40 
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Primer Sequence (5’ to 3’) Length (nt) Tm (°C) % GC 
FGA Forward TCTGGCTGCAGGATGAAAGG 20 60.03 55 
FGA Reverse CAATGTCCACCTCCAGTCGT 20 59.68 55 
 
 
 
2.1.12. Optimisation of CHO cell transfection for fibrinogen expression 
Due to difficulties across research groups with expression of fibrinogen Aα chain 
variants using the established method of CHO cell transfection, and taking into account 
the successful expression of Bβ and γ chain variants, the constructs for individual 
chains were transfected in a different order to investigate whether this would permit 
expression and secretion of fibrinogen. Whole vectors were sequenced to check for 
errors and each vector was linearised prior to transfection to improve integration 
efficiency. New CHO cells were purchased from ATCC (USA) and transfected first of all 
with pMLP-Bβ via the standard method as described in section 2.1.9. Clones were 
analysed for Bβ chain expression by real-time PCR and the best clone was co-
transfected with pMLP-Aα and pMLP-γ for fibrinogen expression. An overview of this 
process is illustrated in figure 12. 
 
 
 
 
 
 
Screening for fibrinogen expression by ELISA
Co-transfection of pMLP-Aα and pMLP-γ into CHO-Bβ cells
Screening for positive CHO-Bβ clones by real-time PCR
Transfection of pMLP-Bβ into CHO cells
Linearisation and purification of pMLP-Aα, -Bβ and -γ constructs 
Table 7. Reverse transcription PCR primers for analysis of fibrinogen Aα chain 
expression in CHO cells. Forward and reverse primer sequences for amplification of fibrinogen 
Aα chain (FGA) cDNA are displayed with nucleotide (nt) length, Tm and GC content. 
Figure 12. The process of pMLP-Aα and pMLP-γ co-transfection into CHO-Bβ cells for 
recombinant fibrinogen expression. Each of the pMLP constructs was linearised by restriction 
digestion prior to transfection. A CHO-Bβ cell line was formed by transfection of pMLP-Bβ into 
CHO cells and selection of the most productive clone using real-time PCR. The pMLP-Aα and 
pMLP-Bβ expression constructs were co-transfected for expression of fibrinogen, which was 
analysed by ELISA with medium harvested from each clone. 
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2.1.12.1. Testing CHO cells for resistance to selection reagents 
All selection reagents were purchased from Source BioScience, UK. New CHO cells 
were incubated with potential selection reagents to check for resistance and to find the 
most effective and suitable reagents for selection of positive clones. Cells were 
passaged and seeded in 100 mm dishes to approximately 50 % confluence in normal 
growth medium. The medium was replaced the next day with selection medium 
containing G418 [400 µg/ml or 700 µ/ml], L-histidinol dihydrochloride [250 µM], 
hygromycin [125 µg/ml], puromycin [50 µg/ml] or zeocin [175 µg/ml] diluted in growth 
medium. After 2 days, cells were split 1:10 into the same selection medium and 
monitored for cell death over 1 week. 
2.1.12.2. Sequencing of pMLP-Aα, -Bβ and -γ constructs 
Whole pMLP-Aα WT, -Bβ and -γ constructs were sequenced by DNA Sequencing & 
Services, University of Dundee (see method 2.1.8.8). Forward and reverse sequencing 
primers designed using GenScript DNA Sequencing Primers Design Tool are listed in 
table 8. Sequencing data was compared to original DNA sequences to screen for 
errors. 
 
Primer Sequence (5’ to 3’) Length (nt) 
Forward -1 CGGGACTATGGTTGCTGAC 19 
Forward 0 CAGTACTCTTGGATCGGAAACC 22 
Forward 1 CTCTCGAGTGAATTGTCG 18 
Forward 8 CATGTCTGGATCCTCTACGC 20 
Forward 9 CAAACGTTTCGGCGAGAAG 19 
Forward 10 GCCTTATCCGGTAACTATCGTC 22 
Forward 11 CTCAGCGATCTGTCTATTTCG 21 
Forward 12 GACTGGTGAGTACTCAACCAAGTC 24 
Forward 13 GATGTTGCAAGTGTGGCG 18 
Reverse 1 CCTCTACAAATGTGGTATGGCTG 23 
Reverse 2 GACTCCTGCATTAGGAAGCAG 21 
 
 
Table 8. pMLP sequencing primers. Forward and reverse primers used for sequencing of 
entire pMLP vectors are listed with their 5’ to 3’ sequences and nucleotide (nt) length.  
 74 
2.1.12.3. Linearisation of pMLP vectors 
To increase efficiency of viable plasmid DNA integration into the host genome, the 
pMLP-Aα WT, pMLP-Bβ and pMLP-γ vectors were linearised at a restriction site 
located within the Ampicillin resistance gene to ensure that recombination occurred 
outside of the Aα, Bβ and γ chain open reading frames. Restriction digestion reagents 
were supplied by New England Biolabs. Plasmid DNA (30 µg) was digested with 50 U 
PvuI restriction enzyme in a 35 µl reaction mix containing 10X Buffer 3, 100X BSA and 
ultrapure H2O for 3 hours at 37°C.  
2.1.12.4. Agarose gel electrophoresis and gel extraction 
Linearised pMLP vectors were separated on a 1 % agarose gel using the method 
outlined in section 2.1.8.7. Relevant bands were excised from the gel and DNA was 
extracted using a QIAquick Gel Extraction Kit (QIAGEN), as per the manufacturer’s 
instructions. In brief, agarose bands were dissolved in a supplied buffer (Buffer QG) 
with an equal volume of isopropanol, and each applied to a spin column that binds the 
DNA. The bound DNA was washed with Buffer PE. Additional wash steps were 
included to remove contaminants and promote purity of DNA samples. The DNA was 
eluted from the columns in 30 µl ultrapure H2O and the concentration determined using 
a NanoDrop ND-1000 spectrophotometer at A260 nm. 
2.1.12.5. Transfection of pMLP-Bβ into CHO cells 
Linearised pMLP-Bβ (10 µg) was transfected into new, untransfected CHO cells using 
protocol 2.1.9. A pSELECT-neo selection vector (Source BioScience) (1µg) was 
co-transfected to confer resistance to G418. On day 3, transfected cells were split into 
varying dilutions and re-plated straight into 10 ml selection medium containing G418 
[700 µg/ml]. Selection pressure was applied until the appearance of large healthy 
colonies, which were selected and transferred to 2 x 60 mm dishes per clone in 
selection medium. As individual fibrinogen chains are not secreted, expression of the 
Bβ chain in 12 selected clones was compared by reverse transcription of cellular RNA 
and real-time PCR. 
2.1.12.6. Reverse transcription of CHO-Bβ RNA 
Ribonucleic acid was extracted from CHO-Bβ clones according to method 2.1.11.3 and 
was reverse transcribed using an Applied Biosystems High Capacity cDNA Reverse 
Transcription Kit (Life Technologies). Template RNA was diluted to 200 ng/µl in 
RNase-free H2O and reactions were set up with 2 µl 10X buffer, 0.8 µl 25X dNTP mix, 
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2 µl 10X RT primers (random), 10 µl template RNA [100 ng/µl], 1 µl MultiScribe reverse 
transcriptase and 4.2 µl RNase-free H2O up to a 20 µl total volume. Reactions were 
held at 25°C for 10 minutes, 37°C for 120 minutes and 85°C for 5 minutes in a 
PTC-200 thermal cycler before proceeding to real-time PCR. 
2.1.12.7. Real-time PCR with CHO-Bβ cDNA 
Reverse transcribed cDNA was amplified by quantitative real-time PCR using SYBR 
Green I. This dye binds to any double stranded DNA, resulting in emission of a 
fluorescence signal which follows a sigmoidal trend during the reaction. The point at 
which the fluorescence of a given reaction exceeds a cycle threshold value (Ct) reflects 
the relative amount of cDNA template. This Ct value can be used to calculate 
fold-differences in expression after normalisation to the Ct value of an internal control – 
an endogenous housekeeping gene – and a reference sample.   
Primers were designed to amplify the following templates reverse transcribed from 
Chinese hamster RNA i) fibrinogen Bβ chain cDNA and ii) glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) cDNA, to be used as an internal control (method 2.1.11.4; 
table 9). Reverse transcription reactions were diluted 1:10 in RNase-free H2O before 
preparing PCR reactions, each with 10 µl Light Cycler 480 SYBR Green I Master Mix 
(Roche, Switzerland), 1 µl each of forward and reverse primers [0.2 µM], 2 µl pre-
diluted cDNA template and 6 µl RNase-free H2O to a 20 µl total volume. Each template 
was analysed with triplicate reactions. A Light Cycler 480 Instrument (Roche) was used 
for thermal cycling and quantification of SYBR green fluorescence over 40 cycles with 
the conditions detailed below: 
1. Activation 95°C 5 minutes 
2. Amplification 
a. Denaturation 95°C 10 seconds 
b. Annealing 55°C 20 seconds 
c. Extension 72°C 30 seconds 
A melting curve was included at the end of each PCR experiment to distinguish 
between specific amplification products and any non-specific products such as primer 
dimers. Reactions were held at 95°C for 30 seconds and 45°C for 1 minute before 
increasing the temperature up to 97°C at a rate of 0.11°C per second, with 5 
fluorescence data acquisitions for every +1°C. Finally, samples were cooled to 40°C for 
10 seconds. 
x 40 
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Light Cycler 480 Software (Version 1.5) (Roche) was used for calculation of Ct values 
and melting curve analysis. Real-time PCR data for fibrinogen β chain expression was 
analysed using the ∆Ct method, whereby ∆Ct is the experiment Ct value normalised to 
that of the endogenous housekeeping gene, GAPDH (Ctexperiment - Ctcontrol = ∆Ct). The 
relative expression level in each clone was compared using a 2-∆Ct calculation. 
 
Primer Sequence (5’ to 3’) Length (nt) Tm (°C) % GC 
FGB Forward AGGAGGGTTTCTTCAGTGCC 20 59.60 55 
FGB Reverse GCTTCTGCCTCTTTTGCCAC 20 60.04 55 
GAPDH Forward GCTTCTGCCTCTTTTGCCAC 20 59.96 55 
GAPDH Reverse GCTTCTGCCTCTTTTGCCAC 20 60.03 60 
 
 
 
2.1.12.8. Co-transfection of pMLP-Aα and pMLP-γ into CHO-Bβ cells 
Linearised pMLP-Aα WT and pMLP-γ vectors (10 µg each) were co-transfected into the 
selected CHO-Bβ cell line, along with pSELECT-zeo-mcs selection vector (Source 
BioScience) (2 µg) for resistance of transfected cells to antibiotic zeocin. Refer to 
section 2.1.9 for details of the transfection method. After splitting and diluting cells (day 
3), they were re-plated into selection medium containing G418 [700 µg/ml] and zeocin 
[200 µg/ml]. As no colonies survived selection, the concentration of zeocin was 
optimised as described below. The transfection was then repeated using the optimal 
zeocin concentration. 
2.1.12.9. Transfection of pSELECT-zeo-mcs into CHO cells and optimisation of 
zeocin concentration for selection 
Selection vector pSELECT-zeo-mcs was transfected (1 µg) into CHO cells using the 
CaPO4 precipitation method (method 2.1.9), with the aim of optimising zeocin 
concentration in selection medium for effective selection pressure. Two days post-
transfection, cells were trypsinised, diluted 1:20 and 1:40 and re-plated in selection 
medium containing three different concentrations of zeocin: 50 µg/ml, 100 µg/ml and 
Table 9. Real-time PCR primers for analysis of fibrinogen Bβ chain expression in CHO 
cells. Forward and reverse primer sequences for amplification of fibrinogen Bβ chain (FGB) and 
GAPDH cDNA are displayed with nucleotide (nt) length, Tm and GC content. 
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150 µg/ml. Medium was replaced with fresh selection medium every 2-3 days until 
colony formation. 
2.1.13. Recombinant fibrinogen expression in Expi293F cells 
Due to difficulties with expression of fibrinogen variants in CHO cells, an alternative 
Expi293TM expression system (Life Technologies) was employed for expression of 
recombinant fibrinogen. This system involves transient transfection of non-adherent 
Expi293F cells, which have been isolated from a human embryonic kidney (HEK) 293 
cell line by selecting for cells with a higher protein productivity. These cells can also be 
seeded at high density for maximal transfection efficiency and protein expression. The 
expression system includes optimised lipid-based transfection reagent ExpiFectamine 
and transfection enhancers, as well as Expi293 expression medium to support high 
density suspension cultures with serum-free conditions. All reagents were purchased 
from Life Technologies unless otherwise stated. 
2.1.13.1. Counting cells with a haemocytometer 
Cultured cells were counted using a haemocytometer chamber and trypan blue dye. 
First, the apparatus was cleaned with 70 % ethanol and the coverslip was moistened 
with water to affix to the haemocytometer. Trypan blue is a “vital stain”, which is 
excluded from healthy cells and selectively taken up by dead cells. After thorough 
mixing, an aliquot of cells was removed from a cell suspension and diluted with trypan 
blue. Ten microliters of this mixture were pipetted into either side of the 
haemocytometer, in between the coverslip and chamber. The haemocytometer was 
viewed under a CKX41 inverted optical microscope (OLYMPUS, Japan) with a 10X 
objective lens. Cells inside both central grids, including boundaries, were counted using 
a hand tally counter and averaged. The haemocytometer is designed such that, when 
the coverslip is in place, each grid has a volume of 1 mm3 (0.1 µl). Hence, the number 
of cells in the starting culture was calculated using the equation below, where d = 
dilution factor, c = average number of cells within the grid, and v = the original volume 
of suspension or culture containing the cells (ml): 
Total number of cells = dcv x 104 
2.1.13.2. Transient transfection of pMLP-Aα, -Bβ and –γ vectors into Expi293F 
cells 
For transfection of pMLP-Aα, -Bβ and –γ constructs, viable cells were counted using a 
haemocytometer chamber and the trypan blue (Sigma-Aldrich) dye exclusion method 
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as detailed above. Cells were seeded at a density of 2.0 x 106 viable cells/ml culture in 
Expi293 expression medium and cultured in suspension in a 125 ml spinner flask at 
37°C, 8 % CO2 with gentle stirring. Cell density and viability were monitored again the 
following day to ensure the cells were in excess of 3.0 x 106 cells/ml with greater than 
95 % overall viability in order to proceed with transfection. For a 30 ml transfection 
culture, a volume of culture containing 7.5 x 107 cells was added to a new flask and 
made up to 25.5 ml with Expi293 expression medium. Each plasmid DNA (10 µg) was 
diluted in OptiMEM I reduced serum medium (Life Technologies) to a final volume of 
1.5 ml. Eighty microliters of ExpiFectamine293 transfection reagent were also diluted in 
OptiMEM I medium to a final volume of 1.5 ml and both mixes were incubated at room 
temperature for 5 minutes. The diluted DNA and ExpiFectamine293 were combined, 
mixed gently and incubated at room temperature for 30 minutes to allow DNA-
ExpiFectamine293 complex formation; the mixture (3ml) was then added to the flask 
containing Expi293F cells for transfection. Cells were incubated on a stirrer at 37°C, 
8 % CO2 for approximately 16-18 hours. Following incubation, 150 µl 
ExpiFectamine293 Transfection Enhancer 1 and 1.5 ml ExpiFectamine293 
Transfection Enhancer 2 were added to the flask, giving a final volume of 30 ml. The 
transfected culture was then incubated on a stirrer at 37°C, 8 % CO2 for 7 days and an 
aliquot of cell suspension was removed on days 3, 5 and 7 for analysis of protein 
expression. Harvested aliquots were centrifuged at 14,000 x g for 10 minutes in a 
bench top centrifuge (Eppendorf MiniSpin Plus) to pellet cells; medium supernatant 
was transferred to a clean 1.5 ml tube, mixed with protease inhibitor cocktail (Sigma-
Aldrich) (1:500) and stored at -20°C.  
On day 7, the remaining 27 ml cell suspension was harvested by centrifugation at 
400 x g for 10 minutes, 4°C (Eppendorf Centrifuge 5702 R). Medium supernatant was 
transferred to a separate tube and pelleted cells were resuspended in 10 ml Dulbecco’s 
PBS (Life Technologies), re-pelleted at 400 x g for 10 minutes at 4°C, snap-frozen on 
liquid nitrogen and stored at -80°C. Protease inhibitor cocktail (1:500), phosphatase 
inhibitor cocktail 2 (Sigma-Aldrich) (1:1000) and phosphatase inhibitor cocktail 3 
(Sigma-Aldrich) (1:1000) were added to the medium to prevent proteolytic degradation 
and loss of phosphate from fibrinogen. The medium was then centrifuged at 4,600 x g 
for 15 minutes, 4°C (Hettich Rotanta 460R) and the supernatant filtered through a 
0.22 µm bottle top filter. Filtered medium was snap-frozen on liquid nitrogen and stored 
at -80°C. 
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2.1.13.3. Analysis of harvested Expi293 medium 
Aliquots of medium removed on days 3, 5 and 7 were first of all analysed for fibrinogen 
content by ELISA according to method 2.1.2. Medium was diluted 1/10, 1/50, 1/100, 
1/200 and 1/400, and added to a 96-well microtiter plate in duplicate. A Calbiochem® 
fibrinogen standard curve ranging from 0-1 µg/ml was used to determine the 
concentration of fibrinogen in each sample. The integrity of secreted fibrinogen in 
medium samples was verified by reducing SDS-PAGE and western blotting with a 
polyclonal anti-fibrinogen antibody (methods 2.1.4 and 2.1.6). Prior to SDS-PAGE, the 
medium was concentrated 4X using an Amicon Ultra-0.5 Centrifugal Filter Unit 
(Millipore) with a 100 kDa MWCO; the membrane was washed twice with 500 µl 20 mM 
Hepes by centrifugation at 14,000 x g in a bench top centrifuge (Eppendorf MiniSpin 
Plus) before concentrating 400 µl of media to 100 µl in the same way. 
2.1.13.4. Cloning of fibrinogen Aα, Bβ and γ chain cDNA into pmaxCloning 
Expression of recombinant fibrinogen in Expi293F cells was successful, but the yield of 
fibrinogen was still low. In attempt to enhance expression levels, the Aα, Bβ and γ 
chain open reading frames from the pMLP vectors were cloned into a new vector – 
pmaxCloning (pmC) (figure 13) – kindly provided by Dr Paul Cordell, University of 
Leeds. The pmC vector contains a cytomegalovirus (CMV) promoter which enables 
high protein expression and is optimal for the Expi293 expression system. The cloning 
process involved i) introducing restriction sites into PCR-amplified fragments containing 
the Aα, Bβ and γ chain open reading frames, ii) restriction digestion of purified PCR 
fragments and pmC, iii) ligation of PCR fragments with the pmC vector and iv) 
amplification of ligated pmC-Aα, -Bβ and –γ vectors in E. Coli and isolation using a 
QIAprep Maxi-prep Kit for transfection. 
 
 
 
 
 
 
 80 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.13.4.1. Polymerase chain reaction: introducing restriction sites 
Due to incompatibility between restriction sites in the pMLP vectors and the multiple 
cloning site of pmaxCloning, new restriction sites were introduced either side of Aα, Bβ 
and γ chain cDNA fragments; fragments containing the desired restriction sites were 
amplified from pMLP by PCR using the primers listed in table 10. Forward and reverse 
A 
Figure 13. pmaxCloning. A) Vector map.  The pmaxCloning vector contains the immediate 
early promoter of cytomegalovirus (PCMV IE) for high protein expression, a chimeric intron 
which enhances gene expression, a multiple cloning site (MCS) and an SV40 late mRNA 
polyadenylation (poly(A)) signal. In the opposite orientation, the vector contains an origin of 
replication, as well as a kanamycin resistance (KanR) gene and its promoter for bacterial 
cloning. Restriction sites within the MCS used for insertion of fibrinogen Aα, Bβ and γ cDNA 
(HindIII, EcoRI, BamHI, NotI) are indicated on the map. B) Multiple cloning site. The 102 bp 
MCS sequence is shown with sequence recognition motifs for restriction enzymes used to insert 
fibrinogen Aα, Bβ and γ cDNA highlighted in red and specific cleavage sites indicated by arrows 
(▲). 
GGTACCGCCATCATGAAGTTTAAACAAGCTTGAATTCTCTAGAGATATCCTG 
 
CAGAGATCTGGATCCCTCGAGGCTAGCGCGGCCGCGTTTAAACAGAGCTC 
Hind III 
B 
Eco RI 
Bam HI Not I 
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primers were designed to be complementary to regions either side of the start and stop 
codons respectively, with a short sequence outside of the open reading frame 
substituted with the chosen restriction site. Criteria for selection of appropriate 
restriction sites included confirmation by restriction mapping that sites were unique 
within the whole vector, as well as maximal compatibility with the original sequence to 
promote primer annealing. Primers were between 30 and 40 bp long with a GC content 
of 40-60 % and a Tm close to 70°C; the annealing temperature during PCR was set to 
5°C below the Tm of the primers. Custom primers were purchased from Life 
Technologies. 
Polymerase chain reaction was carried out using an Expand High Fidelity PCR System 
(Roche, UK). Primers were diluted to 10 µM and pMLP-Aα (WT, S3N and S345N), 
pMLP-Bβ and pMLP-γ vectors were diluted to 100 ng/µl, all in molecular grade H2O. 
Each reaction consisted of 1 µl template DNA (100 ng), 5 µl 10X buffer with MgCl2, 1 µl 
dNTP mix [200 µM], 1.5 µl each of forward and reverse primers [0.3 µM], 1 µl enzyme 
mix and 39.2 µl molecular grade H2O up to a final volume of 50 µl.  Reactions were 
prepared and mixed in PCR tubes and subjected to the following thermal cycling 
conditions in a PTC-200 thermal cycler: 
1. Initial denaturation 94°C 2 minutes 
2. Denaturation 94° 15 seconds 
3. Annealing 64°C (Aα and γ) or 67°C (Bβ) 30 seconds 
4. Elongation 72°C 2 minutes 
5. Denaturation 94°C 15 seconds 
6. Annealing 64°C (Aα and γ) or 67°C (Bβ) 30 seconds 
7. Elongation 72°C 2 minutes + 
  5 seconds/cycle 
8. Final elongation 72°C 7 minutes 
 
 
 
 
 
 
x 10 
x 20 
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2.1.13.4.2. Polymerase chain reaction product purification 
On completion of PCR reactions, PCR products were purified using a QIAquick PCR 
Purification Kit (QIAGEN), following the manufacturer’s instructions. In brief, five 
volumes of Buffer PB (250 µl) were mixed with one volume of PCR sample (50 µl), 
added to a QIAquick spin column and centrifuged at 14,000 x g for 1 minute in a bench 
top centrifuge (Eppendorf MiniSpin Plus) for binding of the DNA to the membrane. The 
flow-through was discarded and the QIAquick column was washed with 3 x 750 µl 
Buffer PE by centrifugation at 14,000 x g for 1 minute each time. After discarding flow-
through, the column was centrifuged for an additional 1 minute to remove residual 
buffer and placed in a clean 1.5 ml tube. To elute DNA, 30 µl molecular grade H2O was 
added directly to the membrane and left to stand for 1 minute before a final 
centrifugation step at 14,000 x g for 1 minute. The concentration of purified DNA was 
determined at A260 nm using a NanoDrop ND-1000 spectrophotometer and samples 
were stored at -20°C until restriction digestion. 
Primer Sequence (5’ to 3’) 
Length 
(nt) 
Tm 
(°C) 
Aα forward 
+ HindIII 
CCAGCCCCA/AGCTTAGAAAAGATGTTTTCCATGAGG 36 70.1 
Aα reverse  
+ NotI 
GAATTGCGGCC/GCCCATTTAACTTAGTCTAGGG 33 70.2 
Bβ forward 
+ EcoRI 
TGCGCCGCTCTCGAGTG/AATTCTCGACATGAAAAGA 36 73.1 
Bβ reverse 
+ NotI 
AATTGCGGCC/GCCCGTATTGGGGACTATTG 30 72.2 
γ forward + 
EcoRI 
CCCGGG/AATTCAGACATCATGAGTTGGTCCTTG 33 69.8 
γ reverse + 
BamHI 
CTCTTTGGATC/CGGTCTTTTAAACGTCTCCAGC 33 68.6 
Table 10. PCR primers used to introduce restriction sites either side of fibrinogen Aa, Bβ 
and γ cDNA fragments. 5’ to 3’ primer sequences are displayed with restriction sites 
highlighted in red and start/stop codons underlined, as well as nucleotide (nt) length and Tm of 
each primer. 
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2.1.13.4.3. Double digestion of PCR products and pmaxCloning 
The PCR-amplified Aα, Bβ and γ chain cDNA fragments were double digested with the 
relevant restriction enzymes: Aα chain fragments with HindIII and NotI (high fidelity), 
the Bβ chain fragment with EcoRI and NotI (high fidelity), and the γ chain fragment with 
EcoRI and BamHI. The pmaxCloning vector was also digested with each pair of 
restriction enzymes to enable sticky-end ligation of fragments into vector. Restriction 
digestion reagents were supplied by New England Biolabs. For both fragment and 
pmaxCloning digestion, 4 µg DNA was mixed with 30 U of each required enzyme, 10X 
buffer 2 or buffer 4 (determined using the online Double Digest Finder tool by New 
England Biolabs), BSA [100 µg/ml] and molecular grade dH2O up to a final volume of 
30 µl. Reactions were incubated at 37°C for 3 hours. Digested DNA products were 
purified from the reaction mix by agarose gel electrophoresis and gel extraction 
(method 2.1.12.4). The DNA yield was determined at A260 nm using a NanoDrop ND-
1000 spectrophotometer. 
2.1.13.4.4. Ligation of Aα, Bβ and γ cDNA fragments with pmaxCloning 
Ligation was performed using a 1:3 ratio of vector to insert, with 100 ng total DNA per 
reaction. Fragments and vectors were diluted to a concentration 25 ng/µl and, for each 
reaction, 1 µl vector was mixed with 3 µl fragment DNA, 10X DNA ligase buffer 
(Promega, USA), 1 U T4 DNA ligase (Promega) and molecular grade dH2O up to a 
final volume of 20 µl. Reactions were incubated at 4°C for 16 hours before 
transformation into XL-1 blue cells (1 µl in 50 µl cells) the following day (method 
2.1.8.3). Plasmids were purified from selected colonies using a QIAprep Maxi-Prep kit 
(method 2.1.8.5) and quantified by measuring absorbance at A260 nm with a NanoDrop 
ND-1000 spectrophotometer. Plasmid size and integrity were verified by restriction 
digestion with EcoRI (method 2.1.8.6) and agarose gel electrophoresis with 
Hyperladder I (200-10,000bp; Bioline) (method 2.1.8.7). Annotated vector maps of the 
new fibrinogen Aα, Bβ and γ chain expression constructs – named pmC-Aα WT or 
S345N, pmC-Bβ and pmC-γ – are displayed in figure 14. 
2.1.13.4.5. Transient transfection of pmC-Aα, -Bβ and –γ vectors into CHO 
cells 
To test the viability of the new pmC constructs prior to transfection into Expi293F cells, 
each vector was transiently transfected into CHO cells by CaPO4 precipitation (method 
2.1.9) and the cells were assayed for fibrinogen Aα, Bβ or γ chain expression by lysis 
and western blotting (methods 2.1.11.1 and 2.1.6 respectively). For each vector, 10 µg 
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plasmid DNA was transfected individually, in the absence of selection vector, into 
untransfected CHO cells, subjected to osmotic shock and assayed 48 hours post-
transfection. Cells lysate (20 µl) was mixed with 10X reducing agent, 4X LDS sample 
buffer and dH2O in a 40 µl total volume and subjected to SDS-PAGE and western 
blotting. Blots were probed for fibrinogen using a polyclonal anti-rabbit primary antibody 
and goat anti-rabbit HRP secondary antibody (table 3). 
2.1.13.4.6. Transient transfection of pmC-Aα, -Bβ and –γ vectors into 
Expi293F cells 
Following confirmation of successful expression of individual fibrinogen chains in CHO 
cells using the pmC-Aα, Bβ and γ vectors, transfection of Expi293F cells with the WT 
vectors was carried out, as well as with pmC-Aα S345N, -Bβ and -γ for expression of 
the Ser345 variant (method 2.1.13.2). Secreted fibrinogen was analysed according to 
method 2.1.13.3; briefly, the fibrinogen was visualised by SDS-PAGE and western 
blotting, while the concentration in medium harvested on day 7 was determined by 
ELISA to establish whether there is increased fibrinogen expression using the pmC 
vectors compared to the pMLP vectors. 
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Figure 14. pmC-Aα, -Bβ and -γ vector maps. The vector maps show the pmaxCloning (pmC) vector with fibrinogen Aα, Bβ or γ chain cDNA inserts in the multiple 
cloning site. Strong, constitutive expression of these polypeptide chains is driven by the upstream cytomegalovirus promoter (PCMV IE). The restriction sites used to 
insert the cDNA fragments (HindIII, NotI, EcoRI and BamHI) are indicated on each map.  
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2.2. Functional studies with fibrinogen phosphorylation isoforms 
As an alternative approach to expression of variant fibrinogen, the naturally occurring 
20-25 % degree of fibrinogen phosphorylation in plasma was exploited, using 
chromatography to enrich the phosphorylated fraction. Fibrinogen phosphorylation 
isoforms were then compared in several functional assays to determine the effect of 
phosphorylation on FXIII cross-linking activity, plasmin digestion, α2-antiplasmin 
incorporation and fibrin clot structure. 
2.2.1. Preparation of fibrinogen phosphorylation isoforms 
2.2.1.1. Purification of commercial fibrinogen 
Calbiochem® human fibrinogen from plasminogen-depleted plasma was purified by 
ammonium sulphate precipitation (AP-fibrinogen) (Smith et al., 2011); this was kindly 
provided by Dr Kerrie Smith, University of Leeds for use in chromatography and 
functional experiments. Calbiochem® fibrinogen was also purified by IF-1 affinity 
chromatography using an ÄKTA avant 25 system (GE Healthcare), and dialysed 
against TBS-1 pH 7.4, following the same process as that used for purification of 
recombinant fibrinogen (section 2.1.3). Coming from the same source, both of these 
fibrinogen samples were confirmed to have a 25 % degree of phosphorylation, using 
the malachite green assay as described below.  
2.2.1.2. Malachite green assay 
A malachite green assay was used to determine the degree of fibrinogen 
phosphorylation in purified samples of fibrinogen. Phosphate standards were prepared 
by diluting appropriate volumes of a stock solution of potassium dihydrogen phosphate 
(KH2PO4) in TBS-1 pH 7.4 to a 300 µl volume, giving a final concentration range of 
0-5 µM KH2PO4 (0-1000 pmol phosphate). An equivalent volume of fibrinogen sample 
at 3 µM was also prepared. For alkaline hydrolysis of protein-bound phosphate, 40 µl of 
8 M sodium hydroxide were added to each standard and fibrinogen sample before 
heating to 95˚C for 15 minutes. Samples were cooled and centrifuged (Eppendorf 
MiniSpin Plus), mixed with 120 µl 5 M hydrochloric acid and incubated on ice to 
encourage precipitation of proteins. Precipitate was removed by centrifugation at 
20,000 x g, 4˚C for 15 minutes in a bench-top centrifuge (Jouan MR1822). Each 
standard and fibrinogen sample was added to a 96-well microtiter plate in duplicate, 
with 200 µl per well. Finally, 100 µl Malachite Green Solution A (Millipore) was added to 
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each well and the absorbance measured at 630 nm after 10, 20 and 30 minutes using 
an ELx808 Absorbance Microplate Reader. Ammonium molybdate in Malachite Green 
Solution A reacts with free inorganic phosphate (Pi) under acidic conditions (H+), 
yielding an intermediate which reacts with malachite green and causes a colour change 
from yellow to green: 
1. Pi   +   (NH4)2MoO4    
H+
→    H3PMo12O40 
 
2. H3PMo12O40   +    HMG
2+    
H+
→    (MG+)(H2PMo12O40)   +    2H
+ 
 
 
 
2.2.1.3. Anion exchange chromatography 
Anion exchange chromatography was employed for the separation of phosphorylated 
and non-phosphorylated fibrinogen molecules using AP-fibrinogen. Anion exchange 
was the method of choice because, with a pI of approximately 5.6, fibrinogen has a net 
negative charge at physiological pH. Figure 15 illustrates the relationship between pH 
and the net charge of a protein at pH values exceeding the pI. Protein phosphorylation 
causes a shift to a more acidic pI due to alteration of the net charge by the negatively 
charged phosphate groups. By this principle, phosphorylated proteins bind a positively 
charged matrix with higher affinity than their non-phosphorylated counterparts and will 
therefore elute later upon application of a buffer gradient with increasing ionic strength.  
 
 
 
 
 
 
 
 
Ammonium molybdate 
Malachite Green 
(Yellow, λmax 446nm) 
 (Green, λmax 640nm) 
Figure 15. The relationship between pH and net charge of a protein. At pH values above 
the isoelectric point (pI), proteins have a net negative charge and can therefore be manipulated 
by anion exchange chromatography. 
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Separation of phosphorylated and non-phosphorylated fibrinogen was performed using 
an ÄKTA prime chromatography system with three connected 1 ml HiTrap 
Diethylaminoethanol (DEAE) Sepharose Fast Flow columns (GE Healthcare). For the 
first run, the columns were equilibrated with 10 ml 20 mM Tris-hydrochloride (HCl) pH 
8.0 before injection of 1 ml AP-fibrinogen diluted to 2 mg/ml in equilibration buffer. A 
flow rate of 1 ml/min was used throughout. After sample addition, 0.5 ml fractions were 
collected for the remainder of the method. A further 10 ml equilibration buffer was 
passed through the column before applying a concentration gradient of 1 M sodium 
chloride (NaCl), increasing from 0-100 % over a 20 ml volume, diluted with equilibration 
buffer. Finally, the column was washed with 30 ml equilibration buffer. Fractions 
corresponding to elution peaks were pooled, concentrated using Vivaspin 20 
concentrators (100 kDa MWCO) and analysed for the presence of fibrinogen by SDS-
PAGE (method 2.1.4).  
Various parameters were optimised from the initial method to promote separation and 
resolution. Initially, the pH of the equilibration buffer was lowered to pH 6.8, closer to 
the pI of fibrinogen. Gradient time was increased from 20 ml (6.7 CV) to 90 ml (30 CV), 
and then further to 180 ml (60 CV), while binding flow rate was decreased to 
0.2 ml/min, collecting 2 ml fractions. Fibrinogen from each peak was pooled separately 
and dialysed overnight against TBS-1 pH 7.4 using dialysis tubing (10 mm) with a 
12 kDa MWCO (Sigma-Aldrich) (method 2.1.3.3). The malachite green assay (method 
2.2.1.2) was used to measure the degree of phosphorylation of fibrinogen from each 
peak. Despite optimisation, there was still insufficient separation of phosphorylated and 
non-phosphorylated fibrinogen using this method; therefore, alternative approaches 
were sourced and tested. 
2.2.1.4. Phos-tag™ affinity chromatography 
As an alternative method for the chromatographic separation of phosphorylated 
fibrinogen from non-phosphorylated fibrinogen, Phos-tag™ Agarose (400 µl) (figure 18; 
section 2.3.4) was purchased from Alpha Laboratories, UK and packed into an empty 
Tricorn 5/50 High Performance Column (GE Healthcare) with two adaptors, giving a 
final bed volume of 0.353 µl. Refer to section 2.3.4 for information on Phos-tag™. 
Chromatography was performed using an ÄKTA avant 25 system (GE Healthcare), 
following a protocol described by Kinoshita et al. (2005), which was adapted to 
encourage binding of phosphorylated fibrinogen to the Phos-tag™ Agarose. Alterations 
to the method included reduction of binding flow rate from 0.25 ml/min to 0.1 ml/min 
and alteration of the elution buffer composition; phosphorylated fibrinogen was eluted 
with 50 mM EDTA rather than NaH2PO4, as trace amounts remaining after dialysis 
89 
interfered with the highly sensitive malachite green assay. See Appendix 1 for buffer 
compositions. The amount of fibrinogen loaded per run was also optimised to give 
sufficient yield of phosphorylated fibrinogen after elution.  
The final optimised method was as follows. Firstly, the storage buffer was removed with 
15 CV of wash buffer at a flow rate of 0.5 ml/min. The column was then equilibrated 
with 30 CV of equilibration buffer, followed by 2 CV of binding buffer, both at 
0.5 ml/min. Fibrinogen (4 mg) was diluted in binding buffer to a 2.5 ml volume and was 
loaded at a flow rate of 0.1 ml/min, collecting 0.5 ml fractions. Phosphorylated 
fibrinogen was eluted by applying a gradient from 0-100 % elution buffer diluted with 
filtered dH2O over 20 CV at 0.25 ml/min, again collecting 0.5ml fractions. Finally, a 
second wash step was performed with 5 CV wash buffer at 0.5 ml/min, followed by 5 
CV storage buffer at 0.5 ml/min. The fibrinogen concentration in each fraction was 
measured at A280 nm using the ÄKTA avant with Unicorn 6 control software and a 
NanoDrop ND-1000 spectrophotometer with extinction coefficient 1.51. Flow through 
and elution peaks were pooled, concentrated to 200 µl using Vivaspin concentrator 
tubes (100 kDa MWCO) and dialysed against TBS-1 pH 7.4 using a Slide-A-Lyzer Mini 
Dialysis Unit with a 7 kDa MWCO (Thermo Scientific). A maximum of 100 µl fibrinogen 
was added to each unit and dialysed for 2 hours at 4°C with gentle stirring, followed by 
an additional hour with fresh TBS-1. Fibrinogen was stored at -80°C until use and the 
degree of fibrinogen phosphorylation in each peak, as well as control fibrinogen, was 
analysed using the malachite green assay (method 2.2.1.2). This method yielded two 
fibrinogen samples for use in functional investigations: 13 % phosphorylated and 33 % 
phosphorylated. 
2.2.1.5. Dephosphorylation of fibrinogen 
Dephosphorylation of fibrinogen was performed according to the method detailed by 
Kinoshita et al. (2005). Calbiochem® fibrinogen was dissolved in 50 mM Tris pH 9.0 to 
a concentration of approximately 8 mg/ml. The dephosphorylation reaction mix was 
prepared with 6 mg fibrinogen, 405 U bovine intestinal alkaline phosphatase (Sigma-
Aldrich), MgCl2 [400 µM] and 50 mM Tris pH 9.0 to a final volume of 3 ml. The reaction 
was incubated overnight at 37°C. Fibrinogen was purified from the reaction mix by IF-1 
affinity chromatography (method 2.1.3.2) using an ÄKTA avant 25 system, 
concentrated by centrifugation using Vivaspin concentrator tubes (100 kDa MWCO) 
and dialysed against TBS-1 pH 7.4 using a Slide-A-Lyzer Mini Dialysis Unit (7 kDa 
MWCO), as explained in method 2.2.1.4. Dephosphorylated fibrinogen was stored at -
80°C. Removal of phosphate was confirmed by malachite green assay (method 
2.2.1.2). 
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2.2.1.6. Fibrinogen samples for functional studies 
As previously mentioned, Calbiochem® fibrinogen was purified by IF-1 affinity 
chromatography using an ÄKTA avant 25 system, and the degree of phosphorylation 
determined by malachite green assay (method 2.2.1.2). This fibrinogen was used as 
the control sample in functional assays, representing physiological phosphorylation 
levels (25 %). The two fibrinogen samples from Phos-tag™ affinity chromatography 
(13 % and 33 % phosphorylation) and dephosphorylated fibrinogen were also used in 
subsequent functional assays. 
2.2.2. Biotin-pentylamine (lysine donor) incorporation FXIII-A activity assay 
The effect of phosphate on FXIII cross-linking of lysine analogue pentylamine to 
glutamine acceptor residues within fibrinogen was examined by comparison of 
phosphorylated (13 %, 25 % and 33 %) and dephosphorylated fibrinogen samples. The 
FXIII-A activity assay was performed in accordance with the method outlined in section 
2.1.7.2 with triplicates of each sample. In both assays, the FXIII-A-mediated 
incorporation of lysine donor 5-(biotinamido) pentylamine to the phosphorylation 
isoforms was compared at 0, 5, 10, 15, 20 and 25 minutes. The experiment was 
repeated to give three independent data sets. 
2.2.3. Plasminogen binding assay 
A 96-well microtiter plate was coated with 100 µl per well of phosphorylated (13 %, 
25 % and 33 %) and dephosphorylated fibrinogen in triplicate at 40 µg/ml in 50 mM 
sodium carbonate (Na2CO3) pH 9.6 and incubated at 4°C overnight. The wells were 
washed with 3 x 300 µl TBS-4-Tween 20 pH 7.4 (Appendix 1) and blocked with 300 µl 
per well of 3 % (w/v) BSA-TBS-4-Tween 20 for 90 minutes at 37°C. The plate was 
washed with 3 x 300 µl TBS-4-Tween 20 and 100 µl per well of plasminogen was 
added at increasing concentrations from 3.75 to 240 nM, diluted in TBS-4 pH 7.4 
(Appendix 1). Plasminogen was incubated in the plate for 1 hour at 37°C before 
washing 3 x 300 µl TBS-4-Tween 20. To detect bound plasminogen, 100 µl per well of 
goat anti-human plasminogen HRP antibody (Enzyme Research Laboratories) diluted 
1/2000 in 1 % (w/v) BSA-TBS-4-Tween 20 was added for 1 hour at 37°C. Finally, the 
plate was washed 3 x 300 µl TBS-4-Tween 20 and developed using OPD substrate as 
previously described (section 2.1.2). Absorbance at 490 nm was measured with a 
Dynex MRX-TC plate reader. Three independent experiments were performed. 
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2.2.4. Plasmin digestion time course experiment by SDS-PAGE 
An initial plasmin digestion experiment was carried out to optimise the concentration of 
plasmin needed to digest 10 µg fibrinogen in 40 minutes. A concentration range of 
plasmin from 27.5 to 440 nM was tested to find the lowest concentration that could give 
sufficient digestion of fibrinogen into X, Y and D fragments. Fibrinogen [1.1 µM; 
374 µg/ml] and plasmin (Enzyme Research Laboratories) were diluted in TBS-1 pH 7.4 
to a final volume of 27 µl and incubated at 37°C for 40 minutes. Reactions were 
stopped by addition of 9 µl 4X LDS sample buffer to denature proteins, and analysed 
by non-reducing SDS-PAGE (method 2.1.4 without reducing agent). The optimal 
concentration of plasmin was found to be 220 nM (18.3 µg/ml) (section 3.2.2.4). The 
experiment was repeated using 220 nM plasmin at different time points, from 
0-40 minutes in 5 minute intervals. As fibrinogen was almost completely digested within 
5 minutes, the time course was shortened from 40 to 4 minutes, with 30 second 
intervals. To determine the influence of phosphorylation on plasmin-mediated 
fibrinogen digestion, the above method was used for digestion of phosphorylated 
(13 %, 25 % or 33 %) and dephosphorylated fibrinogen samples. After non-reducing 
SDS-PAGE, bands corresponding to fibrinogen fragments Y (145 kDa) and D1 
(92 kDa) were analysed by densitometry using ImageJ 1,23y image analysis software 
(National Institutes of Health, USA), normalising the intensity of each band to total 
protein in the lane. 
2.2.5. α2-antiplasmin incorporation assay 
A 96 well microtiter plate was coated with 100 µl per well of phosphorylated (25 %, 
13 %, 33 %) and dephosphorylated fibrinogen, each in triplicate, at 80 µg/ml in TBS-2 
pH 7.4 (Appendix 1) for 40 minutes at room temperature. The plate was washed with 3 
x 300 µl TBS-2 and incubated overnight at 4°C with 300 µl per well of 3% (w/v) BSA-
TBS-2 to block for non-specific binding. Blocking was continued for 1 hour at 37°C the 
next morning before washing with 3 x 300 µl TBS-2-Tween 20 pH 7.4. For conversion 
of fibrinogen to fibrin, 100 µl per well of activation mix containing thrombin [1 U/ml] and 
CaCl2 [5 mM] in TBS-2 was added for 45 minutes at room temperature and cleaved 
fibrinopeptides were removed with 4 x 300 µl high salt washing buffer (TBS-5-Tween 
20 pH 7.4; Appendix 1), followed by 4 x 300 µl regular TBS-2-Tween 20. Ten 
microliters of rFXIII-A master mix [1.1 µg/ml] were added to each well before addition of 
90 µl FXIII reaction mix containing DTT [100 µM], α2-AP [10 µg/ml], thrombin [1 U/ml] 
and CaCl2 [5 mM] in TBS-2. Reactions were stopped at 0, 10, 20, 30, 40 and 50 
minutes by addition of 200 µl 200 mM EDTA stop solution. The plate was washed with 
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4 x 300 µl 6 M urea, followed by 4 x 300 µl TBS-2-Tween 20, and incubated with 100 µl 
per well of goat polyclonal anti-α2-AP HRP antibody (Enzyme Research Laboratories) 
diluted 1/1000 in 3 % (w/v) BSA-TBS-2-Tween 20 for 1 hour at room temperature. A 
final wash step with 4 x 300 µl TBS-2-Tween 20 was carried out before developing the 
plate with ODP substrate (method 2.1.2) and measuring absorbance at 490 nm using 
an ELx808 Absorbance Microplate Reader. The assay was repeated in three 
independent experiments. 
2.2.6. Clot-based plasmin generation assay 
The plasmin generation assay relies on plasmin-mediated cleavage of pNitroaniline 
(pNA) from chromogenic S-2251 substrate (Chromogenix, USA) in the following 
reaction: 
 
H-D-Val-Leu-Lys-pNA    H-D-Val-Leu-Lys-OH + pNA 
 
The pNA produced absorbs light at 405 nm and the increase in absorbance at 405 nm 
is directly proportional to plasmin activity; hence, this assay was used as a measure of 
plasmin activity in clots formed in vitro with phosphorylated (13 %, 25 %, 33 %) and 
dephosphorylated fibrin. Clots were formed in the presence of FXIII-A ± α2-AP to 
examine how phosphorylation affects covalent incorporation of α2-AP. 
Fibrinogen samples were diluted to 0.25 mg/ml in TBS-6-Tween 20 pH 7.4 (Appendix 
1) and 94 µl were added to each well, followed by plasminogen [312.5 µg/ml] and 
rFXIII-A [1.4 µg/ml] ± α2-AP [1.65 µg/ml] to a final volume of 100 µl. The plate was 
inserted into an ELx808 Absorbance Microplate Reader pre-heated to 37°C and 
overlaid with 50 µl per well of activation mix containing thrombin [0.75 U/ml] and CaCl2 
[3.75 mM] diluted in TBS-6-Tween 20. Absorbance at 340 nm was measured every 12 
seconds for 15 minutes, ensuring full clot formation. The plate was then overlaid with 
50 µl per well of lysis mix containing tPA [0.05 µg/ml] and S-2251 substrate [0.6 mM], 
diluted in TBS-6-Tween 20 with 0.1% (w/v) BSA. Plasmin generation was monitored 
over 4 hours at 37°C by measuring absorbance at 405 nm every 48 seconds. Data 
were collected from three independent experiments. 
Plasmin 
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2.2.7. Turbidity analysis 
The effect of fibrinogen phosphorylation on fibre thickness and polymerisation was 
examined using the clot formation stage of the plasmin generation assay, as detailed 
above (section 2.2.6). Briefly, clots were formed using phosphorylated (13 %, 25 %, 
33 %) and dephosphorylated fibrinogen, in the presence of plasminogen and rFXIII-A. 
Clotting was activated by thrombin and CaCl2 before measuring absorbance at 340 nm 
for 15 minutes. Five independent experiments were performed and data were analysed 
using a customised software application for calculation of MaxAbs and clotting rate 
(Carter et al., 2007). 
2.2.8. Scanning electron microscopy of fibrin clots 
Fibrin clots formed from phosphorylated (25 %, 13 %, 33 %) and dephosphorylated 
fibrinogen were imaged by scanning electron microscopy (SEM) for visualisation and 
measurement of the effect of phosphorylation on fibre diameter. Fibrinogen [1 mg/ml], 
thrombin [1 U/ml] and CaCl2 [10 mM] were combined in TBS-1 pH 7.4 to a final volume 
of 110 µl. Seventy five microliters of this mix were pipetted into the lid of a 0.5 ml 
Eppendorf tube, already pierced several times with a needle to facilitate subsequent 
wash steps, and wrapped in parafilm to prevent leakage during clot formation. The 
developing clots were incubated for 2 hours at room temperature in a humidity 
chamber. Washing, fixation and dehydration steps were all performed at room 
temperature with gentle stirring in a 50 ml volume. The clots were washed by removing 
the parafilm and placing in a beaker containing 50 mM sodium cacodylate pH 7.4 for 3 
x 20 minutes. Sodium cacodylate is commonly used during specimen preparation for 
electron microscopy because the cacodylate does not form a precipitate with residual 
ions, as phosphate buffers may do if there is insufficient washing before fixation. Clots 
were transferred to a 2 % (v/v) gluteraldehyde (Sigma-Aldrich) solution in sodium 
cacodylate buffer for fixation, and washed again with sodium cacodylate buffer for 
3 x 20 minutes.  
A stepwise dehydration of the clots was carried out by sequentially transferring them to 
acetone solutions of increasing concentrations for 10 minutes each: 30 %, 50 %, 70 %, 
80 %, 90 %, 95 % and 100 %. Two further 10 minute incubations in 100 % acetone 
were performed before transferring to fresh 100 % acetone for the final time. Fibrin clot 
structures were then subjected to a process known as critical point drying, which 
enables complete dehydration of biological samples whilst preserving surface 
morphology. During this process, water within samples is replaced with liquid CO2; 
when temperature and pressure are raised beyond the critical point for CO2 (31°C and 
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1200 pounds/square inch), the liquid CO2 vaporises without change in density, thereby 
avoiding changes to surface tension which would distort surface ultrastructure. Critical 
point drying was conducted by Martin Fuller, University of Leeds using an E3000 
critical point dryer (Quorum Technologies Ltd, UK). 
On completion of drying, the clots were mounted onto 0.5 inch aluminium specimen 
stubs covered with 12 mm carbon tabs (Agar Scientific, UK) and coated with a 7 nm 
layer of platinum-palladium using a 208HR High Resolution Sputter Coater 
(Cressington, UK). The samples were individually imaged over 5 different areas using a 
Quanta 200F FEGESEM field-emission scanning electron microscope (FEI, USA) and 
fibre diameters (n=100) measured using ImageJ software. 
2.2.9. Statistical analysis 
Statistical analysis was performed where appropriate (n≥3). Data were analysed using 
Microsoft Excel to calculate mean values from independent experiments and standard 
error of the mean. Differences between mean values of different groups were analysed 
for statistical significance using a paired, two-tailed student’s t-test, with significance 
accepted at p<0.05. Data are presented as mean ± standard error of the mean, with 
the level of significance denoted by * (p<0.05), ** (p<0.01), *** (p<0.005), or **** 
(p<0.001).  
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2.3. Characterisation of intracellular fibrinogen phosphorylation 
Methods were developed to investigate the mechanism of in vivo fibrinogen 
phosphorylation, in particular the cellular location of fibrinogen phosphorylation and the 
kinase responsible. Intracellular phosphorylated fibrinogen Aα chains were visualised 
by proximity ligation assay (PLA). Other methods, such as SDS-PAGE, western 
blotting, ELISA and isoelectric focusing, were optimised for comparison of 
phosphorylation levels of secreted fibrinogen from cells incubated with various 
stimulators and inhibitors. 
2.3.1. HepG2 cell culture 
A human hepatoma cell line – HepG2 (ATCC) – was enlisted for investigations into 
cellular fibrinogen phosphorylation as these cells express fibrinogen naturally. Human 
hepatoma cells were cultured at 37°C, 5 % CO2 in full growth medium supplemented 
with L-glutamine, as detailed in Appendix 1. Cells were cultured in 100 mm dishes and 
passaged once a week by incubating with 3 ml trypsin/EDTA solution for up to 30 
minutes before diluting to 10 ml with growth medium. The cells were then passed three 
times through a 19 gauge needle to minimise clumping and re-plated at a 1:10 dilution 
in growth medium. Medium was replaced every 2-3 days. 
2.3.2. Immunofluorescent detection of cellular fibrinogen Aα chains 
Immunofluorescence was used to optimise an anti-fibrinogen Aα antibody, as well as 
markers for the ER and Golgi apparatus, prior to detection of phosphorylated fibrinogen 
Aα chains by PLA. 
2.3.2.1. Slide preparation 
Human hepatoma cells were trypsinised and counted using a haemocytometer 
chamber and the trypan blue dye exclusion method (method 2.1.13.1). For 
immunofluorescence, cells were seeded on LabTek-II 8-well chamber slides (Sigma-
Aldrich) at a density of 100,000 cells per well in 500 µl growth medium (Appendix 1) 
and incubated overnight at 37˚C, 5 % CO2. For fixation, cells were washed quickly with 
800 µl PBS pH 7.4 (Appendix 1) and incubated with 500 µl 3 % (w/v) paraformaldehyde 
(Sigma-Aldrich) solution in PBS, containing CaCl2 [100 µM] and MgCl2 [100 µM], for 20 
minutes at room temperature. After an additional three washes with PBS, cells were 
incubated with 500 µl 50 mM ammonium chloride solution in PBS for 10 minutes at 
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room temperature. Three final wash steps with PBS were performed before storing 
slides in PBS at 4˚C for up to 2 weeks. 
2.3.2.2. Assay procedure 
Slides were incubated in ice-cold methanol at -20˚C for 10 minutes to permeabilise 
cells. After three washes with PBS, slides were incubated in 0.2 % (w/v) fish skin 
gelatin (Sigma-Aldrich) solution in PBS (1X FSG) at room temperature for a minimum 
of 30 minutes to block for non-specific binding. Primary antibody solution in 1X FSG 
was added for 2 hours at room temperature in a humidified chamber, with 50 µl per 
well. After 3 x 5 minute washes with 1X FSG, 50 µl per well of secondary antibody 
solution in 1X FSG was added for 1 hour at room temperature in a humidified chamber 
covered with foil. Slides were washed four times with 1X FSG, once with PBS and once 
with 0.01X PBS, for 5 minutes each time, covered with foil. Once dry, slides were 
mounted using 15 µl per well of Duolink In Situ mounting medium containing 4',6-
diamidino-2-phenylindole (DAPI) nuclei stain (Sigma-Aldrich); glass coverslips were 
positioned and sealed with colourless nail varnish. Slides were stored at -20˚C in the 
dark and brought to room temperature before imaging. Images were captured by LSCM 
as outlined below. 
2.3.2.3. Laser scanning confocal microscopy 
Slides prepared for immunofluorescence were imaged by LSCM using an LSM 700 
inverted confocal microscope with Zen imaging software (Carl Zeiss Microscopy, 
Germany).  Images were captured using a 63x oil objective lens with four solid-state 
lasers (405 nm, 488 nm, 555 nm and 635 nm); those to be compared were taken using 
the same pinhole (1 µm), detector gain and offset settings. 
2.3.2.4. Antibody optimisation 
Various primary and secondary antibodies used for immunofluorescence are listed in 
table 11. Three antibodies were tested for successful detection of fibrinogen Aα chain 
in CHO cells and HepG2 cells, using CHO-Bβγ as a negative control; only the anti-
fibrinogen Aα 290-348/349-406 was validated for this purpose and therefore used in 
future experiments. Antibodies directed against ER and Golgi markers – anti-protein 
disulphide isomerise (anti-PDI) (ER) and anti-TGN46 (trans-Golgi) – were also 
optimised by immunofluorescence using the concentrations detailed below (table 11). 
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Antibody 
Host 
Species 
Clonality 
Concentration/dilution 
Tested Optimal 
Anti-fibrinogen Aα (Abnova, UK) Rabbit Polyclonal 1.5-5 µg/ml N/A 
Anti-fibrinogen Aα (Stratech) Rabbit Polyclonal 1/10-1/50 N/A 
Anti-fibrinogen Aα 290-348/349-406 
(Accurate Chemical) 
Mouse Monoclonal 1.5-5 µg/ml 1.5 µg/ml 
Anti-phosphoserine (abcam) Rabbit Polyclonal 2.5-20 µg/ml 2.5 µg/ml 
Alexa Fluor 488 anti-PDI                 
(New England Biolabs) 
Rabbit Monoclonal 1/25-1/100 1/50 
Anti-TGN 46 (abcam) Sheep Polyclonal 1/200-1/400 1/200 
Anti-cleaved caspase 3                   
(New England Biolabs) 
Rabbit Monoclonal N/A 1/400 
Alexa Fluor 488-AffiniPure donkey anti-
rabbit (Stratech) 
Donkey Polyclonal N/A 1/1000 
Cy3-AffiniPure donkey anti-mouse 
(Stratech) 
Donkey Polyclonal N/A 1/1000 
Alexa Fluor 647-AffiniPure donkey anti-
sheep (Stratech) 
Donkey Polyclonal N/A 1/1000 
 
 
 
2.3.3. Detection of phosphorylated fibrinogen Aα chains in HepG2 cells by 
proximity ligation assay 
The proximity ligation assay was developed to detect and quantify intracellular 
phosphorylated fibrinogen. This technique was used to i) investigate the location of 
fibrinogen phosphorylation using secretion inhibitor Brefeldin A (BFA) (section 2.3.3.3), 
ii) determine whether intracellular phosphorylation of fibrinogen increases in acute 
phase conditions (section 2.3.6), and iii) identify the in vivo fibrinogen kinase using 
broad spectrum kinase inhibitor staurosporine (STSP) (section 2.3.7). 
Table 11. Antibodies used for immunofluorescent techniques. The table lists primary and 
secondary antibodies used for immunofluorescence or the proximity ligation assay, as well as 
their respective species, clonality and chosen dilutions. 
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2.3.3.1. Assay principle 
Proximity ligation assay is a recently developed technique (Fredriksson et al., 2002) 
which enables highly specific detection in situ of two distinct entities in close proximity, 
residing less than 45 nm apart. The general method for PLA can be broken down into 
six stages, as illustrated in figure 16. After fixation of cells or tissues on a microscope 
slide, they are firstly incubated with two primary antibodies from different species. 
Oligonucleotide-conjugated PLA probes with plus or minus strands are added to detect 
each primary antibody; the plus and minus strands of the probes hybridise when in 
proximity. Hybridised oligonucleotides ligate to form a complete circle, which provides a 
template for rolling circle amplification in the presence of a polymerase. Finally, each 
amplification product is detected with fluorescently-labelled probes and appears as an 
individual spot when imaged by fluorescent microscopy. This novel technique can be 
used to detect and quantify protein-protein interactions, post-translational modifications 
and protein expression. Here, this method has been applied for the detection and 
quantification of phosphorylated human fibrinogen Aα chains in CHO cells and HepG2 
cells (figure 17). All reagents are available commercially as part of the Duolink In Situ 
kit from Olink Bioscience, distributed in the UK by Sigma-Aldrich. 
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STEP 1: Fix cells onto microscope slide. 
 
 
 
 
STEP 2: Add two primary antibodies. 
 
 
 
 
STEP 3: Add PLUS and MINUS PLA probes. 
 
 
 
 
 
STEP 4: Ligate hybridised DNA. 
 
 
 
 
 
STEP 5: Amplify ligated DNA template and 
detect with fluorescent probes. 
 
 
 
 
 
STEP 6: Image by confocal microscopy.  
 
 
 
Figure 16. The six stages of a proximity ligation assay. 1) Cultured cells are fixed onto a microscope slide using formaldehyde. 2) Cells are blocked for non-
specific binding and incubated with two different primary antibodies. 3) Cells are incubated with PLA probes directed against each primary antibody; the PLA probes 
are conjugated to plus and minus strands of DNA which hybridise when in close proximity. 4) Hybridised probes are ligated upon incubation with a DNA ligase, 
forming a circular DNA template. 5) A polymerase is added and the DNA is amplified by rolling circle amplification. Fluorescently labelled oligonucleotides that can 
hybridise with the amplification product are used for detection. 6) Cells are imaged by LSCM. Image modified from Gullberg et al. (2011). 
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2.3.3.2. PLA method 
In all experiments, HepG2 cells were incubated with 20 µg/ml BFA for 8 hours prior to 
fixing to increase the signal (refer to method 2.3.3.3 for more details). To investigate 
the mechanism of fibrinogen phosphorylation, cells were also incubated with 10 ng/ml 
IL-6 for 24 hours or 250-500 nM kinase inhibitor STSP for 8 hours (sections 2.3.6 and 
2.3.7). Subsequent fixation, permeabilisation, blocking and primary antibody incubation 
steps were followed according to sections 2.3.2.1 and 2.3.2.2. The following primary 
antibodies were used: i) mouse polyclonal anti-fibrinogen Aα chain, ii) rabbit polyclonal 
anti-phosphoserine and iii) sheep polyclonal anti-trans-Golgi network 46 (TGN46) 
(table 3). Primary antibody concentrations were optimised by immunofluorescence as 
described previously (method 2.3.2.4). The anti-phosphoserine antibody was optimised 
by PLA (table 11) by selecting the concentration which gave the highest signal-to-noise 
ratio; this was determined by subtracting the number of spots in images of control 
CHO-Bβγ cells from the signal in phosphorylated Aα chain-positive CHO-WT cells.   
After incubating cells with the primary antibody solution, Duolink In Situ PLA probes – 
anti-mouse PLUS and anti-rabbit MINUS (Sigma-Aldrich) – were diluted 1:5 in 1X FSG 
and incubated at room temperature for 20 minutes before adding to cells. During this 
time, slides were washed 4 x 5 minutes with 1X FSG on an orbital shaker. Slides were 
incubated in a humidified chamber for 1 hour at 37°C with 40 µl per well of PLA probe 
solution and washed 2 x 5 minutes with Wash Buffer A (Appendix 1). Detection was 
DNA amplification 
and labelling
PLA probe
1 antibody
Phosphorylated 
fibrinogen
Each phosphorylated 
αC produces one 
fluorescent signal
P
Figure 17.  Detection of phosphorylated fibrinogen Aα chain by proximity ligation. Primary 
antibodies directed to the fibrinogen Aα chain (αC) (left) and phosphoserine (P) (right) are 
detected with oligonucleotide-conjugated PLA probes. Ligation and amplification of PLA probes 
enables fluorescent detection, whereby each individual signal corresponds to one 
phosphorylated α chain. Image modified from Gullberg et al. (2011). 
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performed using a Duolink In Situ Detection Reagent (orange; 554 nm) (Sigma-
Aldrich). The supplied 5X ligation stock and ligase were diluted 1:5 and 1:40 
respectively in filtered dH2O, added to cells with 40 µl per well and incubated in a 
humidified chamber at 37°C for 30 minutes. Similarly, 40 µl per well of the 5X 
amplification stock and a DNA polymerase diluted 1:80 in Milli-Q H2O were added for 
100 minutes at 37°C in the dark, followed by 2 x 5 minute washes with Wash Buffer A. 
Alexa Fluor 488 anti-PDI and Alexa Fluor 647-AffiniPure donkey anti-sheep antibodies 
(table 11) were diluted in 1X FSG and added to cells for 1 hour at room temperature in 
the dark. The final washing and mounting procedures are detailed in section 2.3.2.2.  
2.3.3.3. Inhibition of the secretory pathway with BFA 
Brefeldin A inhibits the secretory pathway in cells, specifically blocking movement of 
proteins from the ER to the Golgi apparatus. This fungal metabolite leads to 
disassembly of the Golgi apparatus, with redistribution of cis- and medial-Golgi (but not 
trans-Golgi) components to the ER, disrupting a dynamic membrane recycling process 
between these two organelles (Lippincott-Schwartz et al., 1989). Brefeldin A was used 
to investigate the subcellular location of fibrinogen phosphorylation and to increase 
signal in PLA experiments. The concentration and incubation time were optimised by 
immunofluorescence with 5-20 µg/ml BFA for 4-8 hours. For PLA, cells were incubated 
with 20 µg/ml BFA diluted in 500 µl growth medium per well, for 8 hours prior to 
fixation. 
2.3.3.4. LSCM and image analysis 
Slides from PLA experiments were imaged using an LSM 700 inverted confocal 
microscope with Zen imaging software, as outlined in section 2.3.2.3. Z-stacks were 
captured with 1 µm intervals from the top to the bottom of cells within the field of view. 
Individual z-stack images were combined to form a maximum intensity projection, 
which was used for image analysis to quantify spots from whole cells. The maximum 
intensity projection images were analysed using a macro for ImageJ, designed by 
Gareth Howell, University of Leeds; the macro locates the nucleus and cytoplasmic 
area of each cell within the image and quantifies the number of spots per cell. 
2.3.4. Detection of phosphorylated fibrinogen using Phos-tag™ 
In 2002, the Department of Functional Molecular Science at Hiroshima University 
developed a novel phosphate-capturing molecule – Phos-tag™. The Phos-tag™ 
molecule binds divalent metal cations, enabling high affinity interactions with phosphate 
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monoester di-anions (figure 18A). This presents a wide range of valuable applications 
for the field of phosphoproteomics, which is still largely dependent on the use of 
radioactive isotopes and limited by poor phosphoserine and phosphothreonine 
antibody specificity and sensitivity. Phos-tag™ Biotin, Phos-tag™ Agarose and Phos-
tag™ SuperSep SDS-PAGE gels were purchased from Alpha Laboratories. Phos-tag™ 
Biotin (10 mg) was dissolved in 1.3 ml TBS-4 pH 7.4 containing 10 % (v/v) methanol to 
give a 10 mM stock solution. The applications of Phos-tag™ enlisted for this thesis are 
illustrated in figure 18B-D and detailed below.  
2.3.4.1. Phos-tag™ affinity SDS-PAGE 
Pre-cast Phos-tag™ SuperSep 12.5 % polyacrylamide gels containing 50 µM Phos-
tag™ with 100 µM zinc chloride were used for the capture and slowed migration of 
phosphorylated proteins during electrophoresis. Ammonium sulphate precipitated 
fibrinogen (25 % phosphorylation) and dephosphorylated fibrinogen (200 ng) were 
combined with 4X reducing agent and 10X LDS sample buffer, zinc nitrate [500 µM] to 
quench the equivalent molar concentration of EDTA in the LDS sample buffer, and 
dH2O to a final volume of 20 µl. Samples were heated to 95°C for 15 minutes, cooled 
on ice for 2 minutes and centrifuged briefly (Eppendorf MiniSpin Plus) to collect 
condensation before loading 15 µl per well. Electrophoresis was performed at 20 
milliamperes (mA)/gel in 500 ml Tricine SDS-PAGE running buffer prepared from a 20X 
stock solution (Life Technologies) diluted in filtered dH2O. For details of the standard 
western blotting procedure, refer to section 2.1.6. This was adapted to include a 
preliminary 10 minute wash step in transfer buffer containing 1 mM EDTA to chelate 
Zn2+ ions, followed by the usual 10 minute wash in transfer buffer without EDTA. Blots 
were probed with a mouse anti-fibrinogen Aα chain antibody and rabbit anti-mouse 
HRP secondary antibody (table 3) before developing by chemiluminescence with 
Clarity ECL Substrate. 
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A) Structure of Phos-tag™ 
 
 
B) Phos-tag™ Acrylamide (affinity SDS-PAGE) 
 
 
C) Phos-tag™ Biotin (ELISA and western blotting) 
 
 
D) Phos-tag™ Agarose (affinity chromatography) 
 
 
 
 
 
 
Phosphate 
Fibrinogen 
Figure 18. Applications of Phos-tag™. A) Phos-tag™ structure and Zn2+-mediated interaction 
with protein-bound phosphate. B) Separation of proteins according to phosphorylation state by 
SDS-PAGE with Phos-tag™ Acrylamide. C) Detection of fibrinogen-bound phosphate by ELISA 
or western blotting using Phos-tag™ Biotin and streptavidin HRP. D)  Chromatographic 
enrichment of phosphoproteins with Phos-tag™ Agarose. Images adapted from Kinoshita et al.  
(2009); Wako n.d. Phos-tag™ Series. Available from: http://www.wako-
chem.co.jp/english/labchem/product/life/Phos-tag/pdf/Phos-tag.pdf [Accessed: 10 July 2014]. 
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2.3.4.2. ELISA with Phos-tag™ Biotin  
The high affinity interaction between biotin and streptavidin was exploited for the 
development of an assay to quantify the degree of fibrinogen phosphorylation in 
conditioned medium from HepG2 cells, using Phos-tag™ Biotin. A 96-well microtiter 
plate was coated with 100 µl per well of rabbit polyclonal anti-fibrinogen antibody 
(1/4000) in 50 mM sodium carbonate pH 9.6, at 4°C overnight. The plate was washed 
with 3 x 300 µl TBS-4-Tween 20 pH 7.4 and incubated with 300 µl per well of 3 % (w/v) 
BSA-TBS-4-Tween 20 blocking solution at 37°C for 90 minutes. Another wash step 
was performed before adding 100 µl per well of AP-fibrinogen at 170-680 ng/ml 
(approximately 50-200 fmol phosphate) in duplicate, diluted in TBS-4-Tween 20 for 2 
hours at room temperature on a shaker. Blank wells containing TBS-Tween 20-only 
were included as a negative control. For preparation of a Phos-tag™ Biotin-bound 
Streptavidin HRP conjugate, a 500 µl mix containing Phos-tag™ Biotin [20 µM], zinc 
nitrate [400 µM], 1 µl streptavidin HRP (GE Healthcare) and TBS-4-Tween 20 was 
incubated at room temperature for 30 minutes. This was scaled up depending on the 
desired final volume. The mixture was then concentrated to less than 10 µl using a 
centrifugal filter device (30 kDa MWCO) to remove excess, unbound Phos-tag™. The 
remaining solution was diluted in 500 µl TBS-4-Tween 20 per microliter of Phos-tag™ 
Biotin added to the initial mix (1/500). A serial dilution of Zn2-Phos-tag™ 
Biotin-Streptavidin HRP in TBS-4-Tween 20 was carried out to give a concentration 
range of 1/500 to 1/8000. After 3 x 300 µl washes with TBS-4-Tween 20, the prepared 
dilutions of Zn2-Phos-tag™ Biotin-Streptavidin HRP were added to the plate with 100 µl 
per well for 1 hour at room temperature on a shaker. The plate was washed with 3 x 
300 µl TBS-4-Tween 20 and developed with OPD substrate, reading absorbance at 
490 nm with a Dynex MRX-TC plate reader.  
To check for non-specific binding, a subsequent assay included a streptavidin-only 
negative control, whereby the same amount of streptavidin was diluted in 
TBS-4-Tween 20 to 500 µl without Phos-tag™ Biotin or zinc nitrate. The results 
demonstrated that streptavidin HRP was binding non-specifically to fibrinogen; 
therefore, streptavidin alkaline phosphatase was used in its place in future 
experiments. Due to inconsistencies within and between data sets, the Phos-tag™ 
Biotin and streptavidin alkaline phosphatase were added separately, rather than as a 
pre-prepared complex. After normal coating procedure (described above) and 
incubation with 100 µl per well of AP-fibrinogen and dephosphorylated fibrinogen at 
1 µg/ml, or TBS-4-Tween 20 only, the plate was washed 3 x 300 µl TBS-4-Tween 20 
and 100 µl per well of Phos-tag™ Biotin, diluted to 1 mM in TBS-4-Tween 20 
containing zinc nitrate [100 mM], were added to each well for 1 hour at room 
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temperature on a shaker. Duplicate wells were incubated with TBS-4-Tween 20-only at 
this stage to give a control for non-specific binding of streptavidin alkaline phosphatase. 
Unbound Phos-tag™ Biotin was washed off with 3 x 300 µl TBS-4-Tween 20 before 
detecting bound Phos-tag™ Biotin with 100 µl per well of streptavidin alkaline 
phosphatase diluted to 10 nM in TBS-4-Tween 20; this was added for 1 hour at room 
temperature. A final 3 x 300 µl TBS-4-Tween 20 wash step was performed and the 
plate developed with PNPP in the same way as detailed in method 2.1.7.2. 
2.3.4.3. Western blotting with Phos-tag™ Biotin 
A serial dilution of AP-fibrinogen from 500 ng to 62.5 ng was prepared for gel loading 
by mixing with 4X reducing agent, 10X LDS sample buffer and dH2O; samples were 
then heated to 95°C for 15 minutes before electrophoresis. The protein was blotted 
onto a PVDF membrane following method 2.1.6. After blotting, the membrane was 
soaked in 100 ml TBS-4-Tween 20 pH 7.4 with gentle shaking for 1 hour at room 
temperature. During this time, a Phos-tag™ Biotin-bound Streptavidin HRP conjugate 
was prepared as described in method 2.3.4.1, except the remaining solution after 
centrifugation was diluted with 20 ml TBS-4-Tween 20. The membrane was incubated 
with 10 ml of the Zn2-Phos-tag™ Biotin-Streptavidin HRP complex for 30 minutes at 
room temperature with gentle rotation. Finally, the membrane was washed in 100 ml 
TBS-4-Tween 20 for 2 x 5 minutes and developed using SuperSignal West Pico 
Chemiluminescent Substrate and a G:BOX F3 with GeneSys software. An additional 
experiment was performed in the same way, but with an additional blot probed with 
streptavidin HRP-only (no Phos-tag™ Biotin) as a negative control for non-specific 
binding. 
2.3.5. Developing methods for the detection of phosphorylated fibrinogen using 
anti-phosphoserine antibodies 
2.3.5.1. Fibrinogen-phosphoserine ELISA 
Antibodies to fibrinogen and phosphoserine were used to develop an ELISA for the 
quantification of phosphorylated fibrinogen in conditioned medium. A 96 well microtiter 
plate was coated with rabbit polyclonal anti-fibrinogen antibody (1/250) overnight at 4°C 
in sodium carbonate pH 9.6, washed with 3 x 300 µl TBS-2-Tween 20 pH 7.4 and 
blocked with 3 % (w/v) BSA-TBS-2-Tween 20. After additional washing, AP-fibrinogen 
(25 % phosphorylation) and dephosphorylated fibrinogen were diluted to 1 µg/ml in 
TBS-2-Tween 20 and added to the plate (100 µl per well) for 2 hours at room 
temperature. The plate was washed with 3 x 300 µl TBS-2-Tween 20 and incubated 
 106 
with a concentration range of phosphoserine antibody Q5 (1/10-1/80) or mouse 
monoclonal anti-phosphoserine at 1/100. Details of antibodies can be found in table 3 
below the western blotting protocol. Both antibodies were diluted in 1 % (w/v) BSA-
TBS-2-Tween 20 and incubated overnight at 4°C with rolling. Wells were washed with 3 
x 300 µl TBS-2-Tween 20 before addition of 100 µl per well of rabbit anti-mouse HRP 
secondary antibody diluted in TBS-2-Tween-20 (1/1000) for 1 hour at room 
temperature, followed by a final washing step. The plate was developed with OPD 
substrate and absorbance measured at 490 nm using a Dynex MRX-TC plate reader. 
To reduce non-specific binding, the method was repeated with a 10 % BSA-TBS-2-
Tween 20 blocking solution and the mouse monoclonal anti-phosphoserine antibody 
was diluted in 5 % (w/v) BSA-TBS-2-Tween 20 at 4°C overnight. These improved 
blocking conditions were incorporated in subsequent experiments. For the final 
experiment, a plate was coated with mouse anti-fibrinogen γ chain antibody (1/4000) 
and later incubated with a rabbit polyclonal anti-phosphoserine antibody (1/100), 
followed by goat anti-rabbit HRP (1/1000). 
2.3.5.2. Phosphoserine western blots 
The western blotting protocol for phosphoserine detection was adapted from the 
general protocol in section 2.1.6. Ammonium sulphate precipitated fibrinogen (25 % 
phosphorylation) (0.1-5 µg) was electrophoresed and blotted onto PVDF before 
blocking in 10 % (w/v) BSA-TBS-2-Tween 20 pH 7.4 for 2 hours at room temperature. 
A mouse monoclonal anti-phosphoserine primary antibody was diluted in 5 % (w/v) 
BSA-TBS-2-Tween 20 and incubated with the blot overnight at 4°C. The blot was 
washed 4 x 15 minutes in TBS-2-Tween 20 and the rabbit anti-mouse HRP secondary 
antibody (1/5000), plus StrepTactin HRP, were added in 5 % (w/v) milk-TBS-2-Tween 
20 for 1 hour at room temperature. After 3 x 10 minute washes in TBS-2-Tween 20, the 
blot was develop by chemiluminescence with Clarity ECL Substrate. The same 
procedure was repeated using 2 µg AP-fibrinogen and dephosphorylated fibrinogen 
with a rabbit polyclonal anti-phosphoserine primary antibody and goat anti-rabbit HRP 
secondary antibody. In experiment blots, a mouse monoclonal anti-fibrinogen γ chain 
antibody was included during the primary antibody incubation step, plus an additional 
secondary antibody incubation with goat anti-rabbit HRP prior to addition of rabbit anti-
mouse HRP at 1/10,000 for γ chain detection. Probing for the fibrinogen γ chain 
enabled normalisation of phosphorylated Aα chain bands to γ chain bands during 
densitometry analysis with GeneTools software (Syngene). Refer to table 3 for details 
of antibodies and dilutions. 
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2.3.6. Investigations into the effect of IL-6 on fibrinogen expression and 
phosphorylation in HepG2 cells 
HepG2 cells were incubated with recombinant human IL-6 (expressed in HEK cells) 
(Sigma-Aldrich) to mimic acute phase conditions, addressing the question of whether 
elevated fibrinogen phosphorylation in the acute phase is due to modification inside the 
cell or in circulation. In an initial experiment, a concentration range from 5 to 80 ng/ml 
was added to the cells for 24 hours and the change in fibrinogen expression monitored 
by real-time PCR (method 2.3.6.1) to identify the optimal concentration.  
Quantification of intracellular phosphorylated fibrinogen Aα chains in the presence and 
absence of 10 ng/ml IL-6 for 24 hours was performed by PLA, as described in method 
2.3.3.2. For analysis of secreted fibrinogen, six dishes (60 mm) of HepG2 cells were 
cultured to confluence, washed once with serum-free medium and incubated with 
serum-free medium ± 10 ng/ml IL-6 in triplicate for 24 hours. Conditioned medium was 
harvested, mixed with protease and phosphatase inhibitor cocktails (Sigma-Aldrich) 
(1/500) and incubated on ice during the RNA extraction procedure (method 2.1.11.3). 
Harvested medium was subsequently concentrated to 50 µl using Amicon Ultra-0.5 
Centrifugal Filter Units with a 100 kDa MWCO and stored at -80°C until further 
analysis. The concentration of fibrinogen in each sample was measured by ELISA 
(method 2.1.2) and the degree of phosphorylation compared by SDS-PAGE and 
western blotting with an anti-phosphoserine antibody (method 2.3.5.2). Relative 
fibrinogen expression levels in the presence and absence of IL-6 were quantified by 
reverse transcription and real-time PCR, described below.  
2.3.6.1. Real-time PCR: quantifying the change in fibrinogen and casein kinase 
expression with IL-6 
Ribonucleic acid extracted from HepG2 cells incubated in the presence and absence of 
10 ng/ml IL-6 was reverse transcribed into cDNA (methods 2.1.11.3 and 2.1.12.6). The 
protocol for real-time PCR is outlined in section 2.1.12.7, with adaptations described 
here. Forward and reverse primers were designed to amplify the following human 
cDNA: fibrinogen Aα chain, CK2, Fam20A, Fam20B, Fam20C, Fam198A, Fam20B and 
18S rRNA as an internal control (table 12). Refer to section 2.1.11.4 for primer design 
and details of fibrinogen Aα chain primers. For experiments comparing fibrinogen 
expression, templates were diluted 1:10 or 1:200 for experiment and control reactions 
respectively. For experiments comparing kinase expression, RNA was diluted to 
100 ng/µl instead of 200 ng/µl (due to lower yield) prior to reverse transcription and 
cDNA templates were added to reactions undiluted (experiment) or diluted 1:100 (18S 
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rRNA control). All reactions were performed in triplicate. Real-time PCR data were 
analysed using the ∆∆Ct method by i) normalising experiment Ct values to endogenous 
control 18S rRNA Ct values (Ctexperiment - Ctcontrol = ∆Ct), ii) subtracting ∆Ct values from 
the reference ∆Ct value of the control sample (i.e. without IL-6), and iii) determining the 
relative expression in experiment samples using a 2-∆∆Ct calculation.  
 
Primer Sequence (5’ to 3’) Length (nt) Tm (°C) % GC 
CK2 Forward GCTTCCACCACAGCTCTATCA 21 59.79 52.38 
CK2 Reverse GTGTAAACTCTGGCCCTGCT 20 59.96 55 
Fam20A Forward CTGGAACAGGCGACACAAGA 20 60.25 55 
Fam20A Reverse TGCTCGCTGGAGAGACAAAG 20 60.04 55 
Fam20B Forward CAAATTGGCCAGGTGGGAGTA 21 60.27 52.38 
Fam20B Reverse CCAAAGACATCCAAGGCCACT 21 60.55 52.38 
Fam20C Forward CCATGAAACAAACGAGGGAGC 21 59.80 52.38 
Fam20C Reverse GAGCTTCTTGTCCCGTGTGA 20 59.97 55 
Fam198A Forward TGGAGGGCATAGATGGGTTTC 21 59.51 52.38 
Fam198A Reverse TCCTCGTCCCTGAAGAGTGT 20 59.89 55 
Fam198B Forward CAGAGTTCATCCAAGCAGCAG 21 59.26 52.38 
Fam198B Reverse CCAAATGCCTTGGGTCATGC 20 60.11 55 
18S rRNA Forward GTAACCCGTTGAACCCCATTC 21 59.19 52.38 
18S rRNA Reverse ACCATCCAATCGGTAGTAGCG 21 59.66 52.38 
 
 
 
2.3.7. Incubation of HepG2 cells with STSP 
Staurosporine is a potent and promiscuous ATP-competitive kinase inhibitor, which 
characteristically has no effect on G-CK activity due to a long β1-β2 loop structure 
around the ATP binding site of Fam20 proteins, impeding interaction with the inhibitor 
(Xiao et al., 2013, Meggio et al., 1995). Therefore, cells were incubated with STSP to 
determine whether fibrinogen is phosphorylated by the G-CK. As STSP induces 
Table 12. Real-time PCR primers for analysis of kinase expression in HepG2 cells. 
Forward and reverse primer sequences for amplification of casein kinase and 18S rRNA cDNA 
are displayed with nucleotide (nt) length, Tm and GC content. 
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apoptosis, the best concentration would provide effective kinase inhibition with minimal 
cell death; a concentration range of 0.5-10 µM STSP (Millipore) was added to HepG2 
cells, which were then screened for the appearance of cleaved caspase 3 – a marker 
for apoptosis – by immunofluorescence using an anti-cleaved caspase 3 antibody 
(table 11; method 2.3.2). 
A proximity ligation assay was carried out with the addition of 250-500 nM STSP for 8 
hours prior to fixing cells (method 2.3.3.2) and the number of phosphorylated fibrinogen 
Aα chains in control or STSP-treated cells was compared using ImageJ (method 
2.3.3.4). The phosphorylation status of secreted fibrinogen was also compared by 
western blotting. HepG2 cells were cultured to confluence in 60 mm dishes in full 
growth medium, washed once with serum-free medium and incubated with 0-200 nM 
STSP diluted in serum-free medium for 24 hours. Conditioned medium was harvested 
and mixed with protease and phosphatase inhibitor cocktails (1/500) before 
concentrating to 50 µl using Amicon Ultra-0.5 Centrifugal Filter Units (100 kDa MWCO). 
In a subsequent experiment, cells were cultured ± 200 nM STSP for 24 hours and 
harvested medium was concentrated to 1 ml for immunoprecipitation of fibrinogen 
(method 2.3.8). All samples were analysed by SDS-PAGE and western blotting with an 
anti-phosphoserine antibody (method 2.3.5.2). 
2.3.8. Immunoprecipitation of fibrinogen from conditioned medium 
Fibrinogen was purified from conditioned HepG2 medium by immunoprecipitation using 
Dynabeads® Magnetic Separation Technology (Life Technologies) according to the 
manufacturer’s instructions. A polyclonal anti-fibrinogen antibody (10 µg) was diluted in 
200 µl PBS-Tween 20 pH 7.4 (Appendix 1) and incubated with Dynabeads® Protein G 
for 10 minutes at room temperature with rotation. The tube was placed on a magnetic 
rack and the supernatant removed with a pipette. In this way, the Dynabeads-antibody 
complexes were washed with 200 µl PBS-Tween 20 before addition of target antigen; 
after removal of wash buffer, 1 ml fibrinogen-containing medium was added to the tube 
and incubated at room temperature for 1 hour with rotation. Supernatant was removed 
and the Dynabeads-antibody-fibrinogen complexes were washed with 3 x 200 µl PBS-
Tween 20. For elution of fibrinogen, the supernatant was removed and 20 µl 50 mM 
glycine pH 2.8 were added to the tube with 7.5 µl 4X LDS sample buffer and 3 µl 10X 
reducing agent. The mixture was heated to 95°C for 15 minutes before loading the 
supernatant on a 4-12 % Bis-Tris polyacrylamide gel. Immunoprecipitated fibrinogen 
was subjected to SDS-PAGE and western blotting with anti-phosphoserine and anti-
fibrinogen gamma chain antibodies (method 2.3.5.2), followed by Clean-Blot IP 
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Detection Kit (HRP) (Thermo Scientific) diluted 1/200 in 5 % (w/v) milk-TBS-2-Tween 
20 pH 7.4 for detection of primary antibodies without interference from denatured IgG 
bands. 
2.3.9. Reverse transfection of Fam20A siRNA into HepG2 cells 
To investigate whether Fam20A phosphorylates fibrinogen, Fam20A siRNA and a 
scrambled control siRNA (Santa Cruz Biotechnology, USA) were reverse transfected 
into HepG2 cells using Lipofectamine RNAiMAX, adhering to the protocol from Life 
Technologies. Each siRNA was resuspended in an appropriate volume of supplied 
RNase-free H2O to give a stock concentration of 10 µM. The concentration of siRNA for 
transfection was optimised using a range from 5 to 50 nM in 5 nM intervals and the 
relative knockdown in Fam20A expression determined by RNA extraction and real-time 
PCR (method 2.3.6.1). The optimised transfection protocol is described below. 
HepG2 cells were cultured to confluence in 100 mm dishes and medium was replaced 
one day ahead of transfection. In each well of a 6 well plate, 5 µl lipofectamine 
RNAiMAX and 1.5 µl Fam20A or scrambled control siRNA [5 nM] were diluted in 500 µl 
OptiMEM I reduced serum medium and incubated for 10-20 minutes at room 
temperature. Cells were trypsinised, counted using a haemocytometer (method 
2.1.13.1) and diluted to 100,000 cells/ml in antiobiotic-free growth medium before 
adding 2.5 ml (250,000) cells per well. The plate was shaken gently to evenly distribute 
cells and incubated at 37°C, 5 % CO2. Medium was replaced after 24 hours and 
incubated for a further 48 hours without change. Cells were assayed by RNA extraction 
and real-time PCR, while conditioned medium was harvested for analysis by SDS-
PAGE and western blotting with an anti-phosphoserine antibody (method 2.3.5.2). 
Harvested medium was immediately placed on ice and mixed with protease and 
phosphatase inhibitor cocktails (1/500) before concentrating to 50 µl using Amicon 
Ultra-0.5 Centrifugal Filter Units with a 100 kDa MWCO. The fibrinogen concentration 
was determined by fibrinogen ELISA with serial dilution of each sample (method 2.1.2).   
As harvested medium contained insufficient fibrinogen for downstream analysis of 
phosphoserine content, several steps were taken to improve the yield. To maximise 
cell viability, culture medium was replaced with fresh medium 12 hours post-
transfection and cells were incubated for a further 60 hours before analysis. The 
number of cells seeded per well was also increased to the upper recommended limit of 
375,000.  A final experiment was performed in the presence of 10 ng/ml IL-6 to 
increase fibrinogen expression and determine whether Fam20A is responsible for the 
elevated cellular fibrinogen Aα chain phosphorylation observed previously with IL-6; the 
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cytokine was added to cells 12 hours post-transfection for 60 hours. Harvested medium 
was concentrated to 1 ml and fibrinogen was immunoprecipitated before analysis of 
phosphoserine content by western blotting (method 2.3.8).      
2.3.10. Statistical analysis 
Data from experiments conducted three times or more (n≥3) were analysed for 
statistically significant differences using a paired, two-tailed student’s t-test, according 
to section 2.2.9. 
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Chapter 3 
Results 
3.1. Recombinant fibrinogen expression 
Recombinant WT fibrinogen was expressed using an established in-house CHO cell 
expression system. Site directed mutagenesis and transfection of mutated fibrinogen 
Aα chain constructs into CHO and Expi293F cells was carried out for expression of 
variant fibrinogen without the Ser3 and Ser345 phosphorylation sites, ultimately to 
investigate their function by comparison to WT fibrinogen. 
3.1.1. Expression and purification of recombinant WT fibrinogen 
During expression of recombinant WT fibrinogen in CHO cells, an aliquot of 
conditioned medium was removed from each harvest for further screening by ELISA to 
monitor fibrinogen secretion over time (figure 19). The average fibrinogen 
concentration from harvests 1-36 was 1.6 µg/ml, giving an estimated total of 48 mg 
fibrinogen in 30 L. The CHO cell expression system was terminated after 13 weeks (39 
harvests) due to a steady decline in productivity. 
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Figure 19.  Concentration of recombinant WT fibrinogen in each harvest of cell culture 
medium (1-36). Medium from CHO cells expressing recombinant WT fibrinogen was harvested 
every 2-3 days for 3 months. Productivity of the cells was monitored by measuring the 
fibrinogen concentration in each harvest of medium by ELISA. 
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Recombinant WT fibrinogen was precipitated out of the large volume of medium using 
ammonium sulphate and resuspended in pellet buffer. Fibrinogen was purified by IF-1 
affinity chromatography; figure 20 shows a large flow through peak, followed by a 
smaller fibrinogen-containing elution peak which was collected in fractions. On 
average, 950 µg fibrinogen were eluted per run from 5 ml supernatant. Fractions 
containing fibrinogen from later harvests were pooled separately in case of 
degradation. The final quantity of purified fibrinogen after concentration and dialysis 
was 21.96 mg.  
  
 
 
 
 
3.1.1.1. Functional analysis of recombinant WT fibrinogen 
The quality of purified recombinant WT fibrinogen was assessed by reducing SDS-
PAGE. An equal quantity of fibrinogen (15 µg) from each of the three samples of 
pooled harvests was loaded separately to compare quality, in case of degradation in 
later harvests. Figure 21 shows fibrinogen from harvests 1-29 (lane 1), 30-34 (lane 2) 
and 35-39 (lane 3). Three bands corresponding to the Aα (66kDa), Bβ (54kDa) and γ 
(48kDa) chains of fibrinogen were present in equal proportions and there appeared to 
be no degradation or reduction in quality of fibrinogen purified from later harvests. 
 
 
A 
Figure 20.  Chromatogram of recombinant WT fibrinogen purification by affinity 
chromatography. Ammonium sulphate-precipitated fibrinogen was loaded onto an IF-1 column 
in the presence of 10mM CaCl2 and eluted with 50 mM EGTA. A) Flow through peak; B) 
fibrinogen elution peak. Chromatography was performed using an ÄKTA prime system. 
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The functionality of purified recombinant WT fibrinogen was verified by means of 
turbidity and lysis assay, biotin-pentylamine incorporation rFXIII-A activity assay and a 
fibrin polymerisation time course experiment. Clot formation and fibrinolysis followed a 
typical trend (figure 22), with almost identical Lag and MaxAbs values in the presence 
or absence of rFXIII-A, plus negligible differences in clotting rate, lysis rate and 
Lys50MA (table 13).  
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Figure 21. Reducing SDS-PAGE of purified recombinant WT fibrinogen. Samples of 
purified fibrinogen (15µg) pooled from different harvests of CHO cell medium were separated by 
reducing SDS-PAGE. The Aα, Bβ and γ chains of fibrinogen are indicated with arrows and their 
respective molecular weights. MW: molecular weight marker; lane 1: harvests 1-29; lane 2: 30-
34; lane 3: 35-39. 
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Figure 22. Turbidity and lysis curves with recombinant WT fibrinogen. Recombinant WT 
fibrinogen at 0.5 mg/ml was incubated with plasminogen [35 µg/ml] in the presence (▲) and 
absence (■) of rFXIII-A [1.1 µg/ml], before addition of an activation mix containing 0.5 U/ml 
thrombin, 2.5 mM CaCl2 and 0.3 µg/ml tPA. The graph displays the change in absorbance at 
340 nm over time during clotting and lysis. Absorbance values are an average of duplicate wells 
(n=1).  
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 Lag (s) MaxAbs Clotting rate Lys50MA (s) Lysis rate 
- rFXIII-A 40 0.230 7.18 x 10-4 240 -5.18 x 10-4 
+ rFXIII-A 40 0.237 6.37 x 10-4- 258 -5.85 x 10-4- 
 
 
 
For assays involving cross-linking, rFXIII-A was expressed in E. Coli and purified by 
GST affinity chromatography, with a yield of 952 µg. Reducing SDS-PAGE and western 
blotting showed a strong rFXIII-A band at 83kDa with some minor degradation products 
and co-elution with GST (figure 23A and B). Incorporation of biotin-pentylamine was 
used as a measure of rFXIII-A activity to confirm that recombinant WT fibrinogen is a 
functional substrate for this enzyme. The results showed normal rFXIII-A-mediated 
cross-linking of pentylamine to WT fibrinogen increasing over time (figure 23C).  
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Figure 23. SDS-PAGE, western blotting and activity assay of purified rFXIII-A. A) SDS-
PAGE of purified rFXIII-A (7 µg) and GST elution fractions (4 µl). B) Western blotting of rFXIII-A 
and GST elution fractions with a sheep polyclonal anti-FXIII-A antibody (1/2000). MW: molecular 
weight marker; lane 1: Purified rFXIII-A; lane 2: GST elution fractions. C) FXIII-A activity assay. 
Incorporation of biotin-pentylamine [2.7 µM] to recombinant WT fibrinogen [40 µg/ml] by rFXIII-A 
[1.1µg/ml] in the presence of 1 U/ml thrombin and 1mM CaCl2 was determined by absorbance at 
405 nm. Average absorbance values from duplicate wells are displayed with error bars 
representing standard deviation (n=1). 
Table 13. Turbidity and lysis curve analysis. Turbidity and lysis curves generated using 
recombinant WT fibrinogen ± rFXIII-A were analysed using customised software for calculation 
of turbidimetric variables. Values are calculated from duplicate wells (n=1). 
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Fibrin clots formed in the presence of rFXIII-A were reduced and run on an SDS-PAGE 
gel to visualise α-α, α-γ and γ-γ chain polymer formation (figure 24) and to demonstrate 
cross-linking of fibrinogen chains. The γ-γ polymers appeared first at 10 minutes, 
increasing in intensity over time. Bands corresponding to α-α and α-γ polymers 
appeared from 30 minutes onwards. Coinciding with cross-linked polymer formation, 
there was a visible reduction in fibrin α and γ chain monomers. 
 
 
 
 
 
 
3.1.2. Generation of pMLP-Aα variants by site directed mutagenesis 
Site directed mutagenesis was carried out to produce variant fibrinogen Aα chain 
constructs for expression of recombinant fibrinogen without the Ser3 and Ser345 
phosphorylation sites. Agarose gel electrophoresis confirmed the integrity of purified 
DNA after the mutagenesis procedure, with clean bands at the correct molecular 
weight (6,265bp) indicating good quality templates with no degradation. Plasmids were 
also sequenced to ensure the desired mutations were present before transfection. For 
each variant, the sequencing data revealed base changes exclusive to the codons of 
interest, producing the correct protein sequences with the exception of Ser3 and 
Ser345 when translated using ExPASy Translate Tool. Excerpts of sequencing data 
demonstrating successful mutations can be found in Appendix 2. Variant constructs for 
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Figure 24. Reducing SDS-PAGE fibrin polymerisation time course. Recombinant WT 
fibrinogen [0.5 mg/ml] was incubated with rFXIII-A [1.1 µg/ml] in the presence of 0.05 U/ml 
thrombin and 1.5 mM CaCl2 for 0-180 minutes. Reduced samples were separated on a 4-12 % 
Bis-Tris polyacrylamide gel in MOPS running buffer. Fibrin α, β and γ chains and HMW cross-
linked dimers are indicated with arrows. MW: molecular weight marker (kDa); C: control 
fibrinogen (no rFXIII-A). 
117 
expression of fibrinogen Aα S3N, S345N, S3/345N, S3E, S345E, S3/345E and S345A 
were generated in this way. 
3.1.3. Transfection of pMLP-Aα variants into CHO-Bβγ cells 
Initially, CHO-Bβγ cells were transfected with pMLP-Aα S345N and the pMSVHis 
selection vector. Uptake of DNA by the cells was successfully achieved, as inferred 
from the growth of healthy colonies under selective pressure. However, when 
screening an aliquot of medium from each of the 24 selected clones by fibrinogen 
ELISA, none of the clones were found to be positive for fibrinogen secretion. To 
investigate this further, several clones were selected at random and cultured in 60 mm 
dishes for 1 week without medium change. Conditioned medium was harvested and 
the ELISA was repeated. Again, no secreted fibrinogen was detected for any of the 
clones. At this point, it was unclear whether the absence of positive clones was due to 
an inability of the cells to express non-phosphorylated fibrinogen, or due to a problem 
with the transfection method.  
The process of pMLP-Aα S345N transfection was repeated in the same way, coupled 
with transfection of pMLP-Aα WT as a control. One out of six selected WT clones was 
positive for fibrinogen expression, albeit at a low concentration of 15 ng/ml. In contrast, 
the S345N clones remained blank during the ELISA. Subsequent transfections of 
pMLP-Aα S3N and pMLP-Aα S3/345N had the same outcome. To investigate whether 
this may be an effect of losing the phosphoserine residues, phosphomimetics pMLP-Aα 
S3E and S345E, which would replace Ser3 and Ser345 with negatively charged 
glutamic acid, were also transfected into CHO-Bβγ cells. Again, the 24 well plate 
fibrinogen ELISA revealed a complete absence of secreted fibrinogen, suggesting that 
i) the phosphate groups itself, rather than its negative charge, is required for secretion, 
or ii) the problem lies within the transfection process – a conclusion which is somewhat 
weakened by the viability of pMLP-Aα WT transfection and expression. A final attempt 
to express variant fibrinogen in CHO cells was made by transfection of pMLP-Aα 
S345A to change Ser345 to alanine, which is more typically used for transfection due 
to its small, inoffensive structure. Unfortunately this still did not permit expression and 
no positive clones were detected. 
Intracellular analysis of fibrinogen was performed to establish whether the variants 
were either: i) not expressed by the cells, or ii) expressed but not secreted without the 
phosphorylation sites. Chinese hamster ovary cells transfected with WT fibrinogen 
constructs prior to this thesis (CHO-WT), and used for expression and purification of 
recombinant WT fibrinogen, were used as a positive control in these experiments. 
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Transfected CHO cells were lysed and both lysate and conditioned medium were 
analysed for fibrinogen content by western blotting. Blots were probed with a polyclonal 
anti-fibrinogen antibody (figure 25) or monoclonal anti-fibrinogen Aα chain antibody 
(figure 26). In figure 26, medium was concentrated 5X for stronger detection of 
fibrinogen; lysate was concentrated in both cases. In figure 25, the Aα, Bβ and γ chains 
of fibrinogen were all detected in lysate and conditioned medium from CHO-WT cells. 
An additional non-specific band between the Aα and Bβ chains (approximately 60 kDa) 
also appeared in the cell lysates. To determine if this band was fibrinogen-related, the 
blot was repeated without the anti-fibrinogen antibody incubation step. The results 
demonstrated that the band is a result of cross-reactivity of the secondary goat anti-
rabbit HRP antibody to another protein in CHO cells, or endogenous peroxidase 
activity. In CHO cells transfected with the S345N variant, fibrinogen bands were 
present in the lysate but were very faint. This most likely indicates unequal loading of 
fibrinogen on the gel, and could be improved by performing a cell count prior to seeding 
cells. The Bβ and γ chains of S345N fibrinogen were clearly present, while the Aα 
chain band was only just visible. In a repeat experiment, in which the blot was probed 
with a monoclonal anti-fibrinogen Aα chain antibody (figure 26), an Aα chain band was 
clearly detected for S345N fibrinogen in cell lysate, with no band in the medium. In 
contrast, the WT fibrinogen presented as a very faint band in the lysate and a strong 
band in the medium. Again, this experiment would benefit from cell counting and 
seeding cells at equal densities. The results suggest that the CHO cells were able to 
express the variant Aα chain but could not secrete it, or at least not at a sufficient level 
for detection. The question remains whether the absence of fibrinogen in the medium is 
due to very low expression levels and problems with the transfection, or whether this is 
a direct effect of mutating the phosphorylation sites. 
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Contrary to the aforementioned lysis and blotting, further investigations into fibrinogen 
expression by immunofluorescence failed to detect any variant fibrinogen Aα chain in 
CHO cells, despite positive signal in CHO-WT cells (figure 27). Ideally, more than one 
clone per variant would be screened. However, the S345N clone was the same as 
used for cell lysis and blotting, which detected low levels of Aα chain. The same anti-
fibrinogen Aα chain antibody was also used for both techniques. The absence of Aα 
chain by immunofluorescence suggests a lack, or very low level, of expression. 
Immunofluorescence may not be sensitive enough to detect these low levels of Aα 
chain. 
Figure 26. Western blotting of WT and S345N fibrinogen Aα chain from CHO cell lysate 
and medium. Lysate (L) and conditioned medium (M) from CHO cells transfected with WT or 
S345N fibrinogen constructs (clone 8) were harvested after 5 days in serum-free medium. 
Loading conditions differ to figure 25, with a 5X concentration of harvested medium for clear 
detection of the fibrinogen Aα chain.  Samples (30 µl) were separated by reducing SDS-PAGE 
and probed with a mouse monoclonal anti-fibrinogen Aα chain antibody (αC) (1/1000). MW: 
molecular weight marker. 
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Figure 25. Western blotting of WT and S345N fibrinogen from CHO cell lysate and 
medium. Chinese hamster ovary cells transfected with constructs for expression of WT or 
S345N fibrinogen (clones 8 and 21) were incubated in serum-free medium for 5 days prior to 
lysis and harvest of medium. Lysate was concentrated 5X using centrifugal filters. Lysate (L) 
and conditioned medium (M) (30 µl) were separated by reducing SDS-PAGE and probed with a 
rabbit polyclonal anti-fibrinogen antibody (Fg) (1/1000). The red box highlights a non-specific 
band in CHO cell lysates. MW: molecular weight marker. 
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Finally, fibrinogen Aα chain expression levels in CHO cells transfected with the S3N 
and S345N variant constructs were compared by RNA extraction and end-point 
RT-PCR in a single experiment. Reactions were analysed by agarose gel 
electrophoresis and the results are displayed in figure 28. A strong band at 325bp, 
representing the fibrinogen Aα chain amplification product, was present in the CHO-WT 
reaction but was absent in all of the four selected S3N clones. Faint duplicate bands 
WT Bβγ 
S3N S3E 
S345N S345E 
S3/345N 
Figure 27. Immunofluorescent staining of fibrinogen Aα chain in CHO cells. CHO-WT, 
CHO-Bβγ and CHO cells transfected with variant fibrinogen Aα chain constructs (S3N, S3E, 
S345N, S345E, S3/345N) were fixed onto an 8-well chamber slide and incubated with mouse 
monoclonal anti-fibrinogen Aα chain (red) (1.5 µg/ml) and Cy3-AffiniPure donkey anti-mouse 
(1/1000) antibodies. Mounting medium contained DAPI nucleic acid stain (blue). Images were 
captured by LSCM with a 60x oil objective lens. 
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appeared for the S345N clones, but the lower of the two bands was also present in the 
CHO-Bβ negative control, indicating contamination. The upper band is also likely to be 
contamination given its faint appearance, as well as the limitations of end-point RT-
PCR in detecting changes in expression levels, beyond confirming presence or 
absence. Real-time PCR with melting curve analysis would confirm whether or not 
these amplification products correspond to the fibrinogen Aα chain, and enable 
comparison of expression levels. The lack of fibrinogen Aα chain mRNA in transfected 
CHO cells points to a problem with transfection. However, a higher number of clones 
should be screened to ascertain if this is the case.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. RT-PCR analysis of S3N and S345N variant fibrinogen Aα chain mRNA 
expression in CHO cells. RNA was extracted from CHO-Bβγ cells (negative control) and 
transfected CHO cells expressing WT (positive control), S3N, or S345N fibrinogen. Extracted 
RNA (100 ng) was reverse transcribed and amplified using primers specific to the fibrinogen Aα 
chain [0.6 µM] (FGA; lanes 1-6) or GAPDH control (lanes 7-10) for 40 cycles. The data are from 
a single experiment (n=1). The PCR products were visualised by 2% agarose gel 
electrophoresis. M: Hyperladder I molecular weight marker; lane 1: CHO-WT; lane 2: CHO-Bβγ; 
lanes 3-6: S3N or S345N clones amplified with FGA primers; lanes 7-10: S3N or S345N clones 
amplified with GAPDH primers. S3N clones (left to right): 1, 7 12, 24. S345N clones (left to 
right): 8, 11, 21, 32. 
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3.1.4. Co-transfection of pMLP-Aα and –γ into CHO-Bβ cells 
To test the hypothesis that expression of recombinant fibrinogen in CHO cells may be 
affected by the order of transfection of Aα, Bβ and γ chain cDNA constructs, 
transfections were repeated with co-transfection of pMLP-Aα and –γ into a CHO-Bβ 
cell line. Prior to transfection, each pMLP construct was sequenced to verify sequence 
integrity. This highlighted some minor errors in the previously recorded sequences, 
however the open reading frames were of correct nucleotide sequence for translation 
of the corresponding polypeptide chains. Sequences of pMLP-Aα, -Bβ and –γ are 
displayed in Appendix 2.  
New CHO cells were purchased and transfected with linearised pMLP-Bβ and 
pSELECT-neo selection vector to establish a CHO-Bβ cell line. As individual fibrinogen 
chains are not secreted, expression of the Bβ chain in 12 selected clones was 
compared by RNA extraction and real-time PCR. Clone 12 exhibited significantly higher 
expression than other clones (figure 29) and was therefore the cell line of choice for 
subsequent co-transfection of Aα and γ chain constructs.  
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Figure 29. Comparison of fibrinogen Bβ chain expression in clones of transfected CHO 
cells by real-time PCR. CHO cells transfected with pMLP-Bβ were cultured in selection 
medium to form stable clones. Individual clones were screened for fibrinogen Bβ chain 
expression by RNA extraction and real-time PCR. Extracted RNA (20 ng) was amplified using 
primers specific to the Bβ chain [0.2 µM] for 40 cycles and the relative expression in each clone 
was compared using a 2-∆CT calculation. The clone with the highest expression (clone 12) was 
used for subsequent co-transfection of Aα and γ chain constructs. 
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The established CHO-Bβ cell line was co-transfected with pMLP-Aα WT or S345N, 
pMLP–γ and pSELECT-zeo-ncs selection vector. Cells were split into varying dilutions 
after transfection and cultured in selection medium containing zeocin at a final 
concentration of 200 µg/ml to obtain stable clones expressing fibrinogen. With 
application of selection pressure, only one set of S345N dishes (split 1/80) survived 
and formed colonies. These were transferred to a 24 well plate and screened by 
fibrinogen ELISA. The results showed that none of the medium samples contained 
fibrinogen. No colonies had formed in the other S345N dishes or any of the WT dishes 
and the cells died within a few days, suggesting one of three things: i) the transfection 
was unsuccessful, ii) the cells were diluted too much before adding selection medium, 
or iii) the concentration of zeocin in the selection medium was too high. As there had 
not previously been any problems with uptake of selection vector and stable colony 
formation, the latter two options seemed more likely. Therefore, a subsequent 
experiment was conducted to optimise zeocin concentration by transfection of 
pSELECT-zeo-mcs into CHO cells via the normal method, and incubation of 
transfected cells with medium containing a concentration range of zeocin. Cells were 
plated at different dilutions and the highest concentration of zeocin that permitted 
colony formation (150 µg/ml) was selected as the optimal concentration. The optimal 
dilution factor for cells before selection was in this case 1/40. However, a repeat 
attempt at co-transfection of pMLP-Aα and –γ was again unsuccessful, failing to 
produce healthy colonies despite plating cells at a lower dilution with less zeocin. This 
process was not repeated further due to the lengthy nature of CHO cell transfections; 
instead, a new transient transfection method using Expi293F cells was tested for 
expression of variant fibrinogen. 
3.1.5. Recombinant fibrinogen expression in Expi293F cells 
The pMLP constructs used for transfection of CHO cells were transiently transfected 
into Expi293F cells for expression of recombinant fibrinogen. Initially, pMLP-Aα WT, 
pMLP-Bβ and pMLP-γ were transfected for expression of WT fibrinogen. An aliquot of 
medium was removed on days 3, 5 and 7 post-transfection for analysis of fibrinogen 
expression by ELISA. Fibrinogen was present in the medium, with very similar 
concentrations for each day, suggesting an optimal time course of 7 days. The 
concentration of fibrinogen in medium from day 7 was 4 µg/ml, giving an overall yield of 
200 µg fibrinogen from a 50 ml culture, some of which would also be lost during 
purification. Secreted fibrinogen was visualised by western blotting with an anti-
fibrinogen antibody, which showed three clean bands at the correct molecular weights 
for the fibrinogen Aα, Bβ and γ chains (figure 30). 
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In attempt to achieve a more proficient yield, Aα WT, Aα S345N, Bβ and γ chain 
cDNAs were removed from pMLP by restriction digestion and inserted into the pmC 
vector. This vector contains a CMV promoter, which is recommended for high protein 
expression in Expi293F cells. The new constructs were analysed by agarose gel 
electrophoresis which revealed clean bands at the correct molecular weights of 
4783 bp, 4326 bp and 4178 bp for pmC-Aα, -Bβ or –γ respectively, indicating 
successful ligation of vector and insert (figure 31). Prior to Expi293F transfection, each 
pmC construct was individually transfected into CHO cells to test their viability for 
protein expression, as this is a more cost effective method. Cells were lysed and 
analysed by western blotting (figure 32). After the first attempt, only the γ chain was 
detected in the medium. A repeat attempt confirmed expression of the Bβ chain as 
well, but the WT Aα chain was not detected; this may be due to variability in 
transfection efficiency between experiments. An additional band above the Bβ chain, of 
approximately 60 kDa, is a result of non-specific interaction of the secondary antibody 
or intrinsic peroxidase acitivty, as discussed previously in section 3.1.3.  
 
 
 
 
 M        1         2         3           4 
Aα (66 kDa) 
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Figure 31. Agarose gel electrophoresis of the pmC fibrinogen expression constructs. 
Restriction digestion reactions were prepared with 4 µg pmC-Aα WT (lane 1), pmC-Bβ (lane 2), 
pmC–γ (lane 3) or pmC-Aα S345N (lane 4) maxi-preps and 30 U EcoRI. Reactions were 
incubated for 16 hours at 37°C and analysed by agarose gel electrophoresis on a 1 % gel in TE 
buffer. M: Hyperladder I molecular weight marker. 
75 
50 
Figure 30. Western blot of recombinant fibrinogen secreted by Expi293F cells transfected 
with the pMLP constructs. Conditioned medium from Expi293F cells transiently transfected 
with pMLP-Aα, -Bβ and -γ was harvested, concentrated and analysed by reducing SDS-PAGE 
and western blotting with a rabbit polyclonal anti-fibrinogen antibody (1/1000). MW: molecular 
weight marker; lane 1: Expi293F fibrinogen (20 µl); AP-fibrinogen control (300 ng). 
MW       1         2 
kDa 
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With confirmation that Bβ and γ chains could be expressed in CHO cells, pmC-Aα WT 
or S345N, pmC-Bβ and pmC-γ were transfected together into Expi293F cells for 
fibrinogen expression. Medium was harvested on day 7 and analysed by ELISA and 
western blotting. Both WT and S345N fibrinogen were successfully expressed using 
this system (figure 33). Wild-type fibrinogen was at a concentration of 10 µg/ml and 
S345N fibrinogen was at 16 µg/ml, giving a yield of 300 µg or 480 µg respectively from 
a 30 ml culture. This outcome demonstrates for the first time that fibrinogen can be 
expressed without the Ser345 phosphorylation site; however, the γ chain in S345N 
fibrinogen exhibited a slightly higher molecular weight (approximately 50 kDa) 
compared to the normal 48 kDa, which warrants further investigation. In addition, there 
was only a marginal improvement in yield after cloning into pmC. Given the high cost 
and low yield, this approach did not seem suitable for large-scale expression of 
recombinant fibrinogen variants. 
 
 
 
 
 
MW        1          2          3 
Aα (66 kDa) 
Bβ (54 kDa) 
γ    (48 kDa) 
Figure 32. Western blot of lysate from CHO cells transfected with the pmC expression 
constructs. Fibrinogen expression constructs pmC-Aα WT, -Bβ and –γ were transiently 
transfected into CHO cells and the cells were lysed 2 days later. Cell lysate (20 µl) was 
analysed by SDS-PAGE and western blotting with a rabbit polyclonal anti-fibrinogen antibody 
(1/1000) to screen for expression of the individual chains. MW: molecular weight marker; lane 1: 
AP-fibrinogen control (100 ng); lanes 2-4: lysate of CHO cells transfected with pmC-Aα (2), -Bβ 
(3) and –γ (4). A non-specific band of approximately 60 kDa is present in lysate lanes (2-4). 
Aα (66 kDa) 
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Figure 33. Western blot of recombinant fibrinogen secreted by Expi293F cells transfected 
with the pmC constructs. Conditioned medium from Expi293F cells transiently transfected with 
pmC-Aα WT or S345N, pmC-Bβ and pmC-γ was harvested and concentrated before measuring 
the fibrinogen concentration by ELISA. Fibrinogen (50 ng) was analysed by SDS-PAGE and 
western blotting with a rabbit polyclonal anti-fibrinogen antibody (1/1000). MW: molecular weight 
marker; lane 1: Calbiochem® fibrinogen control; lane 2: Expi293F WT fibrinogen; lane 3: 
Expi293F S345N fibrinogen. 
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3.2. Functional studies with fibrinogen phosphorylation isoforms 
Normally, plasma fibrinogen is approximately 20-25% phosphorylated. Due to problems 
with expression of recombinant fibrinogen lacking the Ser3 and Ser345 
phosphorylation sites, another approach was sought to investigate the function of this 
modification; this involved separation of phosphorylated from non-phosphorylated 
fibrinogen by chromatography. Functional studies were then conducted using these 
samples. 
3.2.1. Preparation of fibrinogen phosphorylation isoforms 
3.2.1.1. Separation of phosphorylated and non-phosphorylated fibrinogen by 
DEAE anion-exchange chromatography 
With a pI of 5.6, fibrinogen has a net negative charge at physiological pH. The addition 
of phosphate to fibrinogen makes the protein more negatively charged. Therefore, a 
positively charged DEAE Fast Flow column was used to bind fibrinogen, with a greater 
affinity for the phosphorylated form. Initially fibrinogen eluted as a single peak, 
therefore several parameters were optimised. The pH of the equilibration buffer was 
lowered from 8 to 6.8 and gradient time was doubled from 4 CV to 8 CV, but 
unfortunately there was still no separation of the phosphorylation isoforms. Extension 
of the gradient time to 30 CV and reduction of the binding flow rate to 0.2 ml/min 
resulted in two elution peaks, but the second peak was very small and not distinct from 
the first peak. Further doubling of the gradient time to 60 CV did not improve resolution 
or the size of the second peak. Figure 34 displays a chromatogram of the elution 
phase. The degree of phosphorylation of fibrinogen in each peak was assessed using 
the malachite green assay. The amount of phosphate in each well was determined 
from a standard curve and used to calculate the mol phosphate/mol fibrinogen. This 
was converted to a percentage of phosphorylation based on the assumption that 
fibrinogen has a theoretical maximum of 4 mol phosphate/mol fibrinogen (two sites per 
Aα chain). The results of this assay confirmed a slight enrichment of phosphorylated 
fibrinogen in the second anion exchange elution peak, from 25 % (1 mol phosphate/mol 
fibrinogen) for control AP-fibrinogen to 36 % phosphorylation (1.45 mol phosphate/mol 
fibrinogen). The first elution peak was only slightly reduced from 25.0 % to 24 % 
phosphorylation (0.94 mol phosphate/mol fibrinogen).  
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3.2.1.2. Separation of phosphorylated and non-phosphorylated fibrinogen by 
Phos-tag™ affinity chromatography 
Phos-tag™ chromatography was employed as an alternative to anion exchange 
chromatography in attempt to achieve greater separation of phosphorylated and non-
phosphorylated fibrinogen. During the first trials of this method, all of the loaded 
fibrinogen (1 mg) came through the column in the flow through and there was no 
detectable elution of bound fibrinogen. Loading more fibrinogen (4 mg) at a reduced 
flow rate of 0.1 ml/min resulted in an elution peak which was collected, dialysed against 
TBS-1 pH 7.4 and analysed by malachite green assay.  An aliquot of phosphate 
buffer-only was also dialysed against TBS-1 pH 7.4 and included in the malachite 
green assay as a control for residual NaH2PO4; unfortunately the control sample and 
the eluted fibrinogen sample both appeared overly green in the assay, indicating 
contamination with phosphate from the elution buffer due to insufficient dialysis. 
Therefore, the elution buffer was changed to 50 mM EDTA, which had an equally 
effective outcome in terms of the resulting elution peak and enabled subsequent 
analysis of phosphate content by malachite green assay. Fibrinogen in the flow through 
36 % phosphorylation 
Figure 34. Anion exchange chromatography with fibrinogen. Calbiochem® fibrinogen 
(2 mg) was applied to a DEAE Sepharose Fast Flow column and eluted with an increasing 
concentration of NaCl up to 1M. The chromatogram shows the elution phase with two peaks of 
24 % and 36 % phosphorylated fibrinogen, as determined by malachite green assay. 
Chromatography was performed using an ÄKTA prime system. 
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and elution fractions was 18 % and 50 % phosphorylated respectively. As this 
produced a greater range in degree of phosphorylation than the anion exchange 
method, Phos-tag™ chromatography was repeated several times to obtain enough 
fibrinogen from each peak for functional studies. Figure 35 shows a typical 
chromatogram of this method with flow through and elution peaks. The phosphate 
content of fibrinogen from each peak was determined by malachite green assay: 13 % 
(0.5 mol phosphate/mol fibrinogen) and 33 % (1.3 mol phosphate/mol fibrinogen) 
phosphorylation for fibrinogen from flow through and elution peaks respectively. Details 
of these samples are summarised in table 14, section 3.2.1.4. Unfortunately there was 
far less enrichment of phosphorylated fibrinogen than the first attempt. However, there 
was a 2.5-fold difference between the 13 % and 33 % samples, which mimics the rise 
in phosphorylation during the acute phase (from 20-25 % to approximately 50-70 %). 
 
 
 
 
 
 
 
 
 
13 % 33 % 
Sample inject 
Flow through Elution 
Figure 35. Phos-tag™ Agarose affinity chromatography with fibrinogen. Calbiochem® 
fibrinogen (4 mg) was loaded onto a Phos-tag™ Agarose column and the bound phosphorylated 
fibrinogen was eluted with a gradient of EDTA up to 50 mM. The chromatogram shows the point 
of sample inject as well as flow through and elution peaks, containing 13 % and 33 % 
phosphorylated fibrinogen respectively. The green lines represent EDTA concentration. 
Chromatography was performed using an ÄKTA avant 25 system. 
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3.2.1.3. Dephosphorylation of fibrinogen 
Ammonium sulphate-precipitated fibrinogen was dephosphorylated using bovine 
intestinal alkaline phosphatase and purified from the reaction mix by IF-1 affinity 
chromatography. Dephosphorylation was confirmed by malachite green assay which 
revealed a 4 % degree of phosphorylation (0.16 mol phosphate/mol fibrinogen) in the 
purified fibrinogen sample – an 84 % reduction from control levels (0.98 mol 
phosphate/mol fibrinogen) (table 14).  
3.2.1.4. Fibrinogen samples for functional studies 
As previously described in section 3.2.1.2, phosphorylated and non-phosphorylated 
fibrinogen were separated by Phos-tag™ affinity chromatography. Control 
Calbiochem® fibrinogen and dephosphorylated Calbiochem® fibrinogen were also 
purified by IF-1 affinity chromatography. Collectively, this produced four fibrinogen 
samples with varying degrees of phosphorylation:  
1. Control IF-1 purified Calbiochem® fibrinogen (25 % phosphorylation)  
2. Dephosphorylated fibrinogen (4 % phosphorylation)  
3. Phos-tag™ chromatography flow through fibrinogen (13 % phosphorylated) 
4. Phos-tag™ chromatography eluted fibrinogen (33 % phosphorylated)  
The degree of phosphorylation of each sample was determined using the malachite 
green assay. Table 14 shows a summary of malachite green assay data, including the 
percentage phosphorylation of each sample. The four samples were then compared in 
a variety of assays to investigate the functional effects of fibrinogen phosphorylation. 
 
 Control Dephosphorylated Flow through Elution 
pmol phosphate 245 40 125 325 
mol phos/mol fg 0.98 0.16 0.50 1.30 
% phosphorylation 25 4 13 33 
 
 
 
 
Table 14. Malachite green assay with Phos-tag™ chromatography peaks and 
dephosphorylated fibrinogen. The degree of phosphorylation of fibrinogen from Phos-tag™ 
chromatography flow through and elution peaks, as well as IF-1 purified control and 
dephosphorylated Calbiochem® fibrinogen, was determined by malachite green assay. The 
data are based on duplicate wells from a single experiment. For each sample, pmol phosphate 
was divided by 250 pmol fibrinogen to convert to mol phosphate/mol fibrinogen. This value was 
divided by four to calculate the percentage phosphorylation, assuming a theoretical maximum of 
4 mol phosphate/mol fibrinogen.  
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3.2.2. The effect of fibrinogen phosphorylation on the interaction between 
fibrinogen and other plasma components  
Fibrin(ogen) interacts with several other plasma proteins during coagulation, including 
FXIII, α2-AP and plasmin(ogen). Given that these proteins bind or become covalently 
cross-linked to the αC region of the fibrinogen Aα chain, in proximity to Ser345, it is 
possible that phosphorylation of fibrinogen may regulate these interactions in some 
way. Studies were therefore conducted to investigate the effect of fibrinogen 
phosphorylation on FXIII cross-linking activity, including fibrin chain cross-linking and 
incorporation of α2-AP, as well as plasminogen binding and the rate of plasmin 
digestion of fibrinogen. 
3.2.2.1. FXIII-mediated cross-linking of fibrin α and γ chains 
A biotin pentylamine incorporation assay was used to investigate the effect of 
fibrinogen phosphorylation on the cross-linking of fibrin α and γ chains by rFXIII-A, 
using phosphorylated (13 %, 25 %, 33 %) and dephosphorylated fibrinogen substrates. 
The results showed a similar trend of biotin-pentylamine incorporation over time for the 
varying degrees of phosphorylation (figure 36). The same trend was observed in three 
independent experiments and suggests that phosphorylation does not influence clot 
stabilisation via inter-chain fibrin cross-linking.  
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Figure 36. Biotin-pentylamine incorporation by rFXIII-A. Cross-linking of biotin-pentylamine 
[2.7 µM] to phosphorylated (13 %, 25 % and 33 %) and dephosphorylated (DP) fibrinogen 
[40 µg/ml] by rFXIII-A [1.1 µg/ml] in the presence of 1 U/ml thrombin and 1mM CaCl2 was 
measured over 25 minutes and detected with streptavidin alkaline phosphatase and PNPP 
substrate. The data shown are an average of three wells from a single experiment, with error 
bars representing standard deviation. The data are representative of three independent 
experiments (n=3). 
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3.2.2.2. Incorporation of α2-AP 
Two separate assays were used to monitor cross-linking of α2-AP to the fibrin α chain: 
an α2-AP incorporation assay and a clot-based plasmin generation assay. For the 
incorporation assay, phosphorylated (13 %, 25 %, 33 %) and dephosphorylated 
fibrinogen samples were converted to fibrin in the presence of thrombin and CaCl2 
before adding a master mix containing rFXIII-A and α2-AP. Incorporation of α2-AP was 
measured over 50 minutes. Figure 37 shows the graph from one of three independent 
experiments, all of which demonstrated no difference in α2-AP incorporation with the 
varying degrees of phosphorylation.  
 
 
 
 
 
 
For the plasmin generation assay, formation of a chromogenic substrate was used as a 
measure of plasmin activity, in the presence or absence of α2-AP. Results are 
displayed in figure 38. As expected, the increase in plasmin activity over time was 
delayed by the addition of plasmin inhibitor α2-AP, reaching the same plateau at 
approximately 1 hour 30 minutes without α2-AP and 2 hours 30 minutes with α2-AP. 
However, plasmin activity in clots formed from the different fibrinogen samples was 
identical whether α2-AP was included or not. This outcome was observed in three 
independent experiments. Taken together, the data from these two assays indicate that 
phosphorylation of fibrinogen neither promotes nor inhibits cross-linking of α2-AP to 
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Figure 37. α2-AP incorporation by rFXIII-A. Fibrin was formed by incubation of fibrinogen 
[80 µg/ml] with 1 U/ml thrombin and 5 mM CaCl2. Cross-linking of α2-AP [10 µg/ml] to 
phosphorylated (13 %, 25 % and 33 %) and dephosphorylated (DP) fibrin by rFXIII-A [1.1 µg/ml] 
was measured over 50 minutes and detected with a HRP-conjugated anti-α2-AP antibody 
(1/1000) and OPD substrate. The data shown are an average of three wells from a single 
experiment, with error bars representing standard deviation. The data are representative of 
three independent experiments (n=3). 
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Lys303 in the α chain, and therefore does not impact the rate of plasmin-mediated 
fibrinogen degradation by this means. 
 
 
 
 
 
 
 
 
 
3.2.2.3. Plasminogen binding 
Binding of plasminogen to phosphorylated (13 %, 25 %, 33 %) and dephosphorylated 
fibrinogen was measured by ELISA at seven concentrations of plasminogen 
(3.75-240 nM), reflecting the published binding affinity of plasminogen to fibrin 
Aα221-610 of 32 nM (Tsurupa and Medved 2001). Three separate experiments 
revealed no difference in trend between the fibrinogen samples (figure 39), implying 
that plasminogen binding to the fibrinogen αC region is not altered by phosphorylation. 
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Figure 38. Plasmin generation assay. Clots composed of phosphorylated (13 %, 25 % and 
33 %) and dephosphorylated (DP) fibrin were formed by incubation of fibrinogen samples at 
0.25 mg/ml with plasminogen [312.5 µg/ml] and rFXIII-A [1.4 µg/ml] in the absence (A) or 
presence (B) of α2-AP [1.65 µg/ml]. Clotting was activated with 0.75 U/ml thrombin and 
3.75 mM CaCl2. Absorbance was monitored over 3 hours after addition of a lysis mix containing 
tPA [0.05 µg/ml] and S225-1 chromogenic substrate [0.6 mM] as an indicator of plasmin activity. 
Blue: control (25 %); red: dephosphorylated; green: 13 %; purple: 33 %. The data are an 
average of three wells from a single experiment, and are representative of three independent 
experiments (n=3). 
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3.2.2.4. Plasmin digestion of fibrinogen 
The effect of fibrinogen phosphorylation on the rate of plasmin digestion was analysed 
using a time course experiment and non-reducing SDS-PAGE. A concentration range 
of plasmin from 27.5 nM to 440 nM at 0 and 40 minutes was tested in the first 
experiment and the optimal concentration of plasmin found to be 220 nM. At this 
concentration, fibrinogen was almost completely degraded and the bands representing 
fibrinogen fragments were clearly defined (figure 40A). A second experiment was 
conducted to optimise the time-scale, using a range of time points from 5 to 40 
minutes. The results demonstrated almost complete digestion in just 5 minutes (figure 
40B). Hence, a total duration exceeding 5 minutes would not be useful for monitoring a 
steady progression. One option to improve this method would have been to lower the 
plasmin concentration, however in the previous experiment there was still a lot of intact 
fibrinogen at the top of the lane using 110 nM plasmin. The time-course was therefore 
shortened from 40 minutes to 4 minutes with 30 second intervals for subsequent 
experiments.  
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Figure 39. Plasminogen binding assay. Phosphorylated (13 %, 25 % and 33 %) and 
dephosphorylated (DP) fibrinogen [40 µg/ml] were incubated with increasing concentrations of 
plasminogen (0-240 nM) for 1 hour. Bound plasminogen was detected with an anti-plasminogen 
HRP antibody (1/2000) and OPD substrate. The data shown are an average from three wells of 
a single experiment, with error bars of standard deviation. The data are representative of three 
independent experiments (n=3). 
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Phosphorylated (13 %, 25 %, 33 %) and dephosphorylated fibrinogen were compared 
using this method. Figure 41 shows an example gel with 0 to 4 minutes plasmin 
digestion of control fibrinogen (25 % phosphorylated) and the appearance of fibrinogen 
degradation products over time. The intensity of fragment Y and fragment D1 in stained 
SDS-PAGE gels were analysed by densitometry, normalising to total protein. The 
results, expressed as a percentage of total protein, are plotted against time in figure 42. 
The graphs represent data averaged from two independent experiments and show an 
increase in fragment Y and fragment D1 over time. There was no difference in 
fragment Y formation over time between the fibrinogen samples, but a slight decrease 
in fragment D1 formation with more phosphorylation. However, this was not significant 
and the DP sample did not fit with this trend, so it is unclear whether this effect is 
genuine or due to experimental error. A more sensitive assay may be needed to clarify 
this result. 
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Figure 40. Optimisation of a plasmin digestion time course experiment. Fibrinogen (25 % 
phosphorylated) (10 µg) was digested with plasmin for controlled time periods before inhibiting 
with LDS sample buffer. Each reaction was separated by non-reducing SDS-PAGE. A) 
Incubation of fibrinogen with 27.5-440 nM plasmin for 0 and 40 minutes. B) Incubation of 
fibrinogen with 220 nM plasmin for 0 and 5 minutes, showing rapid degradation of fibrinogen. 
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Figure 42. Densitometry of fibrinogen degradation products over time with plasmin 
digestion. Phosphorylated (13 %, 25 %, 33 %) and dephosphorylated fibrinogen samples 
(10 µg) were incubated with 220 nM plasmin for 0-4 minutes in 30 second intervals and 
separated by non-reducing SDS-PAGE. The intensity of bands corresponding to fragment Y (A) 
and fragment D1 (B) over time were analysed by densitometry and normalised to total protein in 
each lane. Results are expressed as a percentage of total protein and represent average values 
from two independent experiments (n=2). 
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Figure 41. Plasmin digestion of fibrinogen. Fibrinogen (25 % phosphorylated) (10 µg) was 
incubated with 220 nM plasmin for 0-4 minutes in 30 second intervals and reactions were 
inhibited with LDS sample buffer. Each reaction was separated by non-reducing SDS-PAGE to 
visualise the fibrinogen degradation products (indicated by arrows) and Aα chain (αC) 
degradation products. MW: molecular weight marker. The above gel is an example from one of 
two experiments with phosphorylated (13 %, 25 % and 33 %) and dephosphorylated fibrinogen. 
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3.2.3. The effect of fibrinogen phosphorylation on clot structure 
3.2.3.1. Turbidity analysis 
Comparison of fibrin fibre diameter and overall clot structure was conducted by 
spectrophotometric turbidity analyses and electron microscopy of clots composed of 
phosphorylated (13 %, 25 %, 33 %) and dephosphorylated fibrin. Turbidity data 
averaged from five independent experiments were analysed using a customised 
programme for calculation of MaxAbs and clotting rate variables. The results 
demonstrated a relationship between the degree of phosphorylation and fibre 
thickness. Higher phosphate content produced lower MaxAbs values, with a significant 
reduction from 0.068 for dephosphorylated fibrin to 0.036 for 33 % phosphorylated 
fibrin (p=0.0011) (figure 43A and B). Despite this trend, there was a negligible 
difference between MaxAbs values for the 25 % (0.044) and 13 % phosphorylated 
samples (0.046) (p=0.7727), and only a small difference between the 25 % and 33 % 
phosphorylated samples (p=0.0728). However, the decline in MaxAbs from 13 % to 
33 % phosphorylation was statistically significant (p=0.0247). The observed reduction 
in MaxAbs indicates thinner fibres with increasing phosphorylation. Clotting rate 
showed a similar trend to MaxAbs, with increasing phosphorylation levels leading to 
slower clot formation, but with less of a difference between each sample (figure 43C). 
Again, incremental differences from 13 % to 25 %, and from 25 % to 33 % 
phosphorylation were non-significant (p=0.8484 and p=0.1292 respectively), but the 
difference in clotting rate between 13 % and 33 % phosphorylation was found to be 
significant (p=0.0256). Clotting rate for dephosphorylated fibrin was higher than for 
each of the other three fibrinogens (13 %, 25 % and 33 % phosphorylation), with an 
overall reduction from 2.069 x 10-4 to 1.549 x 10-4 absorbance units/second (p=0.0033). 
Lag time was too short for comparable measurement using this method, so the effect of 
phosphorylation on the rate of lateral aggregation of protofibrils could not be inferred. 
The experiment could be repeated using a lower thrombin concentration to slow down 
this initial stage and enable comparison.  
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3.2.3.2. SEM of fibrin clots 
Electron micrographs of clots showed a visible reduction in fibre diameter with higher 
degrees of phosphorylation (figure 44), supporting the turbidity data. This was analysed 
further using image analysis software, measuring the diameters of 20 fibres from five 
different images (a total of 100 fibres) per sample. Average fibre diameters were 
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Figure 43. Analysis of fibrin clot turbidity. A) Clots composed of phosphorylated (13 %, 25 % 
and 33 %) and dephosphorylated (DP) fibrin were formed by incubation of fibrinogen samples at 
0.25 mg/ml with plasminogen [312.5 µg/ml] and rFXIII-A [1.4 µg/ml], plus an activation mix 
containing 0.75 U/ml thrombin and 3.75 mM CaCl2. The absorbance at 340 nm was recorded 
over 15 minutes. A customised software application was used for calculation of MaxAbs (B) as 
an indication of fibre thickness, and clotting rate (C) in absorbance units per second (AU/s). The 
data in A, B and C are an average of five independent experiments (n=5), with error bars 
representing standard error of the mean. Statistical significance between mean MaxAbs and 
clotting rate values is indicated by * (p<0.05), ** (p<0.01) or ns (non-significant). 
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58.6 nm, 40.6 nm, 35.6 nm and 31.7 nm for dephosphorylated fibrin, and 13 %, 25 % 
and 33 % phosphorylated fibrin respectively (figure 45A). Statistical analysis revealed 
significant differences between mean fibre diameter for each increment in 
phosphorylation level, from dephosphorylated fibrin to 13 % phosphorylation 
(p=0.0002), from 13 % to 25 % phosphorylation (p=0.0006), and from 25 % to 33 % 
phosphorylation (p=0.0055). Highly significant differences were found between 
dephosphorylated and 33 % phosphorylated fibrin, and between 13 % and 33 % 
phosphorylated fibrin (p<0.0001). The trend of lower turbidity with increasing 
phosphorylation was similar to that observed by turbidity analysis, but with more 
pronounced differences when comparing the 13 % and 33 % phosphorylated samples 
to control fibrinogen (25 % phosphorylation). A comparison of turbidity and electron 
microscopy results is displayed in figure 45B. By qualitative speculation, the electron 
micrographs also point to increased branching of fibres with more phosphate (figure 
44), but this was not confirmed by quantitative means and warrants further 
investigation.  
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Figure 44. Scanning electron micrographs of fibrin clots. Phosphorylated (13 %, 25 % and 
33 %) and dephosphorylated (DP) fibrinogen samples at 1 mg/ml were incubated with 1 U/ml 
thrombin and 10 mM CaCl2 for clot formation. Clots were fixed in 2 % (v/v) gluteraldehyde, dried 
and coated with 7nm platinum-palladium before imaging by SEM at 50,000X and 100,000X 
magnification. Five different areas from a single clot were imaged per fibrinogen sample for 
analysis of fibre diameter. True dimensions are indicated by scale bars.  
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Taken together, the results of the turbidity and SEM experiments demonstrate that 
phosphorylation of fibrinogen has a notable impact on clot structure. In addition to the 
slower clotting rate, an elevated degree of phosphorylation is likely to produce clots 
with thinner fibres and increased density due to more extensive branching – a typical 
pro-thrombotic clot structure. This highlights a detrimental role of fibrinogen 
phosphorylation in thrombosis. 
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Figure 45. Comparison of fibrin fibre diameter. A) Diameters of phosphorylated (13 %, 25 % 
and 33 %) and dephosphorylated (DP) fibrin fibres in SEM images at 50,000X magnification 
were measured using ImageJ software. A total of 100 fibres were measured over five different 
areas per clot (20 fibres per image) (n=5). Average values are displayed with error bars 
representing standard error of the mean. Statistical significance between mean fibre diameters 
is indicated by ** (p<0.01), *** (p<0.001), or **** (p<0.0001). B) Comparison of the effect of 
fibrinogen phosphorylation on fibre thickness as determined by turbidity assay (MaxAbs) and 
SEM. Data are expressed as a percentage of the control sample (25 % phosphorylation). 
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3.3. Characterisation of intracellular fibrinogen phosphorylation 
Studies were carried out using HepG2 cells to investigate the intracellular mechanism 
of fibrinogen phosphorylation in control and acute phase conditions. The main aims 
were to i) identify the subcellular site of fibrinogen phosphorylation, ii) identify the 
relevant kinase, and iii) determine whether the rise in fibrinogen phosphorylation in 
acute phase conditions occurs intracellularly or in circulation. Several methods were 
employed, including western blotting, ELISA and PLA. 
3.3.1. Immunofluorescent detection of cellular fibrinogen Aα chains 
Immunofluorescence was used to optimise various antibodies for subsequent PLA 
experiments. First, three different fibrinogen Aα chain antibodies were tested at varying 
concentrations to see which one gave the strongest signal in CHO-WT cells, with 
minimal background in CHO-Bβ cells (negative control). Neither of the rabbit polyclonal 
antibodies detected the fibrinogen Aα chain (figure 46A and B), but the mouse 
monoclonal antibody worked well at an optimal concentration of 1.5 µg/ml (figure 46C). 
 
    
  
 
 
 
 
 
CHO-Bβγ CHO-WT 
 
 
 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
C 
 
 
 
 
Figure 46. Validating antibodies for immunofluorescent detection of the fibrinogen Aα 
chain in CHO cells. CHO-WT and CHO-Bβ cells were fixed onto an 8-well chamber slide and 
incubated with antibodies to the fibrinogen Aα chain (red) at a range of concentrations. A and B: 
rabbit polyclonal anti-fibrinogen Aα chain; C: mouse monoclonal anti-fibrinogen Aα chain. 
Primary antibodies were detected with Alexa Fluor 488-Affini-Pure donkey anti-rabbit (1/1000) or 
Cy3-AffiniPure donkey anti-mouse (1/1000) secondary antibodies. Mounting medium contained 
DAPI nucleic acid stain (blue) and images were taken by LSCM with a 60x oil objective lens. 
 142 
Antibodies against PDI and TGN46 were optimised for the detection of ER and trans-
Golgi respectively. The concentrations that gave the highest signal:background ratio 
were selected for experiments; anti-PDI was used at a 1/50 dilution and anti-TGN46 
was used at a 1/200 dilution. Figure 47 shows the immunofluorescent detection of 
fibrinogen Aα chains, PDI, TGN46 and nuclei in HepG2 cells. There was significant 
overlap between fibrinogen Aα chain and ER staining, which may represent pools of 
Aα-γ complexes in the ER (Yu et al., 1984, Xia and Redman, 2001). As expected, there 
was no significant co-localisation between the fibrinogen Aα chain and Golgi marker 
TGN46, implying that assembled fibrinogen travels quickly through the cell for 
secretion. 
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 Figure 47. Immunofluorescent detection of ER and Golgi markers in HepG2 cells. HepG2 
cells were fixed onto an 8-well chamber slide and incubated with a mouse monoclonal anti-
fibrinogen Aα chain antibody (red) (1.5 µg/ml) plus an anti-PDI (ER marker; green) (1/50) or 
anti-TGN46 (trans-Golgi marker; white) (1/200) antibody. Primary antibodies were detected with 
Cy3-AffiniPure donkey anti-mouse (1/1000) or Alexa Fluor 647-AffiniPure donkey anti-sheep 
secondary antibodies (1/1000). Mounting medium contained DAPI nucleic acid stain (blue) and 
images were taken by LSCM with a 60x oil objective lens. 
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3.3.2. Detection of phosphorylated fibrinogen Aα chains in HepG2 cells by 
proximity ligation assay 
Detection of a target by PLA requires two different primary antibodies to localise in 
close proximity. Having optimised the fibrinogen Aα chain primary antibody by 
immunofluorescence, a proximity ligation assay was performed with a concentration 
range of the second primary antibody – rabbit polyclonal anti-phosphoserine. For 
optimisation purposes, phosphorylated fibrinogen was detected in CHO-WT so that 
CHO-Bβγ cells could be used as a negative control. The optimal concentration of anti-
phosphoserine that produced a reasonable signal, but with low background, was 
2.5 µg/ml. In subsequent experiments, phosphorylated fibrinogen was detected in 
HepG2 cells, as these cells express fibrinogen naturally. Markers for the ER and trans-
Golgi were included to investigate the subcellular location of fibrinogen 
phosphorylation. However, phosphorylated fibrinogen did not co-localise with either 
marker and the signals were fairly sparse (figure 48). This may suggest that, once 
phosphorylated, fibrinogen is secreted rapidly from the cell and therefore not detected 
as a build-up of signal in one specific location. To investigate this further, BFA was 
added to the cells prior to fixation to inhibit protein secretion, as discussed below. 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. Proximity ligation assay to detect phosphorylated fibrinogen Aα chain in 
HepG2 cells. HepG2 cells were fixed onto an 8 well chamber slide and probed with mouse 
monoclonal anti-fibrinogen Aα chain (1.5 µg/ml) and rabbit polyclonal anti-phosphoserine 
(2.5 µg/ml) primary antibodies in a proximity ligation assay to detect phosphorylated Aα chain 
(PαC; red). Cells were also incubated with ER marker Alexa-Fluor 488 anti-PDI (green) (1/50), 
trans-Golgi marker sheep polyclonal anti-TGN46 (white) (1/200), and DAPI nucleic acid stain 
(blue). The anti-TGN46 primary antibody was detected with Alexa Fluor 647-AffiniPure donkey 
anti-sheep (1/1000). Images were taken by LSCM with a 60x oil-objective lens. 
Nucleus  ER  
PαC  trans-Golgi  Merge  
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3.3.3. The effect of secretory pathway inhibitor Brefeldin A on fibrinogen 
phosphorylation in HepG2 cells 
Secretory pathway inhibitor, BFA, was enlisted to facilitate identification of the 
subcellular site of fibrinogen phosphorylation, and to increase signal in later 
experiments. A BFA concentration of 20 µg/ml added for 8 hours gave the best result, 
with the largest increase in signal compared to control cells. This effect is shown in 
figure 49. The average number of phosphorylated fibrinogen Aα chains per cell, in the 
presence and absence of BFA, was calculated using ImageJ software. This figure 
increased significantly with BFA, from an average of 5.0 spots per cell to 16.8 spots per 
cell. Given that BFA blocks the exit of secretory proteins from the ER, but also causes 
redistribution of enzymes from the cis- and medial-Golgi back to the ER, this build-up of 
signal after addition of BFA suggests that fibrinogen is phosphorylated before it 
reaches the trans-Golgi compartment. This rules out the possibility of phosphorylation 
occurring in the trans-Golgi, secretory vesicles or at the cell surface. On the other 
hand, it suggests fibrinogen phosphorylation is likely to occur in the ER or an early 
Golgi compartment, making CK2 and the G-CK valid candidates for the in vivo 
fibrinogen kinase. 
 
 
 
 
 
 
Figure 49. The effect of BFA on fibrinogen phosphorylation in HepG2 cells. HepG2 cells 
were incubated in the presence and absence of 20 µg/ml BFA for 8 hours before fixing. Cells 
were probed with mouse monoclonal anti-fibrinogen Aα chain (1.5 µg/ml) and rabbit polyclonal 
anti-phosphoserine (2.5 µg/ml) primary antibodies in a proximity ligation assay to detect 
phosphorylated Aα chain (PαC; red). Cells were also incubated with ER marker Alexa-Fluor 488 
anti-PDI (green) (1/50) and DAPI nucleic acid stain (blue). Images were taken by LSCM with a 
60x oil-objective lens. Three wells per group were imaged within a single experiment for 
subsequent quantitation of fibrinogen phosphorylation using ImageJ software (n=1).  
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3.3.4. Developing methods for the detection of phosphorylated fibrinogen using 
Phos-tag™ 
Alongside the intracellular detection of phosphorylated fibrinogen by PLA, several 
approaches were tested for the detection of phosphorylated fibrinogen in conditioned 
medium using Phos-tag™, including SDS-PAGE, ELISA and western blotting.  
3.3.4.1. Phos-tag™ affinity SDS-PAGE 
Control (25 % phosphorylated) and dephosphorylated fibrinogen were separated by 
Phos-tag™ affinity SDS-PAGE on a precast Phos-tag™ SuperSep gel, adhering to the 
manufacturer’s instructions. Protein was blotted onto PVDF membrane and probed with 
an anti-fibrinogen Aα chain antibody, as shown in figure 50. As the interaction between 
Phos-tag™ and phosphate is zinc-dependent, EDTA in the sample buffer was 
quenched with an equivalent concentration of zinc nitrate. However, there was some 
band distortion which may be due to chelation of Zn2+ ions by EDTA – a common 
problem with this technique. There was no difference in density or position of the Aα 
chain bands between control and dephosphorylated fibrinogen samples, each 
producing one major band and one minor band of slightly lower molecular weight. This 
may indicate that fibrinogen is not phosphorylated heavily enough for sufficient 
interaction with Phos-tag™ molecules during migration through the gel. This could be 
confirmed by loading a protein with a higher degree of phosphorylation, such as 
β-casein (5 mol phosphate/mol protein), as a control. The concentration of fibrinogen or 
Phos-tag™ in the gel could be optimised to encourage interaction. The current could 
also be reduced for slower electrophoresis and increased contact time between 
Phos-tag™ and fibrinogen molecules. 
 
 
 
 
 
         C      DP 
Figure 50. Phos-tag™ affinity SDS-PAGE and western blot. Control AP-fibrinogen (C; 25 % 
phosphorylated) and dephosphorylated (DP) fibrinogen (200 ng) were reduced and separated 
on a Phos-tag™ affinity SDS-PAGE gel containing 50 µM Phos-tag™ and 100 µM zinc chloride. 
Electrophoresis was performed at 20 mA/gel in Tricine SDS-PAGE running buffer. The gel was 
incubated in transfer buffer containing 1mM EDTA prior to western blotting. The blot was probed 
with a rabbit polyclonal anti-fibrinogen Aα chain antibody (1/1000). 
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3.3.4.2. ELISA with Phos-tag™ Biotin 
The interaction between Phos-tag™ Biotin and streptavidin HRP was utilised for 
quantification of phosphorylated fibrinogen by ELISA. In the first experiment, a serial 
dilution of fibrinogen was overlaid with a concentration range of Zn2+-Phos-tagTM Biotin-
Streptavidin HRP complex. Absorbance values increased with higher concentrations of 
Phos-tag™, but showed little variation with increasing concentrations of fibrinogen, 
suggesting the Phos-tag™ may have been binding non-specifically. A second 
experiment included a Streptavidin HRP-only control, without Phos-tag™ Biotin. 
Unfortunately, signal was present in the streptavidin HRP-only wells, indicating non-
specific binding of streptavidin HRP to fibrinogen or to the plate. This was also 
confirmed by western blotting with Phos-tag™ Biotin (described in section 3.3.4.3), 
which revealed non-specific interaction between streptavidin HRP and the fibrinogen 
Aα and Bβ chains. Therefore, streptavidin alkaline phosphatase was used in place of 
streptavidin HRP in subsequent assays, including a streptavidin alkaline phosphatase-
only control each time. Phos-tag Biotin™ and streptavidin alkaline phosphatase were 
also added separately rather than as a pre-prepared complex. The streptavidin-only 
control remained blank during this experiment, making it a more suitable option that the 
HRP-conjugate. The absorbance value for AP-fibrinogen (25 % phosphorylated) 
(0.875) was slightly higher than for dephosphorylated fibrinogen (0.651), but the 
absorbance in the blank well with no fibrinogen was also high (0.498), suggesting non-
specific binding of Phos-tag™ Biotin to the well or coating antibody. Furthermore, the 
absorbance values for experiment wells were very low after blank-subtraction, despite 
a long development time and high concentration of Phos-tag, indicating poor affinity of 
Phos-tag™ for phosphorylated fibrinogen. 
3.3.4.3. Western blotting with Phos-tag™ Biotin 
In tandem with the Phos-tag™ ELISA optimisation, Phos-tag™ Biotin was also applied 
for the detection of phosphorylated fibrinogen by western blotting. A concentration 
range of AP-fibrinogen was separated by SDS-PAGE, blotted and probed with Phos-
tag™ Biotin, followed by streptavidin HRP. The resulting blot is shown in figure 51. Two 
bands corresponding to the Aα chain and the Bβ chain of fibrinogen were detected. 
Current literature provides no evidence of Bβ chain phosphorylation, hence it is likely 
that the presence of this chain is due to non-specific binding of Phos-tag™ or 
streptavidin HRP to fibrinogen. As the Aα and Bβ chains appear in similar intensity on 
this blot, it is likely that the Aα chain is also a result of non-specific binding, rather than 
detection of phosphate. A repeat experiment was performed in duplicate with i) Zn2+-
Phos-tagTM Biotin-streptavidin HRP or ii) streptavidin HRP-only. The Aα and Bβ 
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fibrinogen chains appeared in both blots, demonstrating non-specific binding of 
streptavidin HRP to fibrinogen. Hence, this approach could not be continued. 
 
 
 
 
 
3.3.5. Developing methods for the detection of phosphorylated fibrinogen using 
anti-phosphoserine antibodies 
As with the Phos-tag™ methods discussed above, anti-phosphoserine antibodies were 
also used to detect phosphorylation of secreted fibrinogen from HepG2 cells, by ELISA 
and western blotting. 
3.3.5.1. Fibrinogen-phosphoserine ELISA 
A sandwich assay was optimised for quantification of the degree of fibrinogen 
phosphorylation relative to a standard curve with an increasing amount of fibrinogen 
and phosphoserine. Initially, a blocking solution containing 3 % (w/v) BSA was used to 
prevent non-specific binding. The phosphoserine Q5 antibody produced high 
background with no specific detection of phosphorylated fibrinogen. The mouse 
monoclonal anti-phosphoserine demonstrated only a marginal difference in absorbance 
between AP-fibrinogen (1.295) and dephosphorylated fibrinogen (1.102) at the highest 
primary antibody concentration (1/100). The blank well at this concentration had an 
absorbance of 0.655, indicating non-specific binding to the plate. This also suggests 
non-specific interactions with fibrinogen, as the absorbance value for dephosphorylated 
fibrinogen was much higher than the blank. Appropriate controls confirmed that the 
primary antibody (mouse monoclonal anti-phosphoserine) was responsible for this. 
Therefore, the percentage of BSA was increased to 10 % (w/v) and the anti-
phosphoserine antibody was added to the plate in a solution containing 5 % (w/v) BSA. 
The primary antibody incubation was also carried out at 4°C overnight for reduced 
binding kinetics in favour of specific antibody-antigen interactions. These changes 
abolished the non-specific binding of mouse monoclonal anti-phosphoserine to 
500       250       125      62.5       ng 
Aα 
Bβ 
Figure 51. Western blot of fibrinogen with Phos-tag™ Biotin. AP-fibrinogen (62.5-500 ng) 
was separated by reducing SDS-PAGE and blotted onto PVDF membrane. The membrane was 
probed with 10 ml Phos-tag™ Biotin-bound Streptavidin HRP conjugate for 30 minutes to detect 
phosphorylation.  
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fibrinogen, with absorbance values of 0.458 and 0.520 for the blank wells and 
dephosphorylated fibrinogen respectively. However, the background caused by non-
specific binding of phosphoserine antibody to the plate was still fairly high, and the 
difference in absorbance between AP- and dephosphorylated fibrinogen remained 
slight (0.250). In a final experiment, the plate was coated with a mouse anti-fibrinogen γ 
chain antibody and fibrinogen-bound phosphate detected with a rabbit polyclonal anti-
phosphoserine antibody. The HRP-catalysed reaction developed very slowly and the 
resulting absorbance values were very similar for AP-fibrinogen, dephosphorylated 
fibrinogen and the blank (no fibrinogen). This again demonstrated insufficient sensitivity 
and specificity of phosphoserine antibodies for this type of assay. 
3.3.5.2. Phosphoserine western blots 
As an alternative approach, fibrinogen was separated by SDS-PAGE and probed for 
phosphoserine by immunoblotting. The mouse anti-phosphoserine produced a clear Aα 
chain band with 1 to 5 µg AP-fibrinogen (figure 52A). However, there was also some 
non-specific detection of the Bβ chain. The rabbit polyclonal anti-phosphoserine 
produced one band corresponding to phosphorylated fibrinogen Aα chain with 2 µg AP-
fibrinogen (figure 52B). The lane with dephosphorylated fibrinogen remained blank, 
demonstrating an acceptable specificity of this antibody with the conditions used. 
Hence, this antibody was used in subsequent investigations into the effect of IL-6, 
STSP and Fam20A siRNA on the degree of fibrinogen phosphorylation in HepG2 cells. 
 
 
 
 
 
 
 
 
75 
50 
75 
kDa 
Aα 
Bβ 
 MW       0.1       0.2       0.5        1         2          5        µg 
kDa  MW       DP       C 
50 
Aα 
Figure 52. Western blotting of fibrinogen with anti-phosphoserine antibodies. 
AP-fibrinogen was separated by reducing SDS-PAGE and immunoblotted using anti-
phosphoserine antibodies. A) Phosphorylated fibrinogen (0.1-5 µg) was probed with mouse 
monoclonal anti-phosphoserine antibody (1/1000) followed by rabbit anti-mouse HRP (1/5000). 
B) Phosphorylated control fibrinogen (C; 25 % phosphorylated) and dephosphorylated 
fibrinogen (DP) (2 µg each) were probed with rabbit polyclonal anti-phosphoserine (1/100) and 
goat anti-rabbit HRP (1/5000). MW: molecular weight marker. 
A 
B 
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The four fibrinogen samples of varying degrees of phosphorylation – control, 
dephosphorylated, 13 % and 33 % – were analysed using this method to qualitatively 
support the malachite green assay data and to validate the phosphoserine blot as a 
useful tool for comparison of fibrinogen phosphorylation. An anti-fibrinogen γ chain 
antibody was also included to monitor loading of fibrinogen, for normalisation purposes. 
The blot image matched the previously described trend with a near absence of 
phosphoserine in the dephosphorylated lane, and a rise in band intensity from 13 % to 
control (25 %), to 33 % phosphorylation (figure 53).   
 
 
 
 
 
 
3.3.6. The effect of IL-6 on fibrinogen expression and phosphorylation in HepG2 
cells 
Human hepatoma cells were incubated with IL-6 to mimic the acute phase, providing a 
platform for investigating the mechanism of fibrinogen phosphorylation in these 
conditions. Real-time PCR was used to measure changes in expression of the 
fibrinogen Aα chain and relevant casein kinase enzymes with IL-6. Proximity ligation 
assay and phosphoserine immunoblotting were then used to determine the influence of 
IL-6 on the degree of fibrinogen phosphorylation after secretion from HepG2 cells.  
3.3.6.1. Optimisation of IL-6 concentration and its effect on fibrinogen 
expression 
The concentration of IL-6 was optimised using a range of 0-80 ng/ml. Interleukin-6 was 
added to the cells at increasing concentrations for 24 hours before extracting RNA for 
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Figure 53. Phosphoserine western blot of fibrinogen phosphorylation isoforms. 
Phosphorylated (13 %, 25 % (C), 33 %) fibrinogens separated by Phos-tag™ affinity 
chromatography and dephosphorylated (DP) fibrinogen (2 µg each) were separated by reducing 
SDS-PAGE and blotted onto PVDF membrane. Blots were probed with rabbit polyclonal anti-
phosphoserine (1/100) and mouse monoclonal anti-fibrinogen γ chain (1/5000) antibodies.  
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analysis of fibrinogen Aα mRNA levels. Extracted RNA was reverse transcribed into 
cDNA and analysed by real-time PCR with primers specific to the fibrinogen Aα chain, 
normalising to housekeeping gene 18S rRNA. Figure 54A shows a graph of fold-
change in fibrinogen Aα chain expression with increasing concentrations of IL-6. The 
expression increases rapidly up to 10 ng/ml IL-6 and then begins to plateau. This trend 
supports data published by Faber et al. (2012). Therefore, 10 ng/ml was selected as 
the optimal concentration of IL-6 for subsequent experiments. The effect of 10 ng/ml 
IL-6 on fibrinogen Aα chain expression was further characterised by incubation of 
HepG2 cells with the optimal concentration of IL-6 in three independent experiments. 
Ribonucleic acid was extracted from the cells each time after a 24 hour incubation 
period and reverse transcribed for real-time PCR. The data from each PCR experiment 
revealed a significant 3.5-fold increase in fibrinogen Aα chain expression in HepG2 
cells incubated with IL-6 (p=0.0442) (figure 54B), in agreement with previous reports 
(Faber et al., 2012, Igaz et al., 1998). 
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Figure 54. The effect of IL-6 on fibrinogen Aα chain expression. RNA extracted from HepG2 
cells incubated with IL-6 was reverse transcribed into cDNA and amplified (20 ng) during 
real-time PCR with fibrinogen Aα chain primers [0.2 µM] for 40 cycles. Relative expression was 
compared using a 2-∆∆Ct calculation, normalising to 18S rRNA. A) Optimisation of IL-6 
concentration. The graph shows the fold increase in fibrinogen Aα chain (αC) expression with 
increasing concentrations of IL-6 from 0-80 ng/ml added for 24 hours. The data are an average 
of triplicate wells within a single experiment (n=1). B) The fold increase in fibrinogen Aα chain 
expression after incubation with 10 ng/ml IL-6 for 24 hours. The data are an average of three 
independent experiments (n=3), with error bars representing standard error of the mean. The 
fold change in Aα chain expression is statistically significant (p<0.05) (*). 
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3.3.6.2. The effect of IL-6 on kinase expression profiles in HepG2 cells 
In searching for the kinase responsible for fibrinogen phosphorylation in vivo, HepG2 
cells were first of all screened for expression of six likely candidates: CK2, Fam20A, 
Fam20B, Fam20C, Fam198A and Fam198B. These kinases are capable of 
phosphorylating the S-X-E motif present at both Ser3 and Ser345. They also reside 
along the secretory pathway in the ER or Golgi compartments. Briefly, HepG2 cells 
were cultured under normal conditions before RNA extraction and real-time PCR with 
primers specific to each of the kinases. Figure 55 shows the relative expression of 
each of the six kinases. Cycle threshold values for Fam198A and Fam198B were late 
(> 35 cycles), indicating very low expression of these two kinases. Expression of the 
other four kinases was easily detected, with CK2 exhibiting the highest mRNA levels. 
However, this experiment was not replicated and the relative expression levels should 
therefore be interpreted with caution, given that minor variations in starting RNA 
concentrations can result in major fluctuations in 2-ΔΔCt values. 
 
 
 
 
 
 
Having confirmed expression of CK2 and the Fam20 Golgi casein kinases in HepG2 
cells, their expression profiles were compared in the presence and absence of IL-6, to 
give an indication of which enzyme might effectuate the elevation in fibrinogen 
phosphorylation during the acute phase response. HepG2 cells were incubated ± 
10 ng/ml IL-6 for 24 hours and RNA was extracted for real-time PCR analysis with the 
kinase-specific primers. Interestingly, there was no change in expression of CK2, 
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Figure 55. Relative expression of casein kinases in HepG2 cells. RNA extracted from 
HepG2 cells was reverse transcribed into cDNA and amplified (100 ng) during real-time PCR 
with primers specific to CK2 and Golgi casein kinases (Fam20A, Fam20B, Fam20C, Fam198A 
and Fam198B) [0.2 µM] for 40 cycles. Relative expression was compared using a 2-∆Ct 
calculation, normalising to GAPDH. The data shown are from triplicate wells within a single 
experiment (n=1). 
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Fam20B or Fam20C, but there was a large increase in Fam20A expression with IL-6 
(figure 56A). The experiment was repeated three times, measuring only the fold-
change in Fam20A expression each time. There was an average 6.0-fold increase in 
Fam20A expression, deemed significant by statistical analysis (p=0.0341) (figure 56B). 
As the p value reflects standard error, the dramatic rise in expression is likely to be 
more significant with a greater number of experimental repeats. This finding has 
exposed for the first time an important role of Fam20A in the hepatocellular response to 
acute phase conditions. Furthermore, it suggests that Fam20A may be responsible for 
phosphorylation of fibrinogen and/or other acute phase proteins that are secreted by 
hepatocytes and have the Golgi casein kinase S-X-E sequence recognition motif. 
 
 
 
 
 
 
 
 
 
0
1
2
3
4
5
6
7
CK2 Fam20A Fam20B Fam20C
F
o
ld
 c
h
a
n
g
e
 i
n
 e
x
p
re
s
s
io
n
0ng/ml IL-6
10ng/ml IL-6
0
1
2
3
4
5
6
7
8
0 10
F
o
ld
 c
h
a
in
g
e
 i
n
 F
a
m
2
0
A
 
e
x
p
re
s
s
io
n
ng/ml IL-6
A 
B 
Figure 56. The effect of IL-6 on casein kinase expression. HepG2 cells were incubated ± 
10 ng/ml IL-6 for 24 hours. Extracted RNA was reverse transcribed into cDNA and amplified 
(100 ng) during real-time PCR with kinase-specific primers [0.2 µM] for 40 cycles. Relative 
kinase expression was compared using a 2-∆∆Ct calculation, normalising to 18S rRNA. A) Fold 
change in expression of CK2, Fam20A, Fam20B and Fam20C with IL-6. The data are an 
average of triplicate wells within a single experiment (n=1). B) Fold increase in Fam20A 
expression with IL-6. The data are an average of three independent experiments (n=3), with 
error bars representing standard error of the mean. The fold change in Fam20A expression is 
statistically significant (p<0.05) (*). 
* 
153 
3.3.6.3. The effect of IL-6 on the degree of fibrinogen phosphorylation 
Interleukin-6 was added to HepG2 cells to monitor its effect on the degree of 
phosphorylation of intracellular fibrinogen by PLA, and of secreted fibrinogen by 
western blotting. For proximity ligation, cells were cultured on an 8-well chamber slide 
and incubated ± 10 ng/ml IL-6 (three wells each) for 24 hours before fixing. The assay 
was performed with anti-fibrinogen Aα chain and anti-phosphoserine antibodies for 
detection of phosphorylated fibrinogen inside the cell by confocal microscopy (figure 
57A). Images were then analysed using an ImageJ macro to determine the average 
number of spots per cell in each sample group. Interleukin-6 caused a 4.0-fold rise in 
the number of spots per cell from 2.1 to 8.3 (figure 57B), representing a greater number 
of phosphorylated fibrinogen molecules. However, this increase was only slightly higher 
than the 3.5-fold increase in fibrinogen expression, previously quantified by real-time 
PCR (section 3.3.7.1). In other words, the increase in phosphorylated fibrinogen was 
similar to that of the total number of fibrinogen molecules, suggesting the proportion, or 
percentage, of fibrinogen phosphorylation is unaltered by IL-6. 
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Figure 57. The effect of IL-6 on the quantity of phosphorylated fibrinogen Aα chains in 
HepG2 cells. HepG2 cells were incubated in the presence and absence of 10 ng/ml IL-6 for 24 
hours before fixing. A) Cells were probed with mouse monoclonal anti-fibrinogen Aα chain 
(1.5 µg/ml) and rabbit polyclonal anti-phosphoserine (2.5 µg/ml) primary antibodies in a PLA to 
detect phosphorylated Aα chain (PαC; red). Nuclei (blue) were stained with DAPI during 
mounting. Images were taken by LSCM with a 60x oil-objective lens. B) Individual spots were 
counted using ImageJ software. The mean number of spots per cell ± IL-6 are presented as an 
average of three wells from a single experiment (n=1), with error bars representing standard 
deviation. 
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The phosphate content of secreted fibrinogen in the presence and absence of IL-6 was 
compared by SDS-PAGE and western blotting. Three dishes of HepG2 cells (n=1) 
were cultured ± 10 ng/ml IL-6 for 24 hours before harvesting conditioned medium for 
analysis by western blotting with anti-phosphoserine and anti-fibrinogen γ chain 
antibodies. Phosphorylated Aα chain bands where much darker in IL-6 lanes compared 
to control lanes, despite consistent loading of the fibrinogen γ chain (figure 58A). 
Densitometry analysis with ImageJ revealed a 3.1-fold increase in phosphorylated Aα 
chain:γ chain ratio from 0.8 to 2.5 (figure 58B). This is equivalent to an elevated degree 
of fibrinogen phosphorylation from the 25 % control value to 78 % – a similar rise to 
that reported previously during the acute phase, although slightly higher. This result 
demonstrates for the first time that the rise in fibrinogen phosphorylation in acute phase 
conditions is mediated within the cell rather than by a circulating kinase. Unfortunately, 
this finding contradicts the PLA data with IL-6, leaving the question of which outcome is 
more reliable. It can be challenging with PLA experiments to image representative 
areas, as there is often large variability even within the same well. They are also limited 
by a lack of suitable negative control for the phosphoserine antibody. The western blot 
is a more stable approach with measurable loading and phosphorylation controls. 
However, repeat experiments are necessary to confirm the result in figure 58, and 
enable statistical analysis. 
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3.3.7. The effect of kinase inhibitor STSP on the degree of fibrinogen 
phosphorylation in HepG2 cells 
Having identified a dramatic increase in Fam20A expression in HepG2 cells incubated 
with IL-6, promiscuous kinase inhibitor STSP was enlisted to investigate whether 
fibrinogen is phosphorylated by the G-CK, which is uniquely insensitive to this inhibitor. 
Staurosporine induces apoptosis, therefore finding the right concentration was critical 
to achieve inhibition of kinases with minimal cell death. Initially, a concentration range 
of 0.5 to 10 µM STSP was tested by immunofluorescence, screening for cleaved 
caspase 3 as a marker of apoptosis. This method failed to detect any cleaved caspase 
3 which most likely reflects a problem with the antibody and a need for optimisation, as 
10 µM STSP should have been a more than adequate concentration to induce 
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Figure 58. The effect of IL-6 on the degree of phosphorylated fibrinogen secreted by 
HepG2 cells.  HepG2 cells were incubated ± 10 ng/ml IL-6 for 24 hours in triplicate. Conditioned 
medium was harvested and fibrinogen concentration determined by ELISA. A) Control 
AP-fibrinogen (C; 25% phosphorylation) and dephosphorylated (DP) fibrinogen (1 µg each), as 
well as samples of conditioned medium containing 1 µg fibrinogen, were separated by reducing 
SDS-PAGE. Western blots were probed with rabbit polyclonal anti-phosphoserine (1/100) and 
mouse monoclonal anti-fibrinogen γ chain (γC) (1/5000) antibodies. PαC: phosphorylated 
fibrinogen Aα chain; MW: molecular weight marker. B) Densitometry analysis of phosphorylated 
Aα chain bands normalised to the fibrinogen γ chain (PαC/γC). Averages of triplicate data from 
a single experiment (n=1) are displayed with error bars representing standard deviation. 
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apoptosis (Giuliano et al., 2004). Chosen concentrations were therefore based on 
observation of cell changes under the microscope. During culture, there was significant 
cell death above 1 µM, accompanied by apparent morphological changes during 
confocal microscopy, including minor changes at 500 nM. Proximity ligation was carried 
out after incubation of cells with 250 nM STSP. The results of the assay ± 250 nM 
STSP are displayed in figure 59A. There was significant detachment of cells from the 
slide during fixation, leaving few areas for imaging. Hence, the results could be slightly 
biased. Analysis of the mean number of spots per cell using ImageJ revealed a 60 % 
reduction from 13.0 to 5.2 spots per cell (figure 59B). This might indicate inhibition of 
the fibrinogen kinase by STSP, and that fibrinogen is not phosphorylated by the G-CK. 
However, this may also be an adverse effect of the toxicity of this concentration of 
STSP on the cells.  
To avoid the various issues surrounding this method, secreted fibrinogen in conditioned 
medium was analysed by western blotting, rather than looking at intracellular 
fibrinogen. First, HepG2 cells were incubated with 0, 50, 100 and 200 nM STSP for 24 
hours and the medium analysed by SDS-PAGE and western blotting with anti-
phosphoserine and anti-fibrinogen γ chain antibodies. Due to concentration of the 
medium prior to loading, the blot image was not very clear, with background and 
bulging of the lanes around the fibrinogen (figure 59C). However, the Aα chain 
appeared to be present even up to 200 nM STSP. The experiment was repeated with 0 
and 200 nM STSP and fibrinogen was immunoprecipitated before electrophoresis. This 
time, bands were much clearer but the phosphorylated fibrinogen Aα chain band was 
weaker with 200 nM STSP compared to control, supporting the PLA data. It could be 
concluded from these data that the G-CK is not responsible for fibrinogen 
phosphorylation. However, the data sets are inconsistent and the final method of 
western blot analysis with immunoprecipitation of fibrinogen should be repeated to 
confirm whether this is a genuine result. 
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Figure 59. The effect of STSP on fibrinogen phosphorylation in HepG2 cells. A) HepG2 
cells were incubated ± 250 nM STSP for 24 hours, including 8 hours with 20 µg/ml BFA.  Cells 
were probed with mouse monoclonal anti-fibrinogen Aα chain (1.5 µg/ml) and rabbit polyclonal 
anti-phosphoserine (2.5 µg/ml) primary antibodies in a PLA to detect phosphorylated Aα chain 
(PαC; red). Nuclei (blue) were stained with DAPI. Images were captured by LSCM with a 60x 
oil-objective lens. B) Individual spots were counted using ImageJ software. The average number 
of spots from three wells within a single experiment (n=1) are displayed with error bars 
representing standard deviation. C) HepG2 cells were incubated with 0, 50, 100 and 200 nM 
STSP (left hand blot), or 0 and 200 nM STSP (right hand blot) for 24 hours. Conditioned 
medium containing 1 µg fibrinogen was analysed by reducing SDS-PAGE and western blotting 
with rabbit polyclonal anti-phosphoserine (1/100) and mouse monoclonal anti-fibrinogen γ chain 
(1/5000) antibodies (left hand blot). In a repeat experiment, fibrinogen was immunoprecipitated 
prior to analysis (right hand blot). MW: molecular weight marker; C: control AP-fibrinogen; DP: 
dephosphorylated fibrinogen; PαC: phosphorylated fibrinogen Aα chain; γC: fibrinogen γ chain. 
-BFA/-STSP  +BFA/-STSP +BFA/+STSP  
         MW     0       50     100    200       nM STSP 
PαC 
γC 
75 
50 
        MW    C      DP     0      200 C kDa 
 158 
3.3.8. Knockdown of Fam20A expression in HepG2 cells with siRNA 
Expression of Fam20A is significantly elevated with IL-6 (section 3.3.6.2). To 
investigate whether Fam20A phosphorylates fibrinogen in vivo, HepG2 cells were 
transfected with siRNA to switch off expression of this kinase. For optimisation, the 
cells were transfected with a concentration range of Fam20A siRNA from 5 to 50 nM in 
5 nM intervals. Cells were assayed by real-time PCR 3 days post-transfection (figure 
60A). The siRNA transfection was successful at the lowest concentration (5 nM) which 
caused an 86 % reduction in Fam20A expression. Subsequently, the transfection was 
repeated with the optimal siRNA concentration for Fam20A siRNA and scrambled 
control siRNA. Again, RNA was extracted 3 days after transfection, and medium was 
also harvested for analysis of fibrinogen phosphorylation. A fibrinogen ELISA was 
carried out to measure the concentration of fibrinogen in each medium sample and 
unfortunately, even after concentration, the yields were too low for analysis by western 
blotting. Due to time constraints, one final experiment was performed with changes to 
the transfection protocol, including addition of IL-6 and medium change 12 hours post-
transfection, in attempt to improve the yield of fibrinogen. Ribonucleic acid was 
extracted from cells after 3 days for real-time PCR (figure 60B). The real-time PCR 
data showed a 6-fold increase in Fam20A expression with IL-6, as expected. However, 
there was only a 53 % reduction in Fam20A expression after siRNA transfection, 
indicating that the changes had compromised transfection efficiency. Further 
optimisation is necessary to achieve substantial knockdown of Fam20A expression 
with sufficient yield of fibrinogen. As for the harvested fibrinogen, ELISA data confirmed 
a good yield which enabled analysis by SDS-PAGE and western blotting with an anti-
phosphoserine antibody (figure 60C). Levels of phosphorylated fibrinogen Aα chain on 
the blot were very similar for each sample, with no apparent reduction in 
phosphorylation with the Fam20A siRNA. However, this outcome is inconclusive as the 
expression was only partially inhibited. This process should be repeated with an 
optimised siRNA transfection protocol to feasibly address the question of whether 
Fam20A phosphorylates fibrinogen. 
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Figure 60. Optimisation of Fam20A siRNA transfection. A) HepG2 cells were transfected 
with 0-15 nM Fam20A siRNA and Fam20A mRNA levels in the cells were assayed by real-time 
PCR. Extracted RNA was reverse transcribed and amplified (100 ng) with Fam20A-specific 
primers [0.2 µM] for 40 cycles. The fold-change in Fam20A expression was calculated using a 
2-ΔΔCt calculation, normalising to 18S rRNA. The data are an average of triplicate wells from a 
single experiment (n=1). B) HepG2 cells were incubated with medium only (C), 10 ng/ml IL-6 
(+IL-6), scrambled control siRNA and 10 ng/ml IL-6, or Fam20A siRNA and 10 ng/ml IL-6. 
Extracted RNA was analysed by real-time PCR in the same way as (A), to compare Fam20A 
expression. C) Fibrinogen in conditioned medium from cells in (B) was immunoprecipitated and 
analysed for phosphate content by reducing SDS-PAGE and western blotting with rabbit 
polyclonal anti-phosphoserine (1/100) and mouse monoclonal anti-fibrinogen γ chain (1/5000) 
antibodies. Lanes 1 and 2 contain purified fibrinogen controls; lanes 3-5 contain conditioned 
medium from HepG2 cells. Each lane has been loaded with 1 µg fibrinogen. Lane 1: control 
AP-fibrinogen; lane 2: dephosphorylated fibrinogen; lane 3: 10 ng/ml IL-6 only; lane 4: control 
siRNA and 10 ng/ml IL-6; lane 5: Fam20A siRNA and 10 ng/ml IL-6. MW: molecular weight 
marker; PαC: phosphorylated fibrinogen Aα chain; γC: fibrinogen γ chain. 
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Chapter 4 
Discussion 
 
In physiological circumstances, there is a delicate haemostatic balance between pro-
coagulant and anti-coagulant activities, which permits crucial vessel repair in a carefully 
executed and self-limiting fashion, so as to avoid harmful bleeding or thrombus 
formation. Disruption of this balance can have devastating consequences. Fibrin(ogen) 
is at the heart of the clotting cascade. Abnormal or variant fibrinogens can affect 
clottability and produce different fibrin clot structures. Two common polymorphisms – 
AαThr312Ala and BβArg448Lys – affect clot stiffness, compactness, porosity and 
persistence (Standeven et al., 2003, Lim et al., 2003, Ajjan et al., 2008), while a higher 
than average proportion of γ’ fibrinogen is associated with coronary artery disease and 
thrombosis, and produces clots with thinner fibres, increased branching and a weaker 
structure (Cooper et al., 2003, Allan et al., 2012). There are also many naturally-
occurring and abnormal post-translational modifications of fibrinogen that lead to 
altered clot phenotypes, affecting fibre diameter and branching, as well as clot porosity, 
stiffness and resistance to lysis, as reviewed in section 1.4. 
Fibrinogen is phosphorylated on its Aα chain at Ser3 in FpA and Ser345 in the αC 
region (Blomback et al., 1963, Blomback et al., 1966, Seydewitz et al., 1984, Wind et 
al., 2003), but the effects of this modification on the developing clot, or on fibrinolysis, 
are poorly understood. The effects of multiple kinases on the phosphorylation state of 
fibrinogen and fibrin clot structure in vitro have been characterised (Engstrom et al., 
1980, Papanikolaou et al., 1982, Guasch et al., 1986, Itarte et al., 1983, Heldin et al., 
1987a, Forsberg, 1989), but these studies produced varied and conflicting results and 
did not shed light on the situation in vivo. There is, however, an agreement that 
changes to clot architecture may have an inhibitory effect on fibrinolysis, as several 
studies have demonstrated that fibrinogen phosphorylation, both in vitro and in vivo, 
leads to increased resistance to plasmin digestion (Forsberg and Martin, 1990, Martin 
et al., 1991, Martin et al., 1992, Martin and Bjork, 1990).  
Phosphorylation of Ser3 causes faster FpA cleavage and enhanced complex formation 
with thrombin (Maurer et al., 1998), but little is known about the role of Ser345 
phosphorylation. This residue is thought to have a special function, as it is surrounded 
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by an extremely polar region with high sequence homology, including eight tandem 
repeats between residues 270 and 372 (Seydewitz et al., 1984, Rixon et al., 1983). 
Additionally, Ser345 is positioned between FXIII-a cross-linking acceptor sites (Gln328 
and Gln366) and close to the FXIII-A2B2 binding region (Smith et al., 2011, Seydewitz 
et al., 1984, Cottrell et al., 1979). Hence, phosphorylation at this site might be 
implicated in the regulation of α chain cross-linking by FXIII and lateral growth of the 
fibrin network. It may also coordinate fibrinolysis as several key proteins which function 
within this system interact with the fibrinogen αC region (Tsurupa and Medved, 2001a, 
Tsurupa and Medved, 2001b, Ritchie et al., 2000, Kimura and Aoki, 1986a).  
Over the last decade, research into the mechanism and effects of fibrinogen 
phosphorylation has been largely neglected.  Such research may be of great 
significance, as there is a body of evidence linking the phosphorylation state of 
fibrinogen with the acute phase response and thrombotic diseases (Ogata et al., 2006, 
Seydewitz et al., 1987, Seydewitz and Witt, 1985, Haglund et al., 2000, Reganon et al., 
1993, Suhre et al., 2011). Recently, two studies have flagged the importance of 
fibrinogen phosphorylation in terms of its potential biomarker or biopharmaceutical 
applications (Suhre et al., 2011, Nagel and Meyer, 2014). The ambiguity of previous in 
vitro work and difficulties with phosphorylation analysis, particularly for the Ser345 
phosphorylation site, may explain the limited progress in establishing the contribution of 
fibrinogen phosphorylation to thrombosis.   
A key aim of this investigation was to express fibrinogen Aα chain variants lacking the 
Ser3 and Ser345 phosphorylation sites, in order to assess their function. Initially, 
recombinant WT fibrinogen was expressed in CHO cells and purified by affinity 
chromatography, producing a good yield of fibrinogen with demonstrable clotting 
capability and susceptibility to FXIII-catalysed cross-linking of fibrin α and γ chains. 
Fibrinogen Aα chain constructs were mutated at Ser3 and Ser345 to non-
phosphorylatable residues, but transfecting and expressing the variant fibrinogens 
using the CHO cell system was troublesome. Recombinant WT and S345N variant 
fibrinogens were both expressed using an alternative transient transfection system with 
Expi293F cells. Although the yield was insufficient, there is potential to optimise this 
system for a much faster approach to recombinant fibrinogen expression compared to 
current methods.  
A novel phosphate capturing molecule – Phos-tag™ – was used to separate 
phosphorylated and non-phosphorylated plasma fibrinogen by affinity chromatography. 
Together with control and dephosphorylated fibrinogens, this produced four fibrinogen 
samples with varying degrees of phosphorylation for use in functional studies. In these 
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studies, the phosphorylation state of fibrinogen did not influence FXIII activity in the 
cross-linking of fibrin α and γ chains, α2-AP binding or covalent incorporation at 
Lys303, or plasminogen binding to fibrinogen. Plasmin digestion of fibrinogen was 
slightly reduced in samples with higher phosphate contents, which may indicate a 
protective effect of phosphorylation against clot lysis. Increased phosphorylation of 
fibrinogen also caused alterations to fibrin clot formation and structure, with notable 
reductions in clotting rate and fibre thickness, and an apparent increase in fibre 
branching. 
Several methods have been developed to explore the cellular mechanism of fibrinogen 
phosphorylation. A proximity ligation assay enabled detection and quantification of 
phosphorylated fibrinogen Aα chains in HepG2 cells. Secretion inhibitor BFA caused a 
significant increase in the number of fibrinogen Aα chains per cell, demonstrating that 
the intracellular phosphorylation of fibrinogen occurs before the trans-Golgi, either in 
the ER or cis/medial-Golgi compartments. Methods were also developed for analysis of 
phosphorylation levels in secreted fibrinogen. The use of anti-phosphoserine antibodies 
and Phos-tag™ Biotin for detection and quantification of phosphorylated fibrinogen by 
ELISA were deemed unsuitable due to issues with poor affinity and non-specific 
binding. However, a western blotting protocol with an antiphosphoserine antibody was 
successfully optimised to give specific detection of phosphorylated fibrinogen Aα chain. 
Real-time PCR and western blotting were used to compare fibrinogen expression and 
phosphorylation, as well as kinase expression, in the presence of acute phase-
mediator IL-6. Incubation of HepG2 cells with IL-6 caused a 3.5-fold increase in 
fibrinogen Aα chain expression and a 3.1-fold increase in the degree of fibrinogen 
phosphorylation. This has demonstrated for the first time that the elevated 
phosphorylation of fibrinogen in acute phase conditions is associated with its 
biosynthesis, rather than modification in plasma. Interleukin-6 also caused a substantial 
increase in expression of Golgi casein kinase Fam20A, suggesting this kinase has an 
important function in the acute phase response and may phosphorylate fibrinogen in 
vivo. Further investigations with kinase inhibitor STSP and Fam20A siRNA are 
ongoing. 
Overall, this work has indicated that elevated fibrinogen phosphorylation in acute phase 
conditions and thrombosis might be attributed to increased cellular kinase activity, and 
ultimately produces clots with different properties which may favour thrombosis. 
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4.1. Recombinant fibrinogen expression 
4.1.1. Wild-type fibrinogen expression in CHO cells 
An established in-house method of CHO cell transfection and protein expression was 
enlisted for the expression of recombinant WT and variant fibrinogen (Binnie et al., 
1993). Chinese hamster ovary cells are commonly used for recombinant protein 
expression due to rapid cell growth and high protein production. Expression of WT 
fibrinogen in CHO cells and subsequent purification successfully produced a good yield 
of fibrinogen, despite some loss of protein during purification. As the IF-1 affinity 
chromatography was estimated to give approximately 80 % recovery of fibrinogen 
during optimisation prior to this investigation (data not shown), protein yield was most 
likely compromised during the ammonium sulphate precipitation step, or due to 
proteolytic degradation in the medium. Analysis of purified fibrinogen confirmed correct 
subunit structure and full functionality in terms of fibrin polymerisation and lysis, and 
fibrin Aα and γ chain cross-linking in the presence of FXIII. This supports data 
published by Gorkun et al. (1997), who reported that the fibrinopeptide release, 
polymerisation and FXIII cross-linking of recombinant fibrin(ogen) resembles that of 
plasma fibrin(ogen). Preliminary mass spectrometric analysis of fibrinogen expressed 
in CHO cells has also demonstrated phosphorylation at Aα Ser3 and Ser345 residues 
(Appendix 3), in support of findings by Binnie et al. (1993), who reported a 22 % degree 
of phosphorylation at Aα Ser3 in recombinant fibrinogen expressed in CHO cells, as 
determined by HPLC experiments. Based on these results, the use of CHO cells 
seems a suitable and viable choice for the large-scale production of recombinant WT 
fibrinogen and fibrinogen Aα chain variants.  
4.1.2. Variant fibrinogen expression in CHO cells 
Unfortunately, attempts to express variant fibrinogen in CHO cells were problematic. 
Mutated fibrinogen Aα cDNA constructs were transfected into CHO-Bβγ cells for 
expression of variant fibrinogen lacking the Ser3 and/or Ser345 phosphorylation sites. 
There was an unmitigated absence of fibrinogen-secreting clones when the medium 
was screened by ELISA, which was not rectified by mutation of serine phosphorylation 
sites to alternative residues – glutamic acid (phospho-mimetic) or alanine – indicating 
that the size and charge of the replacement residue was not responsible for the failed 
expression. This leaves a few possible explanations, the first being unsuccessful 
transfection of the fibrinogen Aα chain constructs. The success of transient transfection 
of the newly cloned pmC constructs into CHO cells by CaPO4 precipitation was 
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inconsistent, and the method had to be repeated. Despite being an easy, cost-effective 
approach, the success of CaPO4 precipitation is dependent on several variables, such 
as reagent concentration, order of addition and pH. Indeed, Wright (2009) has reported 
that deviation of just 0.05 pH units from the optimal range (pH 7.05-7.15) can 
significantly affect precipitate size, compromising transfection efficiency. Cationic lipids, 
such as Lipofectamine® (Life Technologies), are highly efficient in DNA transfection 
and, depending on the cell line, are between 5- and 100-fold more effective than 
CaPO4 transfection (Felgner et al., 1987). This could therefore be a valuable 
replacement in the transfection of fibrinogen constructs into CHO cells. 
However, as the pmC constructs created for variant fibrinogen expression in Expi293F 
cells were successfully transfected into CHO cells by CaPO4 precipitation, as confirmed 
by western blotting, this is unlikely to explain the failure of each stable transfection. 
This suggests the problem may lie at the selection stage. Selection with L-histidinol 
was developed by Hartman and Mulligan (1988). During selection, L-histdinol inhibits 
protein synthesis via inhibition of histidyl-tRNA synthetase. The pMSVHis selection 
vector contains the hisD gene, which encodes histidinol dehydrogenase to catalyse the 
oxidation of L-histdinol to non-toxic L-histidine. Cells that have taken up the selection 
vector are therefore able to survive in selection medium containing L-histidinol. If the 
concentration of L-histidinol is inadequate, cells which have not taken up the vector 
may also survive and form colonies. The concentration of L-histidine in selection 
medium could therefore be re-optimised to prevent untransfected cells from surviving 
selection pressure.  
Cell lysis, immunofluorescence and RT-PCR experiments were conducted to 
investigate the presence of intracellular variant Aα chain in transfected CHO cells. Cell 
lysis and western blotting had an encouraging outcome. Although faint, an Aα S345N 
band was detected in CHO cell lysate, suggesting the transfection had worked and the 
cells were able make this variant polypeptide chain, even if it was not secreted. On its 
own, this outcome indicates that either the expression was too low to obtain a 
measurable yield of secreted fibrinogen, or that variant fibrinogen could not be 
secreted, but instead was degraded inside the cell. Incubation of CHO cells with 
proteasome and lysosome inhibitors would address this possibility. 
The results of immunofluorescence and RT-PCR experiments were not in agreement 
with the cell lysis findings. The fibrinogen Aα chain was not detected in CHO cells 
transfected with pMLP-Aα S3N, S345N, S3/345N, S3E, or S345E by 
immunofluorescence. Similarly, RT-PCR with RNA from transfected CHO cells failed to 
detect amplification of fibrinogen Aα S3N mRNA in any of the four clones that were 
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screened, while the bands corresponding to the Aα chain amplification product in 
S345N clones were very faint and may represent contamination. A better approach 
would be to use real-time PCR for quantitative comparison of Aα mRNA in each clone, 
as well as melting curve analysis to provide information on the source of each band. 
The reason for discrepancy between methods is unclear; however, the Aα chain band 
detected in S345N cell lysate is unlikely to be non-specific, given that it is at the correct 
molecular weight (66kDa). The key limitation of this work is the number of clones that 
were analysed. Healthy clones were selected at random for further analysis, but not all 
surviving clones would be expected to test positive for fibrinogen Aα chain expression. 
However, the results do collectively point to low (or absent) expression of variant 
fibrinogen Aα chain. Notably, a control transfection did result in one positive clone out 
of the six tested by fibrinogen ELISA, suggesting successful transfection of the WT Aα 
chain construct. This result implies that the problem is specific to variant fibrinogen 
expression and secretion in CHO cells, rather than the method used. However, when 
developing this method of recombinant fibrinogen expression, Lord et al. (1993) found 
that 23 out of 24 selected clones transfected with WT fibrinogen expression constructs 
were positive for fibrinogen secretion when screened by ELISA. Hence, the transfection 
efficiency was still low with the WT fibrinogen Aα chain construct. 
If reduced expression in CHO cells is specific to the Aα chain variants, it suggests there 
may be a requirement for phosphate at Ser3 and Ser345 for normal progression of 
fibrinogen along its biosynthetic pathway and release into the extracellular 
environment. Secretory proteins are transported from the ER to Golgi, where they 
migrate from the cis-Golgi compartment to the trans-Golgi network. The Golgi complex 
is a common site of protein phosphorylation due to resident kinases and translocation 
of ATP into the lumen (Capasso et al., 1989). Phosphorylation of casein – a secretory 
protein containing multiple phosphorylation sites – takes place in both the cis-Golgi (α-
casein) and trans-Golgi network (β and γ-casein) (Turner et al., 1993). The 
phosphorylation of secretory proteins can influence a phenomenon known as ‘protein 
targeting’, which refers to delivery of a protein to the correct subcellular location. For 
example, phosphorylation of furin by CK2 regulates its retrieval from the plasma 
membrane and localisation at the trans-Golgi network (Jones et al., 1995). In some 
cases, phosphorylation may regulate the sorting of proteins from the trans-Golgi 
network to secretory vesicles or lysosomes, possibly mediating a switch from one 
destination to the other in response to an extracellular stimulus. This is the case for 
aquaporin 2, whose secretion is dependent on phosphorylation at Ser256 in the Golgi 
apparatus; impaired constitutive phosphorylation of aquaporin 2 directs the protein to 
lysosomes for degradation (Procino et al., 2003). Similarly, indirectly increasing 
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phosphorylation of the amyloid precursor protein, by inhibiting phosphatases, leads to a 
rise in secretion, suggesting that non-phosphorylated molecules may be destined for 
proteolytic degradation (Caporaso et al., 1992). As well as protein targeting, 
phosphorylation may be important for correct protein folding. Misfolded proteins are 
recognised and retained in the ER by molecular chaperones prior to degradation. 
Intracellular phosphorylation can therefore prove fundamental for protein expression 
and secretion. This scenario would require all of the secretory protein in question to be 
phosphorylated inside the cell. If this were the case for fibrinogen, it would need to then 
be partially dephosphorylated either at a later stage of secretion, at the cell surface, or 
in the extracellular environment, to achieve the reported 20-25 % degree of 
phosphorylation in secreted fibrinogen (Binnie et al., 1993, Blomback et al., 1966). 
Indeed, dog fibrinogen is secreted into plasma in an almost entirely phosphorylated 
form (Kudryk et al., 1982). Furthermore, dephosphorylation of human fibrinogen in 
plasma is unlikely given that Binnie et al. (1993) have reported partial phosphorylation 
of FpA in recombinant human fibrinogen expressed in CHO cells. This finding suggests 
that the partial phosphorylation of fibrinogen occurs prior to secretion from the cell, 
unless fibrinogen is susceptible to secreted phosphatases in the conditioned medium. 
One final option to consider is the order of transfection of individual constructs and the 
ratio of each expressed chain within the cell. Published accounts of recombinant 
fibrinogen expression in CHO cells describe three types of transfection: i) transfection 
of Bβ cDNA into a CHO-Aαγ cell line for expression of wild-type or variant fibrinogen 
(Binnie et al., 1993, Ajjan et al., 2008), ii) variant γ cDNA transfection into CHO-AαBβ 
cells (Okumura et al., 1997), and iii) in the case of an Aα chain variant, co-transfection 
of Aα and γ cDNA into CHO-Bβ cells (Park et al., 2013). There is no previous report of 
transfection of fibrinogen Aα cDNA into a CHO-Bβγ cell line. It has come to light during 
this investigation that other research groups have also had difficulties with expression 
of fibrinogen Aα chain variants when transfecting in this way. Given that other 
combinations have been successful, it is possible that expression of fibrinogen is 
affected by the ratio of each chain inside the cell, which may be dictated in part by their 
order of transfection. There are known cases, such as heteromeric ion channels, where 
a defined ratio of individual polypeptides comprising a multi-subunit protein is essential 
for maintaining expression levels (Eertmoed et al., 1998, Tretter et al., 2001). Normally, 
in HepG2 cells, surplus Aα and γ chains in the ER exist as Aα-γ complexes or free γ 
chains, owing to a faster rate of synthesis in comparison to Bβ chains and retention of 
Aα-γ complexes by lectin-like chaperones (Yu et al., 1984, Tamura et al., 2013, Xia and 
Redman, 2001). For the stepwise assembly of fibrinogen, pools of Aα and γ chains 
combine with rate-limiting Bβ chain during their co-translational translocation into the 
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ER and form Bβ-Aα and Bβ-γ complexes, which combine with additional Aα and γ 
chains to form fibrinogen half-molecules and dimers.  
4.1.2.1. Co-transfection of Aα and γ chain constructs into CHO-Bβ cells 
To investigate whether the order of transfection of each construct is important for 
expression, the process was repeated according to methods used by Park et al. (2013) 
for expression of a fibrinogen variant with mutated Aα chain cross-linking acceptor 
sites. A CHO-Bβ cell line was created by transfecting the Bβ chain construct into new, 
untransfected CHO cells and screening for the best clone by real-time PCR. Co-
transfection of Aα and γ chain constructs into CHO-Bβ cells was then carried out for 
expression of fibrinogen. After transfection, cells were split and re-plated at varying 
dilutions in selection medium containing 200 µg/ml zeocin – a broad-spectrum antibiotic 
from Streptomyces verticillus which induces double-strand breaks in DNA (Chankova 
et al., 2007). Only one set of plates formed colonies, but ELISA data revealed that 
none of the selected clones secreted fibrinogen. Cells in all of the other dishes died in 
selection medium. This indicates that either the transfection hadn’t worked, or the 
concentration of zeocin was too high. The concentration of zeocin was optimised and 
lowered slightly in a subsequent transfection, but this did not resolve the problem. As 
zeocin has previously been used successfully at concentrations of 100-500 µg/ml for 
stable CHO cell transfection (Oliva-Trastoy et al., 2005, Chung et al., 2014, Van 
Blokland et al., 2011, Trapani and Korn, 2003), this might suggest that uptake of DNA 
by the cells was unsuccessful. Due to time constraints, optimisation of this method was 
not completed and it remains to be seen whether the order of transfection of fibrinogen 
constructs does indeed affect the cells’ ability to express and secrete fibrinogen. 
4.1.3. Wild-type and variant fibrinogen expression in Expi293F cells  
Due to difficulties with expression of variant fibrinogen in CHO cells, an alternative 
system was sought. Various cell lines and transgenic animals have been used for 
expression of biologically active recombinant fibrinogen, including COS-1, BHK, yeast 
Pichia pastoris, and the murine mammary gland (Roy et al., 1991, Huang et al., 1993b, 
Roy et al., 1995, Prunkard et al., 1996). Our division also uses an Expi293F cell line for 
recombinant protein expression. This cell line is derived from HEK293, from which cells 
were selected for viability in high density cultures and high yields of recombinant 
protein. According to the manufacturers (Life Technologies), transfection of Expi293F 
cells can yield up to 1 mg protein per ml of culture. Therefore, as an alternative to the 
CHO cell expression system, the three fibrinogen cDNA constructs were transiently 
transfected into an Expi293F cell line. An additional advantage over the CHO cell 
 168 
system is the timing of this method, which can be completed in just one week. The 
CHO cell system, on the other hand, takes approximately 2 months to achieve stable 
expression, followed by 2-3 months of harvesting recombinant fibrinogen. With regards 
to fibrinogen expression, the cells were able to express and secrete both WT and 
S345N fibrinogen, raising the question of why biosynthesis could be achieved in 
Expi293F cells but not in CHO cells. This may corroborate a problem with the CHO cell 
transfection methodology. Additionally, the co-transfection of all three chains during 
Expi293F transfection may be more conducive for fibrinogen expression than the lone 
transfection of Aα chain cDNA into CHO-Bβγ cells.  
It should be noted that the γ chain of S345N fibrinogen appeared to be of slightly higher 
molecular weight (approximately 50 kDa) than the WT fibrinogen γ chain (48 kDa) on 
an SDS-PAGE gel. A repeat transfection would therefore be beneficial to confirm 
whether this is a genuine effect. This is unlikely to have been caused by a problem with 
the γ chain construct or alternative splicing, given that the same construct was used for 
expression of both WT and S345N fibrinogen. Equally, the removal of the 
phosphorylation sites is unlikely to affect pre-translational events. The apparent shift in 
molecular weight may reflect additional PTM, such as glycosylation of the γ chain, 
possibly facilitated by the altered conformation of fibrinogen in the absence of 
phosphorylation. Indeed, Tagliabracci et al. (2014) have recently reported some cross-
talk between phosphorylation and O-glycosylation of secretory proteins, revealing that 
phosphorylation of fibroblast growth factor 23 (FGF23) by Fam20C inhibits 
O-glycosylation of FGF23 and promotes its cleavage. However, this scenario also 
seems unlikely given that only 25 % of Ser3 and Ser345 phosphorylation sites are 
modified intracellularly (Binnie et al., 1993), and would therefore give rise to two bands 
on the gel. The reason for this difference remains unclear and could be investigated 
further by mass spectrometry to determine the size of the polypeptide and screen for 
any additional modifications. 
Unfortunately, despite successful expression and secretion of WT and S345N 
fibrinogen in Expi293F cells, the yield was insufficient for purification and functional 
analyses, with only 300 µg and 480 µg from a 30 ml culture respectively. The 
transfection system could be scaled up to a much larger volume, using 500 ml or 1 L 
spinner flasks, but this would be a very costly approach for a small amount of 
fibrinogen. Hence, this method would be unsuitable for large-scale expression of 
recombinant fibrinogen variants. The most likely explanation for the low yield of 
fibrinogen from Expi293F cells is poor transfection efficiency, given that the cDNA for 
each fibrinogen chain was co-transfected in three separate plasmids. In terms of 
recombinant protein expression, achieving expression of a complex multi-subunit 
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protein is always more challenging than expression of a single polypeptide chain. 
Successful transfection is dependent upon integration of plasmid DNA into the genome 
by non-homologous recombination – an event which occurs with very low frequency 
(Murnane et al., 1990). Therefore, the probability of successful integration decreases 
with each additional plasmid transfected. 
One way to increase fibrinogen expression levels in Expi293F cells would be to clone 
Aα, βB and γ chain cDNA into one construct. This can be achieved using multicistronic 
vectors, whereby genes are inserted into more than one multiple cloning site, typically 
separated by internal ribosome entry sites (IRES) for attachment of ribosomes to the 
mRNA transcript and production of separate polypeptide chains (Gurtu et al., 1996, 
Zhu et al., 1999). However, the widely used IRES sequence has two important 
limitations: i) its large size (>500 nucleotides), and ii) reduced transfection efficiency of 
genes after the IRES sequence, leading to differential expression of each gene (de 
Felipe, 2002). An alternative is the use of 2A viral peptides, which provide a ‘ribosomal-
skip’ site for release of individual polypeptides (Szymczak et al., 2004). These peptides 
yield a more even stoichiometry than IRES, but do leave a 2A tag at the end of the 
expressed protein. Both of these methods can also be very time consuming. A novel 
cloning strategy – site-specific recombinational cloning – is becoming more popular 
due to ease of use and high efficiency. An example of a recombinational cloning 
system is the Multisite Gateway® Technology (Cheo et al., 2004). This system exploits 
integrase-mediated recombination between two attachment sites and enables parallel 
transfer of multiple cDNA molecules into the same vector, whilst maintaining their 
correct orientation and reading frame (Hartley et al., 2000, Park and Labaer, 2006). 
This approach could be applied to expression of recombinant fibrinogen variants, 
making for an easier, more effective expression system regardless of the cell line of 
choice.  
4.2. The functional effects of fibrinogen phosphorylation 
4.2.1. Chromatographic enrichment of phosphorylated fibrinogen 
4.2.1.1. Anion exchange chromatography 
As an alternative to expression of recombinant fibrinogen variants, commercial plasma 
fibrinogen (25 % phosphorylated) was subjected to chromatographic procedures to 
produce fibrinogen samples with varying degrees of phosphorylation. Separation of 
phosphorylated and non-phosphorylated proteins by anion exchange chromatography 
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can be heavily influenced by the pH of the equilibration buffer, which should be as 
close as possible to the pI of the protein, without risking precipitation. This would result 
in a weaker affinity between the non-phosphorylated protein and the column, enabling 
earlier elution and better separation. Despite optimisation of the equilibration buffer pH, 
as well as gradient time and flow rate, the enrichment of fibrinogen phosphorylation 
was still small (from 25 % to 36 %) and peaks were not resolved. It may not be possible 
to achieve adequate separation of phosphorylated and non-phosphorylated fibrinogen 
using this method if the degree of phosphorylation does not cause a large enough shift 
in pI. Egg white-constituent ovalbumin has two phosphorylation sites and can be 
separated into three peaks by strong anion exchange chromatography. Different 
grades of ovalbumin with a phosphate/protein mole ratio ranging from 0.37 to 1.64 
have been compared using this technique (Kornfeld et al., 2009). Interestingly, ratios of 
1.14 mol phosphate/mol ovalbumin and below resulted in poor resolution of peaks. As 
fibrinogen molecules have only 0.8-1.0 mol phosphate, this may explain the inadequate 
separation. Furthermore, if phosphorylated fibrinogen molecules are not all fully 
phosphorylated (4 mol phosphate/mol fibrinogen), but instead represent a mixture of 1, 
2, 3 or 4 mol phosphate/mol fibrinogen, the change in pI would be smaller and 
separation would be more difficult.  
4.2.1.2. Phos-tag™ affinity chromatography 
Due to the poor separation of phosphorylated and non-phosphorylated fibrinogen by 
anion exchange chromatography, another method was sourced. Phos-tag™ is an 
alkoxide-bridged dinuclear zinc(II) complex which recognises phosphate monoester 
dianions (Kinoshita et al., 2004). Phos-tag™ Agarose can be used for enrichment of 
phosphorylated proteins by affinity chromatography. The ideal enrichment of fibrinogen 
phosphorylation would have been from 25 % to between 50 and 70 % to mimic the 
phosphorylation levels in acute phase conditions. Although not as effective as hoped, 
Phos-tag™ chromatography did produce two fibrinogen samples with a much greater 
difference in phosphorylation (13 % and 33 %) compared to those from anion 
exchange chromatography (24 % and 36 %). In fact, the difference in phosphorylation 
between the two fractions was similar to the difference between control fibrinogen 
(25 % phosphorylation) and acute phase fibrinogen (50-70 % phosphorylation). 
Therefore, this method was successful in generating fibrinogen samples that could be 
used to investigate the function of phosphorylation.  
However, the limited enrichment of phosphorylated fibrinogen (from 25 % to 33 %) 
suggests there may be poor affinity of Phos-tag™ for fibrinogen. Kinoshita et al. (2005) 
have described the use of a Phos-tag™ Agarose affinity chromatography column for 
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retrieval of phosphorylated ovalbumin, αS1-casein and β-casein, which have two, eight 
and five phosphorylated serine residues respectively. Each phosphoprotein was 
retained by the column and eluted with phosphate buffer, with ovalbumin appearing 
first due to its lesser degree of phosphorylation. The specificity of the method was 
confirmed using dephosphorylated samples of each protein. Prior to optimisation, this 
same method was followed for the separation of phosphorylated and non-
phosphorylated fibrinogen, but was unsuccessful under these conditions. This may 
reflect differences in protein characteristics, such as structure and conformation, or 
differences in the number of phosphorylated residues per protein molecule.  
Another important consideration in assessing the efficacy of this method is the 
distribution of the 25 % of phosphorylated sites between fibrinogen molecules. For 
example, the presence of one to two phosphorylation sites out of four possible 
phosphorylation sites per molecule (two per Aα chain) would convey a 25-50% degree 
of phosphorylation, yet close to 100 % of molecules could potentially contain at least 
one phosphoserine capable of interacting with the column. This could well be the case, 
as Nagel and Meyer (2014) found a 1:1:1 ratio of non-, mono- and di-phosphorylated 
fibrinogen Aα chains, with a 55-71 % proportion of mono- or di-phosphorylated Aα 
chains, in healthy patient samples by liquid chromatography-mass spectrometry. In 
other words, approximately only one third of fibrinogen Aα chains were non-
phosphorylated. However, they did report large variation in the percentage of non- and 
di-phosphorylated fibrinogen Aα chains between patients. On the other hand, given 
that 67 % of fibrinogen phosphorylation sites in the elution fraction were non-
phosphorylated, this might indicate interaction of non-phosphorylated fibrinogen with 
the column. This could be explained by an affinity of Phos-tag™ for other anionic 
residues within fibrinogen, which would also provide competition for specific binding. 
Furthermore, this would support findings from the Phos-tag™ western blotting and 
ELISA experiments (sections 3.3.4.2 and 3.3.4.3), which failed to detect 
phosphorylated fibrinogen and also highlighted non-specific interaction between 
Phos-tag™ and fibrinogen.  
Phosphoserine antibodies exhibit notoriously poor sensitivity and specificity. Unlike 
phosphotyrosine antibodies, which are highly selective, phosphoserine and 
phosphotyrosine antibodies are dependent on the surrounding amino acid sequence as 
well as the phosphorylated side chain itself (Dhein, 2005, Vogel, 2008). This means 
that these antibodies bind a limited range of phosphorylated sites, and can cross-react 
with similar sequences in the absence of phosphorylation. The low specificity of anti-
phosphoserine and anti-phosphothreonine antibodies undermines the use of 
immunoaffinity chromatography for the enrichment of phosphorylated proteins, but 
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there are additional affinity chromatography procedures that might be fitting for this 
purpose. Phosphoproteins can be enriched by immobilised metal affinity 
chromatography (IMAC), in which positively charged metal ions, such as Fe3+, Ga3+, 
Al3+ and Zr4+, are coupled to a stationary phase and interact with negatively charged 
phosphate groups. Phosphoproteins are then eluted with EDTA, phosphate buffer or a 
buffer with alkaline pH (Thingholm and Jensen, 2009). Similarly, metal oxide/hydroxide 
affinity chromatography (MOAC) relies on the affinity of phosphate for metal oxides (i.e. 
titanium dioxide) or hydroxides (i.e. aluminium hydroxide), which have a positively 
charged surface at acidic pH; this is currently the most common technique used prior to 
analysis of protein phosphorylation by mass spectrometry (Wolschin et al., 2005, Dunn 
et al., 2010). However, both methods have their drawbacks. One limitation is the non-
specific binding of acidic protein residues such as glutamic or aspartic acid. In addition, 
proteins with multiple phosphorylation sites bind with high affinity to MOAC columns, 
making elution difficult (Batalha et al., 2012). This would make IMAC a more promising 
option for enrichment of phosphorylated fibrinogen. 
Fibrinogen samples separated by Phos-tag™ affinity chromatography were 13 % and 
33 % phosphorylated. The 2.5-fold increase between the highest and least 
phosphorylated samples is similar to the difference between normal and acute phase 
levels in vivo (from 20-25 % to 50-70 %), but any comparisons would be based on the 
assumption of a linear relationship between the degree of phosphorylation and its 
functional effect. Price et al. (1994) have reported a hyperbolic (i.e. linear until 
saturation) dependence of phosphoprotein activity on kinase activity if only one serine 
is phosphorylated. With two phosphoserines, the relationship becomes sigmoidal, 
meaning the change in phosphoprotein activity would be larger than that of kinase 
activity. If phosphorylated fibrinogen isoforms exist with less than 4 mol phosphate, it is 
possible that the effect of increasing phosphorylation from 20-25 % to 50-70 % might 
be greater than that observed here between the 13 % and 33 % samples, due to fewer 
mono-phosphorylated Aα chains. This scenario is unlikely, however, as both 
phosphorylation sites would need to have the same function in order to exhibit this 
cooperative activity. Although the function of Ser345 has yet to be confirmed, it is 
unlikely to be the same as Ser3 in facilitating interaction with thrombin. 
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4.2.2. The effect of fibrinogen phosphorylation on interactions with other plasma 
components 
4.2.2.1. FXIII-A activity 
Phosphorylated fibrinogen isoforms separated by Phos-tag™ affinity chromatography 
were compared in a variety of assays to determine whether the phosphorylation sites 
promote or inhibit the interaction of fibrinogen with other plasma components, including 
FXIII, α2-antiplasmin and plasmin(ogen). In addressing the question of whether 
phosphorylation alters FXIII cross-linking and stabilisation of fibrin clots, two glutamine 
cross-linking acceptor residues located either side of the Ser345 phosphorylation site – 
Gln328 and Gln366 – are of particular interest. Additional glutamine acceptor sites 
Gln221 and Gln237 may also be affected, as well as several lysine donor residues: 
Lys539, Lys556, Lys580, Lys601 (Matsuka et al., 1996). The results of the biotin 
pentylamine incorporation FXIII-A activity assay showed no difference between 
samples, suggesting that phosphorylation of Ser345 does not affect the FXIII-A-
mediated cross-linking of adjacent fibrin α and γ chains to glutamine acceptor residues 
in the fibrin α chain. However, this does not rule out a potential effect of 
phosphorylation on the availability of fibrin α chain lysine donor residues, which could 
be investigated in a similar assay using a biotin-TVQQEL-OH glutamine donor 
substrate, as described by Smith et al. (2013).  
Moreover, the result of the biotin pentylamine incorporation FXIII-A activity assay does 
not dismiss an effect of fibrinogen phosphorylation on the cross-linking of fibrin α and γ 
chains by FXIII-A2B2. Smith et al. (2011) have demonstrated that both FXIII-A and 
FXIII-A2B2 bind to the αC region of fibrinogen in close proximity to Ser345, at residues 
389-403 and 371-425 respectively. There is evidence to suggest that the B subunits of 
FXIII-A2B2 are important in the binding of this transglutaminase to fibrin(ogen). Firstly, 
the surface of the A subunits of FXIII-A2B2 are largely covered by the B subunits for 
protection from proteolytic digestion (Souri et al., 2008). In addition, FXIII-A has 
relatively low affinity for the αC region of fibrinogen (Kd of ~2.35 ± 0.09 µM), in contrast 
to the high affinity interaction between FXIII-A2B2 and the αC region of fibrinogen (Kd 
of < 35 nM) (Smith et al., 2011). Therefore, under physiological conditions, 
phosphorylation of fibrinogen may affect the nearby anchoring of the B subunits of 
FXIII-A2B2 to residues 371-425 of the fibrinogen αC region, thereby affecting cross-
linking activity.  
The dissociation of the A and B subunits of FXIII-A2B2 is a two-step process, requiring 
initial proteolytic activation by thrombin, followed by full dissociation in the presence of 
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Ca2+ ions. Credo et al. (1981) have shown that the presence of fibrinogen during this 
dissociation significantly lowers the Ca2+ requirement from 10 mM to 1.5 mM, and 
reported that residues 242-424 are important for this Ca2+-modulating function of 
fibrinogen in FXIII activation. Three high affinity calcium binding sites are present in 
fibrinogen – two in fragment D between γ311 and γ336 (Lindsey et al., 1978, Dang et 
al., 1985b), and one in the N-terminal disulphide knot in the central domain 
(Nieuwenhuizen et al., 1982, Nieuwenhuizen et al., 1983). Sialic acid residues on 
fibrinogen function as additional low affinity calcium binding sites (Marguerie et al., 
1977, Dang et al., 1989). Similarly, phosphate groups on proteins can also act as 
carriers of Ca2+ ions, such as those on casein and other proteins phosphorylated by the 
G-CK that are involved in biomineralisation processes (Tagliabracci et al., 2012, West, 
1986). Hence, phosphorylation of fibrinogen may also affect the rate of dissociation of 
the A and B subunits of FXIII-A2B2 through altered Ca2+ binding, either directly with 
phosphorylated Ser345, or by conformational change leading to exposure of Ca2+ 
binding sites in fibrinogen. 
4.2.2.2. Binding and cross-linking of α2-AP  
In addition to cross-linking of fibrin α and γ chains, the effect of fibrinogen 
phosphorylation on the binding and cross-linking of α2-AP to fibrin was investigated by 
means of an α2-AP incorporation assay and a plasmin generation assay. Recombinant 
FXIII-A was included in each assay for covalent incorporation of α2-AP, as well as 
binding. Alpha-2-antiplasmin is cross-linked to the fibrin(ogen) αC region at Lys303 
(Kimura and Aoki, 1986a). More recently, high affinity binding of α2-AP to fibrin(ogen) 
fragments D1 and D-D, as well as the αC region and αC domain of fibrin(ogen), has 
also been characterised, with a proposed function of providing the proper orientation of 
cross-linking sites (Tsurupa et al., 2010).  Tsurupa et al. (2010) demonstrated that 
these binding sites are cryptic in fibrinogen but available in fibrin, or adsorbed 
fibrinogen. In both assays, fibrinogen was converted to fibrin by addition of thrombin 
and Ca2+, permitting interaction with α2-AP. 
The α2-AP incorporation assay and plasmin generation assay both produced identical 
graphical trends for each fibrinogen sample, regardless of the degree of 
phosphorylation. This suggests phosphorylation of fibrinogen does not influence its 
interaction with α2-AP for inhibition of fibrinolysis. Although plasmin generation was 
delayed in the presence of its inhibitor α2-AP, phosphorylation of fibrinogen does not 
appear to regulate this inhibition. Furthermore, these findings support the result of the 
FXIII-A activity assay, providing no evidence for a change in FXIII-A activity with the 
different phosphorylation isoforms. Any effect of fibrinogen phosphorylation on FXIII 
175 
activity, via altered binding affinity for fibrinogen or FXIII-A2B2 subunit dissociation, 
would be expected to indirectly influence α2-AP incorporation at Lys303, which was not 
observed in these experiments. This is of particular importance given that α2-AP 
incorporation, rather than cross-linking of fibrin α and γ chains by FXIII, is the principal 
determinant of resistance to fibrinolysis (Fraser et al., 2011). Plasminogen activator 
inhibitor-2 is also cross-linked in proximity to Ser345, at Lys413 and Lys457 (Ritchie et 
al., 2000, Ritchie et al., 2001). The plasmin generation assay could therefore be 
repeated in the presence and absence of this inhibitor to see whether phosphorylation 
facilitates this interaction.  
4.2.2.3. Interaction with plasmin(ogen) 
It has previously been reported that elevated in vivo fibrinogen phosphorylation leads to 
increased resistance to plasmin digestion (Martin et al., 1992), an effect which is 
irreversible. Interestingly, phosphorylation of fibrinogen in vitro has the same effect, 
irrespective of the conflicting effects of the kinases in question on fibre thickness 
(Martin et al., 1991). This suggests that the principal mechanism of phosphorylation-
induced resistance to fibrinolysis is independent of changes to clot architecture, and 
may result from impaired interactions with fibrinolytic proteins. In this thesis, 
phosphorylation of fibrinogen did not affect incorporation of α2-AP. Therefore, the 
reported increased resistance to plasmin digestion most likely relates directly to the 
interaction of plasmin(ogen) with fibrinogen, either by altered binding, or by protection 
of plasmin cleavage sites due to a phosphorylation-induced conformational change. 
These possibilities are discussed in more detail below. 
4.2.2.3.1. Plasminogen binding to fibrinogen 
Plasminogen binds to the αC region of fibrin with high affinity (Kd of 32 nM) (Tsurupa 
and Medved, 2001a, Tsurupa and Medved, 2001b), and to additional sites in fibrinogen 
D and E fragments (Varadi and Patthy, 1983, Varadi and Patthy, 1984, Lucas et al., 
1983). As with α2-AP binding sites on fibrinogen, plasminogen binding sites in 
fragments D and E, as well as in the αC region, are cryptic in fibrinogen but exposed in 
fibrin (Tsurupa and Medved, 2001a, Varadi and Patthy, 1983). However, while α2-AP 
does not bind soluble fibrinogen, Tsurupa et al. (2010) demonstrated that binding does 
occur in adsorbed fibrinogen. The process of immobilising fibrinogen affects its 
conformation and can expose sites that would otherwise be hidden and unavailable for 
interaction. This has also been demonstrated for the N-terminal fibrinogen Aα chain 
platelet-binding RGD sequence (Ugarova et al., 1993). Therefore, cryptic plasminogen 
binding sites are likely to also be exposed upon adsorption of fibrinogen to a 96-well 
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plate. An ELISA was performed to investigate the binding of plasminogen to adsorbed 
fibrinogen. There was no difference in the amount of bound plasminogen between the 
phosphorylation isoforms, suggesting phosphorylation does not hinder this interaction. 
Surface plasmon resonance (SPR) would enable determination of the Kd for 
plasminogen and immobilised full-length fibrinogen, for further characterisation of 
binding affinity. Both ELISA and SPR could also be used to investigate the effect of 
phosphorylation on the activation of fibrinolysis by the binding of tPA to the αC region. 
However, there was no evidence from the plasmin generation assay of a 
phosphorylation-dependent alteration of plasmin activity by any means, including an 
effect on tPA, which was added to activate plasmin and initiate lysis. 
4.2.2.3.2. Plasmin digestion of fibrinogen 
With regards to conformational change, Martin and Bjork (1990) have reported that 
phosphorylation alters the conformation of fibrinogen. Phosphorylation of fibrinogen by 
PKC or CK2 caused alterations to the secondary structure, while phosphorylation with 
PKA or CK1 showed no such change. Similarly, phosphorylation with PKA or PKC 
caused changes in the tertiary structure of fibrinogen around tryptophan residues, but 
this was not the case after phosphorylation with CK1 or CK2. This study by Martin and 
Bjork highlights that phosphorylation-induced changes to the secondary or tertiary 
structure of fibrinogen are kinase-specific. Furthermore, the observed conformational 
changes and decreased rate of proteolysis by plasmin after phosphorylation were both 
unaltered by removal of phosphate using alkaline phosphatase. This suggests that 
phosphorylation causes an irreversible conformational change, which in turn reduces 
susceptibility to proteolysis. The effect of in vivo fibrinogen phosphorylation on 
conformation has yet to be confirmed, but could be investigated in the same way, using 
nuclear magnetic resonance, x-ray crystallography or circular dichroism. This may 
provide reasoning for any observed effects of fibrinogen phosphorylation on resistance 
to fibrinolysis. 
A plasmin digestion time course experiment was conducted to compare the rate of 
plasmin digestion of fibrinogen with increasing levels of phosphorylation. The levels of 
fibrinogen degradation products – fragment Y and fragment D1 – were measured over 
time. There was no difference seen in the intensity of fragment Y over time between 
the phosphorylation isoforms. For fragment D1, there was a slight difference between 
samples, with the 13 % phosphorylated fibrinogen sample exhibiting a faster rate of 
fragment D1 formation than the control 25 % sample, and the 33 % sample exhibiting a 
slower rate of fragment D1 formation compared to the control. This would suggest that 
phosphorylation has a protective effect over fibrinogen, promoting resistance to 
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fibrinolysis. Although the effect was marginal in this investigation, the reduced rate of 
fragment D1 formation with higher phosphate contents supports previous literature with 
in vitro and in vivo-phosphorylated fibrinogen, reporting that this modification protects 
fibrinogen from plasmin digestion (Martin et al., 1992, Martin et al., 1991, Martin and 
Bjork, 1990, Forsberg and Martin, 1990). This finding may reflect hindered interaction 
with plasmin due to conformational change, or as previously discussed, increased 
binding of Ca2+ ions to fibrinogen, which has been shown to protect fibrinogen from 
degradation by plasmin (Dang et al., 1985a). Had the results demonstrated a 
significant trend, measurement of individual α chain fragments by densitometry could 
have been used as an indication of the particular cleavage site(s) affected by the 
presence of phosphate. 
The removal of fibrinogen-bound phosphate with alkaline phosphatase, following 
incubation with kinases in vitro, has demonstrated an irreversible effect of fibrinogen 
phosphorylation on resistance to plasmin digestion (Martin et al., 1991, Martin and 
Bjork, 1990, Forsberg and Martin, 1990). Martin et al. (1992) have shown the same 
effect with fibrinogen taken from patients on days 0, 1 and 8 following hip-replacement 
surgery. Despite a return to normal phosphorylation levels on day 8, the susceptibility 
to plasmin digestion remained at 50 % of that on day 0. Based on this evidence, the 
expected result for dephosphorylated fibrinogen in this experiment would be to mimic 
control fibrinogen. Appearance of fragment D1 in the dephosphorylated sample was 
similar to the control, but unexpectedly was slightly slower. Hence, the trace of the DP 
fibrinogen sample may indicate some experimental error. Furthermore, cleavage of the 
α chain results in fragment X formation prior to fragment Y formation. Therefore, if 
phosphorylation was affecting α chain cleavage by plasmin, you would expect to see a 
difference in both fragment Y and fragment D1 between samples, which was not the 
case. However, this method may not have permitted detection of subtle differences in 
fragment Y formation as the bands were much darker, possibly approaching saturation. 
Fragment X would also be expected to follow the same trend but was not measured in 
this instance as it was not clearly distinct from the dark full-length fibrinogen band. For 
such reasons, densitometry analysis can be troublesome and somewhat subjective 
(Gassmann et al., 2009). It also may not be sensitive enough to highlight small 
differences in digestion rates.  
Investigations into plasmin digestion of fibrinogen can provide clues as to whether 
phosphorylation of Ser3 and Ser345 causes a conformational change in fibrinogen, 
altering resistance to fibrinolysis. However, plasmin digestion of fibrinogen is not 
physiological, and any effect of fibrinogen phosphorylation on susceptibility to plasmin 
may be more pronounced in polymerised, cross-linked fibrin. This approach would also 
 178 
take into account any phosphorylation-induced changes to clot structure. Turbidity 
analysis and SEM experiments from this investigation revealed thinner fibres and 
increased branching, suggestive of an increase in clot density. Hence, fibrinolysis is 
likely to be compromised. In addition, plasminogen binds to sites that are cryptic in 
fibrinogen but exposed in fibrin (Tsurupa and Medved, 2001a, Varadi and Patthy, 
1983), and the rate of plasminogen activation by tPA is significantly enhanced in the 
presence of fibrin (Hoylaerts et al., 1982). Therefore, examination of the effect of 
phosphorylation on fibrin clot degradation would be a valuable addition to this work. To 
investigate this, turbidity and lysis analysis of fibrin clots could be used to monitor 
changes in lysis rate and Lys50MA over time. Laser scanning confocal microscopy of 
clots could also be used to calculate lysis front velocity by overlaying wells with 
plasminogen and tPA, and measuring the distance the lysis front moves within a 
particular time frame (Collet et al., 2000, Ajjan et al., 2008). However, these methods 
wouldn’t reveal which of the plasmin cleavage sites on fibrinogen are affected by 
phosphorylation.  
4.2.2.4. Additional interactions 
So far, this work has demonstrated that the effect of elevated fibrinogen 
phosphorylation in vivo on resistance to fibrinolysis, as demonstrated by Martin et al. 
(1992), is not mediated by altered FXIII-, α2-AP- or plasminogen-fibrinogen 
interactions. The effects on tPA binding and PAI-2 cross-linking have yet to be 
determined, while plasmin digestion data reported here warrants further investigation. 
Aside from plasma proteins, it would also be interesting to look for any effect of 
fibrinogen phosphorylation on the binding of fibrinogen to cell surfaces. There is one 
integrin-binding RGD sequence at either end of the fibrinogen Aα chain (residues 
95-97 and 572-574), as well as an additional AGDV attachment site in the γ chain C-
terminus (residues 408-411) (Kloczewiak et al., 1984, Hawiger et al., 1989). It has been 
shown that the N-terminal RGD site of the fibrinogen Aα chain is not readily available 
for interaction as it is buried within the coiled-coil domain (Doolittle et al., 1978, 
Ugarova et al., 1993). The C-terminal RGD sequence, on the other hand, is both 
accessible and important for the initial binding of fibrinogen to the αVβ3 integrin on the 
surface of endothelial cells (Cheresh et al., 1989). This initial ligand-receptor interaction 
can induce a conformational change, exposing the Aα 95-97 RGD site (Ugarova et al., 
1993).  
Binding of proteins to human vascular endothelial cells can be analysed by ELISA, by 
culturing the cells on a gelatinised 96-well plate and fixing with 1 % paraformaldehyde 
(Collard et al., 1999). To investigate whether Ser3 phosphorylation alters the 
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availability of  Aα 95-97, or whether Ser345 phosphorylation enhances binding of Aα 
572-574 to αVβ3, an ELISA could be performed by coating a 96-well plate with human 
vascular endothelial cells, incubating with DP, 13 %, 25 % or 33 % phosphorylated 
fibrinogen, and detecting bound fibrinogen with an anti-fibrinogen HRP antibody. With 
regards to platelet binding, only the fibrinogen γ chain AGDV domain is needed for 
interaction with activated GPIIbIIIa (Cheresh et al., 1989, Liu et al., 1997); hence the 
Aα chain RGD sites are less likely to be regulated by phosphorylation at Ser3 or 
Ser345 for this particular purpose. Yet there are still many options to explore, and 
preliminary data to expand, to decipher potential contributions of fibrinogen 
phosphorylation in the co-ordination of coagulation.   
4.2.3. The effect of fibrinogen phosphorylation on fibrin clot formation 
4.2.3.1. Fibre diameter 
The structure of fibrin clots formed from fibrinogen with varying degrees of 
phosphorylation was investigated by turbidity analysis and SEM. Turbidity assays 
revealed that phosphorylation causes a significant reduction in fibre thickness, as 
represented by a lower MaxAbs. Measurement of fibre diameter in electron 
micrographs of fibrin clots supported data from the turbidity analyses. Although the 
measurements are not an accurate representation of diameter due to sample 
dehydration, the trend of relative fibre thickness mimicked that of the turbidity data, 
providing convincing evidence of an inverse relationship between the percentage of 
phosphorylation and fibre thickness.  
In vitro, phosphorylation of fibrinogen with PKA and PKC generates fibres with smaller 
diameters (Heldin et al., 1987a, Martin et al., 1991, Forsberg, 1989), while 
phosphorylation with CK1 and CK2 produces thicker fibrin fibres (Heldin, 1987, Martin 
et al., 1991). It could be argued that the observation of thinner fibres with increasing 
phosphorylation in this study indicates that phosphorylation of fibrinogen by PKA or 
PKC is more likely than phosphorylation by CK1 or CK2. However, subsequent 
characterisation of phosphorylation sites with PKC and CK2 did not identify 
phosphorylation at Ser3 or Ser345. Protein kinase C was found to phosphorylate 
Ser557, Ser558, Ser559 and Ser599, as well as additional sites in the central portion of 
the polypeptide chain (Heldin and Humble, 1987). Casein kinase 2, on the other hand, 
phosphorylated Ser523 and Ser590, plus other undefined serine and threonine 
residues between amino acids 259 and 268 (Heldin, 1987). Hence, the results here 
cannot be related to the effects of kinases in previous studies, as kinases exhibit 
altered specificity in vitro (Olsen et al., 2006). Furthermore, fibrinogen may not be 
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phosphorylated by any of these enzymes in vivo. The effect of elevated fibrinogen 
phosphorylation on fibre diameter has previously been reported by Martin et al. (1992), 
using fibrinogen taken from patients before and after hip-replacement surgery. The 
phosphate content of fibrinogen doubled 24 hours after surgery, with a similar increase 
in fibrin fibre thickness, disagreeing with the data from this investigation. This may 
reflect discrepancies in methodology. The fibrinogen used in this thesis investigation 
was plasma purified, but had not been exposed to acute phase conditions, unlike that 
used by Martin et al. (1992). There may be other factors or modifications to fibrinogen 
that occur in vivo during the acute phase response, such as phosphorylation at 
additional sites in circulation, that could influence fibre diameter. Despite these 
differences, the results of this investigation are specific to Ser3 and Ser345, and 
demonstrate for the first time that an increased degree of phosphorylation at these 
residues leads to thinner fibres in the resulting clot. 
4.2.3.2. Fibre branching 
Clot structures also exhibited increased branching of fibres with higher levels of 
phosphorylation, based on qualitative assessment of SEM images. Fibre branching 
could be analysed quantitatively using software that allows 3D-reconstruction of 
scanning electron micrographs and rotation in the x-, y- and z-directions, in order to 
mark and count fibre branching points, as detailed by Collet et al. (2005b) and Ryan et 
al. (1999). The increased branching may be related to the reduced fibre diameter, as 
Ryan et al. (1999) report a relationship between the two, with large fibres only 
occurring when branching is minimal. Branching can occur during end-to-end binding of 
fibrin monomers (protofibril extension) or by divergence of protofibrils during lateral 
aggregation. The former is a two-step binding process; interference from a third fibrin 
molecule between these two steps creates a branch. This type of branch formation is 
dependent on monomer supply rate (Fogelson and Keener, 2010). Phosphorylation of 
fibrinogen Aα Ser3 has been demonstrated to enhance complex formation between 
fibrinogen and thrombin, leading to faster cleavage of FpA and fibrin monomer 
formation (Maurer et al., 1998). Furthermore, Blomback et al. (1989) describe a clot 
structure with thinner fibres and smaller pores with higher thrombin concentrations. 
Although the thrombin concentration was kept constant here, the greater substrate 
specificity of thrombin for phosphorylated FpA may produce a similar effect. It is 
therefore likely that phosphorylation of FpA contributes to the reduced fibre diameter 
and increased branching that coincide with higher degrees of fibrinogen 
phosphorylation. However, the effect of phosphorylation on FpA cleavage and 
protofibril formation could not be deduced from the turbidity data as lag times were too 
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short. This could be verified by repeating the assays with a lower thrombin 
concentration to extend lag times. 
4.2.3.3. Clotting rate  
In addition to the observed structural changes, the turbidity analysis also revealed an 
inverse relationship between the degree of fibrinogen phosphorylation and the rate of 
clot formation. Although the effect appeared small, statistical analysis confirmed 
significant differences. To the best of my knowledge, this is the first report of in vivo 
fibrinogen phosphorylation leading to a reduction in clotting rate. Interestingly, it has 
previously been reported that phosphorylation of Ser3 promotes complex formation 
with thrombin and facilitates FpA cleavage (Maurer et al., 1998). The findings by 
Maurer et al. coupled with this current observation therefore suggest distinct roles of 
Ser3 and Ser345 in clot formation, with phosphorylation of Ser3 enhancing protofibril 
formation (the ‘lag’ period), and phosphorylation of Ser345 interfering with lateral 
aggregation of protofibrils, leading to a slower clotting rate beyond the initial lag period. 
As mentioned above, lag times were too short in these experiments to be accurately 
determined. For this reason, this may not be the most suitable method for comparison 
of clotting rates, as calculation of this variable is also dependent on lag times. Again, 
further investigations with lower thrombin concentrations and extended lag times would 
be beneficial to clarify the effects of Ser3 and Ser345 phosphorylation on protofibril 
formation and clotting rate. 
4.2.3.4. Clinical implications 
The findings from this thesis suggest that elevated fibrinogen phosphorylation produces 
clots with structural changes that may alter thrombotic potential. In particular, the 
observed clot structure is comparable to that of diabetic patients. Subjects with 
diabetes or metabolic syndrome, who are at greater cardiovascular risk, generate clots 
that are denser and less porous, owing to thinner fibres and more branch points. 
Importantly, these structural changes make the clot more resistant to fibrinolysis (Dunn 
et al., 2005, Carter et al., 2007). It would therefore be interesting to quantify the degree 
of fibrinogen phosphorylation in diabetic patients. This could be done on a small scale 
by malachite green assay, but as this requires plasma-purified fibrinogen, an ELISA 
with phospho-specific antibodies would be the ideal method to screen large sample 
numbers. Clots of patients with other cardiovascular complications, including AMI, 
stroke, PAD and VTE, tend to form thicker fibres compared to healthy controls, but all 
exhibit reduced permeability and prolonged lysis times (Bhasin et al., 2009, Undas et 
al., 2009b, Undas et al., 2008, Undas et al., 2009a). Despite the thinner fibres, the 
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increased branching in clots composed of 33 % phosphorylated fibrinogen is likely to 
raise clot density and lower porosity – properties which antagonise the infiltration of 
fibrinolytic agents. Clot density could be measured by LCSM of fibrin clots and analysis 
using an ImageJ macro to count the number of times the fibres cross a set of gridlines, 
as an estimate of fibre number within the frame. This does not work well with SEM 
images due to insufficient contrast between fibres and background (Greenhalgh, 2013). 
Permeability could also be compared by measuring the flow rate of buffer through the 
fibrin clots and calculating the permeation coefficient, KS, as previously described 
(Ariens et al., 2000). In addition to the observed structural changes, Martin et al. (1992) 
have demonstrated that a doubling of fibrinogen phosphate content in vivo leads to a 
concurrent reduction in susceptibility to plasmin digestion. With all of this in mind, it 
would be reasonable to conclude that elevated fibrinogen phosphorylation yields a pro-
thrombotic clot structure, and therefore deserves attention in the quest to develop new 
therapeutic strategies.  
4.3. Characterisation of intracellular fibrinogen phosphorylation 
To complement the functional characterisation of fibrinogen phosphorylation, 
intracellular studies were conducted to investigate the regulatory processes underlying 
this modification, including the subcellular location of phosphorylation, as well as 
changes to kinase expression and the degree of fibrinogen phosphorylation that occur 
in response to acute phase cytokine IL-6. A range of methods were employed to 
determine the effect of cellular fibrinogen phosphorylation levels in the presence of 
IL-6, kinase inhibitor staurosporine and Fam20A siRNA.  
4.3.1. Developing methods for the detection of phosphorylated fibrinogen 
4.3.1.1. Detection and quantification of intracellular phosphorylated fibrinogen 
Aα chain by PLA 
A proximity ligation assay was developed to visualise and quantify phosphorylated 
fibrinogen Aα chains in CHO and HepG2 cells. Antibodies to the fibrinogen Aα chain, 
PDI (ER marker) and TGN46 (trans-Golgi marker) were optimised first by standard 
immunofluorescence. Fibrinogen Aα chain staining co-localised with the ER marker in 
both cell lines, with little or no co-localisation with TGN46 in the trans-Golgi. This 
agrees with recent findings by Tamura et al. (2013) who have also conducted 
immunofluorescent analysis of fibrinogen in HepG2 cells. They too observed 
co-localisation with an ER marker but not a cis-Golgi marker, and report that the 
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majority of fibrinogen molecules are confined to this early secretory compartment. The 
detection of fibrinogen Aα chains in the ER likely represents the pools of Aα chains that 
have previously been described (Yu et al., 1984, Huang et al., 1993b, Huang et al., 
1996, Xia and Redman, 2001).  
Optimal antibody concentrations were used for subsequent PLA experiments. Initially, 
PLA was performed using CHO cells, so that the signal in CHO-WT cells could be 
compared to CHO-Bβγ cells as a negative control for the anti-fibrinogen Aα chain 
antibody. Previous studies have used liquid chromatography-electrospray ionisation-
tandem mass spectrometry to demonstrate that fibrinogen phosphorylation occurs 
exclusively on the Aα chain (Wind et al., 2003, Nagel and Meyer, 2014). Given that 
phosphoserine antibodies are prone to non-specific binding, and have indeed 
demonstrated non-specific binding to the fibrinogen β chain in a western blot 
(figure 52), this assay would benefit from a suitable control for the non-specific binding 
of anti-phosphoserine to fibrinogen. This would require each chain of fibrinogen to be 
present but not phosphorylated, hence the ideal negative control would be the S3/345N 
variant lacking both of the Aα chain phosphorylation sites. Unfortunately, this was not 
achieved as part of this investigation due to problems with expression of fibrinogen 
variants in CHO cells. 
In the first PLA experiment, a concentration range of anti-phosphoserine antibody was 
optimised to give adequate signal with minimal background. Subsequent assays using 
HepG2 cells included ER and Golgi markers to investigate the intracellular location of 
phosphorylated fibrinogen Aα chains. The signal was low and randomly distributed 
throughout the cell, with no detectable co-localisation of phosphorylated fibrinogen with 
the ER or trans-Golgi. This implies that the intracellular pools of fibrinogen Aα chain, as 
demonstrated previously and by immunofluorescence in this investigation, are non-
phosphorylated (Yu et al., 1984, Huang et al., 1993b, Huang et al., 1996, Xia and 
Redman, 2001). Therefore, phosphorylation is likely to occur only in fully assembled 
fibrinogen. Tamura et al. (2013) have demonstrated that lectin chaperones retain 
fibrinogen intermediate complexes in the ER so that only fully assembled fibrinogen is 
transported out of the cell for secretion. Hence, phosphorylated fibrinogen does not 
appear to accumulate in the cell. The low signal in PLA images, despite abundant 
detection of intracellular fibrinogen Aα chains by immunofluorescence, also suggests 
that the assay is specific to phosphorylated fibrinogen Aα chains.  
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4.3.1.1.1. The subcellular location of fibrinogen phosphorylation 
To further investigate the subcellular location of fibrinogen phosphorylation, and to 
increase the PLA signal, HepG2 cells were incubated with secretion inhibitor BFA. 
Brefeldin A blocks the transit of proteins beyond the ER and redistributes cis- and 
medial-Golgi compartments back to the ER (Lippincott-Schwartz et al., 1989). The 
average number of PLA spots, representing individual phosphorylated fibrinogen Aα 
chains, was counted per cell using an ImageJ macro. The signal was found to increase 
from an average of 5.0 to 16.8 spots per cell in the presence of BFA. Pre-incubation of 
HepG2 cells with BFA is therefore a useful tool to obtain sufficient signal for 
comparison of phosphorylation levels. The build-up of phosphorylated fibrinogen in the 
presence of BFA also indicates that fibrinogen is phosphorylated before it reaches the 
trans-Golgi network, either in earlier Golgi compartments or in the ER. Consequently, 
these data still permit the possibility of phosphorylation by the two suspected fibrinogen 
kinases: i) the G-CK, which has been shown to reside in the lumen of the cis-Golgi 
(Tagliabracci et al., 2012), and ii) CK2, which is predominantly active in the ER in 
hepatocytes (Lasa et al., 1997). 
4.3.1.1.2. Limitations of PLA 
It should be noted that there are some limitations to the PLA method used in these 
investigations to measure fibrinogen phosphorylation in HepG2 cells. Firstly, HepG2 
cells have a tendency to grow in clumps. This was minimised by passing cells through 
a needle during passage, but could not be completely avoided. Imaging was therefore 
restricted to monolayer areas. Secondly, there was significant cell-to-cell variation in 
signal, making it difficult to choose representative areas. Another point to note is the 
potential for additional phosphorylation sites inside the cell that have not been 
characterised; analysis of fibrinogen phosphorylation sites has only been performed on 
fibrinogen from an extracellular environment. Matrix assisted laser desorption 
ionisation-TOF/TOF mass spectrometry could be used to confirm or identify 
phosphorylation sites on fibrinogen from HepG2 cells before and after secretion; this 
technique was used to confirm phosphorylation of Ser3 and Ser345 in recombinant 
fibrinogen expressed in CHO cells (Appendix 3). Finally, it is important to consider that 
fibrinogen Aα chains might represent a mixture of mono- and di-phosphorylated 
polypeptides. In fact, this has recently been demonstrated for the first time by Nagel 
and Meyer (2014), and presents a significant limitation for comparing the degree of 
phosphorylation, as only one site can be detected per Aα chain molecule by PLA. 
Taking all of this into account, together with the lack of negative control, PLA does not 
seem to be the most reliable approach for quantification of intracellular fibrinogen 
185 
phosphorylation. Therefore additional methods were sought, which focused on 
comparing phosphorylation levels of fibrinogen secreted by HepG2 cells into 
conditioned medium. The use of secreted fibrinogen circumvented any additional 
intracellular modification which may occur, and provided a larger yield of fibrinogen for 
analysis than cell lysis. 
4.3.1.2. Phos-tag™ applications for detection of phosphorylated fibrinogen 
Phos-tag™ – a novel molecule which is able to bind phosphate groups with high affinity 
– was employed in several methods for the detection of phosphorylation in secreted 
fibrinogen. Phos-tag™ affinity SDS-PAGE using pre-cast gels from the manufacturer 
did not result in separation of phosphorylated and non-phosphorylated fibrinogen, with 
bands appearing at the same position for control (25 % phosphorylated) and 
dephosphorylated fibrinogen. This outcome most likely indicates inadequate affinity of 
Phos-tag™ for phosphorylated fibrinogen, possibly reflecting a low number of 
phosphorylated residues per molecule. Loading of phosphorylated and 
dephosphorylated β-casein, which is more heavily phosphorylated (5 mol 
phosphate/mol protein), for comparison would be useful to ascertain whether the 
Phos-tag™ agarose is able to capture phosphoproteins and slow their migration under 
the given experimental conditions, thus indicating whether the problem is 
methodological or due to insufficient phosphate on fibrinogen. An ELISA using 
Phos-tag™ Biotin and streptavidin alkaline phosphatase revealed non-specific binding 
of Phos-tag™ Biotin to the plate, as indicated by high absorbance values in blank wells 
without fibrinogen, perhaps due to a large molar excess of Phos-tag™ Biotin. In 
addition, development times were slow and specific detection of phosphorylated 
fibrinogen was minimal. Finally, western blotting with Phos-tag™ Biotin and streptavidin 
HRP was unsuccessful due to non-specific binding of streptavidin HRP to the Aα and 
Bβ chains of fibrinogen, as confirmed with a streptavidin-HRP-only control. The results 
of the SDS-PAGE and ELISA suggest that Phos-tag™ has poor affinity for 
phosphorylated fibrinogen, perhaps because fibrinogen is not phosphorylated heavily 
enough to permit sufficient Phos-tag™-fibrinogen interaction. However, Phos-tag™ has 
been used for enrichment of phosphorylated fibrinogen by affinity chromatography, as 
previously discussed, and therefore does exhibit some affinity for phosphorylated 
fibrinogen. 
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4.3.1.3. Detection of phosphorylated fibrinogen using anti-phosphoserine 
antibodies 
Similar problems were encountered using anti-phosphoserine antibodies, which are 
renowned for exhibiting poor sensitivity and specificity for their phosphorylated 
substrates. For ELISA, conditions were optimised to minimise non-specific interaction 
between the antibodies and fibrinogen, but non-specific binding to the wells or coating 
antibody was still high. Using dephosphorylated fibrinogen as a negative control, there 
was some specific detection of phosphoserine, but the change in absorbance was too 
small to enable comparison of phosphorylation levels. Despite some initial non-specific 
binding to the Bβ chain and high background, a western blotting protocol was 
successfully optimised for specific detection of phosphorylated fibrinogen. The 
optimised protocol abrogated non-specific binding of anti-phosphoserine to 
dephosphorylated fibrinogen, the Bβ chain, and the PVDF membrane. It also 
demonstrated the change in phosphorylation levels between samples separated by 
Phos-tag™ chromatography, supporting the results of the malachite green assay. The 
limitation of this method is the requirement for a relatively large mass (1-2 µg) of 
fibrinogen in the well due to poor antibody sensitivity – approximately 20-40 times more 
than would be needed for detection of fibrinogen using an anti-fibrinogen antibody, 
which presented a challenge for harvesting sufficient fibrinogen from HepG2 culture. 
However, this method was successfully used to compare the degree of fibrinogen 
phosphorylation in subsequent experiments with samples of harvested medium. 
4.3.2. The effect of IL-6 on fibrinogen expression and phosphorylation in HepG2 
cells 
Having established a suitable method for the specific detection of phosphorylation in 
secreted fibrinogen, HepG2 cells were incubated with several reagents to monitor 
changes in phosphorylation levels in acute phase conditions or with kinase inhibitors. 
Interleukin-6 was added to the cells to mimic the acute phase response. While other 
cytokines, notably interleukin-1 and TNF-α, also induce acute phase protein 
expression, IL-6 is the principal mediator of this response (Yudkin et al., 2000). The 
concentration of IL-6 was optimised to 10 ng/ml, resulting in a 3.5-fold increase in 
fibrinogen expression, as determined by real-time PCR. This is similar to previous 
reports by Faber et al. (2012) and Igaz et al. (1998), who both found a 4.5-fold increase 
in fibrinogen expression in HepG2 cells incubated with 10 ng/ml IL-6. Increased 
fibrinogen expression in response to IL-6 is well characterised, and is regulated at the 
transcriptional level via IL-6 response elements in fibrinogen genes (Ray, 2000, Fuller 
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and Zhang, 2001). The effect of IL-6 on fibrinogen phosphorylation was first of all 
examined by PLA.  In the presence of IL-6, the mean number of spots per cell 
increased 4.0-fold, from 2.1 to 8.3. This increase is only slightly higher than the 3.5-fold 
increase in expression, which would suggest almost the same proportion of fibrinogen 
molecules are phosphorylated, and therefore the elevated phosphorylation that occurs 
during the acute phase response is mediated in circulation rather than intracellularly. 
Several studies have indeed suggested that fibrinogen can be phosphorylated in 
circulation by kinases released from activated platelets (Krust et al., 1983, Lerer et al., 
1991, Ekdahl et al., 1997, Zahedi et al., 2008). However, as discussed previously, the 
PLA results should be interpreted with caution due to difficulties with analysis and the 
limitation of only being able to detect one phosphate molecule per Aα chain. 
For more accurate analysis, conditioned medium was harvested from HepG2 cells after 
a 24 hour incubation period with IL-6. Fibrinogen phosphorylation was compared in 
medium samples in the presence and absence of IL-6 by western blotting with an anti-
phosphoserine antibody, normalising to the fibrinogen γ chain using an anti-fibrinogen γ 
chain antibody. The results showed a clear increase in phosphorylation of the Aα chain 
after incubation with IL-6. Further analysis by densitometry revealed a 3.1-fold increase 
– equivalent to a rise from 25 % to 78 % – which is only slightly higher than the values 
reported for acute phase conditions in vivo (Seydewitz and Witt, 1985, Reganon et al., 
1993, Martin et al., 1992). The significant increase in phosphorylation of fibrinogen from 
HepG2 cells incubated with IL-6 suggests that fibrinogen is partially phosphorylated 
when secreted. Otherwise, if fibrinogen molecules were fully phosphorylated when 
secreted from HepG2 cells, there would be no observable increase in phosphorylation 
levels in the presence of IL-6. The exception would be if additional sites, other than 
Ser3 and Ser345, are phosphorylated in the presence of IL-6. Although fibrinogen can 
be phosphorylated in circulation by platelet kinases (Krust et al., 1983, Zahedi et al., 
2008, Ekdahl et al., 1997), these results demonstrate for the first time that the 
mechanism responsible for increased phosphorylation of fibrinogen in acute phase 
conditions occurs at the cellular level rather than in circulation. However, this 
conclusion is based on the assumption that phosphorylation levels are not altered in 
the medium by secreted kinases or phosphatases. This is a reasonable assumption as 
there would be very little phosphate bound to fibrinogen after a 24 hour incubation 
period if fibrinogen was susceptible to secreted phosphatases. An intracellular increase 
in phosphorylation also seems logical given that extracellular ATP concentrations are 
typically very low, with a basal plasma concentration of 2 nM, meaning that 
phosphorylation of fibrinogen in plasma is unlikely to occur without release of ATP and 
kinases from activated platelets (Zhong and Wright, 2013, Ekdahl and Nilsson, 1995). 
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4.3.3. The effect of IL-6 on kinase expression in HepG2 cells 
Having observed an increase in cellular phosphorylation of fibrinogen in the presence 
of IL-6, the next step was to investigate whether there is altered expression of relevant 
fibrinogen kinases, including CK2 and the G-CK. First, HepG2 cells were screened for 
expression of each kinase under control conditions by real-time PCR. Previously, 
Nalbant et al. (2005) have demonstrated by RNA extraction and RT-PCR that Fam20B 
and Fam20C are expressed in a wide variety of tissues, while the Fam20A expression 
pattern was relatively limited. Expression of all three proteins was detected in the liver, 
with highest expression of Fam20C, followed by Fam20A and finally Fam20B. In 
agreement, expression of Fam20A, Fam20B and Fam20C were all detected in HepG2 
cells in this investigation, as well as CK2, but late Ct values indicated low expression of 
Fam198A and Fam198B. These kinases were therefore excluded from the following 
experiments. Second, real-time PCR was repeated using RNA from HepG2 cells 
incubated in the presence and absence of IL-6, to determine the fold-change in 
expression. Interestingly, expression of CK2, Fam20B and Fam20C did not change, 
but there was a significant 6-fold increase in expression of Fam20A. This remarkable 
increase in Fam20A expression indicates that this kinase plays a role in the 
hepatocellular response to acute phase conditions. Fam20A has previously been 
implicated in biomineralisation processes, with mutations in the Fam20A gene leading 
to severe Amelogenesis Imperfecta and Enamel-Renal Syndrome (Vogel et al., 2012, 
Wang et al., 2013), but there are no reports of altered coagulation in these cases.  A 
recent study by Kiliszek et al. (2012) has also implicated Fam20A in the acute phase 
response, revealing significant up-regulation of Fam20A expression in leukocytes from 
AMI patients. The reason for this increased expression is unknown, although Fam20A 
does play a role in haematopoiesis, which is stimulated by cytokines during the acute 
phase response (Nalbant et al., 2005, Trey and Kushner, 1995). To the best of my 
knowledge, however, this is the first time that increased Fam20A expression has been 
demonstrated in HepG2 cells in response to IL-6. This may similarly be linked to the 
hematopoietic function of the liver (Seki et al., 2000), but also highlights a potential 
function of Fam20A in phosphorylating fibrinogen and/or other acute phase proteins. In 
support of this, Szymanski and Farrell (1982) have demonstrated phosphorylation of 
FpA in vitro by a casein kinase isolated from the Golgi apparatus of bovine mammary 
glands.  
It has been suggested by Salvi et al. (2010) that the G-CK has a prominent role in 
generating the human plasma phosphoproteome, with the majority of plasma 
phosphorylation sites satisfying its consensus sequence: S-X-E. The list of plasma 
phosphoproteins also displays a similar profile to that of the G-CK substrates, but 
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distinct from that of CK2 substrates. There are several other acute phase proteins 
secreted by hepatocytes that contain S-X-E motifs, including kininogen, α1-antitrypsin, 
fetuin A, apolipoprotein E, insulin-like growth factor binding proteins (IGFBP) 1 and 3, 
complement C3, plasminogen, plasminogen-related protein B2, fibronectin I, proprotein 
convertase subtilisin/kexin type 9 (PCSK9), kallikrein-6, FV, FIX and serum albumin 
(Tagliabracci et al., 2012). Tagliabracci et al. (2012) have demonstrated 
phosphorylation of kininogen, complement C3, FV and serum albumin by Fam20C in 
vitro. Fibrinogen, on the other hand, was not phosphorylated by Fam20C. It is not yet 
clear whether Fam20C phosphorylates these substrates in vivo, or whether there is 
some cross-over between substrates for the different Fam20 proteins. However, there 
must be additional specificity determinants if secretory proteins are phosphorylated by 
other Fam20 kinases. Phosphorylation of FIX, complement C3 and PCSK9 has been 
shown to promote or diminish the protein’s susceptibility to proteolysis (Dewpura et al., 
2008, Nilsson Ekdahl and Nilsson, 1999, Atoda et al., 2006), as is the case with 
fibrinogen phosphorylation and plasmin digestion (Martin et al., 1992, Martin et al., 
1991, Martin and Bjork, 1990, Forsberg and Martin, 1990). Phosphorylation can also 
increase the affinity of protein-protein interactions. For example, phosphorylation of 
IGFBP-1 leads to increased binding, and therefore reduced bioavailability, of its 
substrate insulin-like growth factor-1 – a negative acute phase protein (Jones et al., 
1991); the significance of this is yet to be characterised. Hence, increased 
phosphorylation of acute phase proteins in hepatocytes may alter their function in 
circulation, possibly to promote coagulation and facilitate wound repair.  
In support of fibrinogen phosphorylation by the G-CK, there are in fact many similarities 
between fibrinogen and κ-casein – a G-CK substrate. Interestingly, Vorbach et al. 
(2006) have postulated that the mammary gland evolved from the innate immune 
system, and, based on structural and sequence similarities, that κ-casein may have 
evolved from fibrinogen. Approximately 80 % of the κ-casein sequence has 
counterparts in the fibrinogen γ chain sequence, with 31-42 % of amino acids at 
identical positions (Jolles et al., 1978). Additionally, as with fibrinogen, κ-casein 
contains two well-established phosphorylation sites at Ser149 and Ser127 (Hernandez-
Hernandez et al., 2011). The similarities of κ-casein and fibrinogen extend further to 
their regulation and function. The mechanism underlying increased fibrinogen 
expression in response to IL-6 in hepatocytes is similar to the transcriptional regulation 
of casein induced by prolactin in mammary epithelial cells, including similarities in 
response factors and activation of the Janus kinase/signal transducers and activators 
of transcription (JAK-STAT) pathway for downstream effects (Standke et al., 1994, 
Vorbach et al., 2006). In terms of function, κ-casein triggers the process of milk clotting 
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(Brinkhuis and Payens, 1985). Micelles are stabilised by transglutaminase activity and 
casein is degraded by a plasmin-like enzyme that acts on lysine residues (Ferranti et 
al., 2004, Smiddy et al., 2006). In addition, fibrinogen and κ-casein exhibit similar 
behaviour in terms of platelet aggregation (Jolles et al., 1986). It is also worth noting 
that the cross-linking of casein is influenced by its phosphorylation status (Aoki et al., 
1992). Given that casein is phosphorylated by the G-CK, these studies provide 
convincing evidence for a similar mechanism of fibrinogen phosphorylation in vivo. 
4.3.4. The effects of kinase inhibitor STSP and Fam20A siRNA on fibrinogen 
phosphorylation in HepG2 cells 
To test the hypothesis that fibrinogen is phosphorylated by Fam20A, HepG2 cells were 
incubated with kinase inhibitor STSP. Staurosporine inhibits the majority of kinases and 
is especially effective for PKC inhibition, but is unable to bind Fam20 proteins due to 
the unique structure of their active site (Xiao et al., 2013, Meggio et al., 1995). In the 
first instance, the effect of STSP on fibrinogen phosphorylation in HepG2 cells was 
investigated by PLA. There was a 60 % reduction in the mean number of spots per cell, 
suggesting that fibrinogen is not phosphorylated by the G-CK. However, STSP is 
known to induce apoptosis in HepG2 cells (Giuliano et al., 2004), which were showing 
visible signs of apoptosis at the concentration used. Many cells detached from the 
wells during fixation which meant there were few areas to image, leading to difficulty in 
finding representative areas. In light of these difficulties, phosphorylation of secreted 
fibrinogen was also analysed by western blotting with an anti-phosphoserine antibody. 
As Fallon and Danaher (1992) have reported half-maximal STSP-induced up-regulation 
of a carbohydrate-binding lectin with only 30 nM STSP, a lower concentration range of 
STSP (0-200 nM) was used for these experiments to minimise apoptosis.  In the first 
attempt, the phosphorylated Aα chain band persisted with increasing concentrations of 
STSP up to 200 nM, suggesting that fibrinogen is phosphorylated by the G-CK. To 
improve clarity of the blot, fibrinogen was immunoprecipitated from the medium prior to 
electrophoresis for the second experiment. Immunoprecipitation was successful, as 
clear fibrinogen bands were detected on the blot. This time, however, the 
phosphorylated Aα chain band appeared weaker with 200 nM STSP compared to 
control, indicating that a kinase other than the G-CK phosphorylates fibrinogen in 
HepG2 cells. The difference between the two results may reflect minor loading errors 
or non-specific binding of the phosphoserine antibody to the highly concentrated 
samples of conditioned medium in the absence of prior immunoprecipitation.  
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To provide a more conclusive answer as to whether Fam20A phosphorylates fibrinogen 
in vivo, Fam20A siRNA was transfected into HepG2 cells to knock down expression of 
this kinase. The protocol was successfully optimised, achieving an 86 % reduction in 
Fam20A expression. However, methodological changes to increase the yield of 
fibrinogen for analysis led to a decrease in efficiency of Fam20A knockdown by siRNA 
(53 %) and no visible difference in Aα chain phosphorylation by western blotting. 
Unfortunately, the question remains whether Fam20A phosphorylates fibrinogen in 
vivo. If this is the case, the significant rise in Fam20A expression in acute phase 
conditions may highlight an important role of Fam20A, not only in fibrinogen 
phosphorylation, but in facilitating elevated phosphorylation of a plethora of acute 
phase proteins. It would therefore be interesting to compare the degree of 
phosphorylation of other proteins with the S-X-E motif in the presence and absence of 
IL-6. This scenario would make Fam20A a valuable therapeutic target.  
In a review article, Cohen (2002) has proposed that protein kinases may be the major 
drug target of the 21st century owing to recent advances in the field, with the 
development of orally active ATP-competitive kinase inhibitors. The first drug to target 
a protein kinase was developed in 2001, named Gleevec. Gleevec inhibits the Abelson, 
c-KIT and platelet derived growth factor receptor tyrosine kinases, and is used in the 
treatment of chronic myelogenous leukaemia and gastrointestinal stromal tumours 
(Buchdunger et al., 2000, Druker et al., 1996, Joensuu et al., 2001). Many more kinase 
inhibitors are undergoing clinical trials, and Cohen (2002) reports that this therapeutic 
category is now the second largest after G protein-coupled receptor inhibitors. It would 
therefore be valuable to establish the specific role(s) of Fam20A in hepatocytes, as well 
as its increased expression in acute phase conditions and how this affects the 
numerous acute phase proteins that are secreted. 
4.4. Summary 
Phosphorylation of fibrinogen is associated with the acute phase response and 
thrombotic disorders, but the mechanism and functional role of this modification in vivo 
is not yet known. Work from this thesis aimed to advance understanding of this 
important regulatory process. Despite problems with variant fibrinogen expression, 
phosphorylation isoforms were separated by affinity chromatography for functional 
analyses. These studies revealed that fibrinogen phosphorylation does not affect FXIII 
cross-linking activity of fibrin α and γ chains, plasminogen binding to fibrinogen, or 
incorporation of α2-AP, but did highlight a potential effect of phosphorylation on 
protection from plasmin digestion. With regards to clot structure, increasing 
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phosphorylation levels caused reductions in fibre thickness and increased branching, 
which may represent a pro-thrombotic structure. Clotting rate was also significantly 
reduced with higher phosphate contents. Finally, intracellular studies demonstrated an 
increase in fibrinogen phosphorylation with acute phase cytokine IL-6, showing for the 
first time that the rise in phosphorylation during the acute phase response occurs inside 
the cell rather than in circulation. In support of this, there was a significant increase in 
expression of Golgi casein kinase Fam20A with IL-6, highlighting a potential role for 
this kinase in the hepatocellular acute phase response, including phosphorylation of 
fibrinogen. Further investigations are underway to determine whether Fam20A does 
indeed phosphorylate fibrinogen in vivo.  
4.5. Future direction  
In recalling one of the original aims of this thesis, expression of fibrinogen with 
mutations at Ser3 and Ser345 would be highly advantageous in deciphering the role of 
each individual phosphorylation site in fibrin clot formation and interactions. If the yield 
could be improved, perhaps by multicistronic cloning, recombinant WT and variant 
fibrinogen could be expressed using the Expi293™ system. Similarly, more efficient 
chromatographic procedures, such as IMAC or MOAC, could be tested for greater 
separation of phosphorylated and non-phosphorylated fibrinogen for functional 
analyses. The functional investigations presented in this thesis could be expanded to 
study the effect of fibrinogen phosphorylation on resistance to fibrinolysis, FXIII cross-
linking at lysine acceptor residues in fibrinogen, the rate of FXIII subunit dissociation 
and activation, incorporation of PAI-2, tPA binding to fibrinogen, and the interaction of 
fibrinogen with platelets and endothelial cells. It would also be valuable to further clarify 
the regulation of fibrinogen phosphorylation in vivo, including identification of the 
relevant kinase. This work would greatly benefit from the use of phospho-specific 
antibodies targeted to the fibrinogen phosphorylation sites, to detect and quantify 
changes in the degree of phosphorylation. Preliminary investigations with Fam20A 
siRNA should be continued to establish whether this kinase phosphorylates fibrinogen 
in HepG2 cells. Other kinase inhibitors, such as STSP and a CK2 inhibitor could also 
be employed to facilitate identification of the fibrinogen kinase.  
There are many additional questions surrounding fibrinogen phosphorylation to be 
addressed in the future. Phospho-specific antibodies could be used to investigate 
whether the degree of Ser3 and Ser345 phosphorylation is altered in other pathologies, 
such as bleeding disorders and diabetes. This could potentially highlight fibrinogen 
phosphorylation as a biomarker for a range of disease states, and further testify to the 
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importance of understanding the regulation and function of this modification at the 
molecular level. One particular aspect which has not been covered during this 
investigation is the phosphorylation of fibrinogen in circulation by platelet kinases, 
which occurs at sites other than Ser3 and Ser345 in resting human platelets (Zahedi et 
al., 2008). Increased phosphorylation of fibrinogen is associated with platelet activation 
(Krust et al., 1983, Ekdahl et al., 1997). Identification of additional phosphorylation sites 
on circulating fibrinogen could be investigated by MALDI-TOF/TOF after incubation of 
fibrinogen with activated platelets. This would enable functional characterisation of 
additional modifications to fibrinogen that are likely to be important in stemming 
bleeding or in contributing to undesired, pathological coagulation. Furthermore, this 
would help decipher a complex but important regulatory aspect of fibrinogen, altering 
its function according to the corresponding stimulus and location. 
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Appendix 1 
Buffer and Media Compositions 
 
Recombinant fibrinogen expression 
 
Growth medium (CHO cells) 
500 ml  Dulbecco’s Modified Eagle Medium:Nutrient Mixture F-12 Invitrogen 
25 ml  Newborn bovine calf serum Fisher Scientific 
25 ml  Nu-Serum IV VWR 
5 ml  100X Antibiotic Antimycotic Solution Sigma-Aldrich  
Stored at +4°C. 
 
1X PBS pH 7.4 
2.7 mM Potassium chloride (KCl) 
1.5 mM Potassium di hydrogen orthophosphate (KH2PO4) 
137 mM NaCl 
8 mM Di-sodium hydrogen orthophosphate dihydrate (Na2HPO4.2H2O) 
Dissolved in dH2O and autoclaved. 
 
ITS medium 
500 ml  Dulbecco’s Modified Eagle Medium:Nutrient Mixture F-12 
5 ml  100X Antibiotic Antimycotic Solution 
1 ml  5 mg/ml ITS Supplement Roche 
1 ml  2 mg/ml Aprotinin Sigma-Aldrich  
Stored at +4°C. 
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Fibrinogen ELISA 
 
Buffer A pH 7.2  
2.5 mM  NaH2PO4.2H2O 
7.5 mM  Na2HPO4.2H2O 
145 mM  NaCl 
Dissolved in dH2O. 
 
Buffer B pH 7.2 
0.2 % v/v Tween 20 
355 mM  NaCl 
Dissolved in Buffer A. 
 
 
Ammonium sulphate precipitation of fibrinogen 
 
Protease inhibitor cocktail 
Per 1 L medium: 
656 mg ε-Amino-caproic acid 
785 mg Benzamidine hydrochloride hydrate Sigma-Aldrich 
130 µl 8 mM Pepstatin A Sigma-Aldrich 
260 µl 4 mM Leupeptin Sigma-Aldrich 
1040 µl 100 mM PMSF Sigma-Aldrich 
30 ml 700 mM MES buffer pH 5.6 
 
Pellet cocktail 
66 mg ε-Amino-caproic acid 
79 mg Benzamidine 
63 µl 8 mM Pepstatin A 
125 µl 4 mM Leupeptin 
100 µl 100 mM PMSF 
17 µl 58594 U/ml Soybean Trypsin Inhibitor Sigma-Aldrich 
200 µl 500 mM EDTA 
6 ml 5 M NaCl 
20 ml 1 M Tris pH 7.4 
Made up to 100 ml with dH2O. 
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IF-1 affinity chromatography 
 
IF-1 equilibration buffer pH 7.4 
20 mM Tris base 
300 mM NaCl 
1 mM CaCl2 
Dissolved in dH2O. 
Filtered through a 0.22 µm filter and degassed. 
 
IF-1 wash buffer I pH 7.4 
20 mM Tris base 
1 M NaCl 
1 mM CaCl2 
Dissolved in dH2O. 
Filtered through a 0.22 µm filter and degassed. 
 
IF-1 wash buffer II pH 6.0 
50 mM Sodium acetate (NaCH3COO) 
300 mM NaCl 
1 mM CaCl2 
Dissolved in dH2O. 
Filtered through a 0.22 µm filter and degassed. 
 
IF-1 elution buffer pH 7.4 
20 mM Tris base 
300 mM NaCl 
50 mM EGTA 
Dissolved in dH2O. 
Filtered through a 0.22 µm filter and degassed. 
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TBS buffers 
 
Buffer Tris (mM) NaCl (mM) % Tween (v/v) pH 
TBS-1 50 100 ̶ 7.4 
TBS-2 40 140 ̶ 7.4 
TBS-2-Tween 20 40 140 0.05 7.4 
TBS-3 40 140 ̶ 8.3 
TBS-3-Tween 20 40 140 0.05 8.3 
TBS-4 10 100 ̶ 7.4 
TBS-4-Tween 20 10 100 0.1 7.4 
TBS-5-Tween 20 40 1000 0.05 7.4 
TBS-6-Tween 20 40 75 0.01 7.4 
 
Reagents were dissolved in dH2O and adjusted to the appropriate pH. 
 
 
Recombinant GST-FXIII-A expression 
 
Terrific broth 
24 g Tryptone 
48 g Yeast extract 
8 ml Glycerol 
Made up to 1800 ml with dH2O and autoclaved. 
Added 200 ml phosphate buffer before use. 
 
Phosphate buffer 
170 mM KH2PO4 
720 mM Di potassium hydrogen phosphate trihydrate (K2HPO4.3H2O) 
Dissolved in dH2O and autoclaved. 
Stored at +4°C. 
 
E. Coli wash buffer 
20 ml 1 M Tris pH 8.0 
10 ml 5 M NaCl 
Dissolved in dH2O and stored at +4°C. 
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1X PBS pH 7.4 
137 mM  NaCl 
2.7 mM  KCl 
10 mM Na2HPO4.2H2O 
2 mM KH2PO4 
Dissolved in dH2O and autoclaved. 
 
 
GST affinity chromatography 
 
GST equilibration buffer (1X PBS) pH 7.4 
15 % v/v Glycerol 
Dissolved in 1X PBS and autoclaved. 
 
GST wash buffer pH 7.4 (1X PBS with 0.2 % (v/v) Triton X-100) 
15 % v/v Glycerol 
0.2 % v/v Triton X-100 
Dissolved in 1X PBS and autoclaved. 
 
GST elution buffer pH 8.0 
50 mM Tris base 
Dissolved in dH2O and adjusted to pH 8.0 with HCl. 
Added 0.92 g Glutathione to 150 ml elution buffer before use. 
 
 
Western blotting 
 
1X TBS-Tween 20 pH 7.4 
40 mM  Tris base 
140 mM NaCl 
0.05 % v/v Tween 20 
Dissolved in dH2O. 
 
Transfer buffer pH 8.1-8.4 
25 mM Tris base 
192 mM Glycine 
20 % v/v Methanol 
Dissolved in dH2O and stored at +4°C. 
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Molecular cloning 
 
Lysogeny broth (LB) 
10 g NaCl 
10 g Tryptone 
5 g Yeast extract 
Dissolved in 1 L dH2O and autoclaved. 
 
LB agar pH 7.0 
5 g NaCl 
5 g Tryptone 
2.5 g Yeast extract 
10 g  Agar 
Dissolved in 500 ml dH2O and autoclaved. 
 
TAE buffer pH 8.0 
40 mM Tris base 
20 mM Glacial acetic acid 
1 mM EDTA 
Dissolved in dH2O and autoclaved. 
 
6X DNA loading buffer 
0.05 g Bromophenol blue 
3 g Ficoll 400 
Dissolved in 20 ml dH2O. 
 
 
Calcium phosphate transfection 
 
2X HeBS pH 7.05 
280 mM NaCl 
50 mM Hepes 
1.2 mM Na2HPO4 
Dissolved in dH2O. 
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CHO cell lysis 
 
1X PBS pH 7.4 
2.7mM KCl 
1.5mM KH2PO4 
137mM NaCl 
8 mM Na2HPO4.2H2O 
1.8 mM CaCl2.2H2O 
1 mM MgCl2.6H2O 
Dissolved in dH2O and filtered through a 0.22 µm filter. 
 
 
HepG2 cell culture 
 
Growth medium 
500 ml  Minimum Essential Eagle Medium Sigma-Aldrich 
50 ml Fetal Bovine Serum Fisher Scientific 
5 ml  100X Antibiotic Antimycotic Solution 
5 ml 200 mM L-glutamine solution Sigma-Aldrich 
Stored at +4°C. 
 
 
Phos-tag™ affinity chromatography 
 
Phos-tag™ storage buffer pH 7.4 
20 mM Tris base 
20 % v/v Propan-2-ol 
Dissolved in dH2O and adjusted to pH 7.4 with glacial acetic acid. 
Filtered through a 0.22 µm filter and degassed. 
 
Phos-tag™ wash buffer pH 7.4 
100 mM Tris base 
Dissolved in dH2O and adjusted to pH 7.4 with glacial acetic acid. 
Filtered through a 0.22 µm filter and degassed. 
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Phos-tag™ equilibration buffer pH 7.4 
100 mM Tris base 
1 M NaCH3COO 
100 µM Zinc acetate (ZnCH3COO) 
Dissolved in dH2O and adjusted to pH 7.4 with glacial acetic acid. 
Filtered through a 0.22 µm filter and degassed. 
 
Phos-tag™ binding buffer pH 7.4 
100 mM Tris base 
1 M NaCH3COO 
Dissolved in dH2O and adjusted to pH 7.4 with glacial acetic acid. 
Filtered through a 0.22 µm filter and degassed. 
 
Phos-tag™ elution buffer pH 7.4 
50 mM EDTA 
100 mM Tris base 
1 M NaCl 
Dissolved in dH2O. 
 
 
Immunofluorescence/PLA 
 
1X PBS pH 7.4 
2.7 mM KCl 
1.5 mM KH2PO4 
137 mM NaCl 
8 mM Na2HPO4.2H2O 
Dissolved in dH2O and filtered through a 0.22 µm filter. 
 
PLA wash buffer A 
10 mM Tris base 
150 mM NaCl 
0.05 % v/v Tween 20 
Dissolved in dH2O and filtered through a 0.22 µm filter. 
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Immunoprecipitation 
 
1X PBS-Tween 20 pH 7.4 
2.7 mM KCl 
1.5 mM KH2PO4 
137 mM NaCl 
8 mM Na2HPO4.2H2O 
0.02 % v/v  Tween 20 
Dissolved in dH2O. 
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Appendix 2 
Sequencing Data 
 
Sequencing of variant fibrinogen Aα chain open reading frames (pMLP-Aα) 
 
 
Sequencing data were compared to the nucleotide sequence of the original pMLP-Aα 
open reading frame to identify base changes. Altered codons of interest are highlighted 
in blue. Nucleotide sequences were translated into protein sequences and BLAST was 
used to identify differences between query (WT sequence) and subject (variant 
sequence) by generating a consensus sequence (middle). For each variant, the only 
differences found were at position 3 and/or 345 (highlighted in red), indicating that 
these residues were successfully changed from serine to asparagine/glutamic 
acid/alanine. 
 
 
Aα S3N 
 
Original nucleotide sequence (Ser3):  ACT GCA GAT AGT GGT GAA GGT 
Mutated nucleotide sequence (Asn3): ACT GCA GAT AAT GGT GAA GGT 
 
Protein sequence BLAST: 
 
Query1    MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
          MFSMRIVCLVLSVVGTAWTAD+GEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
Sbjct1    MFSMRIVCLVLSVVGTAWTADNGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
 
 
 
 
Aα S345N 
         
Original nucleotide sequence (Ser345): AAT CCT GGC AGC TCT GAA CGC 
Mutated nucleotide sequence (Asn345): AAT CCT GGC AAC TCT GAA CGC 
         
Protein sequence BLAST: 
 
Query361  NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV                                                                                                                                                           
NPG+SERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV 
Sbjct361  NPGNSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV 
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S3N 
S345N 
S345E 
S3E 
Aα S3/345N 
 
Original nucleotide sequence (Ser3):  ACT GCA GAT AGT GGT GAA GGT 
Mutated nucleotide sequence (Asn3): ACT GCA GAT AAT GGT GAA GGT 
 
Protein sequence BLAST: 
 
Query1    MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
          MFSMRIVCLVLSVVGTAWTAD+GEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
Sbjct1    MFSMRIVCLVLSVVGTAWTADNGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
 
 
Original nucleotide sequence (Ser345): AAT CCT GGC AGC TCT GAA CGC 
Mutated nucleotide sequence (Asn345): AAT CCT GGC AAC TCT GAA CGC 
         
Protein sequence BLAST: 
 
Query361  NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV                                                                                                                                                           
NPG+SERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV 
Sbjct361  NPGNSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV 
 
 
 
Aα S3E 
 
Original nucleotide sequence (Ser3):  ACT GCA GAT AGT GGT GAA GGT 
Mutated nucleotide sequence (Glu3): ACT GCA GAT GAG GGT GAA GGT 
 
Protein sequence BLAST: 
 
Query1    MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
          MFSMRIVCLVLSVVGTAWTAD+GEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
Sbjct1    MFSMRIVCLVLSVVGTAWTADEGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
 
 
 
 
Aα S345E 
         
Original nucleotide sequence (Ser345): AAT CCT GGC AGC TCT GAA CGC 
Mutated nucleotide sequence (Glu345): AAT CCT GGC GAG TCT GAA CGC 
         
Protein sequence BLAST: 
 
Query361  NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV                                                                                                                                                           
NPG+SERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV 
Sbjct361  NPGESERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV 
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S345A 
S3E 
S345E 
Aα S3/345E 
 
Original nucleotide sequence (Ser3):  ACT GCA GAT AGT GGT GAA GGT 
Mutated nucleotide sequence (Glu3): ACT GCA GAT GAG GGT GAA GGT 
 
Protein sequence BLAST: 
 
Query1    MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
          MFSMRIVCLVLSVVGTAWTAD+GEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
Sbjct1    MFSMRIVCLVLSVVGTAWTADEGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 
 
 
 
Original nucleotide sequence (Ser345): AAT CCT GGC AGC TCT GAA CGC 
Mutated nucleotide sequence (Glu345): AAT CCT GGC GAG TCT GAA CGC 
         
Protein sequence BLAST: 
 
Query361  NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV                                                                                                                                                           
NPG+SERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV 
Sbjct361  NPGESERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV 
 
 
 
 
Aα S345A 
         
Original nucleotide sequence (Ser345): AAT CCT GGC AGC TCT GAA CGC 
Mutated nucleotide sequence (Ala345): AAT CCT GGC GCC TCT GAA CGC 
         
Protein sequence BLAST: 
 
Query361  NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV                                                                                                                                                           
NPG+SERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV 
Sbjct361  NPGASERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV 
 
 
 
 
 
Whole construct sequencing of pMLP-Aα, -Bβ and -γ 
 
 
Nucleotide sequences of the three fibrinogen expression constructs pMLP-Aα, -Bβ and 
–γ were determined from sequencing data. The sequence for each construct is 
displayed below with start/stop, Aα Ser3 and Aα Ser345 codons highlighted in yellow, 
blue and green respectively. 
 
 
pMLP-Aα sequence 
 
TCAGAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTGGCGCGG
GGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATGTTGCAAGTGTGGCGGAACACAT
GTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCG
CGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAA
ACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTAGGGCCC
AAGCTTTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAG
 206 
GCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAACTGGGCG
GAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCATGCTTTG
CATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATGCATGCTT
TGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCACAGCTGGT
TCTTTCCGCCTCAGAAGGTACCCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACGAAGGCTCGC
GTCCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTCCACTCGCT
CCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTGTAGGCCAC
GTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCA
TCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTCCAGTACTC
TTGGATCGGAAACCCGTCGGCCTCCGAACGGTACTCCGCCACCGAGGGACCTGAGCGAGTCCGCATCGAC
CGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCACCGTGGCG
GGCGGCAGCGGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAGTAGGCGG
TCTTGAGACGGCGGATGGTCGAGGTGAGGTGTGGCAGGCTTGAGATCTGGCCATACACTTGAGTGACAAT
GACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGATCAGAATTGCGCCGCTC
TCGAGTGAATTGTCGACCGCGGCCCCTGGAGTGCTCCTCAGGAGCCAGCCCCACCCTTAGAAAAGATGTT
TTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGT
GACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAG
ATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGG
GTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATAT
CAGAAGAACAATAAGGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCT
CAGCCAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTCCTGAA
GCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAAAAAAATGTTAGGGCCCAGTTGGTTGAT
ATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGTCGAGGGTCATGCAGTAGGGCTTTAG
CTCGTGAAGTAGATCTGAAGGACTATGAAGATCAGCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTT
ACTTCCCTCTAGAGATAGGCAACACTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGA
AATTTTAAGAGCCAGCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAA
TGGAGTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGATCAGA
GACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGACCTGGAAGTACT
GGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACCTGGAAACCTGGGAGCTCTGGACCTG
GAAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGAACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCC
TAGACCTGGTAGTACCGGAACCTGGAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCT
GAGAGCTCTGTATCTGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAG
GCTCTGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTAAGTCC
AGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAAGAGCTCAGGACTGGT
AAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCATGCTCTAAAACCGTTACTAAGACTG
TTATTGGTCCTGATGGTCACAAAGAAGTTACCAAAGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCC
CGAGGCAATGGATTTAGGCACATTGTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGAT
GAAGCTGCCTTCTTCGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAG
AGTTTGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCCAGTTC
TCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGCAAACAATTTACTAGT
AGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGCTATAAAATGGCAGATGAGGCCGGAA
GTGAAGCCGATCATGAAGGAACACATAGCACCAAGAGAGGCCATGCTAAATCTCGCCCTGTCAGAGGTAT
CCACACTTCTCCTTTGGGGAAGCCTTCCCTGTCCCCCTAGACTAAGTTAAATGGGCGGCCGCAATTCTGA
TCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAA
CCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAA
AGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAAC
TCATCAATGTATCTTATCATGTCTGGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCAC
AGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTC
ATGAGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCT
TGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCA
GGAGTCGCATAAGGGAGAGCGTCTAGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGT
GGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGT
GCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCG
CTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTTCG
GCGAGAAGCAGGCCATTATCGCCGGCATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGCGAC
GCGAGGCTGGATGGCCTTCCCCATTATGATTCTTCTCGCTTCCGGCGGCATCGGGATGCCCGCGTTGCAG
GCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGCCAGCAAAAGGCCAGGAACC
GTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACG
CTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTC
GTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGG
CGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGT
GCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTA
AGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG
207 
CTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCT
GCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGC
GGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCT
TTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAA
AAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAA
ACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCAT
CCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGC
TGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGG
GCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTA
GAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTCACG
CTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATG
TTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTAT
CACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGAC
TGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCA
ACACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGC
GAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATC
TTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAG
GGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATC
AGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCG
CACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAAT
AGGCGTATCACGAGGCCCTTTCGTCTTCCTGA 
 
Start/stop codon               Ser3 codon               Ser345 codon 
 
 
pMLP-Bβ sequence 
 
TCAGAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTGGCGCGG
GGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATGTTGCAAGTGTGGCGGAACACAT
GTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCG
CGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAA
ACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTAGGGCCC
AAGCTTTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAG
GCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAACTGGGCG
GAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCATGCTTTG
CATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATGCATGCTT
TGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCACAGCTGGT
TCTTTCCGCCTCAGAAGGTACCCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACGAAGGCTCGC
GTCCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTCCACTCGCT
CCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTGTAGGCCAC
GTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCA
TCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTCCAGTACTC
TTGGATCGGAAACCCGTCGGCCTCCGAACGGTACTCCGCCACCGAGGGACCTGAGCGAGTCCGCATCGAC
CGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCACCGTGGCG
GGCGGCAGCGGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAGTAGGCGG
TCTTGAGACGGCGGATGGTCGAGGTGAGGTGTGGCAGGCTTGAGATCTGGCCATACACTTGAGTGACAAT
GACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGATCAGAATTGCGCCGCTC
TCGAGTGAATTGTCGACATGAAAAGAATGGTTTCGTGGAGCTTCCACAAACTTAAAACCATGAAACACCT
ATTATTGCTACTATTGTGTGTTTTTCTAGTTAAGTCCCAAGGTGTCAACGACAATGAGGAGGGTTTCTTC
AGTGCCCGTGGTCATCGACCCCTTGACAAGAAGAGAGAAGAGGCTCCCAGCCTGAGGCCTGCCCCACCGC
CCATCAGTGGAGGTGGCTATCGGGCTCGTCCAGCCAAAGCAGCTGCCACTCAAAAGAAAGTAGAAAGAAA
AGCCCCTGATGCTGGAGGCTGTCTTCACGCTGACCCAGACCTGGGGGTGTTGTGTCCTACAGGATGTCAG
TTGCAAGAGGCTTTGCTACAACAGGAAAGGCCAATCAGAAATAGTGTTGATGAGTTAAATAACAATGTGG
AAGCTGTTTCCCAGACCTCCTCTTCTTCCTTTCAGTACATGTATTTGCTGAAAGACCTGTGGCAAAAGAG
GCAGAAGCAAGTAAAAGATAATGAAAATGTAGTCAATGAGTACTCCTCAGAACTGGAAAAGCACCAATTA
TATATAGATGAGACTGTGAATAGCAATATCGCAACTAACCTTCGTGTGCTTCGTTCAATCCTGGAAAACC
TGAGAAGCAAAATACAAAAGTTAGAATCTGATGTCTCAGCTCAAATGGAATATTGTCGCACCCCATGCAC
TGTCAGTTGCAATATTCCTGTGGTGTCTGGCAAAGAATGTGAGGAAATTATCAGGAAAGGAGGTGAAACA
TCTGAAATGTATCTCATTCAACCTGACAGTTCTGTCAAACCGTATAGAGTATACTGTGACATGAATACAG
AAAATGGAGGATGGACAGTGATTCAGAACCGTCAAGACGGTAGTGTTGACTTTGGCAGGAAATGGGATCC
ATATAAACAGGGATTTGGAAATGTTGCAACCAACACAGATGGGAAGAATTACTGTGGCCTACCAGGTGAA
TATTGGCTTGGAAATGATAAAATTAGCCAGCTTACCAGGATGGGACCCACAGAACTTTTGATAGAAATGG
 208 
AGGACTGGAAAGGAGACAAAGTAAAGGCTCACTATGGAGGATTCACTGTACAGAATGAAGCCAACAAATA
CCAGATCTCAGTGAACAAATACAGAGGAACAGCCGGTAATGCCCTCATGGATGGAGCATCTCAGCTGATG
GGAGAAAACAGGACCATGACCATTCACAACGGCATGTTCTTCAGCACGTATGACAGAGACAATGACGGCT
GGTTAACATCAGATCCCAGAAAACAGTGTTCTAAAGAAGACGGTGGTGGATGGTGGTATAATAGATGTCA
TGCAGCCAATCCAAACGGCAGATACTACTGGGGTGGACAGTACACCTGGGACATGGCAAAGCATGGCACA
GATGATGGTGTAGTATGGATGAATTGGAAGGGGTCATGGTACTCAATGAGGAAGATGAGTATGAAGATCA
GGCCCTTCTTCCCACAGCAATAGTCCCCAATACGGGCGGCCGCAATTCTGATCATAATCAGCCATACCAC
ATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAAT
GCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATT
TCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCA
TGTCTGGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCC
TATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCG
TGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGC
GGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAG
CGTCTAGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTAT
CGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTC
ATTTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCGCTTGCGGTATTCGGAATCT
TGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTTCGGCGAGAAGCAGGCCATTAT
CGCCGGCATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTC
CCCATTATGATTCTTCTCGCTTCCGGCGGCATCGGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGG
TAGATGACGACCATCAGGGACAGCTTCAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCT
GGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGA
AACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGA
CCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACG
CTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAG
CCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCAC
TGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTG
GTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTC
GGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCA
AGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGC
TCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATC
CTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACC
AATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCC
CGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGAC
CCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTC
CTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGT
TAATAGTTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCT
TCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTA
GCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAG
TCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGC
CACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTT
ACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTC
ACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGA
AATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAG
CGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTG
CCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCT
TTCGTCTTCCTGA 
 
Start/stop codon 
 
 
pMLP-γ sequence 
 
TCAGAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTGGCGCGG
GGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATGTTGCAAGTGTGGCGGAACACAT
GTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCG
CGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAA
ACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTAGGGCCC
AAGCTTTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAG
GCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAACTGGGCG
GAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCATGCTTTG
209 
CATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATGCATGCTT
TGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCACAGCTGGT
TCTTTCCGCCTCAGAAGGTACCCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACGAAGGCTCGC
GTCCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTCCACTCGCT
CCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTGTAGGCCAC
GTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCA
TCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTCCAGTACTC
TTGGATCGGAAACCCGTCGGCCTCCGAACGGTACTCCGCCACCGAGGGACCTGAGCGAGTCCGCATCGAC
CGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCACCGTGGCG
GGCGGCAGCGGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAGTAGGCGG
TCTTGAGACGGCGGATGGTCGAGGTGAGGTGTGGCAGGCTTGAGATCTGGCCATACACTTGAGTGACAAT
GACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGATCAGAATTGCGCCGCTC
TCGAGTGAATTGTCGACCGCGGCCCGGGCACTCAGACATCATGAGTTGGTCCTTGCACCCCCGGAATTTA
ATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACT
GCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTAC
TTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACA
TCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAATCCTGATGAATCATCAAAACCAAATA
TGATAGACGCTGCTACTTTGAAGTCCAGGAAAATGTTAGAAGAAATTATGAAATATGAAGCATCGATTTT
AACACATGACTCAAGTATTCGATATTTGCAGGAAATATATAATTCAAATAATCAAAAGATTGTTAACCTG
AAAGAGAAGGTAGCCCAGCTTGAAGCACAGTGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATA
TCACTGGGAAAGATTGTCAAGACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATTAAACC
TCTGAAAGCTAACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAATGGATGGACTGTGTTT
CAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATTCAATATAAAGAAGGATTTGGACATC
TGTCTCCTACTGGCACAACAGAATTTTGGCTGGGAAATGAGAAGATTCATTTGATAAGCACACAGTCTGC
CATCCCATATGCATTAAGAGTGGAACTGGAAGACTGGAATGGCAGAACCAGTACTGCAGACTATGCCATG
TTCAAGGTGGGACCTGAAGCTGACAAGTACCGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAG
ATGCCTTTGATGGCTTTGATTTTGGCGATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGCATGCA
GTTCAGTACCTGGGACAATGACAATGATAAGTTTGAAGGCAACTGTGCTGAACAGGATGGATCTGGTTGG
TGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTACCAAGGTGGCACTTACTCAAAAGCAT
CTACTCCTAATGGTTATGATAATGGCATTATTTGGGCCACTTGGAAAACCCGGTGGTATTCCATGAAGAA
AACCACTATGAAGATAATCCCATTCAACAGACTCACAATTGGAGAAGGACAGCAACACCACCTGGGGGGA
GCCAAACAGGCTGGAGACGTTTAAAAGACCGTTTCAAAAGAGATTTACTTTTTTAAAGGACTTTATCTGA
ACAGAGAGATATAATGGGCGGCCGCAATTCTGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACT
TGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAAC
TTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTT
TTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCCTCTACGC
CGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACC
GATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCC
CCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGG
CCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCTAGACCGATGCCCT
TGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGAC
TGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGACCGC
TTTCGCTGGAGCGCGACGATGATCGGCCTGTCGCTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAG
CCTTCGTCACTGGTCCCGCCACCAAACGTTTCGGCGAGAAGCAGGCCATTATCGCCGGCATGGCGGCCGA
CGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGATTCTTCTC
GCTTCCGGCGGCATCGGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGG
GACAGCTTCAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCT
CCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAA
AGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGAT
ACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTC
GGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTA
TCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTA
ACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTA
CACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGC
TCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCA
GAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTC
ACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGA
AGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGG
CACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTAC
GATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCA
GATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCT
CCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGT
TGTTGCCATTGCTGCAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCC
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CAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGA
TCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTAC
TGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGT
ATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAA
AAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAG
TTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGA
GCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATAC
TCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATG
TATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAA
ACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCCTGA 
Start/stop codon 
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Appendix 3 
Mass Spectrometry Data 
 
Recombinant WT fibrinogen expressed in CHO cells was analysed by mass 
spectrometry for detection of phosphorylation sites. Phosphopeptides were enriched 
using titanium oxide and analysed by MALDI-TOF/TOF using a Bruker Ultraflex-III 
mass spectrometer. Work was carried out by Adam Dowle, University of York. 
 
Mass spectra were matched to the fibrinogen Aα chain by Mascot search against the 
IPI human database. Two phosphopeptides were matched at positions 20-35 and 
354-367, corresponding to fibrinogen Aα chain Ser3 (ADS*GEGDFLAEGGGVR) and 
Ser345 (PGSTGTWNPGS*SER), respectively.  
 
 
Ser3 phosphorylation site 
 
Tandem mass spectrum of the Ser3 phoshopeptide: 
 
  
 
The presence of y13 and y14 (red arrow) identifies the phosphorylation site as Ser3. 
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Sequence overlay on the fragmentation spectrum for the Ser3 phosphopeptide: 
 
 
 
 
Ser345 phosphorylation site 
 
Tandem mass spectrum of the Ser345 phoshopeptide: 
 
 
 
The presence of y3 and y4 (red arrow) identifies the phosphorylation site as Ser345. 
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Sequence overlay on the fragmentation spectrum for the Ser345 phosphopeptide: 
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